


**CUMULATIVE
SUPPLEMENT 8
AUGUST 2019**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2019

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

**Cumulative Supplement 8
August 2019**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	ix
1.5 Availability of the Edition	x
1.6 Report of Counts for the Prescription Drug Product List.....	xi
1.7 Cumulative Supplement Legend	xii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

39th EDITION

**CUMULATIVE SUPPLEMENT 8
AUGUST 2019**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 39th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been

discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

G AND W LABORATORIES INC
(G AND W LABS)

ACP NIMBLE BUYER INC
(ACP NIMBLE)

G AND W LABORATORIES INC
(G AND W LABS INC)

ACP NIMBLE BUYER INC
(ACP NIMBLE)

IVAX PHARMACEUTICALS INC (IVAX PHARMS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX PHARMS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
LUITPOLD PHARMACEUTICALS INC (LUITPOLD)	AMERICAN REGENT INC (AM REGENT)
RISING PHARMACEUTICALS INC (RISING PHARMS)	SUN PHARMACEUTICAL INDUSTRIES LTD (SUN PHARM)
SUN PHARMA GLOBAL FZE (SUN PHARMA GLOBAL)	SUN PHARMACEUTICAL INDUSTRIES LTD (SUN PHARM)
SUN PHARMA GLOBAL INC (SUN PHARMA GLOBAL)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
TEVA PHARMACEUTICALS USA (TEVA PHARMS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
TEVA PHARMACEUTICALS USA (TEVA PHARMS USA)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
TEVA PHARMACEUTICALS USA INC (TEVA)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
WATSON LABORATORIES INC (WATSON LABS)	ANI PHARMACEUTICALS INC (ANI PHARMAS INC)
WATSON LABORATORIES INC (WATSON LABS)	DR REDDYS LABORATORIES LTD (DR REDDYS)
WATSON LABORATORIES INC (WATSON LABS)	HERITAGE PHARMA LABS INC (HERITAGE PHARMA)
WATSON LABORATORIES INC (WATSON LABS INC)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
WATSON LABORATORIES INC (WATSON LABS INC)	HERITAGE PHARMA LABS INC (HERITAGE PHARMA)
WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC (WATSON LABS TEVA)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC (WATSON LABS TEVA)	DR REDDYS LABORATORIES LTD (DR REDDYS)

WATSON LABORATORIES INC AN
INDIRECT WHOLLY OWNED SUB OF
TEVA PHARMACEUTICALS USA INC
(WATSON LABS TEVA)

HERITAGE PHARMA LABS INC
(HERITAGE PHARMA)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Cediprof Inc NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Cediprof Inc NDA 021342), Euthyrox (Provell Pharma LLC NDA 021292), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Cediprof Inc NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	CEDIPROF INC	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVOTHYROXINE	LUPIN	0.025MG	AB2	209713	001

SODIUM	ATLANTIS				
EUTHYROX	PROVELL PHARMS	0.025MG	AB2	021292	001
LEVO-T	CEDIPROF INC	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	CEDIPROF INC	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2018</u>	<u>MAR 2019</u>	<u>JUN 2019</u>	<u>SEP 2019</u>	<u>DEC 2019</u>
DRUG PRODUCTS	20295	20580	20693		
LISTED SINGLE	2724	2713	2729		
SOURCE	(13.4%)	(13.2%)	(13.2%)		
MULTISOURCE	17571	17867	17964		
	(86.6%)	(86.8%)	(86.8%)		
THERAPEUTICALLY	17483	17777	17964		
EQUIVALENT	(86.1%)	(86.4%)	(86.8%)		

NOT THERAPEUTICALLY EQUIVALENT	88 (0.4%)	90 (0.4%)	85 (0.4%)
EXCEPTIONS ¹	58 (0.3%)	58 (0.3%)	58 (0.3%)
NEW MOLECULAR ENTITIES APPROVED	25	3	16
NUMBER OF APPLICANTS	1133	1129	1132

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
NFTG	New first time generic approval.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.

CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

****Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

@ ZYDUS PHARMS EQ 600MG BASE;300MG A208990 001 Nov 15, 2018 Mar DISC

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB MSN LABS PVT LTD 250MG A210686 001 Jul 10, 2019 Jun NEWA
AB WOCKHARDT BIO AG 250MG A208380 001 Feb 27, 2019 Feb NEWA

ACARBOSE

TABLET;ORAL

ACARBOSE

@ MYLAN 25MG A091053 001 Jan 06, 2011 Jun DISC
@ 50MG A091053 002 Jan 06, 2011 Jun DISC
@ 100MG A091053 003 Jan 06, 2011 Jun DISC

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL

ACEBUTOLOL HYDROCHLORIDE

@ ANI PHARMS INC EQ 200MG BASE A074007 001 Oct 18, 1995 Jul CAHN
@ EQ 400MG BASE A074007 002 Oct 18, 1995 Jul CAHN

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL

APADAZ

+ KEMPHARM 325MG;EQ 4.08MG BASE N208653 002 Jan 04, 2019 Jan NEWA
+ 325MG;EQ 8.16MG BASE N208653 003 Jan 04, 2019 Jan NEWA
+ KVK TECH INC 325MG;EQ 4.08MG BASE N208653 002 Jan 04, 2019 Feb CAHN
+ 325MG;EQ 6.12MG BASE N208653 001 Feb 23, 2018 Feb CAHN
>D> + 325MG;EQ 8.16MG BASE N208653 003 Jan 04, 2019 Aug CHRS
>A> +! 325MG;EQ 8.16MG BASE N208653 003 Jan 04, 2019 Aug CHRS
+ 325MG;EQ 8.16MG BASE N208653 003 Jan 04, 2019 Feb CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ LANNETT CO INC 120MG/5ML;12MG/5ML A091238 001 Nov 10, 2011 Jan DISC

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>A> AA ELITE LABS INC 300MG;15MG A212418 001 Sep 10, 2019 Aug NEWA
>A> AA 300MG;30MG A212418 002 Sep 10, 2019 Aug NEWA
>A> AA 300MG;60MG A212418 003 Sep 10, 2019 Aug NEWA
AA WES PHARMA INC 300MG;15MG A211610 001 Jun 27, 2019 Jun NEWA
AA 300MG;30MG A211610 002 Jun 27, 2019 Jun NEWA
AA 300MG;60MG A211610 003 Jun 27, 2019 Jun NEWA

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA WES PHARMA INC 325MG/15ML;7.5MG/15ML A211023 001 Mar 08, 2019 Feb NEWA

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ ALVOGEN PINE BROOK 300MG;5MG A208540 001 Nov 08, 2018 Apr DISC
@ 300MG;7.5MG A208540 002 Nov 08, 2018 Apr DISC
@ 300MG;10MG A208540 003 Nov 08, 2018 Apr DISC
@ 325MG;2.5MG A209958 001 Oct 24, 2018 Apr DISC
@ 325MG;5MG A209958 002 Oct 24, 2018 Apr DISC
@ 325MG;7.5MG A209958 003 Oct 24, 2018 Apr DISC
@ 325MG;10MG A209958 004 Oct 24, 2018 Apr DISC
@ ELITE LABS INC 325MG;2.5MG A209924 001 Nov 16, 2018 May DISC
@ 325MG;5MG A209924 002 Nov 16, 2018 May DISC
@ 325MG;7.5MG A209924 003 Nov 16, 2018 May DISC
@ 325MG;10MG A209924 004 Nov 16, 2018 May DISC
@ UPSHER SMITH LABS 325MG;5MG A206484 001 Mar 24, 2017 Jan DISC
@ 325MG;7.5MG A206484 002 Mar 24, 2017 Jan DISC
@ 325MG;10MG A206484 003 Mar 24, 2017 Jan DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

@ MIKART INC 300MG/5ML; 10MG/5ML

A202142 001 Nov 27, 2018 May DISC

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

>D> AA	CHEMO RESEARCH SL	325MG; 5MG	A207574	001	Dec 13, 2016	Aug CAHN
>A> AA	HALO PHARM CANADA	325MG; 5MG	A207834	001	Aug 15, 2019	Aug NEWA
>A> AA		325MG; 7.5MG	A207834	002	Aug 15, 2019	Aug NEWA
>A> AA		325MG; 10MG	A207834	003	Aug 15, 2019	Aug NEWA
>A> AA	XIROMED	325MG; 5MG	A207574	001	Dec 13, 2016	Aug CAHN

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

	@ ACCORD HLTHCARE	500MG	A207659	001	Oct 18, 2018	Apr DISC
AB	ALEMBIC PHARMS LTD	500MG	A210423	001	Feb 19, 2019	Feb NEWA
AB	CADILA	500MG	A205301	001	Jan 16, 2019	Mar CAHN
AB	HERITAGE PHARMA	500MG	A040904	001	Dec 10, 2008	Jul CAHN
AB	! HERITAGE PHARMS INC	500MG	A090779	001	Jul 14, 2011	Jul CHRS
	@ MYLAN	500MG	A203917	001	Jun 18, 2019	Jul DISC
AB		500MG	A203917	001	Jun 18, 2019	Jun NEWA
	DIAMOX					
	+ @ TEVA BRANDED PHARM	500MG	N012945	001		Jul DISC

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP	ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206533	001	Apr 15, 2019	Apr NEWA
----	--------------	--------------------	---------	-----	--------------	----------

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

	@ PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A205358	001	Jun 20, 2017	Apr DISC
AP	ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206533	001	Apr 15, 2019	Jun CAIN

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC

ACETIC ACID

AT	SAPTALIS PHARMS	2%	A040607	001	Feb 24, 2005	May CAHN
----	-----------------	----	---------	-----	--------------	----------

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

ACETASOL HC

@ ACTAVIS MID ATLANTIC 2%; 1%

A087143 001 Jan 13, 1982 Jun DISC

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETYLCYSTEINE

@ MYLAN INSTITUTIONAL 6GM/30ML (200MG/ML)

A203624 001 Jun 19, 2015 Mar DISC

TABLET, EFFERVESCENT; ORAL

CETYLEV

	+ @ ARBOR PHARMS LLC	500MG	N207916	001	Jan 29, 2016	Mar DISC
	+ @	2.5GM	N207916	002	Jan 29, 2016	Mar DISC

ACITRETIN

CAPSULE; ORAL

SORIATANE

	+ @ STIEFEL LABS INC	17.5MG	N019821	003	Aug 06, 2009	Jan DISC
	+ @	22.5MG	N019821	004	Aug 06, 2009	Jan DISC

ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION

TUDORZA PRESSAIR

+!	CIRCASSIA	0.4MG/INH	N202450	001	Jul 23, 2012	Jun CAHN
----	-----------	-----------	---------	-----	--------------	----------

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED; INHALATION

DUAKLIR PRESSAIR

ASTRAZENECA PHARMS 0.4MG/INH; 0.012MG/INH

N210595 001 Mar 29, 2019 Mar NEWA

CIRCASSIA 0.4MG/INH; 0.012MG/INH

N210595 001 Mar 29, 2019 Apr CAHN

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

>A>	AB	CADILA	200MG	A204313	001	Mar 25, 2016	Aug CAHN
	AB	KENTON	200MG	A075090	001	Jan 26, 1999	Mar CAHN
>D>	AB	ZYDUS PHARMS	200MG	A204313	001	Mar 25, 2016	Aug CAHN

CREAM;TOPICAL

ACYCLOVIR

	AB	PERRIGO UK FINCO	5%	A208702	001	Feb 04, 2019	Jan NFTG
		ZOVIRAX					
	AB	+! BAUSCH	5%	N021478	001	Dec 30, 2002	Feb CAHN
	AB	+! VIB	5%	N021478	001	Dec 30, 2002	Jan CFTG
>D>		OINTMENT;OPHTHALMIC					
>D>		AVACLYR					
>D>		+! FERA PHARMS LLC	3%	N202408	001	Mar 29, 2019	Aug DISC
>A>		+ @	3%	N202408	001	Mar 29, 2019	Aug DISC
		+!	3%	N202408	001	Mar 29, 2019	Mar NEWA

OINTMENT;TOPICAL

ACYCLOVIR

>A>	AB	APOTEX INC	5%	A210774	001	Sep 06, 2019	Aug NEWA
	AB	CIPLA	5%	A211794	001	Jan 18, 2019	Jan NEWA
	AB	GLENMARK PHARMS SA	5%	A205510	001	Jul 31, 2017	Jun CAHN
>D>	AB	PERRIGO UK FINCO	5%	A205659	001	Feb 20, 2019	Aug DISC
>A>		@	5%	A205659	001	Feb 20, 2019	Aug DISC
	AB		5%	A205659	001	Feb 20, 2019	Feb NEWA
	AB	ZYDUS PHARMS	5%	A205974	001	Mar 15, 2019	Mar NEWA
		ZOVIRAX					
	AB	+! BAUSCH	5%	N018604	001	Mar 29, 1982	Feb CAHN

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR SODIUM

!	ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206535	001	Aug 31, 2018	Jan CHRS
!		EQ 1GM BASE/VIAL	A206535	002	Aug 31, 2018	Jan CHRS

ACYCLOVIR; HYDROCORTISONE

CREAM;TOPICAL

XERESE

+!	BAUSCH	5%;1%	N022436	001	Jul 31, 2009	Feb CAHN
----	--------	-------	---------	-----	--------------	----------

ADAPALENE

GEL;TOPICAL

ADAPALENE

AB	P AND L	0.1%	A090962	001	Jun 02, 2010	Jul CAHN
----	---------	------	---------	-----	--------------	----------

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

AB	PERRIGO UK FINCO	0.1%;2.5%	A205033	001	Jan 23, 2018	May CAHN
	@ TARO	0.3%;2.5%	A209148	001	Oct 17, 2018	May DISC

ADENOSINE

INJECTABLE;INJECTION

ADENOSINE

@	LUITPOLD	3MG/ML	A090010	001	Apr 28, 2009	Mar DISC
---	----------	--------	---------	-----	--------------	----------

ALBENDAZOLE

TABLET;ORAL

ALBENDAZOLE

	AB	ACTAVIS ELIZABETH	200MG	A208094	001	May 20, 2019	May NEWA
	AB	EDENBRIDGE PHARMS	200MG	A211117	001	May 14, 2019	Apr NEWA
>A>	AB	STRIDES PHARMA	200MG	A210011	001	Dec 07, 2018	Aug CAHN
>D>	AB	STRIDES VIVIMED	200MG	A210011	001	Dec 07, 2018	Aug CAHN

ALBUTEROL SULFATE

POWDER, METERED;INHALATION

PROAIR DIGIHALER

+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	002	Dec 21, 2018	Jan NEWA
	PROAIR RESPICLICK					
+!	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	001	Mar 31, 2015	Jan CPOT

		SYRUP; ORAL							
		ALBUTEROL SULFATE							
>A>	AA	QUAGEN	EQ 2MG BASE/5ML	A212197	001	Sep 06, 2019	Aug	NEWA	
		TABLET; ORAL							
		ALBUTEROL SULFATE							
AB		AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Mar	NEWA	
AB			EQ 4MG BASE	A210948	002	Mar 15, 2019	Mar	NEWA	
AB		APPCO PHARMA LLC	EQ 2MG BASE	A207046	001	Jun 29, 2018	Feb	CAHN	
AB			EQ 4MG BASE	A207046	002	Jun 29, 2018	Feb	CAHN	
		<u>ALENDRONATE SODIUM</u>							
		TABLET; ORAL							
		ALENDRONATE SODIUM							
		@ MYLAN	EQ 5MG BASE	A076584	001	Aug 04, 2008	Jul	DISC	
		@	EQ 10MG BASE	A076584	002	Aug 04, 2008	Jul	DISC	
		<u>ALFUZOSIN HYDROCHLORIDE</u>							
		TABLET, EXTENDED RELEASE; ORAL							
		ALFUZOSIN HYDROCHLORIDE							
AB		HERITAGE PHARMA	10MG	A079056	001	Jul 18, 2011	May	CAHN	
		<u>ALISKIREN HEMIFUMARATE</u>							
		TABLET; ORAL							
		ALISKIREN HEMIFUMARATE							
AB		ANCHEN PHARMS	EQ 150MG BASE	A206665	001	Mar 22, 2019	Mar	NFTG	
AB			EQ 300MG BASE	A206665	002	Mar 22, 2019	Mar	NFTG	
		TEKTURNA							
AB	+	NODEN PHARMA	EQ 150MG BASE	N021985	001	Mar 05, 2007	Mar	CFTG	
AB	+	!	EQ 300MG BASE	N021985	002	Mar 05, 2007	Mar	CFTG	
		<u>ALITRETINOIN</u>							
		GEL; TOPICAL							
		PANRETIN							
	+	! CONCORDIA	EQ 0.1% BASE	N020886	001	Feb 02, 1999	Jul	CAHN	
		<u>ALLOPURINOL</u>							
		TABLET; ORAL							
		ALLOPURINOL							
AB		UNICHEM LABS LTD	100MG	A211820	001	Mar 12, 2019	Feb	NEWA	
AB			300MG	A211820	002	Mar 12, 2019	Feb	NEWA	
		<u>ALLOPURINOL; LESINURAD</u>							
		TABLET; ORAL							
		DUZALLO							
	+	@ IRONWOOD PHARMS INC	200MG; 200MG	N209203	001	Aug 18, 2017	Apr	DISC	
	+	@	300MG; 200MG	N209203	002	Aug 18, 2017	Apr	DISC	
		<u>ALPELISIB</u>							
		TABLET; ORAL							
		PIQRAY							
	+	NOVARTIS PHARMS CORP	50MG	N212526	001	May 24, 2019	May	NEWA	
	+		150MG	N212526	002	May 24, 2019	May	NEWA	
	+	!	200MG	N212526	003	May 24, 2019	May	NEWA	
		<u>ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K</u>							
		SOLUTION; INTRAVENOUS							
		INFUVITE ADULT							
	+	! SANDOZ CANADA INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163	001	May 18, 2000	Jul	CAHN	
	+	!	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021559	001	Jun 16, 2003	Jul	CAHN	

ALTRETAMINECAPSULE;ORAL
HEXALEN

+ @ EISAI INC 50MG N019926 001 Dec 26, 1990 Feb DISC

AMANTADINE HYDROCHLORIDECAPSULE;ORAL
AMANTADINE HYDROCHLORIDE

AB UPSHER SMITH LABS 100MG A070589 001 Aug 05, 1986 Jul CAHN

TABLET;ORAL
AMANTADINE HYDROCHLORIDE

AB ! UPSHER SMITH LABS 100MG A076186 001 Dec 16, 2002 Jul CAHN

AMBRISENTANTABLET;ORAL
AMBRISENTAN

AB CIPLA 5MG A210715 001 Apr 26, 2019 Apr NEWA

AB 10MG A210715 002 Apr 26, 2019 Apr NEWA

AB MYLAN 5MG A208441 001 Mar 28, 2019 Mar NFTG

AB 10MG A208441 002 Mar 28, 2019 Mar NFTG

AB PAR PHARM INC 5MG A209509 001 Apr 10, 2019 Mar NEWA

AB 10MG A209509 002 Apr 10, 2019 Mar NEWA

AB SIGMAPHARM LABS LLC 5MG A208354 001 Apr 10, 2019 Mar NEWA

AB 10MG A208354 002 Apr 10, 2019 Mar NEWA

AB SUN PHARM 5MG A210784 001 Mar 28, 2019 Mar NFTG

AB 10MG A210784 002 Mar 28, 2019 Mar NFTG

AB WATSON LABS INC 5MG A208252 001 Mar 28, 2019 Mar NFTG

AB 10MG A208252 002 Mar 28, 2019 Mar NFTG

AB ZYDUS PHARMS 5MG A210058 001 Mar 28, 2019 Mar NFTG

AB 10MG A210058 002 Mar 28, 2019 Mar NFTG

LETAIRIS

AB + GILEAD 5MG N022081 001 Jun 15, 2007 Mar CFTG

AB +! 10MG N022081 002 Jun 15, 2007 Mar CFTG

AMIFAMPRIDINETABLET;ORAL
RUZURGI

+! JACOBUS PHARM CO INC 10MG N209321 001 May 06, 2019 May NEWA

AMILORIDE HYDROCHLORIDETABLET;ORAL
AMILORIDE HYDROCHLORIDE

AB WINDLAS HLTHCARE 5MG A204180 001 Aug 07, 2015 Feb CAHN

AMINO ACIDSINJECTABLE;INJECTION
AMINOSYN 10%

@ ICU MEDICAL INC 10% (10GM/100ML) N017673 003 Jul DISC

AMINOSYN 8.5%

@ ICU MEDICAL INC 8.5% (8.5GM/100ML) N017673 004 Jul DISC

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDEINJECTABLE;INJECTION
AMINOSYN 3.5% M

@ ICU MEDICAL INC 3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML N017789 003 Jul DISC

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASICINJECTABLE;INJECTION
AMINOSYN 8.5% W/ELECTROLYTES

@ ICU MEDICAL INC 8.5%;102MG/100ML;487MG/100ML;28MG/100ML;425MG/100ML N017673 009 Oct 25, 2002 Jul DISC

AMINOCAPROIC ACIDSYRUP;ORAL
AMICAR

>D> +! CLOVER PHARMS 1.25GM/5ML N015230 002 Aug CTEC

>A> AA +! 1.25GM/5ML N015230 002 Aug CTEC

AMINOCAPROIC ACID

>A> AA AMNEAL PHARMS LLC 1.25GM/5ML A212780 001 Aug 23, 2019 Aug NEWA

TABLET;ORAL							
AMICAR							
AB	+ CLOVER PHARMS	1GM	N015197	002	Jun 24, 2004	Feb	CHRS
AMINOCAPROIC ACID							
AB	! SUNNY PHARMTECH INC	1GM	A209060	002	Nov 27, 2018	Feb	CHRS
<u>AMINOPHYLLINE</u>							
INJECTABLE;INJECTION							
AMINOPHYLLINE							
	! HOSPIRA	25MG/ML	A087242	001	Oct 26, 1983	Feb	CTEC
	@ LUITPOLD	25MG/ML	A087600	001		Feb	DISC
<u>AMIODARONE HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
AMIODARONE HYDROCHLORIDE							
	@ DR REDDYS	50MG/ML	A076163	001	Sep 05, 2003	May	CAHN
TABLET;ORAL							
AMIODARONE HYDROCHLORIDE							
AB	RUBICON	200MG	A078578	001	Nov 06, 2008	Jul	CAHN
<u>AMLODIPINE BENZOATE</u>							
SOLUTION;ORAL							
KATERZIA							
	+! SILVERGATE PHARMS	EQ 1MG BASE/ML	N211340	001	Jul 08, 2019	Jul	NEWA
<u>AMLODIPINE BESYLATE</u>							
TABLET;ORAL							
AMLODIPINE BESYLATE							
AB	STRIDES PHARMA	EQ 2.5MG BASE	A077516	001	Jul 11, 2007	Apr	CAHN
AB		EQ 5MG BASE	A077516	002	Jul 11, 2007	Apr	CAHN
AB		EQ 10MG BASE	A077516	003	Jul 11, 2007	Apr	CAHN
<u>AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM</u>							
TABLET;ORAL							
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM							
	@ ZYDUS PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Jun	DISC
	@	EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Jun	DISC
	@	EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Jun	DISC
	@	EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Jun	DISC
	@	EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Jun	DISC
	@	EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Jun	DISC
	@	EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Jun	DISC
	@	EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Jun	DISC
	@	EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Jun	DISC
	@	EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Jun	DISC
	@	EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Jun	DISC
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE</u>							
CAPSULE;ORAL							
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE							
	@ CIPLA	EQ 2.5MG BASE;10MG	A077215	001	Dec 07, 2018	May	DISC
	@	EQ 5MG BASE;10MG	A077215	002	Dec 07, 2018	May	DISC
	@	EQ 5MG BASE;20MG	A077215	003	Dec 07, 2018	May	DISC
	@	EQ 10MG BASE;20MG	A077215	004	Dec 07, 2018	May	DISC
	@ MYLAN	EQ 2.5MG BASE;10MG	A077375	001	May 21, 2010	Feb	DISC
	@	EQ 5MG BASE;10MG	A077375	002	May 21, 2010	Feb	DISC
	@	EQ 5MG BASE;20MG	A077375	003	May 21, 2010	Feb	DISC
	@	EQ 5MG BASE;40MG	A079047	001	Jul 05, 2011	Feb	DISC
	@	EQ 10MG BASE;20MG	A077375	004	May 21, 2010	Feb	DISC
	@	EQ 10MG BASE;40MG	A079047	002	Jul 05, 2011	Feb	DISC
	@ TEVA PHARMS	EQ 2.5MG BASE;10MG	A077179	001	May 18, 2007	Jun	DISC
	@	EQ 5MG BASE;10MG	A077179	002	May 18, 2007	Jun	DISC
	@	EQ 5MG BASE;20MG	A077179	003	May 18, 2007	Jun	DISC
	@	EQ 5MG BASE;40MG	A077179	005	Jul 05, 2011	Jun	DISC
	@	EQ 10MG BASE;20MG	A077179	004	May 18, 2007	Jun	DISC
	@	EQ 10MG BASE;40MG	A077179	006	Jul 05, 2011	Jun	DISC

AMLODIPINE BESYLATE; CELECOXIBTABLET; ORAL
CONSENSI

+	COEPTIS	EQ 2.5MG BASE;200MG	N210045	001	May 31, 2018	Mar CAHN
+		EQ 5MG BASE;200MG	N210045	002	May 31, 2018	Mar CAHN
+	!	EQ 10MG BASE;200MG	N210045	003	May 31, 2018	Mar CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

@	TEVA PHARMS USA	EQ 5MG BASE;12.5MG;20MG	A202491	001	Nov 03, 2016	Jul DISC
@		EQ 5MG BASE;12.5MG;40MG	A202491	002	Nov 03, 2016	Jul DISC
@		EQ 5MG BASE;25MG;40MG	A202491	003	Nov 03, 2016	Jul DISC
@		EQ 10MG BASE;12.5MG;40MG	A202491	004	Nov 03, 2016	Jul DISC
@		EQ 10MG BASE;25MG;40MG	A202491	005	Nov 03, 2016	Jul DISC

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

@	TEVA PHARMS	5MG;12.5MG;160MG	A200435	001	Sep 25, 2012	Jul DISC
@		5MG;25MG;160MG	A200435	002	Sep 25, 2012	Jul DISC
@		10MG;12.5MG;160MG	A200435	005	Sep 25, 2012	Jul DISC
@		10MG;25MG;160MG	A200435	003	Sep 25, 2012	Jul DISC
@		10MG;25MG;320MG	A200435	004	Sep 25, 2012	Jul DISC

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

@	ACCORD HLTHCARE INC	EQ 5MG BASE;20MG	A209600	001	Aug 30, 2018	Mar DISC
@		EQ 5MG BASE;40MG	A209600	003	Aug 30, 2018	Mar DISC
@		EQ 10MG BASE;20MG	A209600	002	Aug 30, 2018	Mar DISC
@		EQ 10MG BASE;40MG	A209600	004	Aug 30, 2018	Mar DISC
@	TEVA PHARMS USA	EQ 5MG BASE;20MG	A091154	001	Oct 26, 2016	Jun DISC
@		EQ 5MG BASE;40MG	A091154	002	Oct 26, 2016	Jun DISC
@		EQ 10MG BASE;20MG	A091154	003	Oct 26, 2016	Jun DISC
@		EQ 10MG BASE;40MG	A091154	004	Oct 26, 2016	Jun DISC

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET; ORAL

PRESTALIA

+	ADHERA	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Apr CAHN
+		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Apr CAHN
+	!	EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Apr CAHN

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

@	TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015	Jul DISC
@		EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015	Jul DISC
@		EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015	Jul DISC
@		EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015	Jul DISC

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	DECATUR	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204465	001	Oct 23, 2014	Apr CAHN
----	---------	------------------------------------	---------	-----	--------------	----------

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB	!	PERRIGO ISRAEL	EQ 12% BASE	A075774	001	May 01, 2002	May CAHN
----	---	----------------	-------------	---------	-----	--------------	----------

LOTION; TOPICAL

AMMONIUM LACTATE

AB	!	PERRIGO ISRAEL	EQ 12% BASE	A075570	001	Jun 23, 2004	May CAHN
----	---	----------------	-------------	---------	-----	--------------	----------

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

@	TEVA	125MG/5ML	A061931	001		Jun DISC
---	------	-----------	---------	-----	--	----------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	125MG/5ML;EQ 31.25MG BASE/5ML	A209371	001	Apr 19, 2019	Apr NFTG
AB		250MG/5ML;EQ 62.5MG BASE/5ML	A209371	002	Apr 19, 2019	Apr NEWA
	AUGMENTIN '125'					
AB	+ NEOPHARMA	125MG/5ML;EQ 31.25MG BASE/5ML	N050575	001	Aug 06, 1984	Apr CFTG
	TABLET; ORAL					
	AUGMENTIN '875'					
AB	+ NEOPHARMA	875MG;EQ 125MG BASE	N050720	001	Feb 13, 1996	Feb CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DETROAMP SULFATE AND AMP SULFATE

AB	PAR PHARM INC	1.25MG;1.25MG;1.25MG;1.25MG	A206159	001	May 31, 2019	May NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206159	002	May 31, 2019	May NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206159	003	May 31, 2019	May NEWA
AB		5MG;5MG;5MG;5MG	A206159	004	May 31, 2019	May NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A206159	005	May 31, 2019	May NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206159	006	May 31, 2019	May NEWA
	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE					
AB	AMERIGEN PHARMS LTD	1.25MG;1.25MG;1.25MG;1.25MG	A205401	001	Jan 22, 2019	Jan NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A205401	002	Jan 22, 2019	Jan NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A205401	003	Jan 22, 2019	Jan NEWA
AB		5MG;5MG;5MG;5MG	A205401	004	Jan 22, 2019	Jan NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A205401	005	Jan 22, 2019	Jan NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A205401	006	Jan 22, 2019	Jan NEWA
AB	NESHER PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210080	001	Jul 17, 2019	Jul NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210080	002	Jul 17, 2019	Jul NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210080	003	Jul 17, 2019	Jul NEWA
AB		5MG;5MG;5MG;5MG	A210080	004	Jul 17, 2019	Jul NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A210080	005	Jul 17, 2019	Jul NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210080	006	Jul 17, 2019	Jul NEWA
AB	RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210651	001	May 17, 2019	May NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210651	002	May 17, 2019	May NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210651	003	May 17, 2019	May NEWA
AB		5MG;5MG;5MG;5MG	A210651	004	May 17, 2019	May NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A210651	005	May 17, 2019	May NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210651	006	May 17, 2019	May NEWA
AB	SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A211547	001	Apr 22, 2019	Apr NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211547	002	Apr 22, 2019	Apr NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211547	003	Apr 22, 2019	Apr NEWA
AB		5MG;5MG;5MG;5MG	A211547	004	Apr 22, 2019	Apr NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A211547	005	Apr 22, 2019	Apr NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A211547	006	Apr 22, 2019	Apr NEWA
AB	SUN PHARM INDUSTRIES	1.25MG;1.25MG;1.25MG;1.25MG	A211715	001	May 17, 2019	May NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211715	002	May 17, 2019	May NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211715	003	May 17, 2019	May NEWA
AB		5MG;5MG;5MG;5MG	A211715	004	May 17, 2019	May NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A211715	005	May 17, 2019	May NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A211715	006	May 17, 2019	May NEWA

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

AA	AUROLIFE PHARMA LLC	5MG	A211639	001	Apr 17, 2019	Apr NEWA
AA		10MG	A211639	002	Apr 17, 2019	Apr NEWA
AA	GRANULES PHARMS	5MG	A212619	001	Aug 05, 2019	Jul NEWA
AA		10MG	A212619	002	Aug 05, 2019	Jul NEWA
	TABLET, ORALLY DISINTEGRATING; ORAL					
	EVEKEO ODT					
+	ARBOR PHARMS LLC	5MG	N209905	001	Jan 30, 2019	Jan NEWA
+		10MG	N209905	002	Jan 30, 2019	Jan NEWA
+		15MG	N209905	003	Jan 30, 2019	Jan NEWA
+		20MG	N209905	004	Jan 30, 2019	Jan NEWA

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL

AMPICILLIN TRIHYDRATE

@ HERITAGE PHARMA

EQ 250MG BASE

A 061502 001

May CAHN

@

EQ 500MG BASE

A 061502 002

May CAHN

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

AB FRESenius KABI USA

1MG

A 090088 001 Jun 28, 2010 Feb CAHN

AB KENTON

1MG

A 078944 001 Jun 28, 2010 Mar CAHN

ARIPIPIRAZOLE

SOLUTION;ORAL

ARIPIPIRAZOLE

AA AUROBINDO PHARMA LTD 1MG/ML

A 210479 001 Jan 29, 2019 Jan NEWA

TABLET;ORAL

ARIPIPIRAZOLE

AB ALKEM LABS LTD

2MG

A 207105 001 Feb 21, 2019 Feb NEWA

AB 5MG

A 207105 002 Feb 21, 2019 Feb NEWA

AB 10MG

A 207105 003 Feb 21, 2019 Feb NEWA

AB 15MG

A 207105 004 Feb 21, 2019 Feb NEWA

AB 20MG

A 207105 005 Feb 21, 2019 Feb NEWA

AB 30MG

A 207105 006 Feb 21, 2019 Feb NEWA

@ TEVA PHARMS USA

2MG

A 078607 001 Apr 28, 2015 Jun DISC

@ 5MG

A 078607 002 Apr 28, 2015 Jun DISC

@ 10MG

A 078608 001 Apr 28, 2015 May DISC

@ 15MG

A 078708 001 Apr 28, 2015 May DISC

@ 20MG

A 078708 002 Apr 28, 2015 May DISC

@ 30MG

A 078708 003 Apr 28, 2015 May DISC

@ ZYDUS PHARMS

2MG

A 090472 001 Jan 07, 2019 Jun DISC

@ 5MG

A 090472 002 Jan 07, 2019 Jun DISC

@ 10MG

A 090472 003 Jan 07, 2019 Jun DISC

@ 15MG

A 090472 004 Jan 07, 2019 Jun DISC

@ 20MG

A 090472 005 Jan 07, 2019 Jun DISC

@ 30MG

A 090472 006 Jan 07, 2019 Jun DISC

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

AB APOTEX INC 50MG

A 201514 001 Mar 25, 2019 Mar NEWA

AB 150MG

A 201514 002 Mar 25, 2019 Mar NEWA

AB 250MG

A 201514 003 Mar 25, 2019 Mar NEWA

AB AUROBINDO PHARMA LTD 200MG

A 206069 004 Dec 07, 2018 Mar NEWA

AB MYLAN PHARMS INC 100MG

A 200043 004 May 09, 2019 Apr NEWA

AB 200MG

A 200043 005 May 09, 2019 Apr NEWA

AB NATCO PHARMA LTD 100MG

A 202768 004 Sep 28, 2017 Apr CTEC

ARSENIC TRIOXIDE

INJECTABLE;INJECTION

ARSENIC TRIOXIDE

AP STI PHARMA LLC 1MG/ML

A 209873 001 May 06, 2019 Apr NEWA

>A> AP ZYDUS PHARMS 2MG/ML

A 206228 002 Aug 30, 2019 Aug NFTG

TRISENOX

>D> +! CEPHALON 2MG/ML

N 021248 002 Oct 13, 2017 Aug CFTG

>A> AP +! 2MG/ML

N 021248 002 Oct 13, 2017 Aug CFTG

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE;INTRAVENOUS

INFUVITE PEDIATRIC

+! SANDOZ CANADA INC 80MG/VIAL;0.02MG/VIAL;400
IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14
MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/V
IAL;1.2MG/VIAL;7 IU/VIAL;2,300
IU/VIAL;0.2MG/VIAL

N 021265 001 Feb 21, 2001 Jul CAHN

ASENAPINE MALEATE

TABLET;SUBLINGUAL

ASENAPINE MALEATE

@ SIGMAPHARM LABS LLC EQ 5MG BASE

A206107 001 Jul 17, 2018 Feb DISC

@ EQ 10MG BASE

A206107 002 Jul 17, 2018 Feb DISC

SAPHRIS

+ FOREST LABS LLC EQ 5MG BASE

N022117 001 Aug 13, 2009 Feb CTEC

+! EQ 10MG BASE

N022117 002 Aug 13, 2009 Feb CTEC

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

>A> AA BRECKENRIDGE 325MG;50MG;40MG

A204195 001 Sep 22, 2016 Aug CAHN

>D> AA PII 325MG;50MG;40MG

A204195 001 Sep 22, 2016 Aug CAHN

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

AB ! SANDOZ 770MG;60MG;50MG

A074654 002 Dec 31, 1996 May CTEC

ORPHENGESIC FORTE

AB GALT PHARMS 770MG;60MG;50MG

A075141 002 May 29, 1998 May CMFD

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

ASPIRIN AND DIPYRIDAMOLE

AB GLENMARK PHARMS LTD 25MG;200MG

A210318 001 May 24, 2019 May NEWA

AB GLENMARK PHARMS SA 25MG;200MG

A210318 001 May 24, 2019 Jun CAHN

AB LANNETT CO INC 25MG;200MG

A204552 001 Mar 20, 2019 Mar NEWA

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB ZYDUS PHARMS 50MG;25MG

A210028 001 Mar 08, 2019 Feb NEWA

AB 100MG;25MG

A210028 002 Mar 08, 2019 Feb NEWA

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB ZYDUS PHARMS USA INC 18MG

A079017 001 Sep 17, 2010 Mar CMFD

AB 25MG

A079017 002 Sep 17, 2010 Mar CMFD

AB 40MG

A079017 003 Sep 17, 2010 Mar CMFD

AB 60MG

A079017 004 Sep 17, 2010 Mar CMFD

AB 80MG

A079017 005 Sep 17, 2010 Mar CMFD

AB 100MG

A079017 006 Sep 17, 2010 Mar CMFD

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB LUPIN LTD EQ 10MG BASE

A204991 001 Mar 06, 2019 Feb NEWA

AB EQ 20MG BASE

A204991 002 Mar 06, 2019 Feb NEWA

AB EQ 40MG BASE

A204991 003 Mar 06, 2019 Feb NEWA

AB EQ 80MG BASE

A204991 004 Mar 06, 2019 Feb NEWA

AB MSN LABS PVT LTD EQ 10MG BASE

A211933 001 Feb 08, 2019 Feb NEWA

AB EQ 20MG BASE

A211933 002 Feb 08, 2019 Feb NEWA

AB EQ 40MG BASE

A211933 003 Feb 08, 2019 Feb NEWA

AB EQ 80MG BASE

A211933 004 Feb 08, 2019 Feb NEWA

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB ABHAI LLC 750MG/5ML

A210510 001 May 31, 2019 May NEWA

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

AP HONG KONG 10MG/ML

A091489 001 Feb 17, 2012 Feb CAHN

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP HONG KONG 10MG/ML

A091488 001 Feb 17, 2012 Feb CAHN

ATROPINE

SOLUTION; INTRAMUSCULAR

ATROPEN

+	!	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004	Mar CPOT
+	!		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003	Mar CPOT
+	!		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003	Mar CPOT
+	!		EQ 2MG SULFATE/0.7ML	N017106	001		Mar CPOT

ATROPINE

@	ABBVIE	EQ 2MG SULFATE/0.7ML	A071295	001	Jan 30, 1987	Mar CDFR
---	--------	----------------------	---------	-----	--------------	----------

ATROPINE SULFATE

SOLUTION; INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

+	!	FRESENIUS KABI USA	8MG/20ML (0.4MG/ML)	N209260	001	Jan 26, 2018	May CDFR
---	---	--------------------	---------------------	---------	-----	--------------	----------

AZELAIC ACID

CREAM; TOPICAL

AZELEX

+	!	ALMIRALL	20%	N020428	001	Sep 13, 1995	Apr CAHN
---	---	----------	-----	---------	-----	--------------	----------

GEL; TOPICAL

AZELAIC ACID

>A>	AB	TARO	15%	A210549	001	Aug 23, 2019	Aug NEWA
-----	----	------	-----	---------	-----	--------------	----------

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT		ALEMBIC PHARMS LTD	0.05%	A209620	001	Mar 20, 2019	Mar NEWA
----	--	--------------------	-------	---------	-----	--------------	----------

AT		SOMERSET THERAPS LLC	0.05%	A207411	001	Mar 29, 2019	Mar NEWA
----	--	----------------------	-------	---------	-----	--------------	----------

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE

AB		HI TECH	EQ 0.125MG BASE/SPRAY	A207610	001	May 17, 2019	May NEWA
----	--	---------	-----------------------	---------	-----	--------------	----------

>A>	AB		EQ 0.1876MG BASE/SPRAY	A210032	001	Aug 23, 2019	Aug NEWA
-----	----	--	------------------------	---------	-----	--------------	----------

AZITHROMYCIN

TABLET; ORAL

AZITHROMYCIN

AB		BIONPHARMA INC	EQ 250MG BASE	A210000	001	Feb 26, 2019	Feb NEWA
----	--	----------------	---------------	---------	-----	--------------	----------

AB			EQ 500MG BASE	A210001	001	Feb 26, 2019	Feb NEWA
----	--	--	---------------	---------	-----	--------------	----------

AB		CSPC OUYI	EQ 250MG BASE	A208250	001	Apr 17, 2019	Apr NEWA
----	--	-----------	---------------	---------	-----	--------------	----------

AB	!	PLIVA	EQ 600MG BASE	A065218	001	Nov 14, 2005	Jul CHRS
----	---	-------	---------------	---------	-----	--------------	----------

@	TEVA	EQ 250MG BASE	A065153	001	Nov 14, 2005	Jul DISC
---	------	---------------	---------	-----	--------------	----------

@		EQ 600MG BASE	A065150	001	Nov 14, 2005	Jul DISC
---	--	---------------	---------	-----	--------------	----------

ZITHROMAX

+	@	PFIZER	EQ 600MG BASE	N050730	001	Jun 12, 1996	Jul DISC
---	---	--------	---------------	---------	-----	--------------	----------

AZTREONAM

INJECTABLE; INJECTION

AZACTAM IN PLASTIC CONTAINER

+	@	BRISTOL MYERS SQUIBB	20MG/ML	N050632	002	May 24, 1989	Jul DISC
---	---	----------------------	---------	---------	-----	--------------	----------

+	@		40MG/ML	N050632	001	May 24, 1989	Jul DISC
---	---	--	---------	---------	-----	--------------	----------

BACLOFEN

INJECTABLE; INTRATHECAL

BACLOFEN

>A>	AP	MAIA PHARMS INC	0.5MG/ML	A210048	001	Sep 11, 2019	Aug NEWA
-----	----	-----------------	----------	---------	-----	--------------	----------

AP			1MG/ML	A210315	001	Jul 30, 2019	Jul NEWA
----	--	--	--------	---------	-----	--------------	----------

>A>	AP		2MG/ML	A210048	002	Sep 11, 2019	Aug NEWA
-----	----	--	--------	---------	-----	--------------	----------

GABLOFEN

>D>	AP	PIRAMAL CRITICAL	0.05MG/ML	N022462	001	Nov 19, 2010	Aug CAHN
-----	----	------------------	-----------	---------	-----	--------------	----------

>A>	AP		0.05MG/ML	N022462	001	Nov 19, 2010	Aug CAHN
-----	----	--	-----------	---------	-----	--------------	----------

>D>	AP		0.5MG/ML	N022462	002	Nov 19, 2010	Aug CAHN
-----	----	--	----------	---------	-----	--------------	----------

>A>	AP		0.5MG/ML	N022462	002	Nov 19, 2010	Aug CAHN
-----	----	--	----------	---------	-----	--------------	----------

>D>	AP	+	1MG/ML	N022462	004	Jun 22, 2012	Aug CAHN
-----	----	---	--------	---------	-----	--------------	----------

>A>	AP	+	1MG/ML	N022462	004	Jun 22, 2012	Aug CAHN
-----	----	---	--------	---------	-----	--------------	----------

>D>	AP		2MG/ML	N022462	003	Nov 19, 2010	Aug CAHN
-----	----	--	--------	---------	-----	--------------	----------

>A>	AP		2MG/ML	N022462	003	Nov 19, 2010	Aug CAHN
-----	----	--	--------	---------	-----	--------------	----------

TABLET; ORAL

BACLOFEN

AB		EYWA PHARMA	10MG	A211555	001	Feb 01, 2019	Jan NEWA
----	--	-------------	------	---------	-----	--------------	----------

AB			20MG	A211555	002	Feb 01, 2019	Jan NEWA
----	--	--	------	---------	-----	--------------	----------

AB		UPSHER SMITH LABS	10MG	A074584	001	Aug 19, 1996	Jul CAHN
----	--	-------------------	------	---------	-----	--------------	----------

TABLET;ORAL									
BACLOFEN									
AB		20MG		A074584	002	Aug 19, 1996	Jul	CAHN	
<u>BALSALAZIDE DISODIUM</u>									
CAPSULE;ORAL									
BALSALAZIDE DISODIUM									
	@ MYLAN	750MG		A077807	001	Dec 28, 2007	Feb	DISC	
TABLET;ORAL									
BALSALAZIDE DISODIUM									
	@ PAR PHARM INC	1.1GM		A206336	001	Sep 08, 2015	Apr	DISC	
	GIAZO								
	+ @ VALEANT PHARMS INTL	1.1GM		N022205	001	Feb 03, 2012	Apr	DISC	
<u>BARIUM SULFATE</u>									
FOR SUSPENSION;ORAL									
VARIBAR THIN LIQUID									
	+! BRACCO	81% (120GM/BOT)		N208036	004	Apr 30, 2019	May	NEWA	
<u>BELINOSTAT</u>									
POWDER;INTRAVENOUS									
BELEODAQ									
	+! ACROTECH	500MG/VIAL		N206256	001	Jul 03, 2014	Mar	CAHN	
<u>BENAZEPRIL HYDROCHLORIDE</u>									
TABLET;ORAL									
BENAZEPRIL HYDROCHLORIDE									
	@ HERITAGE PHARMA	5MG		A076267	001	Feb 11, 2004	Feb	CAHN	
	@	10MG		A076267	002	Feb 11, 2004	Feb	CAHN	
	@	20MG		A076267	003	Feb 11, 2004	Feb	CAHN	
	@	40MG		A076267	004	Feb 11, 2004	Feb	CAHN	
<u>BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE</u>									
TABLET;ORAL									
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE									
	@ ANI PHARMS INC	5MG;6.25MG		A076342	001	Feb 11, 2004	May	CAHN	
	@	10MG;12.5MG		A076342	002	Feb 11, 2004	May	CAHN	
	@	20MG;12.5MG		A076342	003	Feb 11, 2004	May	CAHN	
	@	20MG;25MG		A076342	004	Feb 11, 2004	May	CAHN	
<u>BENDAMUSTINE HYDROCHLORIDE</u>									
POWDER;IV (INFUSION)									
TREANDA									
	+! CEPHALON	25MG/VIAL		N022249	002	May 01, 2009	Feb	CTEC	
	+!	100MG/VIAL		N022249	001	Mar 20, 2008	Feb	CTEC	
<u>BENZONATATE</u>									
CAPSULE;ORAL									
BENZONATATE									
AA	ASCENT PHARMS INC	100MG		A211518	001	Feb 22, 2019	Feb	NEWA	
AA		150MG		A211518	002	Feb 22, 2019	Feb	NEWA	
AA		200MG		A211518	003	Feb 22, 2019	Feb	NEWA	
AA	CSPC OUYI	100MG		A202765	002	Aug 25, 2017	Feb	CAHN	
AA		200MG		A202765	001	Jul 31, 2015	Feb	CAHN	
AA	QINGDAO BAHEAL PHARM	100MG		A210562	001	Nov 09, 2018	May	CAHN	
AA		150MG		A210562	002	Nov 09, 2018	May	CAHN	
AA		200MG		A210562	003	Nov 09, 2018	May	CAHN	
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE</u>									
GEL;TOPICAL									
ACANYA									
>A> AB	+! BAUSCH	2.5%;EQ 1.2% BASE		N050819	001	Oct 23, 2008	Aug	CAHN	
>D> AB	+! DOW PHARM	2.5%;EQ 1.2% BASE		N050819	001	Oct 23, 2008	Aug	CAHN	
BENZACLIN									
>A> AB	+! BAUSCH	5%;EQ 1% BASE		N050756	001	Dec 21, 2000	Aug	CAHN	
>A>	@	5%;EQ 1% BASE		N050756	002	Apr 20, 2007	Aug	CAHN	
>D> AB	+! VALEANT BERMUDA	5%;EQ 1% BASE		N050756	001	Dec 21, 2000	Aug	CAHN	
>D>	@	5%;EQ 1% BASE		N050756	002	Apr 20, 2007	Aug	CAHN	
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE									
AB	GLENMARK PHARMS	5%;EQ 1% BASE		A209252	001	Mar 14, 2019	Jun	CMS1	
AB		5%;1% BASE		A209252	001	Mar 14, 2019	Mar	NEWA	
>A> AB	PERRIGO ISRAEL	2.5%;EQ 1.2% BASE		A205397	001	Sep 09, 2019	Aug	NEWA	

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB	PERRIGO UK FINCO	5%;EQ 1% BASE	A202440	001	Sep 21, 2015	May CAHN
>A> AB	TARO	2.5%;EQ 1.2% BASE	A206575	001	Aug 19, 2019	Aug NEWA
	@	3.75%;EQ 1.2% BASE	A208683	001	Jun 05, 2018	May DISC
>A> AB	TOLMAR	2.5%;EQ 1.2% BASE	A207194	001	Aug 19, 2019	Aug NEWA
	ONEXTON					
>A>	+! BAUSCH	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	Aug CAHN
>D>	+! DOW PHARM	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	Aug CAHN
	+!	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	May CTEC

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL;TOPICAL

>D>	AKTIPAK					
>D>	+! BIOFRONTERA	5%;3%	N050769	001	Nov 27, 2000	Aug DISC
>A>	+ @	5%;3%	N050769	001	Nov 27, 2000	Aug DISC
	+!	5%;3%	N050769	001	Nov 27, 2000	May CAHN

BENZTROPINE MESYLATE

INJECTABLE;INJECTION

BENZTROPINE MESYLATE

	@ LUITPOLD	1MG/ML	A091152	001	Mar 29, 2010	Feb DISC
	TABLET;ORAL					
	BENZTROPINE MESYLATE					
AA	! ASPEN GLOBAL INC	0.5MG	A204713	001	Apr 14, 2015	Apr CHRS
AA	!	1MG	A204713	002	Apr 14, 2015	Apr CHRS
AA	!	2MG	A204713	003	Apr 14, 2015	Apr CHRS
	@ OXFORD PHARMS	0.5MG	A040706	002	Feb 14, 2008	Mar DISC
	@	1MG	A040706	003	Feb 14, 2008	Mar DISC
	@ UPSHER SMITH LABS	0.5MG	A040103	001	Dec 12, 1996	Jul CAHN
	@	1MG	A040103	002	Dec 12, 1996	Jul CAHN
	@	2MG	A040103	003	Dec 12, 1996	Jul CAHN
	@ USL PHARMA	0.5MG	A040103	001	Dec 12, 1996	Apr DISC
	@	1MG	A040103	002	Dec 12, 1996	Apr DISC
	@	2MG	A040103	003	Dec 12, 1996	Apr DISC

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC

BEPOTASTINE BESILATE

AT	MICRO LABS	1.5%	A206220	001	Mar 18, 2019	Mar NEWA
AT	MYLAN	1.5%	A206220	001	Mar 18, 2019	Apr CAHN
	BEPREVE					
AT	+! BAUSCH AND LOMB INC	1.5%	N022288	001	Sep 08, 2009	Feb CFTG

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB	PERRIGO ISRAEL	EQ 0.05% BASE	A076592	001	Dec 09, 2003	May CAHN
	SPRAY;TOPICAL					
	SERNIVO					
	+! ENCORE DERMAT	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Mar CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

OINTMENT;TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB	PERRIGO ISRAEL	0.064%;0.005%	A200174	001	Dec 12, 2014	Mar CAIN
AB	PERRIGO UK FINCO	0.064%;0.005%	A200174	001	Dec 12, 2014	May CAHN
AB	TOLMAR	0.064%;0.005%	A201615	001	Jan 14, 2013	Mar CAIN
	TACLONEX					
AB	+! LEO PHARMA AS	0.064%;0.005%	N021852	001	Jan 09, 2006	Mar CAIN
	SUSPENSION;TOPICAL					
	TACLONEX					
	+! LEO PHARMA AS	0.064%;0.005%	N022185	001	May 09, 2008	Mar CAIN

BETHANECHOL CHLORIDE

TABLET;ORAL

DUVOID

AA	CHARTWELL RX	10MG	A086262	001		Mar CAHN
AA		25MG	A086263	001		Mar CAHN
AA		50MG	A085882	003		Mar CAHN

BEXAROTENEGEL;TOPICAL
TARGRETIN

+! BAUSCH 1% N021056 001 Jun 28, 2000 Jun CAHN

BICALUTAMIDETABLET;ORAL
BICALUTAMIDE

AB	FRESENIUS KABI USA	50MG	A 079045	001	May 13, 2010	Feb	CAHN
AB	KENTON	50MG	A 091011	001	Jun 10, 2015	Jun	CAHN

BIMATOPROSTSOLUTION/DROPS;OPHTHALMIC
BIMATOPROST

AT	ALEMBIC PHARMS LTD	0.03%	A 210263	001	Apr 12, 2019	Apr	NEWA
AT	GLAND PHARMA LTD	0.03%	A 210126	001	Mar 22, 2019	Mar	NEWA
	@ HI-TECH PHARMA CO	0.03%	A 203299	001	Nov 08, 2018	Jul	DISC
AT	SOMERSET THERAPS LLC	0.03%	A 207601	001	Jun 19, 2019	Jun	NEWA

BISOPROLOL FUMARATETABLET;ORAL
BISOPROLOL FUMARATE

AB	FRONTIDA BIOPHARM	5MG	A 075474	001	Oct 25, 2002	Jul	CMFD
	@	5MG	A 075474	001	Oct 25, 2002	Jan	CAHN
AB		10MG	A 075474	002	Oct 25, 2002	Jul	CMFD
	@	10MG	A 075474	002	Oct 25, 2002	Jan	CAHN
AB	MYLAN	10MG	A 075831	002	Dec 14, 2005	Jul	CHRS
AB	! UNICHEM PHARMS (USA)	10MG	A 078635	002	Aug 18, 2009	Jul	CHRS

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDETABLET;ORAL
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

@	MYLAN	2.5MG; 6.25MG	A 075768	001	Sep 25, 2000	Jul	DISC
@		5MG; 6.25MG	A 075768	002	Sep 25, 2000	Jul	DISC
@		10MG; 6.25MG	A 075768	003	Sep 25, 2000	Jul	DISC

BIVALIRUDINSOLUTION;INTRAVENOUS
ANGIOMAX RTU

+! MAIA PHARMS INC 250MG/50ML (5MG/ML) N211215 001 Jul 25, 2019 Jul NEWA

BLEOMYCIN SULFATEINJECTABLE;INJECTION
BLEOMYCIN SULFATE

AP	CIPLA	EQ 15 UNITS BASE/VIAL	A 209439	001	Mar 11, 2019	Feb	NEWA
----	-------	-----------------------	----------	-----	--------------	-----	------

BORTEZOMIBPOWDER;INTRAVENOUS, SUBCUTANEOUS
BORTEZOMIB

+ @ HOSPIRA INC 1MG/VIAL N209191 002 Dec 28, 2018 Mar DISC

BOSENTANTABLET;ORAL
BOSENTAN

AB	ALVOGEN PINE BROOK	62.5MG	A 206002	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A 206002	002	Apr 26, 2019	Apr	NFTG
AB	AMNEAL PHARMS CO	62.5MG	A 209742	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A 209742	002	Apr 26, 2019	Apr	NFTG
AB	NATCO PHARMA LTD	62.5MG	A 206987	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A 206987	002	Apr 26, 2019	Apr	NFTG
AB	PAR PHARM INC	62.5MG	A 205699	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A 205699	002	Apr 26, 2019	Apr	NFTG
AB	SUN PHARM	62.5MG	A 209324	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A 209324	002	Apr 26, 2019	Apr	NFTG
AB	WATSON LABS INC	62.5MG	A 207110	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A 207110	002	Apr 26, 2019	Apr	NFTG
AB	WEST-WARD PHARMS INT	62.5MG	A 208695	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A 208695	002	Apr 26, 2019	Apr	NFTG
AB	ZYDUS PHARMS	62.5MG	A 207760	001	Apr 26, 2019	Apr	NFTG
AB		125MG	A 207760	002	Apr 26, 2019	Apr	NFTG

TABLET;ORAL

TRACLEER

AB	+	ACTELION PHARMS LTD	62.5MG	N021290	001	Nov 20, 2001	Apr CFTG
AB	+	!	125MG	N021290	002	Nov 20, 2001	Apr CFTG

BREMELANOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

VYLEESI (AUTOINJECTOR)

	+	AMAG PHARMS INC	EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	N210557	001	Jun 21, 2019	Jun NEWA
--	---	-----------------	--	---------	-----	--------------	----------

BRETYLIUM TOSYLATE

INJECTABLE;INJECTION

BRETYLIUM TOSYLATE

>D>	!	BAS ANDA	50MG/ML	A204386	001	Dec 21, 2018	Aug CAHN
	!		50MG/ML	A204386	001	Dec 21, 2018	Jun CAHN
>A>	!	BRECKENRIDGE	50MG/ML	A204386	001	Dec 21, 2018	Aug CAHN

BREXANOLONE

SOLUTION;INTRAVENOUS

ZULRESSO

	+	SAGE THERAP	100MG/20ML (5MG/ML)	N211371	001	Jun 17, 2019	Jun NEWA
--	---	-------------	---------------------	---------	-----	--------------	----------

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

AT		SOMERSET THERAPS LLC	0.2%	A208992	001	Mar 11, 2019	Feb NEWA
----	--	----------------------	------	---------	-----	--------------	----------

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMFENAC SODIUM

AT2		ALEMBIC PHARMS LTD	EQ 0.09% ACID	A210560	001	Jun 21, 2019	Jun NEWA
AT2	!	HI TECH	EQ 0.09% ACID	A203395	001	Jan 22, 2014	May CTEC
AT2		INNOPHARMA LICENSING	EQ 0.09% ACID	A203368	001	Jun 03, 2019	May NEWA

BUDESONIDE

CAPSULE;ORAL

BUDESONIDE

AB		APPCO PHARMA LLC	3MG	A207367	001	Apr 07, 2017	Feb CAHN
----	--	------------------	-----	---------	-----	--------------	----------

CAPSULE, EXTENDED RELEASE;ORAL

ORTIKOS

	+	SUN PHARMA GLOBAL	6MG	N211929	001	Jun 13, 2019	Jun NEWA
	+	!	9MG	N211929	002	Jun 13, 2019	Jun NEWA

TABLET, EXTENDED RELEASE;ORAL

UCERIS

AB	+	SALIX	9MG	N203634	001	Jan 14, 2013	Mar CAHN
----	---	-------	-----	---------	-----	--------------	----------

BUMETANIDE

TABLET;ORAL

BUMETANIDE

AB		HERITAGE PHARMA	0.5MG	A074225	001	Apr 24, 1995	Feb CAHN
AB			1MG	A074225	002	Apr 24, 1995	Feb CAHN
AB			2MG	A074225	003	Apr 24, 1995	Feb CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

	@	NOVOCOL HEALTHCARE	0.5%	A211096	001	Feb 19, 2019	Jun DISC
AP			0.5%	A211096	001	Feb 19, 2019	Feb NEWA

INJECTABLE;SPINAL

BUPIVACAINE HYDROCHLORIDE

AP		B BRAUN MEDICAL INC	0.75%	A209087	001	Apr 02, 2019	Mar NEWA
----	--	---------------------	-------	---------	-----	--------------	----------

BUPRENORPHINE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

@ BARR

EQ 2MG BASE

A090360	001	May 07, 2010	Jul DISC
---------	-----	--------------	----------

@

EQ 8MG BASE

A090360	002	May 07, 2010	Jul DISC
---------	-----	--------------	----------

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	ALVOGEN PINE BROOK	EQ 2MG BASE;EQ 0.5MG BASE	A205954	001	Jan 24, 2019	Jan NEWA
AB		EQ 4MG BASE;EQ 1MG BASE	A205954	002	Jan 24, 2019	Jan NEWA
AB		EQ 8MG BASE;EQ 2MG BASE	A205954	003	Jan 24, 2019	Jan NEWA
AB		EQ 12MG BASE;EQ 3MG BASE	A205954	004	Jan 24, 2019	Jan NEWA

FILM;SUBLINGUAL

CASSIPA

+	@ TEVA PHARMS USA	EQ 16MG BASE;EQ 4MG BASE	N208042	001	Sep 07, 2018	Mar DISC
---	-------------------	--------------------------	---------	-----	--------------	----------

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

@	TEVA PHARMS USA	EQ 2MG BASE;EQ 0.5MG BASE	A091149	001	Sep 08, 2014	Jan DISC
@		EQ 8MG BASE;EQ 2MG BASE	A091149	002	Sep 08, 2014	Jan DISC

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AB	APNAR PHARMA LP	75MG	A075584	001	Feb 07, 2000	Jun CAHN
AB		100MG	A075584	002	Feb 07, 2000	Jun CAHN
@	HERITAGE PHARMA	75MG	A075310	001	Nov 29, 1999	May CAHN
@		100MG	A075310	002	Nov 29, 1999	May CAHN

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB2	!	ACTAVIS LABS FL INC	150MG	A079094	001	Mar 24, 2009	Jul CHRS
AB3		GRAVITI PHARMS	150MG	A211020	001	Jan 28, 2019	Jan NEWA
AB3			300MG	A211020	002	Jan 28, 2019	Jan NEWA
	@	MYLAN	150MG	A090942	001	Jul 14, 2010	Jul DISC
	@	YICHANG HUMANWELL	100MG	A211347	001	Oct 16, 2018	Apr DISC
	@		150MG	A211347	002	Oct 16, 2018	Apr DISC
	@		200MG	A211347	003	Oct 16, 2018	Apr DISC
>A>	AB3	ZHEJIANG JUTAI PHARM	300MG	A211200	001	Sep 05, 2019	Aug NEWA
		ZYBAN					
	+	@ GLAXOSMITHKLINE	150MG	N020711	003	May 14, 1997	Jul DISC

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

>D>	@	APOTEX	5MG	A075521	001	Apr 05, 2002	Aug CAHN
>D>	@		10MG	A075521	002	Apr 05, 2002	Aug CAHN
>D>	@		15MG	A075521	003	Apr 05, 2002	Aug CAHN
AB		EPIC PHARMA LLC	5MG	A208972	001	Apr 16, 2019	Apr NEWA
AB			7.5MG	A208972	002	Apr 16, 2019	Apr NEWA
AB			10MG	A208972	003	Apr 16, 2019	Apr NEWA
AB			15MG	A208972	004	Apr 16, 2019	Apr NEWA
AB			30MG	A208972	005	Apr 16, 2019	Apr NEWA
>A>	@	RUBICON	5MG	A075521	001	Apr 05, 2002	Aug CAHN
>A>	@		10MG	A075521	002	Apr 05, 2002	Aug CAHN
>A>	@		15MG	A075521	003	Apr 05, 2002	Aug CAHN

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

AP	ACCORD HLTHCARE INC	6MG/ML	A210148	001	Feb 22, 2019	Feb NEWA
AP	APOTEX INC	6MG/ML	A210448	001	May 07, 2019	Apr NEWA
AP	ATHENEX INC	6MG/ML	A205106	001	Sep 21, 2018	Jan CAHN
AP	SHILPA MEDICARE LTD	6MG/ML	A210931	001	Apr 18, 2019	Apr NEWA
	MYLERAN					
AP	MYLAN INSTITUTIONAL	6MG/ML	A208536	001	Nov 20, 2017	Jul CAHN

CABERGOLINE

TABLET;ORAL

CABERGOLINE

>D>	AB	ACTAVIS LABS FL INC	0.5MG	A078035	001	Apr 21, 2008	Aug DISC
>A>	@		0.5MG	A078035	001	Apr 21, 2008	Aug DISC

CAFFEINE CITRATESOLUTION; INTRAVENOUS
CAFCIT

>A>	AP	+!	HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	001	Sep 21, 1999	Aug CAHN
>D>	AP	+!	WEST-WARD PHARMS INT	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	001	Sep 21, 1999	Aug CAHN

SOLUTION; ORAL
CAFCIT

>A>	AA	+!	HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Aug CAHN
>D>	AA	+!	WEST-WARD PHARMS INT	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Aug CAHN
			CAFFEINE CITRATE					
			@ LUITPOLD	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090064	001	Nov 20, 2009	Mar DISC

CAFFEINE; ERGOTAMINE TARTRATESUPPOSITORY; RECTAL
MIGERGOT

!	COSETTE	100MG; 2MG		A086557	001	Oct 04, 1983	Jul CAHN
---	---------	------------	--	---------	-----	--------------	----------

CALCITONIN SALMONINJECTABLE; INJECTION
MIACALCIN

>D>		@	MYLAN IRELAND LTD	100 IU/ML	N017808	001	Jul 03, 1986	Aug CRLD
>A>		+	@	100 IU/ML	N017808	001	Jul 03, 1986	Aug CRLD

CALCITRIOLCAPSULE; ORAL
CALCITRIOL

		@	SUN PHARM	0.25MCG	A204556	001	Feb 21, 2019	Jul DISC
AB				0.25MCG	A204556	001	Feb 21, 2019	Feb NEWA
		@		0.5MCG	A204556	002	Feb 21, 2019	Jul DISC
AB				0.5MCG	A204556	002	Feb 21, 2019	Feb NEWA

CALCIUM ACETATETABLET; ORAL
CALCIUM ACETATE

AB			CHARTWELL MOLECULAR	667MG	A202420	001	Feb 05, 2013	Jan CAHN
----	--	--	---------------------	-------	---------	-----	--------------	----------

CALCIUM CHLORIDEINJECTABLE; INJECTION
CALCIUM CHLORIDE 10%

AP			MEDEFIL INC	100MG/ML	A211553	001	May 01, 2019	Apr NEWA
----	--	--	-------------	----------	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	001	Dec 04, 1992	Jun CRLD
----	---	-----------------	---	---------	-----	--------------	----------

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

>D>	+	BAXTER HLTHCARE	18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	002	Dec 04, 1992	Aug CTEC
-----	---	-----------------	---	---------	-----	--------------	----------

>A>	AT	+	18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	002	Dec 04, 1992	Aug CTEC
-----	----	---	---	---------	-----	--------------	----------

	+		18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	002	Dec 04, 1992	Jun CRLD
--	---	--	---	---------	-----	--------------	----------

DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	003	Dec 04, 1992	Jun CRLD
---	-----------------	---	---------	-----	--------------	----------

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

>D>	+	BAXTER HLTHCARE	18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	004	Dec 04, 1992	Aug CTEC
-----	---	-----------------	--	---------	-----	--------------	----------

>A>	AT	+	18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	004	Dec 04, 1992	Aug CTEC
-----	----	---	--	---------	-----	--------------	----------

	+		18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	004	Dec 04, 1992	Jun CRLD
--	---	--	--	---------	-----	--------------	----------

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

>A>	AT	+	BAXTER HLTHCARE	18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	012	Jan 10, 1989	Aug NEWA
-----	----	---	-----------------	---	---------	-----	--------------	----------

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

>A>	AT	+	BAXTER HLTHCARE	18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	013	Jul 11, 1990	Aug NEWA
-----	----	---	-----------------	---	---------	-----	--------------	----------

DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

>A>	AT	+	BAXTER HLTHCARE	18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	014	Jul 11, 1990	Aug NEWA
-----	----	---	-----------------	---	---------	-----	--------------	----------

SOLUTION;INTRAPERITONEAL

>A>		DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER							
>A>	AT	+	BAXTER HLTHCARE	18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	015	Jul 11, 1990	Aug	NEWA
>D>	AT	+	BAXTER HLTHCARE	18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	004		Aug	CPOT
	AT	+		18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	004		Jun	CRLD
>A>	AT	+		25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	004		Aug	CPOT
	AT	+		25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020163	001	Dec 04, 1992	Jun	CRLD
			DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER						
	AT	+	BAXTER HLTHCARE	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	005		Jun	CRLD
	AT	+		25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020163	002	Dec 04, 1992	Jun	CRLD
			DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER						
		+	@ BAXTER HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	011	Nov 18, 1985	Jun	CRLD
			DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER						
	AT	+	BAXTER HLTHCARE	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	006		Jun	CRLD
	AT	+		25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020163	003	Dec 04, 1992	Jun	CRLD

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML	A209338	001	Jan 28, 2019	Jan	NEWA
----	--	--------------------	---	---------	-----	--------------	-----	------

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB		SUN PHARM	150MG	A204668	001	Jun 21, 2019	Jun	NEWA
AB			500MG	A204668	002	Jun 21, 2019	Jun	NEWA

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

AB		BOSCOGEN	12.5MG	A074677	004	May 30, 1997	Jun	CMFD
AB			25MG	A074677	002	May 30, 1997	Jun	CMFD
AB			50MG	A074677	001	May 30, 1997	Jun	CMFD
AB			100MG	A074677	003	May 30, 1997	Jun	CMFD

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

		@ MYLAN IRELAND LTD	100MG	A076697	001	May 20, 2011	Jul	DISC
		@	200MG	A076697	002	May 20, 2011	Jul	DISC
		@	300MG	A076697	003	May 20, 2011	Jul	DISC

CARBATROL

AB	+	SHIRE DEV LLC	100MG	N020712	003	Sep 30, 1997	Jan	CAHN
AB	+		200MG	N020712	001	Sep 30, 1997	Jan	CAHN
AB	+	!	300MG	N020712	002	Sep 30, 1997	Jan	CAHN

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB		ZYDUS PHARMS	100MG	A205571	001	Feb 07, 2019	Jan	NEWA
AB			200MG	A205571	002	Feb 07, 2019	Jan	NEWA
AB			400MG	A205571	003	Feb 07, 2019	Jan	NEWA

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

>D>	AB		WOCKHARDT LTD	12.5MG;200MG;50MG	A090786	001	Nov 20, 2012	Aug	DISC
>A>		@		12.5MG;200MG;50MG	A090786	001	Nov 20, 2012	Aug	DISC
>D>	AB			18.75MG;200MG;75MG	A090833	001	Nov 20, 2012	Aug	DISC
>A>		@		18.75MG;200MG;75MG	A090833	001	Nov 20, 2012	Aug	DISC
>D>	AB			25MG;200MG;100MG	A090833	002	Nov 20, 2012	Aug	DISC
>A>		@		25MG;200MG;100MG	A090833	002	Nov 20, 2012	Aug	DISC
>D>	AB			31.25MG;200MG;125MG	A090833	003	Nov 20, 2012	Aug	DISC
>A>		@		31.25MG;200MG;125MG	A090833	003	Nov 20, 2012	Aug	DISC

TABLET;ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

>D>	AB		37.5MG;200MG;150MG	A090833	004	Nov 20, 2012	Aug DISC	
>A>		@	37.5MG;200MG;150MG	A090833	004	Nov 20, 2012	Aug DISC	
>D>	AB		50MG;200MG;200MG	A090833	005	Nov 20, 2012	Aug DISC	
>A>		@	50MG;200MG;200MG	A090833	005	Nov 20, 2012	Aug DISC	
			STALEVO 125					
>D>	AB	+	ORION PHARMA	31.25MG;200MG;125MG	N021485	006	Aug 29, 2008	Aug CTEC
>A>		+		31.25MG;200MG;125MG	N021485	006	Aug 29, 2008	Aug CTEC
			STALEVO 200					
>D>	AB	+	ORION PHARMA	50MG;200MG;200MG	N021485	004	Aug 02, 2007	Aug CTEC
>A>		+		50MG;200MG;200MG	N021485	004	Aug 02, 2007	Aug CTEC
			STALEVO 50					
>D>	AB	+	ORION PHARMA	12.5MG;200MG;50MG	N021485	001	Jun 11, 2003	Aug CTEC
>A>		+		12.5MG;200MG;50MG	N021485	001	Jun 11, 2003	Aug CTEC
			STALEVO 75					
>D>	AB	+	ORION PHARMA	18.75MG;200MG;75MG	N021485	005	Aug 29, 2008	Aug CTEC
>A>		+		18.75MG;200MG;75MG	N021485	005	Aug 29, 2008	Aug CTEC

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE;ORAL

CARBIDOPA AND LEVODOPA

AB		ALEMBIC PHARMS LTD	25MG;100MG	A210341	001	Jun 05, 2019	May NEWA
AB			50MG;200MG	A210341	002	Jun 05, 2019	May NEWA

CARBINOXAMINE MALEATE

SOLUTION;ORAL

CARBINOXAMINE MALEATE

!	MIKART	4MG/5ML	A040458	001	Apr 25, 2003	Jun CTEC
@	VINTAGE PHARMS	4MG/5ML	A040814	001	Feb 26, 2008	Jun DISC

TABLET;ORAL

CARBINOXAMINE MALEATE

!	MIKART	6MG	A207484	001	May 31, 2016	Mar CHRS
---	--------	-----	---------	-----	--------------	----------

CARBOPLATIN

INJECTABLE;INTRAVENOUS

CARBOPLATIN

AP		ACCORD HLTHCARE	50MG/5ML (10MG/ML)	A206775	001	Feb 09, 2017	May CDFR
AP			150MG/15ML (10MG/ML)	A206775	002	Feb 09, 2017	May CDFR
AP			450MG/45ML (10MG/ML)	A206775	003	Feb 09, 2017	May CDFR
AP			600MG/60ML (10MG/ML)	A206775	004	Feb 09, 2017	May CDFR
		@ ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Mar CDFR
		@	150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Mar CDFR
		@	450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Mar CDFR
		@	600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Mar CDFR
AP		AKORN	50MG/5ML (10MG/ML)	A090475	001	Jul 29, 2009	May CDFR
AP			150MG/15ML (10MG/ML)	A090475	002	Jul 29, 2009	May CDFR
AP			450MG/45ML (10MG/ML)	A090475	003	Jul 29, 2009	May CDFR
AP			600MG/60ML (10MG/ML)	A091268	002	Jul 28, 2010	May CDFR
AP		CIPLA LTD	50MG/5ML (10MG/ML)	A077861	001	Jan 18, 2007	May CDFR
AP			150MG/15ML (10MG/ML)	A077861	002	Jan 18, 2007	May CDFR
AP			450MG/45ML (10MG/ML)	A077861	003	Jan 18, 2007	May CDFR
AP			600MG/60ML (10MG/ML)	A077861	004	Jan 18, 2007	May CDFR
AP		EUGIA PHARMA	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	May CDFR
AP			150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	May CDFR
AP			450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	May CDFR
AP		FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077432	001	Sep 29, 2006	May CDFR
AP			150MG/15ML (10MG/ML)	A077432	002	Sep 29, 2006	May CDFR
AP			450MG/45ML (10MG/ML)	A077432	003	Sep 29, 2006	May CDFR
		@	50MG/5ML (10MG/ML)	A077247	001	Oct 21, 2004	Mar CDFR
		@	50MG/5ML (10MG/ML)	A077266	001	Feb 15, 2006	Mar CDFR
		@	150MG/15ML (10MG/ML)	A077247	002	Oct 21, 2004	Mar CDFR
		@	150MG/15ML (10MG/ML)	A077266	002	Feb 15, 2006	Mar CDFR
AP			450MG/45ML (10MG/ML)	A077247	003	Oct 21, 2004	Mar CDFR
AP			450MG/45ML (10MG/ML)	A077266	003	Feb 15, 2006	May CDFR
AP			600MG/60ML (10MG/ML)	A077266	004	Feb 15, 2006	May CDFR
AP		GLAND PHARMA LTD	150MG/15ML (10MG/ML)	A207324	002	Feb 15, 2017	May CDFR
AP			450MG/45ML (10MG/ML)	A207324	003	Feb 15, 2017	May CDFR
AP			600MG/60ML (10MG/ML)	A207324	004	Feb 15, 2017	May CDFR
AP		HONG KONG	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005	May CDFR
AP			150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005	May CDFR
AP			450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005	May CDFR
AP			600MG/60ML (10MG/ML)	A077096	004	Jun 03, 2013	May CDFR

INJECTABLE; INTRAVENOUS
CARBOPLATIN

AP		HOSPIRA	50MG/5ML (10MG/ML)	A076517	001	Oct 14, 2004	May CDFR
AP			150MG/15ML (10MG/ML)	A076517	002	Oct 14, 2004	May CDFR
AP			450MG/45ML (10MG/ML)	A076517	003	Oct 14, 2004	May CDFR
AP			600MG/60ML (10MG/ML)	A077059	001	Nov 23, 2004	May CDFR
AP		INGENUS PHARMS LLC	50MG/5ML (10MG/ML)	A208487	001	Apr 26, 2017	May CDFR
AP			150MG/15ML (10MG/ML)	A208487	002	Apr 26, 2017	May CDFR
AP			450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	May CDFR
AP			600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	May CDFR
		@ MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007	Apr CDFR
		@	150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007	Apr CDFR
		@	450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007	Apr CDFR
AP		MYLAN LABS LTD	50MG/5ML (10MG/ML)	A091063	001	Nov 09, 2011	May CDFR
AP			150MG/15ML (10MG/ML)	A091063	002	Nov 09, 2011	May CDFR
AP			450MG/45ML (10MG/ML)	A091063	003	Nov 09, 2011	May CDFR
AP			600MG/60ML (10MG/ML)	A091063	004	Nov 09, 2011	May CDFR
		@	1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011	Mar CDFR
AP	!	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077269	001	Oct 14, 2004	May CDFR
		@	50MG/5ML (10MG/ML)	A077679	001	Feb 25, 2009	Mar CDFR
AP	!		150MG/15ML (10MG/ML)	A077269	002	Oct 14, 2004	May CDFR
		@	150MG/15ML (10MG/ML)	A077679	002	Feb 25, 2009	Mar CDFR
AP	!		450MG/45ML (10MG/ML)	A077269	003	Oct 14, 2004	May CDFR
		@	450MG/45ML (10MG/ML)	A077679	003	Feb 25, 2009	Mar CDFR
AP	!		600MG/60ML (10MG/ML)	A077269	004	Dec 28, 2007	May CDFR
AP		PLIVA LACHEMA	50MG/5ML (10MG/ML)	A078631	001	Dec 02, 2008	May CDFR
AP			150MG/15ML (10MG/ML)	A078631	002	Dec 02, 2008	May CDFR
AP			450MG/45ML (10MG/ML)	A078631	003	Dec 02, 2008	May CDFR
AP			600MG/60ML (10MG/ML)	A078631	004	Dec 02, 2008	May CDFR
AP		SANDOZ INC	50MG/5ML (10MG/ML)	A078280	001	May 08, 2008	May CDFR
AP			150MG/15ML (10MG/ML)	A078280	002	May 08, 2008	May CDFR
AP			450MG/45ML (10MG/ML)	A078280	003	May 08, 2008	May CDFR
AP		SUN PHARM	50MG/5ML (10MG/ML)	A077926	001	Sep 19, 2008	May CDFR
AP			150MG/15ML (10MG/ML)	A077926	002	Sep 19, 2008	May CDFR
AP			450MG/45ML (10MG/ML)	A077926	003	Sep 19, 2008	May CDFR
		@ TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389	001	Mar 30, 2007	Mar CDFR
		@	150MG/15ML (10MG/ML)	A077389	002	Mar 30, 2007	Mar CDFR
		@	450MG/45ML (10MG/ML)	A077389	003	Mar 30, 2007	Mar CDFR
AP	!	TEVA PHARMS USA	50MG/5ML (10MG/ML)	A077139	001	Sep 21, 2005	May CDFR
AP	!		150MG/15ML (10MG/ML)	A077139	002	Sep 21, 2005	May CDFR
AP	!		450MG/45ML (10MG/ML)	A077139	003	Sep 21, 2005	May CDFR
AP	!		600MG/60ML (10MG/ML)	A077139	004	Sep 21, 2005	May CDFR
AP		WEST-WARD PHARMS INT	50MG/5ML (10MG/ML)	A077244	001	Oct 15, 2004	May CDFR
AP			150MG/15ML (10MG/ML)	A077244	002	Oct 15, 2004	May CDFR
AP			450MG/45ML (10MG/ML)	A077244	003	Oct 15, 2004	May CDFR
AP			600MG/60ML (10MG/ML)	A077244	004	Jan 20, 2006	May CDFR
		PARAPLATIN					
		+ @ CORDENPHARMA	50MG/5ML (10MG/ML)	N020452	001	Jul 14, 2003	Mar CDFR
		+ @	150MG/15ML (10MG/ML)	N020452	002	Jul 14, 2003	Mar CDFR
		+ @	450MG/45ML (10MG/ML)	N020452	003	Jul 14, 2003	Mar CDFR
		+ @	600MG/60ML (10MG/ML)	N020452	004	Jan 15, 2004	Mar CDFR

INJECTABLE; IV (INFUSION)
CARBOPLATIN

AP		GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A207324	001	Feb 15, 2017	May CDFR
AP		HONG KONG	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005	Feb CAHN
AP			150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005	Feb CAHN
AP			450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005	Feb CAHN
AP			600MG/60ML (10MG/ML)	A077096	004	Jun 03, 2013	Feb CAHN
		@ MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007	Mar DISC
		@	150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007	Mar DISC
		@	450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007	Mar DISC

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION
CARBOPROST TROMETHAMINE

AP		DR REDDYS LABS LTD	EQ 0.25MG BASE/ML	A211941	001	Jul 02, 2019	Jun NFTG
		HEMABATE					
AP	+	PHARMACIA AND UPJOHN	EQ 0.25MG BASE/ML	N017989	001		Jun CFTG

CARFILZOMIB

		POWDER; INTRAVENOUS				
>A>		CARFILZOMIB				
>A>	AP	DR REDDYS	60MG/VIAL	A209422	001	Sep 09, 2019 Aug NFTG
		KYPROLIS				
>D>		+! ONYX THERAP	60MG/VIAL	N202714	001	Jul 20, 2012 Aug CFTG
>A>	AP	+!	60MG/VIAL	N202714	001	Jul 20, 2012 Aug CFTG

CARGLUMIC ACID

		TABLET; ORAL				
		CARBAGLU				
		+! RECORDATI RARE	200MG	N022562	001	Mar 18, 2010 May CAHN

CARISOPRODOL

		TABLET; ORAL				
		CARISOPRODOL				
>D>		@ ALLIED	350MG	A040245	001	Sep 08, 1997 Aug CMFD
>A>	AA		350MG	A040245	001	Sep 08, 1997 Aug CMFD
		@	350MG	A040245	001	Sep 08, 1997 Jun CAHN
		@ VINTAGE PHARMS	350MG	A040245	001	Sep 08, 1997 Feb DISC

CARMUSTINE

		INJECTABLE; INJECTION				
		CARMUSTINE				
AP		STI PHARMA LLC	100MG/VIAL	A209278	001	Apr 02, 2019 Mar NEWA

CARTEOLOL HYDROCHLORIDE

		SOLUTION/DROPS; OPHTHALMIC				
		CARTEOLOL HYDROCHLORIDE				
		@ BAUSCH AND LOMB	1%	A075546	001	Jan 20, 2000 May DISC
		! SANDOZ INC	1%	A075476	001	Jan 03, 2000 May CTEC

CARVEDILOL

		TABLET; ORAL				
		CARVEDILOL				
>D>	AB	APOTEX INC	3.125MG	A078165	001	Sep 05, 2007 Aug CAHN
>D>	AB		6.25MG	A078165	002	Sep 05, 2007 Aug CAHN
>D>	AB		12.5MG	A078165	003	Sep 05, 2007 Aug CAHN
>D>	AB		25MG	A078165	004	Sep 05, 2007 Aug CAHN
>A>	AB	RUBICON	3.125MG	A078165	001	Sep 05, 2007 Aug CAHN
>A>	AB		6.25MG	A078165	002	Sep 05, 2007 Aug CAHN
>A>	AB		12.5MG	A078165	003	Sep 05, 2007 Aug CAHN
>A>	AB		25MG	A078165	004	Sep 05, 2007 Aug CAHN

CASPOFUNGIN ACETATE

		POWDER; INTRAVENOUS				
		CASPOFUNGIN ACETATE				
		@ CIPLA	50MG/VIAL	A209489	001	Jul 12, 2018 Jan DISC
		@	70MG/VIAL	A209489	002	Jul 12, 2018 Jan DISC

CEFAZOLIN SODIUM

		INJECTABLE; INJECTION				
		ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER				
>D>		@ BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566	003	Jun 08, 1983 Aug CRLD
>A>		+ @	EQ 10MG BASE/ML	N050566	003	Jun 08, 1983 Aug CRLD
>D>		@	EQ 20MG BASE/ML	N050566	004	Jun 08, 1983 Aug CRLD
>A>		+ @	EQ 20MG BASE/ML	N050566	004	Jun 08, 1983 Aug CRLD
		ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
>D>		@ BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566	001	Jun 08, 1983 Aug CRLD
>A>		+ @	EQ 10MG BASE/ML	N050566	001	Jun 08, 1983 Aug CRLD
>D>		@	EQ 20MG BASE/ML	N050566	002	Jun 08, 1983 Aug CRLD
>A>		+ @	EQ 20MG BASE/ML	N050566	002	Jun 08, 1983 Aug CRLD

CEFIXIME

		FOR SUSPENSION; ORAL				
		CEFIXIME				
		@ SANDOZ INC	100MG/5ML	A206144	001	Nov 17, 2017 Feb DISC
		@	200MG/5ML	A206144	002	Nov 17, 2017 Feb DISC
		SUPRAX				
AB		! LUPIN PHARMS	200MG/5ML	A065355	001	Apr 10, 2007 Apr CHRS

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL

CEFPODOXIME PROXETIL

AUROBINDO PHARMA LTD	EQ 50MG BASE/5ML	A065409	001	Jun 08, 2007	Jan CTEC
!	EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007	Jan CHRS
	EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007	Jan CTEC
@ SANDOZ	EQ 50MG BASE/5ML	A090031	001	Jan 14, 2009	Jan DISC
@	EQ 100MG BASE/5ML	A090031	002	Jan 14, 2009	Jan DISC

CELECOXIB

CAPSULE;ORAL

CELECOXIB

AB	QINGDAO BAHEAL PHARM	50MG	A208856	001	Aug 07, 2019	Jul NEWA
AB		100MG	A208856	002	Aug 07, 2019	Jul NEWA
AB		200MG	A208856	003	Aug 07, 2019	Jul NEWA
AB		400MG	A208856	004	Aug 07, 2019	Jul NEWA

CEPHALEXIN

FOR SUSPENSION;ORAL

CEPHALEXIN

AB	ALKEM LABS LTD	EQ 125MG BASE/5ML	A210221	001	Mar 26, 2019	Mar NEWA
AB		EQ 250MG BASE/5ML	A210221	002	Mar 26, 2019	Mar NEWA

CERITINIB

CAPSULE;ORAL

ZYKADIA

+ @	NOVARTIS PHARMS CORP	150MG	N205755	001	Apr 29, 2014	Jun DISC
-----	----------------------	-------	---------	-----	--------------	----------

TABLET;ORAL

ZYKADIA

+!	NOVARTIS PHARMS CORP	150MG	N211225	001	Mar 18, 2019	Mar NEWA
----	----------------------	-------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

>A> AA	@ LANNETT CO INC	5MG/5ML	A078496	001	Sep 25, 2009	May DISC
	MLV	5MG/5ML	A090191	001	Nov 12, 2009	Aug CAHN
	@ PD PARTNERS	5MG/5ML	A078412	001	Jun 18, 2008	May CAHN
AA	! PERRIGO PHARMS CO	5MG/5ML	A078398	001	Jun 17, 2008	May CAHN
>D> AA	SAPTALIS PHARMS	5MG/5ML	A090191	001	Nov 12, 2009	Aug CAHN
AA	TORRENT	5MG/5ML	A078870	001	Apr 27, 2009	Jan CAHN

CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

OINTMENT;TOPICAL

ELASE-CHLOROMYCETIN

>D>	@ PARKE DAVIS	10MG/GM;666 UNITS/GM;1 UNITS/GM	N050294	001		Aug CRLD
>A>	+ @	10MG/GM;666 UNITS/GM;1 UNITS/GM	N050294	001		Aug CRLD

CHLORDIAZEPOXIDE HYDROCHLORIDE

INJECTABLE;INJECTION

LIBRIUM

@ BAUSCH	100MG/AMP	N012301	001		Mar CAHN
----------	-----------	---------	-----	--	----------

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

CHLORHEXIDINE GLUCONATE

AT	PD PARTNERS	0.12%	A074522	001	Dec 15, 1995	Jun CAHN
----	-------------	-------	---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

>D>	AA	ACELLA	4MG/5ML;5MG/5ML	A206891	001	Jun 09, 2017	Aug DISC
>A>		@	4MG/5ML;5MG/5ML	A206891	001	Jun 09, 2017	Aug DISC
>D>		VITUZ					
>D>	AA	+! PERSION	4MG/5ML;5MG/5ML	N204307	001	Feb 20, 2013	Aug DISC
>A>		+ @	4MG/5ML;5MG/5ML	N204307	001	Feb 20, 2013	Aug DISC
	AA	+!	4MG/5ML;5MG/5ML	N204307	001	Feb 20, 2013	Apr CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	!	PADDOCK LLC	4MG/5ML; 5MG/5ML; 60MG/5ML	A204627	001	Apr 29, 2014	Jun CHRS
	@	TORRENT	4MG/5ML; 5MG/5ML; 60MG/5ML	A206660	001	May 15, 2017	Jan CAHN
		ZUTRIPRO					
	+	@ PERSION	4MG/5ML; 5MG/5ML; 60MG/5ML	N022439	001	Jun 08, 2011	Jul DISC
AA	+	!	4MG/5ML; 5MG/5ML; 60MG/5ML	N022439	001	Jun 08, 2011	Apr CAHN

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB		UPSHER SMITH LABS	10MG	A083386	001		Jul CAHN
AB	!		25MG	A084112	001		Jul CAHN
AB			50MG	A084113	001		Jul CAHN
AB	!		100MG	A084114	001		Jul CAHN
AB			200MG	A084115	001		Jul CAHN

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

	@	MYLAN	100MG	A088549	002	Jun 01, 1984	May DISC
	@		250MG	A088549	001	Jun 01, 1984	May DISC

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB		AMNEAL PHARMS CO	25MG	A207204	001	Jul 01, 2019	Jun NEWA
AB			50MG	A207204	002	Jul 01, 2019	Jun NEWA
AB		INVATECH PHARMA	25MG	A211063	001	Feb 26, 2019	Feb NEWA
AB			50MG	A211063	002	Feb 26, 2019	Feb NEWA
AB		UNICHEM LABS LTD	25MG	A211627	001	Aug 06, 2019	Jul NEWA
AB			50MG	A211627	002	Aug 06, 2019	Jul NEWA
AB		ZYDUS PHARMS	25MG	A207813	001	May 10, 2019	Apr NEWA
AB			50MG	A207813	002	May 10, 2019	Apr NEWA

CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

AP		DECATUR	4-33.1mCi/ML	A206319	001	Nov 13, 2015	Apr CAHN
----	--	---------	--------------	---------	-----	--------------	----------

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

AB		AUROBINDO PHARMA LTD	EQ 45MG FENOFIBRIC ACID	A212598	001	Jul 25, 2019	Jul NEWA
AB			EQ 135MG FENOFIBRIC ACID	A212598	002	Jul 25, 2019	Jul NEWA
AB		GRAVITI PHARMS	EQ 45MG FENOFIBRIC ACID	A211626	001	Jul 18, 2019	Jul NEWA
AB			EQ 135MG FENOFIBRIC ACID	A211626	002	Jul 18, 2019	Jul NEWA
	@	MYLAN PHARMS INC	EQ 45MG FENOFIBRIC ACID	A200913	001	Mar 25, 2013	May DISC
	@		EQ 135MG FENOFIBRIC ACID	A200913	002	Mar 25, 2013	May DISC
AB		TWI PHARMS	EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Jun NEWA
AB			EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Jun NEWA

CHROMIC PHOSPHATE P-32

INJECTABLE; INJECTION

PHOSPHOCOL P32

	@	CURIUM	5mCi/ML	N017084	001		Jan CAHN
--	---	--------	---------	---------	-----	--	----------

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

+	!	COVIS PHARMA BV	0.08MG/INH	N021658	002	Jan 10, 2008	Mar CAHN
+	!		0.16MG/INH	N021658	003	Jan 10, 2008	Mar CAHN

AEROSOL, METERED; NASAL

ZETONNA

+	!	COVIS PHARMA BV	0.037MG/INH	N202129	001	Jan 20, 2012	Mar CAHN
---	---	-----------------	-------------	---------	-----	--------------	----------

SPRAY, METERED; NASAL

OMNARIS

+	!	COVIS PHARMA BV	0.05MG/INH	N022004	001	Oct 20, 2006	Mar CAHN
---	---	-----------------	------------	---------	-----	--------------	----------

CICLOPIROXCREAM; TOPICAL
CICLOPIROX

AB	PERRIGO ISRAEL	0.77%	A077364	001	Mar 03, 2006	May CAHN
----	----------------	-------	---------	-----	--------------	----------

SHAMPOO; TOPICAL
LOPROX

AT	+! BAUSCH	1%	N021159	001	Feb 28, 2003	Apr CAHN
----	-----------	----	---------	-----	--------------	----------

SOLUTION; TOPICAL
CICLOPIROX

AT	ACELLA	8%	A078172	001	Sep 18, 2007	May CAHN
>A> AT	ANDA REPOSITORY	8%	A077687	001	Sep 18, 2007	Aug CAHN
>D> AT	TOLMAR	8%	A077687	001	Sep 18, 2007	Aug CAHN

CILASTATIN SODIUM; IMIPENEM; RELEBACTAMPOWDER; INTRAVENOUS
RECARBIO

+!	MSD MERCK CO	EQ 500MG BASE/VIAL; 500MG/VIAL; 250MG/VIAL	N212819	001	Jul 16, 2019	Jul NEWA
----	--------------	---	---------	-----	--------------	----------

CILOSTAZOLTABLET; ORAL
CILOSTAZOL

>D> AB	FRONTIDA BIOPHARM	50MG	A077208	002	Mar 29, 2006	Aug CAHN
>D> AB		100MG	A077208	001	Mar 29, 2006	Aug CAHN
>A> AB	SLATE	50MG	A077208	002	Mar 29, 2006	Aug CAHN
>A> AB		100MG	A077208	001	Mar 29, 2006	Aug CAHN

CIMETIDINETABLET; ORAL
CIMETIDINE

AB	HIKMA	200MG	A074890	001	Dec 18, 1998	Jun CAHN
AB		300MG	A074890	002	Dec 18, 1998	Jun CAHN
AB		400MG	A074890	003	Dec 18, 1998	Jun CAHN
AB		800MG	A074890	004	Dec 18, 1998	Jun CAHN

CIMETIDINE HYDROCHLORIDESOLUTION; ORAL
CIMETIDINE HYDROCHLORIDE

@	PD PARTNERS	EQ 300MG BASE/5ML	A075560	001	Mar 15, 2000	May CAHN
---	-------------	-------------------	---------	-----	--------------	----------

CINACALCET HYDROCHLORIDETABLET; ORAL
CINACALCET HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 30MG BASE	A210570	001	May 17, 2019	May NEWA
AB		EQ 60MG BASE	A210570	002	May 17, 2019	May NEWA
AB		EQ 90MG BASE	A210570	003	May 17, 2019	May NEWA
AB	LUPIN LTD	EQ 30MG BASE	A210548	001	Jun 28, 2019	Jun NEWA
AB		EQ 60MG BASE	A210548	002	Jun 28, 2019	Jun NEWA
AB		EQ 90MG BASE	A210548	003	Jun 28, 2019	Jun NEWA

CIPROFLOXACININJECTABLE; INJECTION
CIPROFLOXACIN

@	DR REDDYS	200MG/20ML (10MG/ML)	A077782	001	Aug 28, 2006	May CAHN
@		400MG/40ML (10MG/ML)	A077782	002	Aug 28, 2006	May CAHN

CIPROFLOXACIN HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
CIPROFLOXACIN HYDROCHLORIDE

@	RUBICON	EQ 0.3% BASE	A075928	001	Jun 09, 2004	Jul CAHN
---	---------	--------------	---------	-----	--------------	----------

TABLET; ORAL
CIPROFLOXACIN HYDROCHLORIDE

AB	CHARTWELL MOLECULES	EQ 250MG BASE	A076896	001	Nov 04, 2004	Jul CAHN
AB		EQ 500MG BASE	A076896	002	Nov 04, 2004	Jul CAHN
AB		EQ 750MG BASE	A076896	003	Nov 04, 2004	Jul CAHN

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

	!	ANCHEN PHARMS	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	May CTEC
AB	!		212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	May CHRS
AB	!		425.2MG;EQ 574.9MG BASE	A078166	001	Nov 27, 2007	May CHRS
	@	ANI PHARMS INC	212.6MG;EQ 287.5MG BASE	A077417	001	Nov 30, 2010	May CAHN
	@		425.2MG;EQ 574.9MG BASE	A077809	001	Nov 30, 2010	May CAHN
	@	MYLAN PHARMS INC	212.6MG;EQ 287.5MG BASE	A078183	001	Mar 22, 2007	May DISC
	@		425.2MG;EQ 574.9MG BASE	A078183	002	Mar 22, 2007	May DISC

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

	@	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205873	001	Jun 16, 2017	Feb DISC
AP		NANJING KING-FRIEND	EQ 2MG BASE/ML	A211668	001	Apr 25, 2019	Apr NEWA
AP			EQ 2MG BASE/ML	A211669	001	Apr 25, 2019	Apr NEWA
AP			EQ 10MG BASE/ML	A211668	002	Apr 25, 2019	Apr NEWA
AP		SOMERSET THERAPS LLC	EQ 2MG BASE/ML	A209132	001	Apr 24, 2019	Apr NEWA
		CISATRACURIUM BESYLATE PRESERVATIVE FREE					
	@	ACCORD HLTHCARE	EQ 2MG BASE/ML	A205872	001	Jun 16, 2017	Feb DISC
	@		EQ 10MG BASE/ML	A205872	002	Jun 16, 2017	Feb DISC
AP		SOMERSET THERAPS LLC	EQ 2MG BASE/ML	A206791	001	Feb 20, 2019	Feb NEWA
AP			EQ 10MG BASE/ML	A206791	002	Feb 20, 2019	Feb NEWA
		NIMBEX PRESERVATIVE FREE					
AP	+	ABBVIE	EQ 10MG BASE/ML	N020551	002	Dec 15, 1995	Feb CTEC

CITALOPRAM HYDROBROMIDE

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE

	@	PD PARTNERS	EQ 10MG BASE/5ML	A077601	001	Nov 15, 2005	May CAHN
		CITALOPRAM HYDROBROMIDE					
	@	HERITAGE PHARMA	EQ 10MG BASE	A077033	001	Oct 28, 2004	May CAHN
	@		EQ 10MG BASE	A077213	001	Mar 31, 2006	May CAHN
AB			EQ 10MG BASE	A077232	001	Oct 31, 2005	May CAHN
	@		EQ 20MG BASE	A077033	002	Oct 28, 2004	May CAHN
	@		EQ 20MG BASE	A077213	002	Mar 31, 2006	May CAHN
AB			EQ 20MG BASE	A077232	002	Oct 31, 2005	May CAHN
	@		EQ 40MG BASE	A077033	003	Oct 28, 2004	May CAHN
	@		EQ 40MG BASE	A077213	003	Mar 31, 2006	May CAHN
AB			EQ 40MG BASE	A077232	003	Oct 31, 2005	May CAHN

CLADRIBINE

TABLET;ORAL

MAVENCLAD

	+	EMD SERONO INC	10MG	N022561	001	Mar 29, 2019	Mar NEWA
--	---	----------------	------	---------	-----	--------------	----------

CLARITHROMYCIN

TABLET;ORAL

CLARITHROMYCIN

AB		AJANTA PHARMA LTD	250MG	A206714	001	Apr 25, 2019	Apr NEWA
AB			500MG	A206714	002	Apr 25, 2019	Apr NEWA
>D> AB		APOTEX CORP	250MG	A065384	001	Aug 20, 2007	Aug CAHN
>D> AB			500MG	A065384	002	Aug 20, 2007	Aug CAHN
>A> AB		CHARTWELL	250MG	A065384	001	Aug 20, 2007	Aug CAHN
>A> AB			500MG	A065384	002	Aug 20, 2007	Aug CAHN
AB		STRIDES PHARMA	250MG	A202710	001	Jun 10, 2013	Feb CAHN
AB			500MG	A202710	002	Jun 10, 2013	Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

CLARITHROMYCIN

AB		NOSTRUM LABS INC	500MG	A203243	001	Feb 29, 2016	Jul CAHN
----	--	------------------	-------	---------	-----	--------------	----------

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

	@	MYLAN	EQ 75MG BASE/5ML	A203063	001	May 25, 2016	Mar DISC
--	---	-------	------------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE

GEL;TOPICAL							
CLINDAGEL							
BT	+! BAUSCH	EQ 1% BASE	N050782	001	Nov 27, 2000	May	CAHN
SOLUTION;TOPICAL							
CLINDAMYCIN PHOSPHATE							
AT	ENCUBE ETHICALS	EQ 1% BASE	A209914	001	Jan 28, 2019	Jan	NEWA

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL							
VELTIN							
BX	+! ALMIRALL	1.2%;0.025%	N050803	001	Jul 16, 2010	Feb	CAHN

CLOBAZAM

SUSPENSION;ORAL							
CLOBAZAM							
AB	TARO	2.5MG/ML	A210978	001	Apr 15, 2019	Apr	NEWA
AB	VISTAPHARM	2.5MG/ML	A210746	001	Jul 10, 2019	Jun	NEWA
TABLET;ORAL							
CLOBAZAM							
AB	ACCORD HLTHCARE	10MG	A212398	001	May 23, 2019	May	NEWA
AB		20MG	A212398	002	May 23, 2019	May	NEWA
>A> AB	ALKEM LABS LTD	10MG	A212714	001	Sep 06, 2019	Aug	NEWA
>A> AB		20MG	A212714	002	Sep 06, 2019	Aug	NEWA
AB	MICRO LABS	10MG	A211711	001	Jan 30, 2019	Jan	NEWA
AB		20MG	A211711	002	Jan 30, 2019	Jan	NEWA
	@ TARO	10MG	A209440	001	Oct 22, 2018	Jul	DISC
	@	20MG	A209440	002	Oct 22, 2018	Jul	DISC

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL							
CLOBETASOL PROPIONATE							
AB1	GLENMARK PHARMS LTD	0.05%	A210809	001	Feb 15, 2019	Feb	NEWA
>A> AB2		0.05%	A211450	001	Sep 09, 2019	Aug	NEWA
AB2	PERRIGO UK FINCO	0.05%	A201402	001	Aug 14, 2012	May	CAHN
CREAM;TOPICAL							
CLOBETASOL PROPIONATE							
>D> AB1	CHEMO RESEARCH SL	0.05%	A210034	001	Jun 15, 2018	Aug	CAHN
>A> AB1	XIROMED	0.05%	A210034	001	Jun 15, 2018	Aug	CAHN
LOTION;TOPICAL							
CLOBETASOL PROPIONATE							
	@ HI TECH	0.05%	A211348	001	Oct 26, 2018	Jul	DISC
OINTMENT;TOPICAL							
CLOBETASOL PROPIONATE							
AB	ALEOR DERMACEUTICALS	0.05%	A211800	001	Mar 04, 2019	Feb	NEWA
	@ AMNEAL PHARMS LLC	0.05%	A210551	001	Aug 21, 2018	Feb	DISC
>D> AB	CHEMO RESEARCH SL	0.05%	A209701	001	Apr 17, 2018	Aug	CAHN
AB	TELIGENT PHARMA INC	0.05%	A208589	001	Jan 23, 2019	Jan	NEWA
>A> AB	XIROMED	0.05%	A209701	001	Apr 17, 2018	Aug	CAHN
SPRAY;TOPICAL							
CLOBETASOL PROPIONATE							
>D> AT	GLENMARK PHARMS	0.05%	A209004	001	Mar 26, 2018	Aug	CAHN
>A> AT		0.05%	A209004	001	Mar 26, 2018	Aug	CAHN

CLOFARABINE

SOLUTION;INTRAVENOUS							
CLOFARABINE							
AP	ACCORD HLTHCARE	20MG/20ML (1MG/ML)	A212034	001	Feb 22, 2019	Feb	NEWA
	@ HOSPIRA INC	20MG/20ML (1MG/ML)	A210283	001	Dec 27, 2018	Feb	DISC

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL							
CLOMIPRAMINE HYDROCHLORIDE							
AB	MANKIND PHARMA	25MG	A211767	001	Apr 08, 2019	Mar	NEWA
AB		50MG	A211767	002	Apr 08, 2019	Mar	NEWA
AB		75MG	A211767	003	Apr 08, 2019	Mar	NEWA

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

>D>	@ APOTEX INC	0.5MG	A075468	001	Oct 06, 2000	Aug CAHN
>D>	@	1MG	A075468	002	Oct 06, 2000	Aug CAHN
>D>	@	2MG	A075468	003	Oct 06, 2000	Aug CAHN
>A>	@ RUBICON	0.5MG	A075468	001	Oct 06, 2000	Aug CAHN
>A>	@	1MG	A075468	002	Oct 06, 2000	Aug CAHN
>A>	@	2MG	A075468	003	Oct 06, 2000	Aug CAHN

TABLET, ORALLY DISINTEGRATING; ORAL
CLONAZEPAM

AB	ALEMBIC PHARMS LTD	0.125MG	A211033	001	Jun 28, 2019	Jun NEWA
AB		0.25MG	A211033	002	Jun 28, 2019	Jun NEWA
AB		0.5MG	A211033	003	Jun 28, 2019	Jun NEWA
AB		1MG	A211033	004	Jun 28, 2019	Jun NEWA
AB		2MG	A211033	005	Jun 28, 2019	Jun NEWA

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

@ LUITPOLD	1MG/10ML (0.1MG/ML)	A091104	001	Oct 08, 2009	Feb DISC
@	5MG/10ML (0.5MG/ML)	A091104	002	Oct 08, 2009	Feb DISC

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

AB	FRONTIDA BIOPHARM	0.1MG	A070923	003	Sep 04, 1987	Apr CMS1
AB		0.2MG	A070923	002	Sep 04, 1987	Apr CMS1

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE HYDROCHLORIDE

AB1	NOVAST LABS	0.1MG	A209675	001	Mar 05, 2019	Feb NEWA
@ UPSHER SMITH LABS	0.1MG	A211433	001	Oct 12, 2018	May DISC	

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	ANI PHARMS INC	EQ 300MG BASE	A091216	001	May 17, 2012	May CAHN
@ CADILA	EQ 75MG BASE	A201686	001	Oct 10, 2012	Jun DISC	
AB		EQ 75MG BASE	A201686	001	Oct 10, 2012	Apr CAHN
>A> AB	CELLTRION	EQ 75MG BASE	A202266	001	Aug 14, 2012	Aug CAHN
>A> AB		EQ 300MG BASE	A202266	002	Nov 20, 2012	Aug CAHN
@ MYLAN PHARMS INC	EQ 300MG BASE	A077665	002	May 17, 2012	Feb DISC	
>D> AB	WOCKHARDT LTD	EQ 75MG BASE	A202266	001	Aug 14, 2012	Aug CAHN
>D> AB		EQ 300MG BASE	A202266	002	Nov 20, 2012	Aug CAHN

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC	3.75MG	A072514	002	May 11, 1990	Jan CMS1
@	7.5MG	A072514	003	May 11, 1990	Jan CMS1

CLOTTRIMAZOLE

SOLUTION; TOPICAL

CLOTTRIMAZOLE

AT	NOVITIUM PHARMA	1%	A209815	001	Feb 14, 2019	Feb NEWA
AT	TASMAN PHARMA	1%	A212281	001	Jul 25, 2019	Jul NEWA

CLOZAPINE

TABLET; ORAL

CLOZARIL

AB	+ HERITAGE LIFE	50MG	N019758	003	May 20, 2019	May NEWA
AB	+	200MG	N019758	004	May 20, 2019	May NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
FAZACLO ODT

AB	+ JAZZ	12.5MG	N021590	004	May 30, 2007	Jun CAHN
AB	+	25MG	N021590	001	Feb 10, 2004	Jun CAHN
@		50MG	N021590	003	Jun 03, 2005	Jun CAHN
AB	+!	100MG	N021590	002	Feb 10, 2004	Jun CAHN
AB	+	150MG	N021590	005	Jul 09, 2010	Jun CAHN
AB	+	200MG	N021590	006	Jul 09, 2010	Jun CAHN

CODEINE SULFATE

SOLUTION;ORAL							
CODEINE SULFATE							
	@ HIKMA	30MG/5ML	N202245	001	Jun 30, 2011	Mar	CAHN
TABLET;ORAL							
CODEINE SULFATE							
AB	+ HIKMA	15MG	N022402	001	Jul 16, 2009	Mar	CAHN
AB	+	30MG	N022402	002	Jul 16, 2009	Mar	CAHN
AB	+!	60MG	N022402	003	Jul 16, 2009	Mar	CAHN

COLCHICINE

CAPSULE;ORAL							
COLCHICINE							
	@ PAR PHARM INC	0.6MG	A208678	001	Nov 29, 2018	May	DISC
MITIGARE							
	+! HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014	May	CTEC
SOLUTION;ORAL							
GLOPERBA							
	+! AVION PHARMS	0.6MG/5ML	N210942	001	Jan 30, 2019	Jul	CAHN
	+! ROMEG THERAPS LLC	0.6MG/5ML	N210942	001	Jan 30, 2019	Jan	NEWA
TABLET;ORAL							
COLCHICINE							
AB	ALKEM LABS LTD	0.6MG	A211250	001	Feb 08, 2019	Feb	NEWA
AB	AMNEAL PHARMS	0.6MG	A204711	001	Sep 28, 2016	Jan	NEWA
>A> AB	DR REDDYS	0.6MG	A209876	001	Sep 06, 2019	Aug	NEWA
AB	WATSON LABS INC	0.6MG	A204461	001	Jul 31, 2019	Jul	NEWA
	@ ZYDUS PHARMS	0.6MG	A211519	001	Feb 19, 2019	Jul	DISC
AB		0.6MG	A211519	001	Feb 19, 2019	Feb	NEWA
COLCRYST							
AB	+! TAKEDA PHARMS USA	0.6MG	N022352	001	Jul 29, 2009	Jan	CTEC

COLESEVELAM HYDROCHLORIDE

BAR, CHEWABLE;ORAL							
WELCHOL							
	+! DAIICHI SANKYO INC	3.75GM	N210895	001	Apr 03, 2019	Apr	NEWA
FOR SUSPENSION;ORAL							
COLESEVELAM HYDROCHLORIDE							
AB	ALKEM LABS LTD	3.75GM/PACKET	A210316	001	May 06, 2019	Apr	NEWA
	GLENMARK PHARMS LTD	1.875GM/PACKET	A202190	001	Jul 16, 2018	Mar	CTEC
WELCHOL							
	+ @ DAIICHI SANKYO	1.875GM/PACKET	N022362	001	Oct 02, 2009	Mar	DISC

CROMOLYN SODIUM

SOLUTION;INHALATION							
CROMOLYN SODIUM							
	@ HIKMA	10MG/ML	A075333	001	Apr 30, 2002	Jun	CAHN
	@ MYLAN SPECIALITY LP	10MG/ML	A074209	001	Apr 26, 1994	Mar	DISC

CROTAMITON

>D>	CREAM;TOPICAL						
>D>	EURAX						
>D>	+! SUN PHARM INDS INC	10%	N006927	001		Aug	DISC
>A>	+ @	10%	N006927	001		Aug	DISC

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL							
AMRIX							
AB	+ TEVA PHARMS INTL	15MG	N021777	001	Feb 01, 2007	Mar	CTEC
	+	15MG	N021777	001	Feb 01, 2007	Jan	CTEC
AB	+!	30MG	N021777	002	Feb 01, 2007	Mar	CTEC
	+!	30MG	N021777	002	Feb 01, 2007	Jan	CTEC
CYCLOBENZAPRINE HYDROCHLORIDE							
AB	APOTEX INC	15MG	A206703	001	Jul 24, 2018	Feb	CMFD
	@	15MG	A206703	001	Jul 24, 2018	Jan	DISC
AB		30MG	A206703	002	Jul 24, 2018	Feb	CMFD
	@	30MG	A206703	002	Jul 24, 2018	Jan	DISC
AB	TWI PHARMS INC	15MG	A091281	001	Jan 31, 2013	Mar	CMFD
AB		30MG	A091281	002	Jan 31, 2013	Mar	CMFD

TABLET;ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

>A>	AB	ANDA REPOSITORY	5MG	A073541	002	Apr 06, 2006	Aug CAHN
>A>	AB		10MG	A073541	001	May 23, 1995	Aug CAHN
>D>	AB	FRONTIDA BIOPHARM	5MG	A073541	002	Apr 06, 2006	Aug CAHN
>D>	AB		10MG	A073541	001	May 23, 1995	Aug CAHN

CYCLOPHOSPHAMIDE

CAPSULE;ORAL

CYCLOPHOSPHAMIDE

AB	CIPLA	25MG	A211608	001	Jan 18, 2019	Jan NEWA
AB		50MG	A211608	002	Jan 18, 2019	Jan NEWA

CYCLOSERINE

CAPSULE;ORAL

SEROMYCIN

>A>	!	PURDUE	250MG	A060593	001		Aug CAHN
>D>	!	PURDUE GMP	250MG	A060593	001		Aug CAHN

CYCLOSPORINE

CAPSULE;ORAL

CYCLOSPORINE

AB1	APOTEX INC	25MG	A210721	001	Jul 10, 2019	Jun NEWA
AB1		50MG	A210721	002	Jul 10, 2019	Jun NEWA
AB1		100MG	A210721	003	Jul 10, 2019	Jun NEWA
AB1	IVAX SUB TEVA PHARMS	50MG	A065110	001	Mar 29, 2005	Jun CTEC

SOLUTION;ORAL

CYCLOSPORINE

@ PD PARTNERS	100MG/ML	A065167	001	Jan 05, 2005	May CAHN
---------------	----------	---------	-----	--------------	----------

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	PATRIN PHARMA INC	2MG/5ML	A204823	001	Dec 27, 2016	Jul CAHN
AA	QUAGEN	2MG/5ML	A212423	001	May 22, 2019	May NEWA
AA	TORRENT	2MG/5ML	A204823	001	Dec 27, 2016	Jan CAHN

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	BEXIMCO PHARMS USA	4MG	A206676	001	Apr 12, 2019	Apr NEWA
AA	! HERITAGE PHARMA	4MG	A087056	001		Feb CAHN

CYSTEINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

ELCYS

+! EXELA PHARMA SCS LLC	500MG/10ML (50MG/ML)	N210660	001	Apr 16, 2019	Apr NEWA
-------------------------	----------------------	---------	-----	--------------	----------

DACLATASVIR DIHYDROCHLORIDE

TABLET;ORAL

DAKLINZA

+ @ BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843	001	Jul 24, 2015	Jun DISC
+ @	EQ 60MG BASE	N206843	002	Jul 24, 2015	Jun DISC
+ @	EQ 90MG BASE	N206843	003	Apr 13, 2016	Feb DISC

DACTINOMYCIN

INJECTABLE;INJECTION

DACTINOMYCIN

AP	HISUN PHARM HANGZHOU	0.5MG/VIAL	A207232	001	Jul 16, 2019	Jul NEWA
AP	X-GEN PHARMS INC	0.5MG/VIAL	A203999	001	May 20, 2019	May NEWA

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL

DALFAMPRIDINE

AB	MICRO LABS	10MG	A210158	001	Mar 11, 2019	Feb NEWA
AB	SUN PHARM	10MG	A208292	001	May 21, 2019	May NEWA

DANTROLENE SODIUM

INJECTABLE;INJECTION

DANTROLENE SODIUM

@ MYLAN INSTITUTIONAL	20MG/VIAL	A205239	001	Feb 18, 2016	Mar DISC
-----------------------	-----------	---------	-----	--------------	----------

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
QTERNMET XR

+	ASTRAZENECA AB	2.5MG;1GM;EQ 2.5MG BASE	N210874	001	May 02, 2019	May NEWA
+		5MG;1GM;EQ 2.5MG BASE	N210874	002	May 02, 2019	May NEWA
+		5MG;1GM;EQ 5MG BASE	N210874	003	May 02, 2019	May NEWA
+	!	10MG;1GM;EQ 5MG BASE	N210874	004	May 02, 2019	May NEWA

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL
QTERN

+	ASTRAZENECA AB	5MG;EQ 5MG BASE	N209091	002	May 02, 2019	May NEWA
---	----------------	-----------------	---------	-----	--------------	----------

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
DAPIPRAZOLE HYDROCHLORIDE
BARADAINA LLC

0.5%	A204902	001	May 30, 2019	May NEWA
------	---------	-----	--------------	----------

DAPSONE

GEL; TOPICAL
ACZONE

AB	+	ALMIRALL	7.5%	N207154	001	Feb 24, 2016	Jun CFTG
	+		7.5%	N207154	001	Feb 24, 2016	Feb CAHN

DAPSONE

AB		TARO PHARMS	7.5%	A210191	001	Jun 26, 2019	Jun NFTG
----	--	-------------	------	---------	-----	--------------	----------

TABLET; ORAL

DAPSONE

AB		SAI LIFE SCIENCES	100MG	A207165	001	May 08, 2019	Apr NEWA
	@	TARO	25MG	A209430	001	Mar 01, 2019	May DISC
	@		100MG	A209430	002	Mar 01, 2019	May DISC
AB		TARO PHARM	25MG	A209430	001	Mar 01, 2019	Feb NEWA
AB			100MG	A209430	002	Mar 01, 2019	Feb NEWA

DAPTOMYCIN

POWDER; INTRAVENOUS
DAPTOMYCIN

AP		ACCORD HLTHCARE	500MG/VIAL	A211961	001	Jun 24, 2019	Jun NEWA
AP		BE PHARMS	500MG/VIAL	A212513	001	Jun 26, 2019	Jun NEWA
AP		DR REDDYS	500MG/VIAL	A208375	001	May 01, 2019	Apr NEWA
>A> AP		JIANGSU HENGRUI MED	500MG/VIAL	A212022	001	Aug 22, 2019	Aug NEWA
AP		XELLIA PHARMS APS	500MG/VIAL	A206005	001	Jun 15, 2016	Mar CAHN

POWDER; IV (INFUSION)

DAPTOMYCIN

AP		ACCORD HLTHCARE	350MG/VIAL	A212667	001	Jul 12, 2019	Jul NFTG
AP	+	SAGENT PHARMS	350MG/VIAL	N208385	001	Sep 12, 2017	Jul CTEC

DAROLUTAMIDE

TABLET; ORAL
NUBEQA

+	!	BAYER HEALTHCARE	300MG	N212099	001	Jul 30, 2019	Jul NEWA
---	---	------------------	-------	---------	-----	--------------	----------

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET, EXTENDED RELEASE; ORAL
VIEKIRA XR

+	@	ABBVIE INC	EQ 200MG BASE; 8.33MG; 50MG; 33.33MG	N208624	001	Jul 22, 2016	Apr DISC
---	---	------------	--------------------------------------	---------	-----	--------------	----------

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DAUNORUBICIN HYDROCHLORIDE

AP		HISUN PHARM HANGZHOU	EQ 5MG BASE/ML	A208759	001	Apr 12, 2019	Apr NEWA
AP			EQ 20MG BASE/VIAL	A206195	001	Apr 25, 2019	Apr NEWA

DECITABINE

INJECTABLE; INTRAVENOUS
DECITABINE

>A> AP		MSN LABS PVT LTD	50MG/VIAL	A212265	001	Aug 28, 2019	Aug NEWA
AP		WOCKHARDT BIO AG	50MG/VIAL	A209056	001	Apr 09, 2019	Mar NEWA

DEFERIPRONE

TABLET;ORAL							
DEFERIPRONE							
AB	@ TARO PHARM INDS LTD	500MG	A208800	001	Feb 08, 2019	May	DISC
		500MG	A208800	001	Feb 08, 2019	Feb	NFTG
FERRIPROX							
AB	+! APOPHARMA INC	500MG	N021825	001	Oct 14, 2011	May	CTEC
	+!	500MG	N021825	001	Oct 14, 2011	Feb	CFTG
	+	1GM	N021825	002	Jul 25, 2019	Jul	NEWA

DELAVIRDINE MESYLATE

TABLET;ORAL							
RESCRIPTOR							
	+ @ VIIV HLTHCARE	100MG	N020705	001	Apr 04, 1997	Jun	DISC

DESLORATADINE

TABLET;ORAL							
DESLORATADINE							
AB	@ MYLAN PHARMS INC	5MG	A078351	001	Feb 10, 2012	May	DISC
	PERRIGO	5MG	A078361	001	Dec 22, 2011	Apr	CAHN

DESMOPRESSIN ACETATE

INJECTABLE;INJECTION							
DESMOPRESSIN ACETATE							
AP	TEVA PHARMS USA	0.004MG/ML	A074888	001	Oct 15, 1997	Mar	CMFD
SOLUTION;NASAL							
DDAVP							
	+! FERRING PHARMS INC	0.01%	N017922	001		Jul	CTEC
DESMOPRESSIN ACETATE							
	@ SUN PHARM INDS	0.01%	A077212	001	Apr 12, 2012	Jul	DISC
SPRAY, METERED;NASAL							
NOCTIVA							
	+ @ ALYVANT	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Jun	DISC
	+	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Apr	CAHN
	+ @	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Jun	DISC
	+!	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Apr	CAHN
TABLET;ORAL							
DESMOPRESSIN ACETATE							
AB	ABHAI LLC	0.1MG	A210371	001	Jan 28, 2019	Jan	NEWA
AB		0.2MG	A210371	002	Jan 28, 2019	Jan	NEWA
AB	NOVAST LABS	0.1MG	A208357	001	Jun 06, 2019	May	NEWA
AB		0.2MG	A208357	002	Jun 06, 2019	May	NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28							
DESOGEN							
	@ ORGANON USA INC	0.15MG;0.03MG	N020071	002	Dec 10, 1992	May	DISC
DESOGESTREL AND ETHINYL ESTRADIOL							
	@ ACCORD HLTHCARE	0.15MG;0.03MG	A207067	001	Sep 13, 2018	Mar	DISC
ISIBLOOM							
>D> AB	LABS LEON FARMA	0.15MG;0.03MG	A202789	001	Aug 12, 2015	Aug	CAHN
>A> AB	XIROMED	0.15MG;0.03MG	A202789	001	Aug 12, 2015	Aug	CAHN
VOLNEA							
>D> AB	LABS LEON FARMA	0.15MG,N/A;0.02MG,0.01MG	A202689	001	Sep 09, 2016	Aug	CAHN
>A> AB	XIROMED	0.15MG,N/A;0.02MG,0.01MG	A202689	001	Sep 09, 2016	Aug	CAHN

DESONIDE

AEROSOL, FOAM;TOPICAL							
VERDESO							
	+! ALMIRALL	0.05%	N021978	001	Sep 19, 2006	Feb	CAHN
OINTMENT;TOPICAL							
DESONIDE							
AB	ENCUBE ETHICALS	0.05%	A210998	001	Jan 30, 2019	Jan	NEWA
AB	TELIGENT PHARMA INC	0.05%	A212002	001	Mar 12, 2019	Feb	NEWA

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

@ ZYDUS PHARMS	0.25%	A205620	001	Sep 28, 2018	Feb DISC
----------------	-------	---------	-----	--------------	----------

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

+! ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013	May CTEC
+! KHEDEZLA	100MG	N204150	002	Mar 04, 2013	May CTEC
@ OSMOTICA PHARM CORP	50MG	N204683	001	Jul 10, 2013	May DISC
@	100MG	N204683	002	Jul 10, 2013	May DISC

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

AB INTELLIPHARMACEUTICS	EQ 50MG BASE	A204805	001	May 07, 2019	Apr NEWA
AB	EQ 100MG BASE	A204805	002	May 07, 2019	Apr NEWA
AB MYLAN	EQ 50MG BASE	A204095	001	Jun 29, 2015	Jul CMFD
@	EQ 50MG BASE	A204095	001	Jun 29, 2015	May DISC
@	EQ 100MG BASE	A204095	002	Jun 29, 2015	May DISC
@ YICHANG HUMANWELL	EQ 50MG BASE	A210014	001	Oct 01, 2018	Mar DISC
@	EQ 100MG BASE	A210014	002	Oct 01, 2018	Mar DISC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP AUROBINDO PHARMA LTD	EQ 10MG PHOSPHATE/ML	A210967	001	Jun 07, 2019	May NEWA
AP ! FRESSENIUS KABI USA	EQ 4MG PHOSPHATE/ML	A084916	001		Feb CHRS
@ LUITPOLD	EQ 4MG PHOSPHATE/ML	A087440	001	Jul 21, 1982	Feb DISC
AP SOMERSET THERAPS LLC	EQ 10MG PHOSPHATE/ML	A211036	001	May 10, 2019	Apr NEWA
SOLUTION/DROPS; OPHTHALMIC, OTIC					
DEXAMETHASONE SODIUM PHOSPHATE					
! BAUSCH AND LOMB	EQ 0.1% PHOSPHATE	A040069	001	Jul 26, 1996	May CTEC
@ SANDOZ INC	EQ 0.1% PHOSPHATE	A088771	001	Jan 16, 1985	May DISC

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

@ CIPLA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Jul DISC
AP	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A204843	001	Jan 18, 2019	Jan NEWA
SOLUTION; INTRAVENOUS					
DEXMEDETOMIDINE HYDROCHLORIDE					
+ HQ SPCLT PHARMA	EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N206628	003	Jun 22, 2018	Mar CPOT
+	EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N206628	004	Jun 22, 2018	Mar CPOT

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB ALKEM LABS LTD	2.5MG	A212631	001	Jul 19, 2019	Jul NEWA
AB	5MG	A212631	002	Jul 19, 2019	Jul NEWA
AB	10MG	A212631	003	Jul 19, 2019	Jul NEWA
@ TEVA PHARMS	2.5MG	A077107	003	Jan 29, 2007	May DISC
@	5MG	A077107	001	Jan 29, 2007	May DISC
@	10MG	A077107	002	Jan 29, 2007	May DISC

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMPHETAMINE SULFATE

>A> AB	ANDA REPOSITORY	5MG	A205077	001	Jun 21, 2019	Aug CAHN
>A> AB		10MG	A205077	002	Jun 21, 2019	Aug CAHN
>A> AB		15MG	A205077	003	Jun 21, 2019	Aug CAHN
>D> AB	MYLAN	5MG	A206735	001	Jan 27, 2016	Aug DISC
>A>	@	5MG	A206735	001	Jan 27, 2016	Aug DISC
>D> AB		10MG	A206735	002	Jan 27, 2016	Aug DISC
>A>	@	10MG	A206735	002	Jan 27, 2016	Aug DISC
>D> AB		15MG	A206735	003	Jan 27, 2016	Aug DISC

CAPSULE, EXTENDED RELEASE; ORAL
DEXTROAMPHETAMINE SULFATE

>A>	@	15MG	A206735	003	Jan 27, 2016	Aug DISC	
>D>	AB	PII	5MG	A205077	001	Jun 21, 2019	Aug CAHN
	AB		5MG	A205077	001	Jun 21, 2019	Jun NEWA
>D>	AB		10MG	A205077	002	Jun 21, 2019	Aug CAHN
	AB		10MG	A205077	002	Jun 21, 2019	Jun NEWA
>D>	AB		15MG	A205077	003	Jun 21, 2019	Aug CAHN
	AB		15MG	A205077	003	Jun 21, 2019	Jun NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE DM

@ VINTAGE	15MG/5ML; 6.25MG/5ML	A040649	001	Feb 14, 2006	May DISC
-----------	----------------------	---------	-----	--------------	----------

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 224MG/100ML	N018371	003		Jul DISC
-------------------	------------------------	---------	-----	--	----------

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 298MG/100ML	N018371	002		Jul DISC
-------------------	------------------------	---------	-----	--	----------

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

+ @ ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 225MG/100ML	N018365	002	Jul 05, 1983	Jul DISC
---------------------	--------------------------------------	---------	-----	--------------	----------

+ @	5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	006	Mar 28, 1988	Jul DISC
-----	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 300MG/100ML	N018876	001	Jan 17, 1986	Jul DISC
-------------------	--------------------------------------	---------	-----	--------------	----------

@	5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	006	Mar 28, 1988	Jul DISC
---	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 225MG/100ML	N018365	008	Mar 28, 1988	Jul DISC
-------------------	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 300MG/100ML	N018876	007	Mar 28, 1988	Jul DISC
-------------------	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

+ @ ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 225MG/100ML	N018365	009	Mar 28, 1988	Jul DISC
---------------------	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 300MG/100ML	N018876	008	Mar 28, 1988	Jul DISC
-------------------	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	002	Jan 17, 1986	Jul DISC
-------------------	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 225MG/100ML	N018365	003	Jul 05, 1983	Jul DISC
-------------------	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 300MG/100ML	N018876	003	Jan 17, 1986	Jul DISC
-------------------	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 225MG/100ML	N018365	004	Jul 05, 1983	Jul DISC
-------------------	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 300MG/100ML	N018876	004	Mar 28, 1988	Jul DISC
-------------------	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 225MG/100ML	N018365	005	Mar 28, 1988	Jul DISC
-------------------	--------------------------------------	---------	-----	--------------	----------

@	5GM/100ML; 149MG/100ML; 225MG/100ML	N018365	007	Mar 28, 1988	Jul DISC
---	-------------------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@ ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 300MG/100ML	N018876	005	Mar 28, 1988	Jul DISC
-------------------	--------------------------------------	---------	-----	--------------	----------

@	5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	009	Mar 28, 1988	Jul DISC
---	-------------------------------------	---------	-----	--------------	----------

DIAZEPAM

GEL; RECTAL

DIASTAT

+ BAUSCH	2.5MG/0.5ML (5MG/ML)	N020648	001	Jul 29, 1997	Feb CAHN
----------	----------------------	---------	-----	--------------	----------

+ @	5MG/ML (5MG/ML)	N020648	002	Jul 29, 1997	Feb CAHN
-----	-----------------	---------	-----	--------------	----------

+ @	10MG/2ML (5MG/ML)	N020648	003	Jul 29, 1997	Feb CAHN
-----	-------------------	---------	-----	--------------	----------

+ @	15MG/3ML (5MG/ML)	N020648	004	Jul 29, 1997	Feb CAHN
-----	-------------------	---------	-----	--------------	----------

+ @	20MG/4ML (5MG/ML)	N020648	005	Jul 29, 1997	Feb CAHN
-----	-------------------	---------	-----	--------------	----------

DIASTAT ACUDIAL

+ BAUSCH	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005	Feb CAHN
----------	-------------------	---------	-----	--------------	----------

+!	20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005	Feb CAHN
----	-------------------	---------	-----	--------------	----------

INJECTABLE; INJECTION

DIAZEPAM

AP	BELOTECA INC	10MG/2ML (5MG/ML)	A210363	001	Mar 18, 2019	Mar NEWA
----	--------------	-------------------	---------	-----	--------------	----------

AP	! HOSPIRA	10MG/2ML (5MG/ML)	A072079	001	Dec 20, 1988	Mar CTEC
----	-----------	-------------------	---------	-----	--------------	----------

DICLOFENACCAPSULE;ORAL
ZORVOLEX

+	EGALET	18MG	N204592	001	Oct 18, 2013	Feb CAHN
+	!	35MG	N204592	002	Oct 18, 2013	Feb CAHN
+	ZYLA	18MG	N204592	001	Oct 18, 2013	Jul CAHN
+	!	35MG	N204592	002	Oct 18, 2013	Jul CAHN

DICLOFENAC EPOLAMINESYSTEM;TOPICAL
LICART

+	@ IBSA INST BIO	1.3%	N206976	001	Dec 19, 2018	Feb DISC
---	-----------------	------	---------	-----	--------------	----------

DICLOFENAC POTASSIUMTABLET;ORAL
DICLOFENAC POTASSIUM

AB	AMICI	50MG	A076561	001	Mar 18, 2004	May CAHN
----	-------	------	---------	-----	--------------	----------

DICLOFENAC SODIUMGEL;TOPICAL
DICLOFENAC SODIUM

AB	MYLAN	1%	A204306	001	May 06, 2019	Apr NEWA
AB	PERRIGO UK FINCO	1%	A211253	001	May 16, 2019	May NEWA

SOLUTION;INTRAVENOUS
DICLOFENAC SODIUM

@ MYLAN LABS LTD	37.5MG/ML (37.5MG/ML)	A208786	001	Jun 18, 2019	Jul DISC
	37.5MG/ML (37.5MG/ML)	A208786	001	Jun 18, 2019	Jun NEWA

TABLET, EXTENDED RELEASE;ORAL
DICLOFENAC SODIUM

@ MYLAN	100MG	A076152	001	Dec 13, 2001	Jun DISC
---------	-------	---------	-----	--------------	----------

DICYCLOMINE HYDROCHLORIDEINJECTABLE;INJECTION
DICYCLOMINE HYDROCHLORIDE

@ APC PHARMS LLC	10MG/ML	A210979	001	Jul 02, 2018	Feb DISC
AP CUSTOPHARM INC	10MG/ML	A210788	001	Feb 11, 2019	Jan NEWA
AP FRESENIUS KABI USA	10MG/ML	A210257	001	Jan 25, 2019	Jan NEWA
AP NEXUS PHARMS	10MG/ML	A206468	001	Feb 01, 2019	Jan NEWA
AP SLATE	10MG/ML	A207076	001	Nov 02, 2018	Feb CAHN
AP SUNGEN PHARMA	10MG/ML	A212058	001	Apr 26, 2019	Apr NEWA

DIETHYLPROPION HYDROCHLORIDETABLET;ORAL
DIETHYLPROPION HYDROCHLORIDE

AA ! LANNETT CO INC	25MG	A200177	001	Jul 18, 2011	Jul CHRS
TENUATE					
+ @ TEVA BRANDED PHARM	25MG	N011722	002		Jul DISC

TABLET, EXTENDED RELEASE;ORAL
DIETHYLPROPION HYDROCHLORIDE

AB ! LANNETT CO INC	75MG	A091680	001	Oct 24, 2011	Jul CHRS
TENUATE DOSPAN					
+ @ TEVA BRANDED PHARM	75MG	N012546	001		Jul DISC

DIGOXINELIXIR;ORAL
DIGOXIN

+	! HIKMA	0.05MG/ML	N021648	001	Aug 26, 2004	Apr CAHN
---	---------	-----------	---------	-----	--------------	----------

DIHYDROERGOTAMINE MESYLATEINJECTABLE;INJECTION
D.H.E. 45

AP +! BAUSCH	1MG/ML	N005929	001		Apr CAHN	
SPRAY, METERED;NASAL						
MIGRANAL						
+	! BAUSCH	0.5MG/SPRAY	N020148	001	Dec 08, 1997	Apr CAHN
+	! VALEANT	0.5MG/SPRAY	N020148	001	Dec 08, 1997	Jan CPOT

DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
CARDIZEM CD

AB3	+	BAUSCH	120MG	N020062	001	Aug 10, 1992	Feb CAHN
AB3	+		180MG	N020062	002	Dec 27, 1991	Feb CAHN
AB3	+		240MG	N020062	003	Dec 27, 1991	Feb CAHN
AB3	+		300MG	N020062	004	Dec 27, 1991	Feb CAHN
AB3	+		360MG	N020062	005	Aug 24, 1999	Feb CAHN

DILTIAZEM HYDROCHLORIDE

>D>	AB2		APOTEX	120MG	A074943	003	Dec 19, 2000	Aug CTEC
>A>				120MG	A074943	003	Dec 19, 2000	Aug CTEC
	AB2	!		240MG	A074943	001	Aug 06, 1998	May CHRS
>D>	AB2		MYLAN	120MG	A075124	002	Mar 18, 1998	Aug DISC
>A>		@		120MG	A075124	002	Mar 18, 1998	Aug DISC
	AB2			240MG	A075124	001	Mar 18, 1998	May CHRS
	AB3		NOVAST LABS	120MG	A208783	001	Jun 14, 2019	Jun NEWA
	AB3			180MG	A208783	002	Jun 14, 2019	Jun NEWA
	AB3			240MG	A208783	003	Jun 14, 2019	Jun NEWA
	AB3			300MG	A208783	004	Jun 14, 2019	Jun NEWA
	AB3			360MG	A208783	005	Jun 14, 2019	Jun NEWA
		@	PAR PHARM	360MG	A209766	001	May 30, 2018	Mar DISC
			TIAZAC					
	AB4	+	BAUSCH	120MG	N020401	001	Sep 11, 1995	Feb CAHN
	AB4	+		180MG	N020401	002	Sep 11, 1995	Feb CAHN
	AB4	+		240MG	N020401	003	Sep 11, 1995	Feb CAHN
	AB4	+		300MG	N020401	004	Sep 11, 1995	Feb CAHN
	AB4	+		360MG	N020401	005	Sep 11, 1995	Feb CAHN
	AB4	+		420MG	N020401	006	Oct 16, 1998	Feb CAHN

INJECTABLE;INJECTION

DILTIAZEM HYDROCHLORIDE

@ DR REDDYS 5MG/ML

A074894 001 Aug 26, 1997 May CAHN

TABLET;ORAL

CARDIZEM

AB	+	BAUSCH	30MG	N018602	001	Nov 05, 1982	Mar CAHN
AB	+		60MG	N018602	002	Nov 05, 1982	Mar CAHN
AB	+		90MG	N018602	003	Dec 08, 1986	Mar CAHN
AB	+		120MG	N018602	004	Dec 08, 1986	Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

CARDIZEM LA

AB	+	BAUSCH	120MG	N021392	001	Feb 06, 2003	Mar CAHN
AB	+		180MG	N021392	002	Feb 06, 2003	Mar CAHN
AB	+		240MG	N021392	003	Feb 06, 2003	Mar CAHN
AB	+		300MG	N021392	004	Feb 06, 2003	Mar CAHN
AB	+		360MG	N021392	005	Feb 06, 2003	Mar CAHN
AB	+		420MG	N021392	006	Feb 06, 2003	Mar CAHN

DIMETHYL SULFOXIDE

SOLUTION;INTRAVESICAL

DIMETHYL SULFOXIDE

@ MYLAN INSTITUTIONAL 50%
RIMSO-50

A076185 001 Nov 29, 2002 Mar DISC

+! MYLAN INSTITUTIONAL 50%

N017788 001 Mar CTEC

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

! HERITAGE PHARMA 50MG

A080738 001 May CAHN

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

@ DR REDDYS 10MG/ML

A080873 001 May CAHN

@ 50MG/ML

A080873 002 May CAHN

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

@ DR REDDYS 50MG/ML

A080873 003 May CAHN

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

@ DR REDDYS 5MG/ML

A074952 001 Nov 26, 1997 May CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL
DIVALPROEX SODIUM

>A>	AB	CELLTRION	EQ 125MG VALPROIC ACID	A077296	001	Jul 31, 2008	Aug CAHN
>A>	AB		EQ 250MG VALPROIC ACID	A077296	002	Jul 31, 2008	Aug CAHN
>A>	AB		EQ 500MG VALPROIC ACID	A077296	003	Jul 31, 2008	Aug CAHN
>D>	AB	WOCKHARDT	EQ 125MG VALPROIC ACID	A077296	001	Jul 31, 2008	Aug CAHN
>D>	AB		EQ 250MG VALPROIC ACID	A077296	002	Jul 31, 2008	Aug CAHN
>D>	AB		EQ 500MG VALPROIC ACID	A077296	003	Jul 31, 2008	Aug CAHN

DOCETAXEL

INJECTABLE;INJECTION
DOCETAXEL

AP	ACTAVIS LLC	160MG/8ML (20MG/ML)	N203551	004	Sep 21, 2015	Jun NEWA
	@ CIPLA	20MG/2ML (10MG/ML)	A209634	001	Aug 24, 2018	Mar DISC
	@	80MG/8ML (10MG/ML)	A209634	002	Aug 24, 2018	Mar DISC
	@	160MG/16ML (10MG/ML)	A209634	003	Aug 24, 2018	Mar DISC
AP	MYLAN LABS LTD	160MG/8ML (20MG/ML)	A208137	001	Apr 01, 2019	Mar NEWA
AP	SHILPA MEDICARE LTD	20MG/ML (20MG/ML)	A210327	001	May 16, 2019	May NEWA
AP		80MG/4ML (20MG/ML)	A210327	002	May 16, 2019	May NEWA
AP		160MG/8ML (20MG/ML)	A210327	003	May 16, 2019	May NEWA
AP	TEIKOKU PHARMA	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Mar CAHN
AP		80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Mar CAHN
AP		160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Mar CAHN

SOLUTION;INTRAVENOUS
DOCETAXEL

AP	SUN PHARMA GLOBAL	20MG/ML (20MG/ML)	N022534	003	Jan 08, 2019	Jan NEWA
AP		80MG/4ML (20MG/ML)	N022534	004	Jan 08, 2019	Jan NEWA
AP		160MG/8ML (20MG/ML)	N022534	005	Jan 08, 2019	Jan NEWA

DOFETILIDE

CAPSULE;ORAL
DOFETILIDE

AB	AUROBINDO PHARMA LTD	0.125MG	A210740	001	Jan 22, 2019	Jan NEWA
AB		0.25MG	A210740	002	Jan 22, 2019	Jan NEWA
AB		0.5MG	A210740	003	Jan 22, 2019	Jan NEWA

DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL
DOVATO

+	!	VIIV HLTHCARE	EQ 50MG BASE;300MG	N211994	001	Apr 08, 2019	Apr NEWA
---	---	---------------	--------------------	---------	-----	--------------	----------

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL
DONEPEZIL HYDROCHLORIDE

AB	CADILA	5MG	A090100	001	Oct 24, 2012	Mar CAHN
AB		10MG	A090100	002	Oct 24, 2012	Mar CAHN
AB	HERITAGE PHARMA	5MG	A077344	001	May 31, 2011	May CAHN
AB		10MG	A077344	002	May 31, 2011	May CAHN
	@ OSMOTICA PHARM US	23MG	A203114	001	Jan 26, 2016	Mar DISC
AB	STRIDES PHARMA	5MG	A090551	001	May 31, 2011	Apr CAHN
AB		10MG	A090551	002	May 31, 2011	Apr CAHN
	@ SUN PHARM	23MG	A204293	001	Jun 05, 2015	Jul DISC
	@ WOCKHARDT	5MG	A091267	001	May 31, 2011	Jul DISC
	@	10MG	A091267	002	May 31, 2011	Jul DISC

TABLET, ORALLY DISINTEGRATING;ORAL
DONEPEZIL HYDROCHLORIDE

	@ HERITAGE PHARMA	5MG	A078388	002	Nov 26, 2010	May CAHN
	@	10MG	A078388	001	Nov 26, 2010	May CAHN

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE

AT	ALEMBIC PHARMS LTD	EQ 2% BASE	A212639	001	Aug 09, 2019	Jul NEWA
>D>	@ APOTEX INC	EQ 2% BASE	A078395	001	Oct 28, 2008	Aug CAHN
AT	FDC LTD	EQ 2% BASE	A205294	001	Jan 24, 2019	Jan NEWA
	@ LUITPOLD	EQ 2% BASE	A079186	001	Nov 18, 2009	Mar DISC
>A>	@ RUBICON	EQ 2% BASE	A078395	001	Oct 28, 2008	Aug CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT	FDC LTD	EQ 2% BASE;EQ 0.5% BASE	A205295	001	Jun 13, 2019	Jun	NEWA
	@ RUBICON	EQ 2% BASE;EQ 0.5% BASE	A078201	001	Oct 28, 2008	Jul	CAHN
AT	SOMERSET THERAPS LLC	EQ 2% BASE;EQ 0.5% BASE	A207523	001	Jun 25, 2019	Jun	NEWA

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOPRAM

AP	+! HIKMA	20MG/ML	N014879	001		Mar	CAHN
----	----------	---------	---------	-----	--	-----	------

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 10MG BASE	A211603	001	Mar 27, 2019	Mar	NEWA
AB		EQ 25MG BASE	A211603	002	Mar 27, 2019	Mar	NEWA
AB		EQ 50MG BASE	A211603	003	Mar 27, 2019	Mar	NEWA
AB		EQ 75MG BASE	A211603	004	Mar 27, 2019	Mar	NEWA
AB		EQ 100MG BASE	A211603	005	Mar 27, 2019	Mar	NEWA
>A> AB	PAR PHARM	EQ 10MG BASE	A071422	002	Nov 09, 1987	Aug	CMS1
>A> AB		EQ 25MG BASE	A071422	003	Nov 09, 1987	Aug	CMS1
>A> AB		EQ 50MG BASE	A071422	004	Nov 09, 1987	Aug	CMS1
>A> AB		EQ 75MG BASE	A071422	005	Nov 09, 1987	Aug	CMS1
>A> AB		EQ 150MG BASE	A071422	006	Nov 09, 1987	Aug	CMS1

TABLET;ORAL

SILENOR

+	CURRAX	EQ 3MG BASE	N022036	001	Mar 17, 2010	Apr	CAHN
+!		EQ 6MG BASE	N022036	002	Mar 17, 2010	Apr	CAHN
+	PERNIX	EQ 3MG BASE	N022036	001	Mar 17, 2010	Feb	CAHN
+!		EQ 6MG BASE	N022036	002	Mar 17, 2010	Feb	CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

+	@ HOSPIRA INC	10MCG/5ML (2MCG/ML)	N208614	002	Jul 24, 2018	Jun	DISC
---	---------------	---------------------	---------	-----	--------------	-----	------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	HISUN PHARM HANGZHOU	20MG/VIAL	A206062	001	May 13, 2019	Apr	NEWA
----	----------------------	-----------	---------	-----	--------------	-----	------

INJECTABLE, LIPOSOMAL;INJECTION

DOXIL (LIPOSOMAL)

>A> AB	+	BAXTER HLTHCARE CORP	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Aug	CAHN
>A> AB	+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Aug	CAHN
>D> AB	+	JANSSEN RES AND DEV	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Aug	CAHN
>D> AB	+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Aug	CAHN

DOXYCYCLINE

CAPSULE;ORAL

MONODOX

AB	+	ALMIRALL	EQ 50MG BASE	N050641	002	Feb 10, 1992	Feb	CAHN
AB	+		EQ 75MG BASE	N050641	003	Oct 18, 2006	Feb	CAHN
AB	+!		EQ 100MG BASE	N050641	001	Dec 29, 1989	Feb	CAHN

TABLET;ORAL

DOXYCYCLINE

@ MYLAN

@

@

@

EQ 50MG BASE	A065377	001	Nov 07, 2006	Apr	DISC
EQ 75MG BASE	A065377	002	Nov 07, 2006	Apr	DISC
EQ 100MG BASE	A065377	003	Nov 07, 2006	May	DISC
EQ 150MG BASE	A065427	001	Jun 07, 2007	May	DISC

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

ACTICLATE CAP

+	@ ALMIRALL	EQ 75MG BASE	N208253	001	Apr 26, 2016	Feb	CAHN
	DOXYCYCLINE HYCLATE						
@	AJANTA PHARMA LTD	EQ 50MG BASE	A211012	001	Sep 24, 2018	Mar	DISC
@		EQ 100MG BASE	A211012	002	Sep 24, 2018	Mar	DISC
@	MYLAN	EQ 50MG BASE	A062337	001	Mar 29, 1982	Apr	DISC
@		EQ 100MG BASE	A062337	002	Mar 29, 1982	Apr	DISC

TABLET;ORAL
ACTICLATE

AB	+	ALMIRALL	EQ 75MG BASE	N205931	001	Jul 25, 2014	Feb CAHN
AB	+	!	EQ 150MG BASE	N205931	002	Jul 25, 2014	Feb CAHN
DOXYCYCLINE HYCLATE							
AB		APOTEX INC	EQ 75MG BASE	A209243	001	Apr 15, 2019	Apr NEWA
AB			EQ 150MG BASE	A209243	002	Apr 15, 2019	Apr NEWA
AB		CADILA	EQ 100MG BASE	A207773	001	Oct 30, 2017	Feb CAHN
>D>		@ EPIC PHARMA LLC	EQ 20MG BASE	A065182	001	May 13, 2005	Aug CMFD
>A>	AB		EQ 20MG BASE	A065182	001	May 13, 2005	Aug CMFD
AB		HERITAGE PHARMA	EQ 20MG BASE	A065163	001	May 13, 2005	May CAHN
TABLET, DELAYED RELEASE;ORAL							
DOXYCYCLINE HYCLATE							
		@ MYLAN	EQ 75MG BASE	A090431	001	Dec 28, 2010	Jul DISC
		@	EQ 100MG BASE	A090431	002	Dec 28, 2010	Jul DISC
		@	EQ 200MG BASE	A090431	005	May 19, 2016	Jul DISC
		@ ZYDUS PHARMS	EQ 75MG BASE	A206772	001	Dec 21, 2018	May DISC
		@	EQ 100MG BASE	A206772	002	Dec 21, 2018	May DISC
		@	EQ 150MG BASE	A206772	003	Dec 21, 2018	May DISC

DROSPIRENONE

TABLET;ORAL
SLYND

+	!	EXELTIS USA INC	4MG	N211367	001	May 23, 2019	May NEWA
---	---	-----------------	-----	---------	-----	--------------	----------

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL							
>A>	AB	ANDA REPOSITORY	3MG;0.02MG	A203291	001	Jul 18, 2017	Aug CAHN
	AB	HETERO LABS LTD	3MG;0.02MG	A211944	001	Mar 22, 2019	Mar NEWA
>D>	AB	PII	3MG;0.02MG	A203291	001	Jul 18, 2017	Aug CAHN
KYRA							
	AB	SUN PHARM	3MG;0.02MG	A202318	001	Jul 23, 2019	Jul NEWA
LORYNA							
>D>	AB	LABS LEON FARMA	3MG;0.02MG	A079221	001	Mar 28, 2011	Aug CAHN
>A>	AB	XIROMED	3MG;0.02MG	A079221	001	Mar 28, 2011	Aug CAHN
TABLET;ORAL-28							
KEMEYA							
	AB	SUN PHARM	3MG;0.03MG	A202138	001	Mar 13, 2019	Feb NEWA
SYEDA							
>D>	AB	LABS LEON FARMA	3MG;0.03MG	A090114	001	Mar 28, 2011	Aug CAHN
>A>	AB	XIROMED	3MG;0.03MG	A090114	001	Mar 28, 2011	Aug CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL
DULOXETINE HYDROCHLORIDE

AB		AJANTA PHARMA LTD	EQ 40MG BASE	A208706	004	Mar 11, 2019	Feb NEWA
>A>	AB	INVENTIA	EQ 20MG BASE	A202336	001	Oct 28, 2015	Aug CAHN
>A>	AB		EQ 30MG BASE	A202336	002	Oct 28, 2015	Aug CAHN
>A>	AB		EQ 60MG BASE	A202336	003	Oct 28, 2015	Aug CAHN
>D>	AB	INVENTIA HLTHCARE	EQ 20MG BASE	A202336	001	Oct 28, 2015	Aug CAHN
>D>	AB		EQ 30MG BASE	A202336	002	Oct 28, 2015	Aug CAHN
>D>	AB		EQ 60MG BASE	A202336	003	Oct 28, 2015	Aug CAHN
	AB	QINGDAO BAHEAL PHARM	EQ 20MG BASE	A210599	001	Apr 17, 2019	Apr NEWA
	AB		EQ 30MG BASE	A210599	002	Apr 17, 2019	Apr NEWA
	AB		EQ 60MG BASE	A210599	003	Apr 17, 2019	Apr NEWA
>D>	AB	TEVA PHARMS USA	EQ 20MG BASE	A090783	001	Dec 11, 2013	Aug DISC
>A>		@	EQ 20MG BASE	A090783	001	Dec 11, 2013	Aug DISC
>D>	AB		EQ 30MG BASE	A090783	002	Dec 11, 2013	Aug DISC
>A>		@	EQ 30MG BASE	A090783	002	Dec 11, 2013	Aug DISC
>D>	AB		EQ 60MG BASE	A090783	003	Dec 11, 2013	Aug DISC
>A>		@	EQ 60MG BASE	A090783	003	Dec 11, 2013	Aug DISC
>A>	AB	YAOPHARMA CO LTD	EQ 20MG BASE	A207219	001	Aug 16, 2019	Aug NEWA
>A>	AB		EQ 30MG BASE	A207219	002	Aug 16, 2019	Aug NEWA
>A>	AB		EQ 60MG BASE	A207219	003	Aug 16, 2019	Aug NEWA

CAPSULE, DELAYED RELEASE;ORAL
DRIZALMA SPRINKLE

+		SUN PHARMA GLOBAL	EQ 20MG BASE	N212516	001	Jul 19, 2019	Jul NEWA
+			EQ 30MG BASE	N212516	002	Jul 19, 2019	Jul NEWA
+			EQ 40MG BASE	N212516	003	Jul 19, 2019	Jul NEWA
+	!		EQ 60MG BASE	N212516	004	Jul 19, 2019	Jul NEWA

DUTASTERIDE

CAPSULE;ORAL							
DUTASTERIDE							
	@ BRECKENRIDGE	0.5MG	A204705	001	Nov 20, 2015	Jun	DISC
	@	0.5MG	A208227	001	Jun 22, 2018	Jun	DISC
AB	CADILA	0.5MG	A204373	001	Oct 04, 2017	Feb	CAHN

ECONAZOLE NITRATE

CREAM;TOPICAL							
ECONAZOLE NITRATE							
	@ CASI PHARMS INC	1%	A076075	001	Nov 26, 2002	Jun	DISC
AB	! PERRIGO ISRAEL	1%	A076479	001	Jun 23, 2004	May	CAHN

EFAVIRENZ

TABLET;ORAL							
EFAVIRENZ							
	@ AUROBINDO PHARMA LTD	600MG	A077673	001	Sep 21, 2018	Feb	DISC

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL							
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE							
AB	CIPLA	600MG;200MG;300MG	A206894	001	Jun 03, 2019	May	NEWA
	@ TEVA PHARMS USA	600MG;200MG;300MG	A091215	001	Nov 09, 2018	May	DISC

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL							
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE							
	@ MACLEODS PHARMS LTD	400MG;300MG;300MG	N210649	001	Mar 15, 2019	Jun	DISC
		400MG;300MG;300MG	N210649	001	Mar 15, 2019	Mar	NEWA

EFINACONAZOLE

SOLUTION;TOPICAL							
JUBLIA							
+!	BAUSCH	10%	N203567	001	Jun 06, 2014	Feb	CAHN

ELTROMBOPAG OLAMINE

TABLET;ORAL							
PROMACTA							
+	@ NOVARTIS PHARMS CORP	EQ 100MG ACID	N022291	005	Nov 16, 2012	Feb	DISC

EMEDASTINE DIFUMARATE

SOLUTION/DROPS;OPHTHALMIC							
EMADINE							
+	@ NOVARTIS PHARMS CORP	0.05%	N020706	001	Dec 29, 1997	Jul	DISC

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL							
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE							
	@ AMNEAL PHARMS CO	100MG;150MG	A209721	001	Aug 22, 2018	Feb	DISC
	@	133MG;200MG	A209721	002	Aug 22, 2018	Feb	DISC
	@	167MG;250MG	A209721	003	Aug 22, 2018	Feb	DISC
	@	200MG;300MG	A209721	004	Aug 22, 2018	Feb	DISC
>D> AB	LAURUS LABS LTD	200MG;300MG	A212114	001	Jul 26, 2019	Aug	DISC
>A>	@	200MG;300MG	A212114	001	Jul 26, 2019	Aug	DISC
AB		200MG;300MG	A212114	001	Jul 26, 2019	Jul	NEWA
TRUVADA							
+	GILEAD	100MG;150MG	N021752	002	Mar 10, 2016	Feb	CTEC
+		133MG;200MG	N021752	003	Mar 10, 2016	Feb	CTEC
+		167MG;250MG	N021752	004	Mar 10, 2016	Feb	CTEC

ENALAPRIL MALEATE

FOR SOLUTION;ORAL							
EPANED KIT							
+	@ SILVERGATE PHARMS	1MG/ML	N204308	001	Aug 13, 2013	Mar	DISC
TABLET;ORAL							
ENALAPRIL MALEATE							
	@ BEXIMCO PHARMS USA	2.5MG	A075621	001	Aug 22, 2000	Feb	CAHN
	@	5MG	A075621	002	Aug 22, 2000	Feb	CAHN
	@	10MG	A075621	003	Aug 22, 2000	Feb	CAHN
	@	20MG	A075621	004	Aug 22, 2000	Feb	CAHN
AB	HERITAGE PHARMA	2.5MG	A075479	001	Aug 22, 2000	Feb	CAHN

TABLET;ORAL
ENALAPRIL MALEATE

AB		5MG	A075479	002	Aug 22, 2000	Feb CAHN
AB		10MG	A075479	003	Aug 22, 2000	Feb CAHN
AB		20MG	A075479	004	Aug 22, 2000	Feb CAHN
	@ MYLAN	5MG	A075480	002	Aug 22, 2000	Jun DISC
	@	10MG	A075480	003	Aug 22, 2000	Feb DISC
	VASOTEC					
AB	+ BAUSCH	2.5MG	N018998	005	Jul 26, 1988	Mar CAHN
AB	+	5MG	N018998	001	Dec 24, 1985	Mar CAHN
AB	+	10MG	N018998	002	Dec 24, 1985	Mar CAHN
AB	+	20MG	N018998	003	Dec 24, 1985	Mar CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
VASERETIC

AB	+ BAUSCH	5MG;12.5MG	N019221	003	Jul 12, 1995	Mar CAHN
AB	+	10MG;25MG	N019221	001	Oct 31, 1986	Mar CAHN

ENALAPRILAT

INJECTABLE;INJECTION
ENALAPRILAT

AP	DR REDDYS	1.25MG/ML	A075578	001	Aug 22, 2000	May CAHN
----	-----------	-----------	---------	-----	--------------	----------

ENCORAFENIB

CAPSULE;ORAL
BRAFTOVI

	+ @ ARRAY BIOPHARMA INC	50MG	N210496	001	Jun 27, 2018	Jul DISC
--	-------------------------	------	---------	-----	--------------	----------

ENOXAPARIN SODIUM

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
ENOXAPARIN SODIUM

AB	AMPHASTAR PHARMS INC	300MG/3ML (100MG/ML)	A208600	001	Mar 14, 2019	Mar NEWA
----	----------------------	----------------------	---------	-----	--------------	----------

ENTECAVIR

TABLET;ORAL
ENTECAVIR

AB	MYLAN	0.5MG	A206226	001	Mar 26, 2019	Mar NEWA
AB		1MG	A206226	002	Mar 26, 2019	Mar NEWA

>A> ENTRECTINIB

>A> CAPSULE;ORAL
>A> ROZLYTREK

>A>	+ GENENTECH INC	100MG	N212725	001	Aug 15, 2019	Aug NEWA
>A>	+	200MG	N212725	002	Aug 15, 2019	Aug NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
EPINASTINE HYDROCHLORIDE

	@ CASI PHARMS INC	0.05%	A203384	001	Dec 07, 2016	Jun DISC
	@ SUN PHARM INDS	0.05%	A091626	001	Oct 31, 2011	Jul DISC

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE (AUTOINJECTOR)

AB	TEVA PHARMS USA	0.15MG/DELIVERY	A090589	002	Aug 16, 2018	Jul CMFD
	@	0.15MG/DELIVERY	A090589	002	Aug 16, 2018	Mar DISC
	EPIPEN JR.					
AB	+! MYLAN SPECIALITY LP	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Jul CTEC
	+!	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Mar CTEC

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
ADRENALIN

>D> AP	+! PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Aug CTEC
>A>	+!	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Aug CTEC
AP	+!	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jan CDFR
	+!	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Jan CDFR

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

>D> EPINEPHRINE

>D> AP	AM REGENT	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A207568	001	Jul 06, 2018	Aug DISC
>A>	@	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A207568	001	Jul 06, 2018	Aug DISC

SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE

+! BELCHER PHARMS LLC EQ 1MG BASE/ML (EQ 1MG BASE/ML) N205029 001 Jul 29, 2014 May CDFR

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION
EPIRUBICIN HYDROCHLORIDE

FRESENIUS KABI USA 150MG/75ML (2MG/ML) A065408 003 Oct 15, 2007 Mar CTEC

EPTIFIBATIDE

INJECTABLE;INJECTION
EPTIFIBATIDE

AP	BAXTER HLTHCARE CORP	2MG/ML	A208554	001	Nov 23, 2018	Jan CAHN
AP		75MG/100ML	A208554	002	Nov 23, 2018	Jan CAHN
AP	HAINAN POLY PHARM	2MG/ML	A209864	001	Jan 25, 2019	Jan NEWA
AP		75MG/100ML	A209864	002	Jan 25, 2019	Jan NEWA
AP	USV	2MG/ML	A204361	001	Mar 14, 2019	Mar NEWA
AP		2MG/ML	A204362	001	Mar 11, 2019	Feb NEWA
AP		75MG/100ML	A204361	002	Mar 14, 2019	Mar NEWA

ERDAFITINIB

TABLET;ORAL
BALVERSA

+	JANSSEN BIOTECH	3MG	N212018	001	Apr 12, 2019	Apr NEWA
+		4MG	N212018	002	Apr 12, 2019	Apr NEWA
+		5MG	N212018	003	Apr 12, 2019	Apr NEWA

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL
ERLOTINIB HYDROCHLORIDE

AB	MYLAN	EQ 25MG BASE	A091002	001	Jun 11, 2014	Feb CMFD	
AB		EQ 100MG BASE	A091002	002	Jun 11, 2014	Feb CMFD	
AB		EQ 150MG BASE	A091002	003	Jun 11, 2014	Feb CMFD	
AB	TEVA PHARMS USA	EQ 100MG BASE	A091059	002	Aug 28, 2015	Mar CMFD	
AB		EQ 150MG BASE	A091059	003	Aug 28, 2015	Mar CMFD	
TARCEVA							
AB	+	OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004	
AB	+		EQ 25MG BASE	N021743	001	Nov 18, 2004	Mar CAHN
AB	+		EQ 100MG BASE	N021743	002	Nov 18, 2004	Feb CTEC
AB	+		EQ 100MG BASE	N021743	002	Nov 18, 2004	Mar CAHN
AB	+		EQ 150MG BASE	N021743	003	Nov 18, 2004	Feb CTEC
AB	+		EQ 150MG BASE	N021743	003	Nov 18, 2004	Mar CAHN
AB	+		EQ 150MG BASE	N021743	003	Nov 18, 2004	Feb CTEC

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS
ERTAPENEM SODIUM

AP SAVIOR LIFETEC CORP EQ 1GM BASE/VIAL A207647 001 Mar 19, 2019 Mar NEWA

ERYTHROMYCIN

OINTMENT;TOPICAL
AKNE-MYCIN

+ @ BAUSCH 2% N050584 001 Jan 10, 1985 Apr CAHN

SOLUTION;TOPICAL
ERYTHRA-DERM

>A>	@ MLV	2%	A062687	001	Feb 05, 1988	Aug CAHN
>D>	@ SAPTALIS PHARMS	2%	A062687	001	Feb 05, 1988	Aug CAHN
	@	2%	A062687	001	Feb 05, 1988	Feb CAHN

TABLET, DELAYED RELEASE;ORAL
ERY-TAB

AB	ARBOR PHARMS LLC	250MG	A062298	001		Jun CTEC
AB		333MG	A062298	003	Mar 29, 1982	Jun CTEC
AB	!	500MG	A062298	002		Jun CTEC

ERYTHROMYCIN

AB	AMNEAL PHARMS CO	250MG	A210954	001	Jul 02, 2019	Jun NEWA
AB		333MG	A210954	002	Jul 02, 2019	Jun NEWA
AB		500MG	A210954	003	Jul 02, 2019	Jun NEWA

ESCITALOPRAM OXALATE

TABLET; ORAL

ESCITALOPRAM OXALATE

AB	CADILA	EQ 5MG BASE	A077734	001	Sep 11, 2012	Apr CAHN
AB		EQ 10MG BASE	A077734	002	Sep 11, 2012	Apr CAHN
AB		EQ 20MG BASE	A077734	003	Sep 11, 2012	Apr CAHN

ESKETAMINE HYDROCHLORIDE

SPRAY; NASAL

SPRAVATO

+	JANSSEN PHARMS	EQ 28MG BASE	N211243	001	Mar 05, 2019	Mar NEWA
---	----------------	--------------	---------	-----	--------------	----------

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

ESMOLOL HYDROCHLORIDE

AP	GLAND PHARMA LTD	10MG/ML	A208538	001	Aug 14, 2019	Jul NEWA
----	------------------	---------	---------	-----	--------------	----------

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

ESOMEPRAZOLE MAGNESIUM

	@ AMNEAL PHARMS NY	EQ 20MG BASE	A209647	001	Apr 10, 2019	Jun DISC
AB		EQ 20MG BASE	A209647	001	Apr 10, 2019	Mar NEWA
	@	EQ 40MG BASE	A209647	002	Apr 10, 2019	Jun DISC
AB		EQ 40MG BASE	A209647	002	Apr 10, 2019	Mar NEWA
AB	GLENMARK PHARMS	EQ 20MG BASE	A209495	001	May 10, 2019	Apr NEWA
AB		EQ 40MG BASE	A209495	002	May 10, 2019	Apr NEWA
	@ HEC PHARM	EQ 20MG BASE	A207265	002	May 18, 2018	Mar DISC
	@	EQ 40MG BASE	A207265	001	May 18, 2018	Mar DISC
AB	HETERO LABS LTD III	EQ 20MG BASE	A202784	001	Sep 21, 2015	Jun CTEC
AB		EQ 40MG BASE	A202784	002	Sep 21, 2015	Jun CTEC
AB	ZYDUS PHARMS	EQ 20MG BASE	A206296	001	May 22, 2019	May NEWA
AB		EQ 40MG BASE	A206296	002	May 22, 2019	May NEWA

>D> ESOMEPRAZOLE STRONTIUM

>D> CAPSULE, DELAYED RELEASE; ORAL

>D> ESOMEPRAZOLE STRONTIUM

>D>	+	R2 PHARMA LLC	49.3MG	N202342	002	Aug 06, 2013	Aug DISC
>A>	+	@	49.3MG	N202342	002	Aug 06, 2013	Aug DISC

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ESTRADIOL

AB1	AMNEAL PHARMS LLC	0.025MG/24HR	A211293	001	Feb 04, 2019	Jan NEWA
AB1		0.0375MG/24HR	A211293	002	Feb 04, 2019	Jan NEWA
AB1		0.05MG/24HR	A211293	003	Feb 04, 2019	Jan NEWA
AB1		0.075MG/24HR	A211293	004	Feb 04, 2019	Jan NEWA
AB1		0.1MG/24HR	A211293	005	Feb 04, 2019	Jan NEWA

GEL; TRANSDERMAL

DIVIGEL

+	VERTICAL PHARMS LLC	0.1%	N022038	001	Jun 04, 2007	Jan CHRS
---	---------------------	------	---------	-----	--------------	----------

ESTRADIOL VALERATE

INJECTABLE; INJECTION

ESTRADIOL VALERATE

@	DR REDDYS	40MG/ML	A083714	001		May CAHN
---	-----------	---------	---------	-----	--	----------

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

	@ ACCORD HLTHCARE	1MG; 0.5MG	A210233	001	Feb 28, 2018	Mar DISC
AB	NOVAST LABS	0.5MG; 0.1MG	A210612	001	Apr 03, 2019	Mar NEWA
AB		1MG; 0.5MG	A210612	002	Apr 03, 2019	Mar NEWA

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

+	@ ASPEN	0.3MG	N020992	001	Jun 21, 2002	Feb CAHN
+	@	0.45MG	N020992	005	Feb 05, 2004	Feb CAHN
+	@	0.625MG	N020992	002	Mar 24, 1999	Feb CAHN
+	@	0.9MG	N020992	003	Mar 24, 1999	Feb CAHN
+	@	1.25MG	N020992	004	Mar 13, 2000	Feb CAHN

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

@ ASPEN	0.3MG	N021443	001	Dec 20, 2004	Feb CAHN
@	0.45MG	N021443	002	Dec 20, 2004	Feb CAHN
@	0.625MG	N021443	003	May 10, 2004	Feb CAHN
@	0.9MG	N021443	005	Apr 27, 2007	Feb CAHN
@	1.25MG	N021443	004	May 10, 2004	Feb CAHN

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

@ BRECKENRIDGE	1MG	A203087	001	May 08, 2019	May DISC
@	2MG	A203087	002	May 08, 2019	May DISC
@	3MG	A203087	003	May 08, 2019	May DISC
AB BRECKENRIDGE PHARM	1MG	A203087	001	May 08, 2019	Apr NEWA
AB	2MG	A203087	002	May 08, 2019	Apr NEWA
AB	3MG	A203087	003	May 08, 2019	Apr NEWA

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

EDECIN

AP +! BAUSCH	EQ 50MG BASE/VIAL	N016093	001		Mar CAHN
AP +! VALEANT PHARMS INTL	EQ 50MG BASE/VIAL	N016093	001		Jan CAHN

ETHACRYNIC ACID

TABLET; ORAL

EDECIN

AB +! BAUSCH	25MG	N016092	001		Mar CAHN
@	50MG	N016092	002		Mar CAHN
AB +! VALEANT PHARMS INTL	25MG	N016092	001		Jan CAHN
@	50MG	N016092	002		Jan CAHN
	ETHACRYNIC ACID				
AB AGNITIO	25MG	A211809	001	Jul 12, 2019	Jul NEWA
>A> AB LUPIN LTD	25MG	A211719	001	Sep 06, 2019	Aug NEWA
>A> AB SCIEGEN PHARMS INC	25MG	A211232	001	Aug 27, 2019	Aug NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

LO-MALMOREDE

AB NOVAST LABS	0.035MG; 1MG	A209548	001	Feb 11, 2019	Jan NEWA
----------------	--------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

INTROVALE

>D> AB LABS LEON FARMA	0.03MG; 0.15MG	A079064	001	Sep 27, 2010	Aug CAHN
>A> AB XIROMED	0.03MG; 0.15MG	A079064	001	Sep 27, 2010	Aug CAHN
	JAIMIESS				
>D> AB LABS LEON FARMA	0.03MG; 0.01MG; 0.15MG, N/A	A203770	001	Dec 27, 2017	Aug CAHN
>A> AB XIROMED	0.03MG; 0.01MG; 0.15MG, N/A	A203770	001	Dec 27, 2017	Aug CAHN
	LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL				
>D> AB LABS LEON FARMA	0.02MG; 0.1MG; 0.01MG, N/A	A205131	001	Dec 14, 2017	Aug CAHN
>A> AB XIROMED	0.02MG; 0.1MG; 0.01MG, N/A	A205131	001	Dec 14, 2017	Aug CAHN
	SYLEVIA				
AB SUN PHARM	0.03MG; 0.15MG	A202988	001	Feb 06, 2019	Jan NEWA
	TABLET; ORAL-28				
	ALTAVERA				
>D> AB LABS LEON FARMA	0.03MG; 0.15MG	A079102	001	Aug 03, 2010	Aug CAHN
>A> AB XIROMED	0.03MG; 0.15MG	A079102	001	Aug 03, 2010	Aug CAHN
	ELIFEMME				
>D> AB LABS LEON FARMA	0.03MG; 0.04MG; 0.03MG; 0.05MG; 0.075MG, 0.125MG	A202507	001	Dec 04, 2015	Aug CAHN
>A> AB XIROMED	0.03MG; 0.04MG; 0.03MG; 0.05MG; 0.075MG, 0.125MG	A202507	001	Dec 04, 2015	Aug CAHN
	LEVONORGESTREL AND ETHINYL ESTRADIOL				
@ MYLAN LABS LTD	0.02MG; 0.1MG	A202247	001	Dec 08, 2014	Jun DISC
	VIENVA				
>D> AB1 LABS LEON FARMA	0.02MG; 0.1MG	A201088	001	May 21, 2015	Aug CAHN
>A> AB1 XIROMED	0.02MG; 0.1MG	A201088	001	May 21, 2015	Aug CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28							
NORTREL 1/35-28							
AB	! BARR	0.035MG;1MG	A072696	001	Feb 28, 1992	Mar	CHRS
ORTHO-NOVUM 1/35-28							
	+ @ JANSSEN PHARMS	0.035MG;1MG	N017919	002		Mar	DISC
TABLET, CHEWABLE; ORAL							
FEMCON FE							
	+ @ APIL	0.035MG;0.4MG	N021490	001	Nov 14, 2003	Mar	DISC
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB	! MYLAN LABS LTD	0.035MG;0.4MG	A202086	001	Apr 01, 2015	Mar	CHRS

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21							
HAILEY 1.5/30							
AB	GLENMARK PHARMS	0.03MG;1.5MG	A209297	001	Jun 05, 2018	Jan	CDFR
LOESTRIN 21 1.5/30							
AB	+ APIL	0.03MG;1.5MG	N017875	001		Jan	CRLD
LOESTRIN 21 1/20							
AB	+ APIL	0.02MG;1MG	N017876	001		Jan	CRLD
TABLET, CHEWABLE; ORAL							
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
>D> AB	CHEMO RESEARCH SL	0.02MG;1MG	A209609	001	Jul 16, 2018	Aug	CAHN
>A> AB	XIROMED	0.02MG;1MG	A209609	001	Jul 16, 2018	Aug	CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28							
ESTARYLLA							
>D> AB	LABS LEON FARMA	0.035MG;0.25MG	A090794	001	Jan 30, 2013	Aug	CAHN
>A> AB	XIROMED	0.035MG;0.25MG	A090794	001	Jan 30, 2013	Aug	CAHN
NORGESTIMATE AND ETHINYL ESTRADIOL							
	@ MYLAN LABS LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A202132	001	Sep 09, 2015	Jan	DISC
ORTHO CYCLEN-28							
	+ @ JANSSEN PHARMS	0.035MG;0.25MG	N019653	002	Dec 29, 1989	Apr	DISC
SPRINTEC							
AB	! BARR	0.035MG;0.25MG	A075804	001	Sep 25, 2002	Apr	CHRS
TRI-ESTARYLLA							
>D> AB	LABS LEON FARMA	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A090793	001	Jan 30, 2013	Aug	CAHN
>A> AB	XIROMED	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A090793	001	Jan 30, 2013	Aug	CAHN
TRI-LO-ESTARYLLA							
>D> AB	LABS LEON FARMA	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A091232	001	Jun 29, 2015	Aug	CAHN
>A> AB	XIROMED	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A091232	001	Jun 29, 2015	Aug	CAHN

ETHINYL ESTRADIOL; SEGESTERONE ACETATE

RING; VAGINAL							
ANNOVERA							
	+! THERAPEUTICSMD INC	0.013MG/24HR;0.15MG/24HR	N209627	001	Aug 10, 2018	May	CMFD
	+ @	0.013MG/24HR;0.15MG/24HR	N209627	001	Aug 10, 2018	Feb	DISC

ETHOSUXIMIDE

CAPSULE; ORAL							
ETHOSUXIMIDE							
AB	STRIDES PHARMA	250MG	A211928	001	Feb 19, 2019	Feb	NEWA
SYRUP; ORAL							
ETHOSUXIMIDE							
	@ TEVA PHARMS	250MG/5ML	A081306	001	Jul 30, 1993	May	DISC

ETOMIDATE

INJECTABLE; INJECTION							
ETOMIDATE							
	@ LUITPOLD	2MG/ML	A078867	001	Dec 22, 2009	Feb	DISC
	@ PAR STERILE PRODUCTS	2MG/ML	A091297	001	Jun 20, 2012	Apr	DISC

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION
ETOPHOS PRESERVATIVE FREE

+! CHEPLAPHARM EQ 100MG BASE/VIAL N020457 001 May 17, 1996 May CAHN

EVEROLIMUS

TABLET; ORAL
AFINITOR

+! NOVARTIS 5MG N022334 001 Mar 30, 2009 Apr CHRS

+ 10MG N022334 002 Mar 30, 2009 Apr CHRS

ZORTRESS

+ NOVARTIS 1MG N021560 004 Aug 10, 2018 Mar NEWA

TABLET, FOR SUSPENSION; ORAL
AFINITOR DISPERZ

+ NOVARTIS PHARM 2MG N203985 001 Aug 29, 2012 Apr CTEC

AB + 2MG N203985 001 Aug 29, 2012 Apr CFTG

+ 3MG N203985 002 Aug 29, 2012 Apr CTEC

AB + 3MG N203985 002 Aug 29, 2012 Apr CFTG

+! 5MG N203985 003 Aug 29, 2012 Apr CTEC

AB +! 5MG N203985 003 Aug 29, 2012 Apr CFTG

EVEROLIMUS

@ MYLAN 2MG A210130 001 Apr 19, 2019 Apr NFTG

@ 3MG A210130 002 Apr 19, 2019 Apr NFTG

@ 5MG A210130 003 Apr 19, 2019 Apr NFTG

EXEMESTANE

TABLET; ORAL

EXEMESTANE

@ AMNEAL PHARMS 25MG A206421 001 Dec 28, 2018 Jul DISC

@ BRECKENRIDGE 25MG A211031 001 Feb 21, 2019 May DISC

AB BRECKENRIDGE PHARM 25MG A211031 001 Feb 21, 2019 Feb NEWA

AB MAYNE PHARMA INC 25MG A208764 001 Aug 08, 2019 Jul NEWA

EZETIMIBE

TABLET; ORAL

EZETIMIBE

@ ACCORD HLTHCARE 10MG A211550 001 Oct 26, 2018 Apr DISC

AB MYLAN 10MG A201790 001 Apr 26, 2019 Apr NEWA

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

EZETIMIBE AND SIMVASTATIN

AB GLENMARK PHARMS LTD 10MG; 10MG A208699 001 Jun 27, 2019 Jun NEWA

AB 10MG; 20MG A208699 002 Jun 27, 2019 Jun NEWA

AB 10MG; 40MG A208699 003 Jun 27, 2019 Jun NEWA

AB 10MG; 80MG A208699 004 Jun 27, 2019 Jun NEWA

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

>A> AB CELLTRION 20MG A075786 001 Apr 16, 2001 Aug CAHN

>A> AB 40MG A075786 002 Apr 16, 2001 Aug CAHN

@ MYLAN 40MG A075704 002 Apr 16, 2001 Apr DISC

>D> AB WOCKHARDT LTD 20MG A075786 001 Apr 16, 2001 Aug CAHN

>D> AB 40MG A075786 002 Apr 16, 2001 Aug CAHN

FEBUXOSTAT

TABLET; ORAL

FEBUXOSTAT

AB ALEMBIC PHARMS LTD 40MG A205421 001 Jul 01, 2019 Jun NFTG

AB 80MG A205421 002 Jul 01, 2019 Jun NFTG

AB MYLAN 40MG A205385 001 Jul 01, 2019 Jun NFTG

AB 80MG A205385 002 Jul 01, 2019 Jun NFTG

AB SUN PHARM 40MG A205467 001 Jul 01, 2019 Jun NFTG

AB 80MG A205467 002 Jul 01, 2019 Jun NFTG

ULORIC

AB + TAKEDA PHARMS USA 40MG N021856 001 Feb 13, 2009 Jun CFTG

AB +! 80MG N021856 002 Feb 13, 2009 Jun CFTG

>A>	<u>FEDRATINIB HYDROCHLORIDE</u>							
>A>	CAPSULE;ORAL							
>A>	INREBIC							
>A>	+!	IMPACT	EQ 100MG BASE		N212327	001	Aug 16, 2019	Aug NEWA
	<u>FELBAMATE</u>							
	SUSPENSION;ORAL							
	FELBAMATE							
AB		VISTAPHARM	600MG/5ML		A211333	001	May 31, 2019	May NEWA
	TABLET;ORAL							
	FELBAMATE							
AB		CADILA	400MG		A208970	001	May 30, 2017	Jul CAHN
AB			600MG		A208970	002	May 30, 2017	Jul CAHN
	<u>FELODIPINE</u>							
	TABLET, EXTENDED RELEASE;ORAL							
	FELODIPINE							
AB		YUNG SHIN PHARM	2.5MG		A204800	001	Apr 29, 2019	Apr NEWA
AB			5MG		A204800	002	Apr 29, 2019	Apr NEWA
AB			10MG		A204800	003	Apr 29, 2019	Apr NEWA
	<u>FENOFIBRATE</u>							
	CAPSULE;ORAL							
	FENOFIBRATE (MICRONIZED)							
AB		AUSTARPHARMA	67MG		A207805	001	Nov 16, 2017	Jan CAHN
AB			134MG		A207805	002	Nov 16, 2017	Jan CAHN
AB			200MG		A207805	003	Nov 16, 2017	Jan CAHN
AB		INGENUS PHARMS LLC	67MG		A207564	001	Apr 19, 2019	Apr NEWA
AB			134MG		A207564	002	Apr 19, 2019	Apr NEWA
AB			200MG		A207564	003	Apr 19, 2019	Apr NEWA
	TABLET;ORAL							
	FENOFIBRATE							
AB		ALEMBIC PHARMS LTD	48MG		A210476	001	Aug 09, 2019	Jul NEWA
AB			145MG		A210476	002	Aug 09, 2019	Jul NEWA
>A> AB		APPCO PHARMA LLC	54MG		A210670	001	Sep 06, 2019	Aug NEWA
>A> AB			160MG		A210670	002	Sep 06, 2019	Aug NEWA
AB		AUSTARPHARMA	54MG		A207803	001	Dec 19, 2017	Jan CAHN
AB			160MG		A207803	002	Dec 19, 2017	Jan CAHN
		@ GRAVITI PHARMS	54MG		A210606	001	Aug 17, 2018	Feb DISC
		@	160MG		A210606	002	Aug 17, 2018	Feb DISC
AB		ORIT LABS LLC	54MG		A209660	001	Feb 11, 2019	Jan NEWA
AB			160MG		A209660	002	Feb 11, 2019	Jan NEWA
	FENOGLIDE							
AB	+	SALIX	40MG		N022118	001	Aug 10, 2007	Mar CAHN
AB	+	!	120MG		N022118	002	Aug 10, 2007	Mar CAHN
	<u>FENOFIBRIC ACID</u>							
	TABLET;ORAL							
	FIBRICOR							
	+	ATHENA	35MG		N022418	001	Aug 14, 2009	Feb CAHN
	+	!	105MG		N022418	002	Aug 14, 2009	Feb CAHN
	<u>FENOPROFEN CALCIUM</u>							
	TABLET;ORAL							
	FENOPROFEN CALCIUM							
	@	ANI PHARMS INC	EQ 600MG BASE		A072274	001	May 02, 1988	May CAHN
	<u>FENTANYL</u>							
	FILM, EXTENDED RELEASE;TRANSDERMAL							
	FENTANYL-100							
>D>	@	MAYNE PHARMA	100MCG/HR		A077062	004	Aug 20, 2007	Aug CMFD
>A> AB			100MCG/HR		A077062	004	Aug 20, 2007	Aug CMFD
		@	100MCG/HR		A077062	004	Aug 20, 2007	Jul DISC
	FENTANYL-25							
>D>	@	MAYNE PHARMA	25MCG/HR		A077062	001	Aug 20, 2007	Aug CMFD
>A> AB			25MCG/HR		A077062	001	Aug 20, 2007	Aug CMFD
		@	25MCG/HR		A077062	001	Aug 20, 2007	Jul DISC
	FENTANYL-50							
>D>	@	MAYNE PHARMA	50MCG/HR		A077062	002	Aug 20, 2007	Aug CMFD
>A> AB			50MCG/HR		A077062	002	Aug 20, 2007	Aug CMFD
		@	50MCG/HR		A077062	002	Aug 20, 2007	Jul DISC

FILM, EXTENDED RELEASE;TRANSDERMAL							
FENTANYL-75							
>D>	@ MAYNE PHARMA	75MCG/HR	A077062	003	Aug 20, 2007	Aug	CMFD
>A>	AB	75MCG/HR	A077062	003	Aug 20, 2007	Aug	CMFD
	@	75MCG/HR	A077062	003	Aug 20, 2007	Jul	DISC
<u>FENTANYL CITRATE</u>							
INJECTABLE;INJECTION							
FENTANYL CITRATE PRESERVATIVE FREE							
AP	FRESENIUS KABI USA	EQ 0.05MG BASE/ML	A210762	001	May 03, 2019	Apr	NEWA
<u>FERRIC CARBOXYMALTOSE</u>							
INJECTABLE;INTRAVENOUS							
INJECTAFER							
+	! AM REGENT	750MG IRON/15ML (50MG IRON/ML)	N203565	001	Jul 25, 2013	Jun	CAHN
<u>FERRIC MALTOL</u>							
CAPSULE;ORAL							
ACCRUFER							
+	! SHIELD TX	30MG IRON	N212320	001	Jul 25, 2019	Jul	NEWA
<u>FESOTERODINE FUMARATE</u>							
TABLET, EXTENDED RELEASE;ORAL							
FESOTERODINE FUMARATE							
AB	DR REDDYS LABS LTD	4MG	A204975	001	Aug 13, 2019	Jul	NEWA
AB		8MG	A204975	002	Aug 13, 2019	Jul	NEWA
<u>FEXOFENADINE HYDROCHLORIDE</u>							
SUSPENSION;ORAL							
FEXOFENADINE HYDROCHLORIDE							
>D>	@ ACTAVIS MID ATLANTIC	30MG/5ML	A201311	001	Jul 25, 2012	Aug	CAHN
>A>	@ P AND L	30MG/5ML	A201311	001	Jul 25, 2012	Aug	CAHN
TABLET;ORAL							
FEXOFENADINE HYDROCHLORIDE							
	@ MYLAN	30MG	A077081	002	Apr 11, 2008	Jul	DISC
<u>FINAFLOXACIN</u>							
SUSPENSION/DROPS;OTIC							
XTORO							
+	@ MERLION PHARMS GMBH	0.3%	N206307	001	Dec 17, 2014	Apr	DISC
<u>FINASTERIDE</u>							
TABLET;ORAL							
FINASTERIDE							
	@ MYLAN	5MG	A077578	001	Dec 18, 2006	Jul	DISC
<u>FLOXURIDINE</u>							
INJECTABLE;INJECTION							
FLOXURIDINE							
	@ LUITPOLD	500MG/VIAL	A203008	001	Nov 22, 2017	Mar	DISC
<u>FLUCONAZOLE</u>							
INJECTABLE;INJECTION							
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%							
	@ DR REDDYS	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004	May	CAHN
	@	400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004	May	CAHN
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
	@ DR REDDYS	200MG/100ML (2MG/ML)	A076837	001	Jan 13, 2005	May	CAHN
	@	400MG/200ML (2MG/ML)	A076837	002	Jan 13, 2005	May	CAHN
TABLET;ORAL							
FLUCONAZOLE							
AB	CHARTWELL	50MG	A076665	001	Jul 29, 2004	Jun	CAHN
AB		100MG	A076665	002	Jul 29, 2004	Jun	CAHN
AB		150MG	A076665	003	Jul 29, 2004	Jun	CAHN
AB		200MG	A076665	004	Jul 29, 2004	Jun	CAHN

FLUCYTOSINECAPSULE;ORAL
ANCOBON

AB	+	BAUSCH	250MG	N017001	001		Feb CAHN
AB	+	!	500MG	N017001	002		Feb CAHN

FLUDEOXYGLUCOSE F-18INJECTABLE;INTRAVENOUS
FLUDEOXYGLUCOSE F18

AP		DECATUR	20-300mCi/ML	A204463	001	Oct 21, 2014	Apr CAHN
----	--	---------	--------------	---------	-----	--------------	----------

FLUMAZENILINJECTABLE;INJECTION
FLUMAZENIL

	@	DR REDDYS	0.5MG/5ML (0.1MG/ML)	A076589	002	Oct 12, 2004	May CAHN
	@		1MG/10ML (0.1MG/ML)	A076589	001	Oct 12, 2004	May CAHN
>D> AP		HIKMA FARMACEUTICA	1MG/10ML (0.1MG/ML)	A078527	002	Mar 23, 2009	Aug CHRS
>A> AP	!		1MG/10ML (0.1MG/ML)	A078527	002	Mar 23, 2009	Aug CHRS
>D> AP	!	MYLAN LABS LTD	1MG/10ML (0.1MG/ML)	A078595	002	May 13, 2008	Aug DISC
>A>	@		1MG/10ML (0.1MG/ML)	A078595	002	May 13, 2008	Aug DISC

FLUNISOLIDEAEROSOL, METERED;INHALATION
AEROSPAN HFA

	+	@ MYLAN SPECIALITY LP	0.078MG/INH	N021247	001	Jan 27, 2006	Jul DISC
		SPRAY, METERED;NASAL					
		FLUNISOLIDE					
		APOTEX INC	0.029MG/SPRAY	A077436	001	Aug 09, 2007	Jun CMFD
AB			0.029MG/SPRAY	A077436	001	Aug 09, 2007	Jun CMFD

FLUOCINOLONE ACETONIDESOLUTION;TOPICAL
FLUOCINOLONE ACETONIDE

	@	ACTAVIS LABS UT INC	0.01%	A208386	001	Oct 21, 2016	Mar DISC
AT		ENCUBE ETHICALS	0.01%	A209913	001	Feb 13, 2019	Jan NEWA
AT		GLASSHOUSE PHARMS	0.01%	A209596	001	Dec 26, 2017	Jan CMFD
AT		LUPIN	0.01%	A206422	001	Sep 02, 2015	Feb CAHN

FLUOCINONIDECREAM;TOPICAL
FLUOCINONIDE

	@	AMNEAL PHARMS LLC	0.05%	A210554	001	Aug 21, 2018	Feb DISC
AB		TELIGENT PHARMA INC	0.1%	A211758	001	Apr 03, 2019	Mar NEWA

SOLUTION;TOPICAL
FLUOCINONIDE

AT		TELIGENT PHARMA INC	0.05%	A207554	001	Mar 18, 2019	Mar NEWA
----	--	---------------------	-------	---------	-----	--------------	----------

FLUOROMETHOLONESUSPENSION/DROPS;OPHTHALMIC
FML FORTE

	+	!	ALLERGAN	0.25%	N019216	001	Apr 23, 1986	Jun CHRS
	+			0.25%	N019216	001	Apr 23, 1986	Jun CRLD

FLUOROMETHOLONE ACETATESUSPENSION/DROPS;OPHTHALMIC
FLAREX

	+	!	EYEVANCE	0.1%	N019079	001	Feb 11, 1986	Feb CAHN
--	---	---	----------	------	---------	-----	--------------	----------

FLUOROMETHOLONE ACETATE; TOBRAMYCINSUSPENSION/DROPS;OPHTHALMIC
TOBRASONE

	@	EYEVANCE	0.1%;0.3%	N050628	001	Jul 21, 1989	May CAHN
--	---	----------	-----------	---------	-----	--------------	----------

FLUOROURACILCREAM;TOPICAL
EFUDEX

>A> AB	+	!	BAUSCH	5%	N016831	003	Aug CAHN
>D> AB	+	!	VALEANT PHARM INTL	5%	N016831	003	Aug CAHN
			FLUOROPLEX				
	+	!	ALMIRALL	1%	N016988	001	Feb CAHN

SOLUTION; TOPICAL
EFUDEX

>A>	AT	+	!	BAUSCH	2%	N016831	001		Aug	CAHN
>A>	AT	+	!		5%	N016831	002		Aug	CAHN
>D>	AT	+	!	VALEANT PHARM INTL	2%	N016831	001		Aug	CAHN
>D>	AT	+	!		5%	N016831	002		Aug	CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

AB1	APNAR PHARMA LP	EQ	10MG	BASE	A075049	001	Aug 02, 2001	Jun	CAHN
AB1		EQ	20MG	BASE	A075049	002	Jan 29, 2002	Jun	CAHN
AB		EQ	40MG	BASE	A075049	003	Jan 29, 2002	Jun	CAHN
	@ BEXIMCO PHARMS USA	EQ	10MG	BASE	A075807	001	Jan 29, 2002	Feb	CAHN
	@	EQ	20MG	BASE	A075807	002	Jan 29, 2002	Feb	CAHN
AB1	CADILA PHARMS LTD	EQ	10MG	BASE	A206993	001	May 23, 2019	May	NEWA
AB1		EQ	20MG	BASE	A206993	002	May 23, 2019	May	NEWA
AB		EQ	40MG	BASE	A206993	003	May 23, 2019	May	NEWA
>A>	@ CELLTRION	EQ	10MG	BASE	A078143	001	Jan 16, 2008	Aug	CAHN
>A>	@	EQ	20MG	BASE	A078143	002	Jan 16, 2008	Aug	CAHN
>A>	@	EQ	40MG	BASE	A078143	003	Jan 16, 2008	Aug	CAHN
	@ PAR PHARM	EQ	40MG	BASE	A076922	003	Dec 16, 2004	Mar	DISC
>D>	@ WOCKHARDT LTD	EQ	10MG	BASE	A078143	001	Jan 16, 2008	Aug	CAHN
>D>	@	EQ	20MG	BASE	A078143	002	Jan 16, 2008	Aug	CAHN
>D>	@	EQ	40MG	BASE	A078143	003	Jan 16, 2008	Aug	CAHN

CAPSULE, DELAYED REL PELLETS; ORAL

FLUOXETINE HYDROCHLORIDE

	@ BARR	EQ	90MG	BASE	A076237	001	Mar 24, 2010	Apr	DISC
	! DR REDDYS LABS LTD	EQ	90MG	BASE	A078572	001	Mar 22, 2010	Apr	CTEC
AB	!	EQ	90MG	BASE	A078572	001	Mar 22, 2010	Apr	CHRS
	PROZAC WEEKLY								
	+ @ LILLY	EQ	90MG	BASE	N021235	001	Feb 26, 2001	Apr	DISC

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

	@ NOSTRUM LABS INC	EQ	20MG	BASE/5ML	A075292	001	Feb 07, 2002	May	CAHN
--	--------------------	----	------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

AB	APPCO PHARMA LLC	EQ	10MG	BASE	A211696	001	Jan 30, 2019	Jan	NEWA
AB		EQ	20MG	BASE	A211696	002	Jan 30, 2019	Jan	NEWA
AB	DR REDDYS LABS LTD	EQ	60MG	BASE	A211721	001	Jan 25, 2019	Jan	NEWA
AB	G AND W LABS INC	EQ	60MG	BASE	A212191	001	Jul 05, 2019	Jun	NEWA
AB	LUPIN LTD	EQ	10MG	BASE	A211653	001	Apr 15, 2019	Apr	NEWA
AB		EQ	20MG	BASE	A211653	002	Apr 15, 2019	Apr	NEWA
AB		EQ	60MG	BASE	A211632	001	Feb 08, 2019	Feb	NEWA
AB	SCIEGEN PHARMS INC	EQ	10MG	BASE	A210935	001	Mar 20, 2019	Mar	NEWA
AB		EQ	20MG	BASE	A210935	002	Mar 20, 2019	Mar	NEWA
AB	UPSHER SMITH LABS	EQ	10MG	BASE	A211696	001	Jan 30, 2019	May	CAHN
AB		EQ	20MG	BASE	A211696	002	Jan 30, 2019	May	CAHN

FLUOXYMESTERONE

TABLET; ORAL

FLUOXYMESTERONE

	!	UPSHER SMITH LABS	10MG		A088342	001	Oct 21, 1983	Jul	CAHN
--	---	-------------------	------	--	---------	-----	--------------	-----	------

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

AB	!	LANNETT CO INC	10MG		A089743	001	Aug 25, 1988	May	CHRS
AB		MYLAN	10MG		A089804	001	Aug 12, 1988	May	CHRS

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

	+	!	ALMIRALL	0.025%	N012806	003		Feb	CAHN
AT		+	!		N012806	002		Feb	CAHN

LOTION; TOPICAL

CORDRAN

AT	+	!	ALMIRALL	0.05%	N013790	001		Feb	CAHN
----	---	---	----------	-------	---------	-----	--	-----	------

OINTMENT; TOPICAL

CORDRAN

	+	@	ALMIRALL	0.025%	N012806	004		Feb	CAHN
AT		+	!		N012806	001		Feb	CAHN

TAPE; TOPICAL
CORDRAN

+! ALMIRALL 0.004MG/SQ CM N016455 001 Feb CAHN

FLUTAMIDE

CAPSULE; ORAL
FLUTAMIDE

@ ACTAVIS LABS FL INC 125MG A075820 001 Sep 18, 2001 Apr DISC

FLUTICASONE PROPIONATE

CREAM; TOPICAL
FLUTICASONE PROPIONATE

AB ! PERRIGO ISRAEL 0.05% A076793 001 May 14, 2004 May CAHN

POWDER; INHALATION
ARMONAIR RESPICLICK

+ @ TEVA PHARM 0.113MG/INH N208798 002 Jan 27, 2017 Jul DISC

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION
ADVAIR DISKUS 100/50

AB +! GLAXO GRP LTD 0.1MG/INH; EQ 0.05MG BASE/INH N021077 001 Aug 24, 2000 Jan CFTG

ADVAIR DISKUS 250/50

AB +! GLAXO GRP LTD 0.25MG/INH; EQ 0.05MG BASE/INH N021077 002 Aug 24, 2000 Jan CFTG

ADVAIR DISKUS 500/50

AB +! GLAXO GRP LTD 0.5MG/INH; EQ 0.05MG BASE/INH N021077 003 Aug 24, 2000 Jan CFTG

AIRDUO DIGIHALER

+ TEVA PHARM 0.055MG/INH; EQ 0.014MG BASE/INH N208799 004 Jul 12, 2019 Jul NEWA

+ 0.113MG/INH; EQ 0.014MG BASE/INH N208799 005 Jul 12, 2019 Jul NEWA

+ 0.232MG/INH; EQ 0.014MG BASE/INH N208799 006 Jul 12, 2019 Jul NEWA

AIRDUO RESPICLICK

+! TEVA PHARM 0.232MG/INH; EQ 0.014MG BASE/INH N208799 003 Jan 27, 2017 Jul CMS1

WIXELA INHUB

AB MYLAN 0.1MG/INH; EQ 0.05MG BASE/INH A208891 001 Jan 30, 2019 Jan NFTG

AB 0.25MG/INH; EQ 0.05MG BASE/INH A208891 002 Jan 30, 2019 Jan NFTG

AB 0.5MG/INH; EQ 0.05MG BASE/INH A208891 003 Jan 30, 2019 Jan NFTG

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE; ORAL
FLUVASTATIN SODIUM

@ MYLAN EQ 80MG BASE A202458 001 Sep 11, 2015 Jun DISC

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

@ MYLAN 25MG A075889 001 Nov 29, 2000 May DISC

@ 50MG A075889 002 Nov 29, 2000 May DISC

@ 100MG A075889 003 Nov 29, 2000 May DISC

FOLIC ACID

TABLET; ORAL
FOLIC ACID

AA INVATECH PHARMA 1MG A211064 001 Mar 08, 2019 Feb NEWA

AA QINGDAO BAHEAL PHARM 1MG A091145 001 Jul 12, 2013 May CAHN

FOMEPIZOLE

INJECTABLE; INJECTION
ANTIZOL

+ @ PAR PHARM INC 1.5GM/1.5ML (1GM/ML) N020696 001 Dec 04, 1997 Jun DISC

FOMEPIZOLE

AP ! MYLAN INSTITUTIONAL 1.5GM/1.5ML (1GM/ML) A078639 001 Mar 03, 2008 Jun CHRS

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION
DULERA

>A> + MERCK SHARP DOHME 0.005MG/INH; 0.05MG/INH N022518 003 Aug 12, 2019 Aug NEWA

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

>A>	AP	APOTEX INC	EQ 150MG BASE/VIAL	A205020	001	Sep 05, 2019	Aug NEWA
>A>	AP	BAXTER HLTHCARE CORP	EQ 150MG BASE/VIAL	A211860	001	Sep 05, 2019	Aug NEWA
>A>	AP	BE PHARMS	EQ 150MG BASE/VIAL	A212309	001	Sep 05, 2019	Aug NEWA
>A>	AP	LUPIN LTD	EQ 150MG BASE/VIAL	A210689	001	Sep 05, 2019	Aug NEWA
>A>	AP	MSN LABS PVT LTD	EQ 150MG BASE/VIAL	A209965	001	Sep 05, 2019	Aug NEWA
>A>		MYLAN LABS LTD	EQ 115MG BASE/VIAL	A204015	001	Sep 05, 2019	Aug NFTG
>A>	AP		EQ 150MG BASE/VIAL	A204015	002	Sep 05, 2019	Aug NEWA
>A>	AP	SUNGEN PHARMA	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019	Aug NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

@ ANI PHARMS INC 10MG; 12.5MG
 @ 20MG; 12.5MG

A076608 001 Dec 03, 2004 May CAHN
 A076608 002 Dec 03, 2004 May CAHN

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

@ DR REDDYS EQ 50MG PHENYTOIN NA/ML
 @ LUITPOLD EQ 50MG PHENYTOIN NA/ML
 @ EQ 50MG PHENYTOIN NA/ML

A076886 001 Aug 06, 2007 May CAHN
 A078277 001 Aug 06, 2007 Feb DISC
 A090099 001 May 13, 2010 Feb DISC

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVATRIPTAN SUCCINATE

>D> @ AMNEAL PHARMS CO EQ 2.5MG BASE
 >A> AB EQ 2.5MG BASE
 @ EQ 2.5MG BASE

A211292 001 Nov 06, 2018 Aug CMFD
 A211292 001 Nov 06, 2018 Aug CMFD
 A211292 001 Nov 06, 2018 May DISC

FULVESTRANT

INJECTABLE; INTRAMUSCULAR

FASLODEX

AO +! ASTRAZENECA 50MG/ML
 AP +! 50MG/ML

N021344 001 Apr 25, 2002 Apr CMS1
 N021344 001 Apr 25, 2002 Feb CFTG

FULVESTRANT

AO AMNEAL PHARMS CO 50MG/ML
 AP 50MG/ML
 >A> AO GLENMARK PHARMS INC 50MG/ML
 AO MYLAN INSTITUTIONAL 50MG/ML
 >A> AO SAGENT PHARMS 50MG/ML
 AO SANDOZ INC 50MG/ML

A210044 001 Mar 04, 2019 Apr CMS1
 A210044 001 Mar 04, 2019 Feb NFTG
 A207754 001 Aug 22, 2019 Aug NEWA
 A208811 001 Jul 23, 2019 Jul NEWA
 A205871 001 Aug 22, 2019 Aug NEWA
 A205935 001 May 14, 2019 Apr NEWA

SOLUTION; INTRAMUSCULAR

FULVESTRANT

>A> FRESENIUS KABI USA 250MG/5ML (50MG/ML)
 TEVA PHARMS USA INC 250MG/5ML (50MG/ML)

N210326 001 May 20, 2019 May NEWA
 N210063 001 Aug 19, 2019 Aug NEWA

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP AUROBINDO PHARMA LTD 10MG/ML

A212174 001 May 03, 2019 Apr NEWA

TABLET; ORAL

FUROSEMIDE

@ ANI PHARMS INC 20MG
 AB HERITAGE PHARMA 20MG
 AB 40MG
 AB HIKMA 20MG
 AB 40MG

A071379 001 Jan 02, 1987 Jul CAHN
 N018413 001 Nov 30, 1983 Feb CAHN
 N018413 002 Nov 30, 1983 Feb CAHN
 N018823 001 Nov 10, 1983 Apr CAHN
 N018823 002 Nov 10, 1983 Apr CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB GRANULES INDIA LTD 100MG
 AB 300MG
 AB 400MG

A075360 001 Apr 06, 2005 Jun CAHN
 A075360 002 Apr 06, 2005 Jun CAHN
 A075360 003 Apr 06, 2005 Jun CAHN

TABLET; ORAL

GABAPENTIN

>D> AB APOTEX INC 600MG
 >D> AB 800MG

A077661 004 Sep 13, 2006 Aug CAHN
 A077661 005 Sep 13, 2006 Aug CAHN

TABLET;ORAL

GABAPENTIN

	@	IVAX SUB TEVA PHARMS	600MG	A076017	004	Apr 29, 2005	Jul	DISC
	@		800MG	A076017	005	Apr 29, 2005	Jul	DISC
	@	LUPIN LTD	600MG	A209306	001	Aug 24, 2018	Mar	DISC
	@		800MG	A209306	002	Aug 24, 2018	Mar	DISC
>A>	AB	RUBICON	600MG	A077661	004	Sep 13, 2006	Aug	CAHN
>A>	AB		800MG	A077661	005	Sep 13, 2006	Aug	CAHN

GALANTAMINE HYDROBROMIDE

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

	@	HERITAGE PHARMA	EQ 4MG BASE	A077585	001	Sep 15, 2009	May	CAHN
	@		EQ 8MG BASE	A077585	002	Sep 15, 2009	May	CAHN
	@		EQ 12MG BASE	A077585	003	Sep 15, 2009	May	CAHN

GALLIUM CITRATE GA-67

INJECTABLE;INJECTION

GALLIUM CITRATE GA 67

BS		CURIUM	2mCi/ML	N018058	001		Jan	CAHN
----	--	--------	---------	---------	-----	--	-----	------

>A>		<u>GALLIUM DOTATOC GA-68</u>						
>A>		SOLUTION;INTRAVENOUS						
>A>		GALLIUM DOTATOC GA 68						
>A>	+	UIHC PET IMAGING	0.5-4mCi/ML	N210828	001	Aug 21, 2019	Aug	NEWA

GALLIUM NITRATE

INJECTABLE;INJECTION

GANITE

>D>		@ CHAPTER 7 TRUSTEE	25MG/ML	N019961	002	Jan 17, 1991	Aug	CAHN
>A>		@ CHEPLAPHARM	25MG/ML	N019961	002	Jan 17, 1991	Aug	CAHN

GANCICLOVIR SODIUM

INJECTABLE;INJECTION

CYTOVENE

>A>	AP	+	CHEPLAPHARM	EQ 500MG BASE/VIAL	N019661	001	Jun 23, 1989	Aug	CAHN
>D>	AP	+	ROCHE PALO	EQ 500MG BASE/VIAL	N019661	001	Jun 23, 1989	Aug	CAHN
			GANCICLOVIR SODIUM						
	AP		CUSTOPHARM INC	EQ 500MG BASE/VIAL	A212001	001	Jun 20, 2019	Jun	NEWA
	AP		FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A090658	001	Jun 21, 2010	Jul	CTNA
	AP		HAINAN POLY PHARM	EQ 500MG BASE/VIAL	A204204	001	Nov 08, 2018	Jul	CTNA
		@	LUITPOLD	EQ 500MG BASE/VIAL	A202624	001	Sep 18, 2013	Jul	CTNA
		@		EQ 500MG BASE/VIAL	A202624	001	Sep 18, 2013	Feb	DISC
	AP		MYLAN LABS LTD	EQ 500MG BASE/VIAL	A204560	001	Nov 17, 2017	Jul	CTNA
	AP		PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A204950	001	Dec 06, 2016	Jul	CTNA

GANIRELIX ACETATE

INJECTABLE;INJECTION

GANIRELIX ACETATE

AP		+	ORGANON USA INC	250MCG/0.5ML	N021057	001	Jul 29, 1999	Mar	CPOT
AP			SUN PHARM	250MCG/0.5ML	A204246	001	Nov 30, 2018	Mar	CPOT

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

AP			FRESENIUS KABI USA	EQ 200MG BASE/VIAL	A090799	001	Jul 25, 2011	Jan	CAHN
AP				EQ 1GM BASE/VIAL	A090799	002	Jul 25, 2011	Jan	CAHN
AP				EQ 2GM BASE/VIAL	A090799	003	May 16, 2011	Jan	CAHN
AP			INGENUS PHARMS LLC	200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019	Feb	NEWA
AP				1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019	Feb	NEWA
AP				2GM/52.6ML (38MG/ML)	A210383	003	Feb 14, 2019	Feb	NEWA
		@	LUITPOLD	EQ 200MG BASE/VIAL	A202031	001	May 07, 2013	Feb	DISC
		@		EQ 1GM BASE/VIAL	A202031	002	May 07, 2013	Feb	DISC
AP			SHILPA MEDICARE LTD	EQ 200MG BASE/VIAL	A207575	001	Feb 22, 2019	Feb	NEWA
AP				EQ 1GM BASE/VIAL	A207575	002	Feb 22, 2019	Feb	NEWA

GENTAMICIN SULFATE

INJECTABLE;INJECTION

GENTAMICIN SULFATE

AP		!	FRESENIUS KABI USA	EQ 10MG BASE/ML	A062366	002	Feb 06, 1986	Jul	CHRS
----	--	---	--------------------	-----------------	---------	-----	--------------	-----	------

GLASDEGIB MALEATETABLET; ORAL
DAURISMO

+	PFIZER INC	EQ 25MG BASE	N210656	001	Nov 21, 2018	Feb CAHN
+	!	EQ 100MG BASE	N210656	002	Nov 21, 2018	Feb CAHN

GLIMEPIRIDETABLET; ORAL
GLIMEPIRIDE

AB	MICRO LABS	1MG	A091220	001	Jun 29, 2012	Mar CAHN
AB		2MG	A091220	002	Jun 29, 2012	Mar CAHN
		3MG	A091220	003	Jun 29, 2012	Mar CAHN
AB		4MG	A091220	004	Jun 29, 2012	Mar CAHN
		6MG	A091220	005	Jun 29, 2012	Mar CAHN
AB		8MG	A091220	006	Jun 29, 2012	Mar CAHN

GLIPIZIDETABLET; ORAL
GLIPIZIDE

@	BEXIMCO PHARMS USA	5MG	A074542	001	Jun 20, 1995	Feb CAHN
@		10MG	A074542	002	Jun 20, 1995	Feb CAHN

TABLET, EXTENDED RELEASE; ORAL
GLIPIZIDE

@	MYLAN	2.5MG	A202298	001	May 19, 2015	Feb DISC
@		5MG	A202298	002	May 19, 2015	Feb DISC
@		10MG	A202298	003	May 19, 2015	Feb DISC

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE
@ MYLAN 2.5MG; 250MG

A078083	001	Apr 12, 2007	Apr DISC
---------	-----	--------------	----------

GLUCAGONPOWDER; NASAL
BAQSIMI

+	!	ELI LILLY AND CO	3MG	N210134	001	Jul 24, 2019	Jul NEWA
---	---	------------------	-----	---------	-----	--------------	----------

GLYBURIDETABLET; ORAL
GLYBURIDE

	@	ORIENT PHARMA CO LTD	1.25MG	A206483	001	Feb 22, 2019	Jul DISC
AB1			1.25MG	A206483	001	Feb 22, 2019	Feb NEWA
	@		2.5MG	A206483	002	Feb 22, 2019	Jul DISC
AB1			2.5MG	A206483	002	Feb 22, 2019	Feb NEWA
	@		5MG	A206483	003	Feb 22, 2019	Jul DISC
AB1			5MG	A206483	003	Feb 22, 2019	Feb NEWA

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

>D>	AB	HERITAGE PHARMS INC	1.25MG; 250MG	A079009	001	Jun 03, 2009	Aug DISC
>A>		@	1.25MG; 250MG	A079009	001	Jun 03, 2009	Aug DISC
>D>	AB		2.5MG; 500MG	A079009	002	Jun 03, 2009	Aug DISC
>A>		@	2.5MG; 500MG	A079009	002	Jun 03, 2009	Aug DISC
>D>	AB		5MG; 500MG	A079009	003	Jun 03, 2009	Aug DISC
>A>		@	5MG; 500MG	A079009	003	Jun 03, 2009	Aug DISC

GLYCEROL PHENYLBUTYRATELIQUID; ORAL
RAVICTI

+	!	HORIZON THERAP	1.1GM/ML	N203284	001	Feb 01, 2013	Feb CAHN
---	---	----------------	----------	---------	-----	--------------	----------

GLYCOPYRROLATEINJECTABLE; INJECTION
GLYCOPYRROLATE

AP	CAPLIN	0.2MG/ML	A211705	001	Mar 20, 2019	Mar NEWA	
AP	PIRAMAL CRITICAL	0.2MG/ML	A210842	001	Oct 25, 2018	Jun CAHN	
AP	SANDOZ INC	0.2MG/ML	A211334	001	May 14, 2019	Apr NEWA	
	ROBINUL						
>A>	+	@ HIKMA	0.2MG/ML	N017558	001		Aug CAHN
>D>	+	@ WEST-WARD PHARMS INT	0.2MG/ML	N017558	001		Aug CAHN

TABLET;ORAL

GLYCOPYRROLATE

AA	AUROLIFE PHARMA LLC	2MG	A202675	002	Oct 30, 2018	May NEWA
AA	KENTON	1MG	A091182	001	Feb 03, 2014	Mar CAHN
AA		2MG	A091182	002	Feb 03, 2014	Mar CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

AP	BIONPHARMA INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Apr CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Apr CAHN
AP	! DR REDDYS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078392	001	Dec 31, 2007	May CAHN
AP	!	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077297	001	Jun 30, 2008	May CAHN
	@ LUITPOLD	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A091274	001	Sep 22, 2010	Feb DISC
	GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP	BIONPHARMA INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Apr CAHN
	@ DR REDDYS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007	May CAHN

TABLET;ORAL

GRANISETRON HYDROCHLORIDE

	@ TEVA PHARMS	EQ 1MG BASE	A078080	001	Dec 31, 2007	Jan DISC
AB	! WEST-WARD PHARMS INT	EQ 1MG BASE	A077842	001	Dec 31, 2007	Jan CHRS

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

OBREDON

	+ @ SOVEREIGN PHARMS	200MG/5ML;2.5MG/5ML	N205474	001	Nov 14, 2014	Jun DISC
--	----------------------	---------------------	---------	-----	--------------	----------

TABLET;ORAL

XTRELUS

	+ @ ECI PHARMS LLC	400MG;5MG	N208085	001	Apr 25, 2018	Jun DISC
--	--------------------	-----------	---------	-----	--------------	----------

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

AB	EPIC PHARMA LLC	EQ 1MG BASE	A074673	001	Feb 28, 1997	Apr CMFD
AB		EQ 2MG BASE	A074673	002	Feb 28, 1997	Apr CMFD

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

	@ MYLAN	EQ 1MG BASE	A202578	001	Jun 02, 2015	May DISC
	@	EQ 2MG BASE	A202578	002	Jun 02, 2015	May DISC
	@	EQ 3MG BASE	A202578	003	Jun 02, 2015	May DISC
	@	EQ 4MG BASE	A202578	004	Jun 02, 2015	May DISC

HALCINONIDE

CREAM;TOPICAL

HALCINONIDE

AB	MYLAN	0.1%	A211027	001	Aug 12, 2019	Jul NEWA
	HALOG					
>D>	+! SUN PHARM INDS INC	0.1%	N017556	001		Aug CFTG
>A> AB	+!	0.1%	N017556	001		Aug CFTG

HALOBETASOL PROPIONATE

LOTION;TOPICAL

BRYHALI

	+! BAUSCH	0.01%	N209355	001	Nov 06, 2018	Apr CAHN
	+! DOW PHARM	0.01%	N209355	001	Nov 06, 2018	Jan CHRS
	+	0.01%	N209355	001	Nov 06, 2018	Jan CRLD

HALOBETASOL PROPIONATE; TAZAROTENE

LOTION;TOPICAL

DUOBRII

	+! BAUSCH	0.01%;0.045%	N209354	001	Apr 25, 2019	Apr NEWA
--	-----------	--------------	---------	-----	--------------	----------

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

	@ INNOGENIX	0.5MG	A071173	002	Jan 02, 1987	May CMS1
	@	1MG	A071173	003	Jan 02, 1987	May CMS1
	@	2MG	A071173	004	Jan 02, 1987	May CMS1
	@	5MG	A071173	005	Jan 07, 1988	May CMS1
	@	10MG	A071173	001	Jan 07, 1988	Mar CAHN

TABLET;ORAL
HALOPERIDOL

	@	20MG	A071173	006	Jan 07, 1988	May CMS1	
	!	MYLAN	2MG	A070278	001	Jun 10, 1986	Jan CTEC
AB	!		2MG	A070278	001	Jun 10, 1986	Jan CHRS
	@	SANDOZ	2MG	A071208	001	Nov 17, 1986	Jan DISC

HALOPERIDOL LACTATE

CONCENTRATE;ORAL
HALOPERIDOL

AA	!	PHARM ASSOC	EQ 2MG BASE/ML	A073037	001	Feb 26, 1993	May CHRS
	@	TEVA PHARMS	EQ 2MG BASE/ML	A071617	001	Dec 01, 1988	May DISC

INJECTABLE;INJECTION
HALOPERIDOL

AP		FRESENIUS KABI USA	EQ 5MG BASE/ML	A210356	001	Jul 01, 2019	Jun NEWA
----	--	--------------------	----------------	---------	-----	--------------	----------

HEPARIN SODIUM

INJECTABLE;INJECTION
HEPARIN SODIUM

>A>		B BRAUN MEDICAL INC	5,000 UNITS/0.5ML	A208827	001	Nov 19, 2018	Aug CAHN
AP	+	HIKMA	1,000 UNITS/ML	N017037	001		Feb CAHN
AP	+		5,000 UNITS/ML	N017037	002		Feb CAHN
	@		5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Feb CAHN
AP	+		10,000 UNITS/ML	N017037	003		Feb CAHN
AP		NANJING KING-FRIEND	1,000 UNITS/ML	A211007	001	May 28, 2019	May NEWA
AP			5,000 UNITS/ML	A211007	002	May 28, 2019	May NEWA
AP			10,000 UNITS/ML	A211007	003	May 28, 2019	May NEWA
>D>		STERINOVA INC	5,000 UNITS/0.5ML	A208827	001	Nov 19, 2018	Aug CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL
HYCODAN

AA	+	GENUS LIFESCIENCES	1.5MG/5ML;5MG/5ML	N005213	002	Jul 26, 1988	Jun CMFD
		HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE					
	@	BRECKENRIDGE	1.5MG/5ML;5MG/5ML	A210663	001	Jun 11, 2019	Jul DISC
AA		BRECKENRIDGE PHARM	1.5MG/5ML;5MG/5ML	A210663	001	Jun 11, 2019	May NEWA
AA		TORRENT	1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	May CMFD
	@		1.5MG/5ML;5MG/5ML	A204765	001	Mar 06, 2017	Jan CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION
HYDRALAZINE HYDROCHLORIDE

	@	LUITPOLD	20MG/ML	A040136	001	Jun 30, 1997	Feb DISC
--	---	----------	---------	---------	-----	--------------	----------

TABLET;ORAL

		HYDRALAZINE HYDROCHLORIDE					
AA		UPSHER SMITH LABS	10MG	A209251	001	Jul 09, 2018	Jun CAHN
AA			25MG	A209251	002	Jul 09, 2018	Jun CAHN
AA			50MG	A209251	003	Jul 09, 2018	Jun CAHN
AA			100MG	A209251	004	Jul 09, 2018	Jun CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

		IRBESARTAN AND HYDROCHLOROTHIAZIDE					
	@	APOTEX INC	12.5MG;150MG	A201505	001	Oct 15, 2012	Jul DISC
	@		12.5MG;300MG	A201505	002	Oct 15, 2012	Jul DISC

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET;ORAL

		LISINAPRIL AND HYDROCHLOROTHIAZIDE					
>D>	AB	HERITAGE PHARMA	12.5MG;10MG	A075776	001	Jul 01, 2002	Aug DISC
>A>		@	12.5MG;10MG	A075776	001	Jul 01, 2002	Aug DISC
	AB		12.5MG;10MG	A075776	001	Jul 01, 2002	Feb CAHN
>D>	AB		12.5MG;20MG	A075776	002	Jul 01, 2002	Aug DISC
>A>		@	12.5MG;20MG	A075776	002	Jul 01, 2002	Aug DISC
	AB		12.5MG;20MG	A075776	002	Jul 01, 2002	Feb CAHN
>D>	AB		25MG;20MG	A075776	003	Jul 01, 2002	Aug DISC
>A>		@	25MG;20MG	A075776	003	Jul 01, 2002	Aug DISC
	AB		25MG;20MG	A075776	003	Jul 01, 2002	Feb CAHN

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

>D>	AB	ACCORD HLTHCARE	12.5MG;20MG	A209281	001	Feb 07, 2019	Aug DISC
>A>		@	12.5MG;20MG	A209281	001	Feb 07, 2019	Aug DISC
	AB		12.5MG;20MG	A209281	001	Feb 07, 2019	Jan NEWA
>D>	AB		12.5MG;40MG	A209281	002	Feb 07, 2019	Aug DISC
>A>		@	12.5MG;40MG	A209281	002	Feb 07, 2019	Aug DISC
	AB		12.5MG;40MG	A209281	002	Feb 07, 2019	Jan NEWA
>D>	AB		25MG;40MG	A209281	003	Feb 07, 2019	Aug DISC
>A>		@	25MG;40MG	A209281	003	Feb 07, 2019	Aug DISC
	AB		25MG;40MG	A209281	003	Feb 07, 2019	Jan NEWA
		@ TEVA PHARMS USA	12.5MG;20MG	A200532	001	Apr 24, 2017	Jul DISC
		@	25MG;40MG	A200532	003	Apr 24, 2017	Jul DISC

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

		@ MYLAN	12.5MG;EQ 10MG BASE	A077093	001	Mar 28, 2005	May DISC
		@	12.5MG;EQ 20MG BASE	A077093	002	Mar 28, 2005	May DISC
		@	25MG;EQ 20MG BASE	A077093	003	Mar 28, 2005	May DISC
		QUINARETIC					
AB		LUPIN	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	Feb CAHN
AB			12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	Feb CAHN
AB			25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	Feb CAHN

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB		GLENMARK PHARMS LTD	12.5MG;40MG	A202544	001	Mar 04, 2019	Feb NEWA
AB			12.5MG;80MG	A202544	002	Mar 04, 2019	Feb NEWA
AB			25MG;80MG	A202544	003	Mar 04, 2019	Feb NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

		@ ANI PHARMS INC	25MG;50MG	A074259	001	Mar 30, 1995	Jun DISC
		@ CASI PHARMS INC	25MG;50MG	A073191	001	Jul 31, 1991	Jun DISC
AB		ZYDUS PHARMS	25MG;37.5MG	A208358	001	Feb 11, 2019	Jan NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

>D>	AB	ZYDUS PHARMS	12.5MG;80MG	A203000	001	Mar 15, 2019	Aug DISC
>A>		@	12.5MG;80MG	A203000	001	Mar 15, 2019	Aug DISC
	AB		12.5MG;80MG	A203000	001	Mar 15, 2019	Mar NEWA
>D>	AB		12.5MG;160MG	A203000	002	Mar 15, 2019	Aug DISC
>A>		@	12.5MG;160MG	A203000	002	Mar 15, 2019	Aug DISC
	AB		12.5MG;160MG	A203000	002	Mar 15, 2019	Mar NEWA
>D>	AB		12.5MG;320MG	A203000	003	Mar 15, 2019	Aug DISC
>A>		@	12.5MG;320MG	A203000	003	Mar 15, 2019	Aug DISC
	AB		12.5MG;320MG	A203000	003	Mar 15, 2019	Mar NEWA
>D>	AB		25MG;160MG	A203000	004	Mar 15, 2019	Aug DISC
>A>		@	25MG;160MG	A203000	004	Mar 15, 2019	Aug DISC
	AB		25MG;160MG	A203000	004	Mar 15, 2019	Mar NEWA
>D>	AB		25MG;320MG	A203000	005	Mar 15, 2019	Aug DISC
>A>		@	25MG;320MG	A203000	005	Mar 15, 2019	Aug DISC
	AB		25MG;320MG	A203000	005	Mar 15, 2019	Mar NEWA

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

ZOHYDRO ER

+	!	PERSION	10MG	N202880	001	Oct 25, 2013	Apr CAHN
+			15MG	N202880	002	Oct 25, 2013	Apr CAHN
+			20MG	N202880	003	Oct 25, 2013	Apr CAHN
+			30MG	N202880	004	Oct 25, 2013	Apr CAHN
+			40MG	N202880	005	Oct 25, 2013	Apr CAHN
+			50MG	N202880	006	Oct 25, 2013	Apr CAHN

TABLET, EXTENDED RELEASE; ORAL

HYSINGLA ER

+	!	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014	Jul CMS1
+			30MG	N206627	002	Nov 20, 2014	Jul CMS1

TABLET, EXTENDED RELEASE;ORAL
HYSINGLA ER

+	40MG	N206627	003	Nov 20, 2014	Jul CMS1
+	60MG	N206627	004	Nov 20, 2014	Jul CMS1
+	80MG	N206627	005	Nov 20, 2014	Jul CMS1
+	100MG	N206627	006	Nov 20, 2014	Jul CMS1
+	120MG	N206627	007	Nov 20, 2014	Jul CMS1

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

@ ANI PHARMS INC	5MG;200MG	A077454	001	Jun 23, 2010	May CAHN
------------------	-----------	---------	-----	--------------	----------

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ MAYNE PHARMA INC	5MG/5ML;60MG/5ML	A205658	001	Nov 17, 2015	Jun DISC
@ PADDOCK LLC	5MG/5ML;60MG/5ML	A204658	001	Apr 29, 2014	Jun DISC
@ TORRENT	5MG/5ML;60MG/5ML	A206661	001	Jan 23, 2019	Feb DISC
AA	5MG/5ML;60MG/5ML	A206661	001	Jan 23, 2019	Jan NEWA
REZIRA					
+ @ PERSION	5MG/5ML;60MG/5ML	N022442	001	Jun 08, 2011	Jun DISC
AA +!	5MG/5ML;60MG/5ML	N022442	001	Jun 08, 2011	Apr CAHN

HYDROCORTISONE

CREAM;TOPICAL

NUTRACORT

@ BAUSCH	0.5%	A080442	002		Feb CAHN
@	1%	A080442	003		Feb CAHN

LOTION;TOPICAL

CETACORT

@ BAUSCH	0.5%	A080426	002		Feb CAHN
@	1%	A080426	001		Feb CAHN

TABLET;ORAL

HYDROCORTISONE

>A> AB	BRECKENRIDGE	5MG	A207029	001	Apr 27, 2017	Aug CAHN
>A> AB		10MG	A207029	002	Apr 27, 2017	Aug CAHN
>A> AB		20MG	A207029	003	Apr 27, 2017	Aug CAHN
>D> AB	PII	5MG	A207029	001	Apr 27, 2017	Aug CAHN
>D> AB		10MG	A207029	002	Apr 27, 2017	Aug CAHN
>D> AB		20MG	A207029	003	Apr 27, 2017	Aug CAHN

HYDROCORTISONE BUTYRATE

CREAM;TOPICAL

LOCOID

AB1 +!	BAUSCH	0.1%	N018514	001	Mar 31, 1982	May CAHN
--------	--------	------	---------	-----	--------------	----------

LOTION;TOPICAL

LOCOID

AB +!	BAUSCH	0.1%	N022076	001	May 18, 2007	May CAHN
-------	--------	------	---------	-----	--------------	----------

SOLUTION;TOPICAL

LOCOID

AT +!	BAUSCH	0.1%	N019116	001	Feb 25, 1987	May CAHN
-------	--------	------	---------	-----	--------------	----------

HYDROCORTISONE VALERATE

CREAM;TOPICAL

HYDROCORTISONE VALERATE

>A> AB	LUPIN LTD	0.2%	A210307	001	Aug 15, 2019	Aug NEWA
AB	PERRIGO ISRAEL	0.2%	A075666	001	May 24, 2000	May CAHN

>D> HYDROGEN PEROXIDE

>D> SOLUTION;TOPICAL

>D> ESKATA

>D> +!	ACLARIS	40%	N209305	001	Dec 14, 2017	Aug DISC
>A> + @		40%	N209305	001	Dec 14, 2017	Aug DISC

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

EXALGO

+ @ SPECGX LLC	8MG	N021217	001	Mar 01, 2010	Mar DISC
+ @	12MG	N021217	002	Mar 01, 2010	Mar DISC
+ @	16MG	N021217	003	Mar 01, 2010	Mar DISC
+ @	32MG	N021217	004	Aug 24, 2012	Mar DISC

TABLET, EXTENDED RELEASE;ORAL
HYDROMORPHONE HYDROCHLORIDE

AB ! OSMOTICA 32MG A205629 004 Jul 07, 2016 Mar CHRS

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

HYDROXYCHLOROQUINE SULFATE

@ LUPIN LTD 200MG

A210543 001 Jul 06, 2018 Feb DISC

HYDROXYPROGESTERONE CAPROATE

SOLUTION;INTRAMUSCULAR

HYDROXYPROGESTERON CAPROATE

AP1 AM REGENT 1250MG/5ML (250MG/ML)

A210724 001 Aug 09, 2019 Jul NEWA

HYDROXYPROGESTERONE CAPROATE

AP ASPEN 250MG/ML (250MG/ML)

A211777 001 Aug 08, 2019 Jul NEWA

AP2 ! ASPEN GLOBAL INC 1250MG/5ML (250MG/ML)

A200271 001 Aug 24, 2015 Apr CPOT

AP2 ! 250MG/ML (250MG/ML)

A200271 001 Aug 24, 2015 Apr CTEC

AP EUGIA PHARMA 250MG/ML (250MG/ML)

A211071 001 Apr 16, 2019 Apr NEWA

AP1 1250MG/5ML (250MG/ML)

A211070 001 Apr 16, 2019 Apr NEWA

AP2 1250MG/5ML (250MG/ML)

A211142 001 May 09, 2019 Apr NEWA

AP SLAYBACK PHARMA LLC 250MG/ML (250MG/ML)

A210877 001 Mar 22, 2019 Mar NEWA

AP1 1250MG/5ML (250MG/ML)

A210618 001 Dec 28, 2018 Apr CTEC

AP1 SUN PHARM 1250MG/5ML (250MG/ML)

A208381 001 Apr 09, 2019 Apr CTEC

AP 1250MG/5ML (250MG/ML)

A208381 001 Apr 09, 2019 Mar NEWA

MAKENA

AP1 +! AMAG PHARMA USA 1250MG/5ML (250MG/ML)

N021945 001 Feb 03, 2011 Apr CTEC

HYDROXYPROPYL CELLULOSE

INSERT;OPHTHALMIC

LACRISERT

+! VALEANT PHARMS INTL 5MG

N018771 001 Jan CAHN

HYDROXYZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDROXYZINE HYDROCHLORIDE

! LUITPOLD 50MG/ML

A087408 002 Mar CMFD

@ 50MG/ML

A087408 002 Feb DISC

SYRUP;ORAL

HYDROXYZINE HYDROCHLORIDE

AA TORRENT 10MG/5ML

A210634 001 Feb 26, 2019 Feb NEWA

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

AB EPIC PHARMA LLC 10MG

A040604 002 Dec 28, 2004 Jan CAHN

AB 25MG

A040604 003 Dec 28, 2004 Jan CAHN

AB 50MG

A040604 001 Dec 28, 2004 Jan CAHN

AB KVK TECH 25MG

A040786 002 Mar 20, 2007 Feb CMS1

AB 50MG

A040786 003 Mar 20, 2007 Feb CMS1

>D> AB MYLAN 10MG

A091176 001 Jun 07, 2010 Aug DISC

>A> @ 10MG

A091176 001 Jun 07, 2010 Aug DISC

>D> AB 25MG

A091176 002 Jun 07, 2010 Aug DISC

>A> @ 25MG

A091176 002 Jun 07, 2010 Aug DISC

>D> AB 50MG

A091176 003 Jun 07, 2010 Aug DISC

>A> @ 50MG

A091176 003 Jun 07, 2010 Aug DISC

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

@ BEXIMCO PHARMS USA EQ 25MG HYDROCHLORIDE

A081127 001 Jun 28, 1991 Feb CAHN

IBUPROFEN

SOLUTION;INTRAVENOUS

CALDOLOR

+! CUMBERLAND PHARMS 800MG/200ML (4MG/ML)

N022348 003 Jan 25, 2019 Jan NEWA

SUSPENSION;ORAL

IBUPROFEN

AB L PERRIGO CO 100MG/5ML

A076925 001 Sep 23, 2004 May CAHN

TABLET;ORAL

IBUPROFEN

@ HEC PHARM 400MG

A204062 001 Sep 10, 2018 Mar DISC

@ 600MG

A204062 002 Sep 10, 2018 Mar DISC

@ 800MG

A204062 003 Sep 10, 2018 Mar DISC

AB PERRIGO PHARMS CO 400MG

A077114 001 Jul 18, 2005 May CAHN

TABLET;ORAL
IBUPROFEN

AB		600MG	A077114	002	Jul 18, 2005	May CAHN
AB		800MG	A077114	003	Jul 18, 2005	May CAHN

IBUTILIDE FUMARATE

INJECTABLE;INJECTION
IBUTILIDE FUMARATE
@ LUITPOLD

0.1MG/ML	A090240	001	Jan 11, 2010	Feb DISC
----------	---------	-----	--------------	----------

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS
FIRAZYR

AP	+!	SHIRE ORPHAN THERAP	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N022150	001	Aug 25, 2011	Jul CFTG
		ICATIBANT ACETATE					
AP		TEVA PHARMS USA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A210118	001	Jul 15, 2019	Jul NFTG

ILOPERIDONE

TABLET;ORAL
FANAPT

>D>	AB	+!	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Aug CTEC
>A>		+!		1MG	N022192	001	May 06, 2009	Aug CTEC
>D>	AB	+		2MG	N022192	002	May 06, 2009	Aug CTEC
>A>		+		2MG	N022192	002	May 06, 2009	Aug CTEC
>D>	AB	+		4MG	N022192	003	May 06, 2009	Aug CTEC
>A>		+		4MG	N022192	003	May 06, 2009	Aug CTEC
>D>	AB	+		6MG	N022192	004	May 06, 2009	Aug CTEC
>A>		+		6MG	N022192	004	May 06, 2009	Aug CTEC
>D>	AB	+		8MG	N022192	005	May 06, 2009	Aug CTEC
>A>		+		8MG	N022192	005	May 06, 2009	Aug CTEC
>D>	AB	+		10MG	N022192	006	May 06, 2009	Aug CTEC
>A>		+		10MG	N022192	006	May 06, 2009	Aug CTEC
>D>	AB	+		12MG	N022192	007	May 06, 2009	Aug CTEC
>A>		+		12MG	N022192	007	May 06, 2009	Aug CTEC

ILOPERIDONE

>A>		@	INVENTIA	1MG	A207231	001	Nov 28, 2016	Aug CAHN
>A>		@		2MG	A207231	002	Nov 28, 2016	Aug CAHN
>A>		@		4MG	A207231	003	Nov 28, 2016	Aug CAHN
>A>		@		6MG	A207231	004	Nov 28, 2016	Aug CAHN
>A>		@		8MG	A207231	005	Nov 28, 2016	Aug CAHN
>A>		@		10MG	A207231	006	Nov 28, 2016	Aug CAHN
>A>		@		12MG	A207231	007	Nov 28, 2016	Aug CAHN
>D>		@	INVENTIA HLTHCARE	1MG	A207231	001	Nov 28, 2016	Aug CAHN
		@		1MG	A207231	001	Nov 28, 2016	Jul DISC
>D>		@		2MG	A207231	002	Nov 28, 2016	Aug CAHN
		@		2MG	A207231	002	Nov 28, 2016	Jul DISC
>D>		@		4MG	A207231	003	Nov 28, 2016	Aug CAHN
		@		4MG	A207231	003	Nov 28, 2016	Jul DISC
>D>		@		6MG	A207231	004	Nov 28, 2016	Aug CAHN
		@		6MG	A207231	004	Nov 28, 2016	Jul DISC
>D>		@		8MG	A207231	005	Nov 28, 2016	Aug CAHN
		@		8MG	A207231	005	Nov 28, 2016	Jul DISC
>D>		@		10MG	A207231	006	Nov 28, 2016	Aug CAHN
		@		10MG	A207231	006	Nov 28, 2016	Jul DISC
>D>		@		12MG	A207231	007	Nov 28, 2016	Aug CAHN
		@		12MG	A207231	007	Nov 28, 2016	Jul DISC
>D>	AB		TARO PHARM INDS LTD	1MG	A207098	001	Jul 22, 2019	Aug DISC
>A>		@		1MG	A207098	001	Jul 22, 2019	Aug DISC
	AB			1MG	A207098	001	Jul 22, 2019	Jul NEWA
>D>	AB			2MG	A207098	002	Jul 22, 2019	Aug DISC
>A>		@		2MG	A207098	002	Jul 22, 2019	Aug DISC
	AB			2MG	A207098	002	Jul 22, 2019	Jul NEWA
>D>	AB			4MG	A207098	003	Jul 22, 2019	Aug DISC
>A>		@		4MG	A207098	003	Jul 22, 2019	Aug DISC
	AB			4MG	A207098	003	Jul 22, 2019	Jul NEWA
>D>	AB			6MG	A207098	004	Jul 22, 2019	Aug DISC
>A>		@		6MG	A207098	004	Jul 22, 2019	Aug DISC
	AB			6MG	A207098	004	Jul 22, 2019	Jul NEWA
>D>	AB			8MG	A207098	005	Jul 22, 2019	Aug DISC
>A>		@		8MG	A207098	005	Jul 22, 2019	Aug DISC
	AB			8MG	A207098	005	Jul 22, 2019	Jul NEWA
>D>	AB			10MG	A207098	006	Jul 22, 2019	Aug DISC
>A>		@		10MG	A207098	006	Jul 22, 2019	Aug DISC

TABLET;ORAL
ILOPERIDONE

AB		10MG	A207098	006	Jul 22, 2019	Jul NEWA
>D>	AB	12MG	A207098	007	Jul 22, 2019	Aug DISC
>A>	@	12MG	A207098	007	Jul 22, 2019	Aug DISC
AB		12MG	A207098	007	Jul 22, 2019	Jul NEWA

IMATINIB MESYLATE

TABLET;ORAL
IMATINIB MESYLATE

>D>	AB	AMNEAL PHARMS	EQ 100MG BASE	A207495	001	Feb 08, 2019	Aug DISC
>A>	@		EQ 100MG BASE	A207495	001	Feb 08, 2019	Aug DISC
	AB		EQ 100MG BASE	A207495	001	Feb 08, 2019	Feb NEWA
>D>	AB		EQ 400MG BASE	A207495	002	Feb 08, 2019	Aug DISC
>A>	@		EQ 400MG BASE	A207495	002	Feb 08, 2019	Aug DISC
	AB		EQ 400MG BASE	A207495	002	Feb 08, 2019	Feb NEWA
	AB	BRECKENRIDGE	EQ 100MG BASE	A205990	001	Feb 08, 2019	Feb NEWA
	AB		EQ 400MG BASE	A205990	002	Feb 08, 2019	Feb NEWA
	AB	NATCO PHARMA LTD	EQ 100MG BASE	A207818	001	Mar 01, 2019	Feb NEWA
	AB		EQ 400MG BASE	A207818	002	Mar 01, 2019	Feb NEWA
	AB	SHILPA MEDICARE LTD	EQ 100MG BASE	A208302	001	Jan 17, 2019	Jan NEWA
	AB		EQ 400MG BASE	A208302	002	Jan 17, 2019	Jan NEWA
	AB	WOCKHARDT BIO AG	EQ 100MG BASE	A208429	001	Jan 17, 2019	Jan NEWA
	AB		EQ 400MG BASE	A208429	002	Jan 17, 2019	Jan NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL
IMIPRAMINE HYDROCHLORIDE

@	OXFORD PHARMS	10MG	A040751	003	Feb 28, 2008	Mar DISC
@		25MG	A040751	002	Feb 28, 2008	Mar DISC

IMIQUIMOD

CREAM;TOPICAL

ALDARA

>A>	AB	+! BAUSCH	5%	N020723	001	Feb 27, 1997	Aug CAHN
>D>	AB	+! MEDICIS	5%	N020723	001	Feb 27, 1997	Aug CAHN
		ZYCLARA					
>A>		+! BAUSCH	2.5%	N022483	002	Jul 15, 2011	Aug CAHN
>A>		+!	3.75%	N022483	001	Mar 25, 2010	Aug CAHN
>D>		+! MEDICIS	2.5%	N022483	002	Jul 15, 2011	Aug CAHN
>D>		+!	3.75%	N022483	001	Mar 25, 2010	Aug CAHN

INDIUM IN-111 CHLORIDE

INJECTABLE;INJECTION

INDICLOR

+	@	GE HEALTHCARE	2mCi/0.2ML	N019862	001	Dec 29, 1992	Jun DISC
		INDIUM IN 111 CHLORIDE					
+	!	CURIUM	5mCi/0.5ML	N019841	001	Sep 27, 1994	Jan CAHN

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE;INJECTION

OCTREOSCAN

+	!	CURIUM	3mCi/ML	N020314	001	Jun 02, 1994	Jan CAHN
---	---	--------	---------	---------	-----	--------------	----------

INDOMETHACIN

CAPSULE;ORAL

INDOCIN

+	@	EGALET	25MG	N016059	001		Feb CAHN
+	@		50MG	N016059	002		Feb CAHN

INDOMETHACIN

	@	ANI PHARMS INC	25MG	A071148	001	Mar 18, 1987	May CAHN
	@		50MG	A071149	001	Mar 18, 1987	May CAHN
AB		CADILA	25MG	A090403	001	Nov 15, 2010	May CAHN
AB			50MG	A090403	002	Nov 15, 2010	May CAHN
>D>	AB	GLENMARK GENERICS	50MG	A091276	002	Dec 22, 2010	Aug CHRS
>A>	AB	!	50MG	A091276	002	Dec 22, 2010	Aug CHRS
	AB	HERITAGE PHARMA	25MG	A070719	001	Feb 12, 1986	Feb CAHN
	AB		50MG	A070756	001	Feb 12, 1986	Feb CAHN
>D>	AB	MYLAN	25MG	N018858	001	Apr 20, 1984	Aug DISC
>A>	@		25MG	N018858	001	Apr 20, 1984	Aug DISC
>D>	AB	!	50MG	A070624	001	Sep 04, 1985	Aug DISC
>A>	@		50MG	A070624	001	Sep 04, 1985	Aug DISC

CAPSULE;ORAL
TIVORBEX+ EGALET 20MG
+! 40MGN204768 001 Feb 24, 2014 Feb CAHN
N204768 002 Feb 24, 2014 Feb CAHNCAPSULE, EXTENDED RELEASE;ORAL
INDOCIN SR

+ @ EGALET 75MG

N018185 001 Feb 23, 1982 Feb CAHN

SUPPOSITORY;RECTAL
INDOCIN

+ @ EGALET 50MG

N017814 001 Aug 13, 1984 Feb CAHN

SUSPENSION;ORAL
INDOCIN

+! EGALET 25MG/5ML

N018332 001 Oct 10, 1985 Feb CAHN

INSULIN ASPARTSOLUTION;SUBCUTANEOUS
FIASP PENFILL

+! NOVO 300 UNITS/3ML (100 UNITS/ML)

N208751 003 Sep 24, 2018 Jun NEWA

INSULIN ASPART; INSULIN DEGLUDECSOLUTION;SUBCUTANEOUS
RYZODEG 70/30

+ @ NOVO 90 UNITS/3ML;210 UNITS/3ML (30 UNITS/ML;70 UNITS/ML)

N203313 001 Sep 25, 2015 Jun DISC

INSULIN DEGLUDECSOLUTION;SUBCUTANEOUS
TRESIBA

NOVO 1000 UNITS/10ML (100 UNITS/ML)

N203314 003 Nov 21, 2018 Jun NEWA

INSULIN HUMANSOLUTION;INTRAVENOUS
MYXREDLIN

+! BAXTER HLTHCARE CORP 100 UNITS/100ML (1 UNIT/ML)

N208157 001 Jun 20, 2019 Jul CAHN

+! CELERITY PHARMS 100 UNITS/100ML (1 UNIT/ML)

N208157 001 Jun 20, 2019 Jun NEWA

IOPROMIDEINJECTABLE;INJECTION
ULTRAVIST (PHARMACY BULK)

>D> +! BAYER HLTHCARE 49.9%

N021425 003 Mar 12, 2004 Aug DISC

>A> + @ 49.9%

N021425 003 Mar 12, 2004 Aug DISC

+! 49.9%

N021425 003 Mar 12, 2004 Apr CMFD

+ @ 49.9%

N021425 003 Mar 12, 2004 Feb DISC

>D> ULTRAVIST 240

>D> +! BAYER HLTHCARE 49.9%

N020220 003 May 10, 1995 Aug DISC

>A> + @ 49.9%

N020220 003 May 10, 1995 Aug DISC

+! 49.9%

N020220 003 May 10, 1995 Apr CMFD

+ @ 49.9%

N020220 003 May 10, 1995 Feb DISC

IOTHALAMATE MEGLUMINEINJECTABLE;INJECTION
CONRAY 43

+ @ LIEBEL-FLARSHEIM 43%

N013295 002 Jun DISC

IPRATROPIUM BROMIDESPRAY, METERED;NASAL
IPRATROPIUM BROMIDE

@ MYLAN SPECIALITY LP 0.021MG/SPRAY

A075552 001 Mar 31, 2003 Mar DISC

@ 0.042MG/SPRAY

A075553 001 Mar 31, 2003 Mar DISC

IRINOTECAN HYDROCHLORIDEINJECTABLE;INJECTION
IRINOTECAN HYDROCHLORIDE

AP FRESENIUS KABI USA 40MG/2ML (20MG/ML)

A078188 001 Feb 27, 2008 Jan CAHN

AP 100MG/5ML (20MG/ML)

A078188 002 Feb 27, 2008 Jan CAHN

IRON DEXTRANINJECTABLE; INJECTION
DEXFERRUM

@ LUITPOLD	EQ 50MG IRON/ML	N040024	001	Feb 23, 1996	Mar DISC
PROFERDEX					
@ NEW RIVER	EQ 50MG IRON/ML	N017807	001		Mar DISC

IRON SUCROSEINJECTABLE; INTRAVENOUS
VENOFER

+ AM REGENT	EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135	002	Mar 20, 2005	Apr CAHN
@	EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N021135	005	Mar 29, 2013	Apr CAHN
@	EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)	N021135	003	Mar 29, 2005	Apr CAHN
+!	EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N021135	001	Nov 06, 2000	Apr CAHN
+	EQ 200MG BASE/10ML (EQ 20MG BASE/ML)	N021135	004	Feb 09, 2007	Apr CAHN

ISONIAZIDTABLET; ORAL
ISONIAZID

>D> AA	BARR	100MG	A080936	001		Aug CHRS
>A> AA	!	100MG	A080936	001		Aug CHRS
>D> AA		300MG	A080937	002		Aug CHRS
>A> AA	!	300MG	A080937	002		Aug CHRS
>D> AA	+! SANDOZ	100MG	N008678	002		Aug DISC
>A>	+ @	100MG	N008678	002		Aug DISC
>D> AA	+!	300MG	N008678	003		Aug DISC
>A>	+ @	300MG	N008678	003		Aug DISC

ISOPROPYL ALCOHOLSOLUTION; TOPICAL
ZURAGARD

+! ZUREX PHARMA	70% (10.5ML)	N210872	001	Apr 26, 2019	Apr NEWA
-----------------	--------------	---------	-----	--------------	----------

ISOPROTERENOL HYDROCHLORIDEINJECTABLE; INJECTION
ISOPROTERENOL HYDROCHLORIDE

AP	CIPLA	0.2MG/ML	A211738	001	Jun 28, 2019	Jun NEWA
	ISUPREL					
AP	+! BAUSCH	0.2MG/ML	N010515	001		Mar CAHN

ISOSORBIDE DINITRATETABLET; ORAL
ISORDIL

AB	+ BAUSCH	5MG	N012093	007	Jul 29, 1988	Mar CAHN
	+ @	10MG	N012093	002	Jul 29, 1988	Mar CAHN
	+ @	20MG	N012093	006	Jul 29, 1988	Mar CAHN
	+ @	30MG	N012093	005	Jul 29, 1988	Mar CAHN
	+!	40MG	N012093	001	Jul 29, 1988	Mar CAHN

ISOSORBIDE MONONITRATETABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE

AB	HIKMA INTL PHARMS	30MG	A076813	002	Mar 30, 2006	Mar CAHN
AB		60MG	A076813	001	Jan 07, 2005	Mar CAHN

ISOSULFAN BLUEINJECTABLE; INJECTION
ISOSULFAN BLUE

	@ BELOTECA INC	1%	A210714	001	Jan 16, 2019	Jul DISC
AP	SOMERSET THERAPS LLC	1%	A210558	001	Jul 12, 2019	Jul NEWA

>A> ISTRADEFYLLINE>A> TABLET; ORAL
>A> NOURIANZ

>A>	+ KYOWA KIRIN	20MG	N022075	001	Aug 27, 2019	Aug NEWA
>A>	+!	40MG	N022075	002	Aug 27, 2019	Aug NEWA

ITRACONAZOLE

CAPSULE;ORAL

ITRACONAZOLE

>A>	AB	ANDA REPOSITORY	100MG	A206410	001	Jul 02, 2019	Aug CAHN
>D>	AB	PII	100MG	A206410	001	Jul 02, 2019	Aug CAHN
	AB		100MG	A206410	001	Jul 02, 2019	Jun NEWA

SOLUTION;ORAL

ITRACONAZOLE

AA		APOTEX INC	10MG/ML	A208481	001	Aug 02, 2019	Jul NEWA
----	--	------------	---------	---------	-----	--------------	----------

IVABRADINE

SOLUTION;ORAL

CORLANOR

+	!	AMGEN INC	5MG/5ML (1MG/ML)	N209964	001	Apr 22, 2019	Apr NEWA
---	---	-----------	------------------	---------	-----	--------------	----------

IVACAFTOR

GRANULE;ORAL

KALYDECO

+		VERTEX PHARMS INC	25MG/PACKET	N207925	003	Apr 29, 2019	May NEWA
---	--	-------------------	-------------	---------	-----	--------------	----------

TABLET;ORAL

KALYDECO

+		VERTEX PHARMS	75MG	N203188	002	May 20, 2019	May NEWA
---	--	---------------	------	---------	-----	--------------	----------

IVACAFTOR; IVACAFTOR, TEZACAFTOR

TABLET, TABLET;ORAL

SYMDEKO (COPACKAGED)

+	!	VERTEX PHARMS INC	75MG,N/A;75MG, 50MG	N210491	002	Jun 21, 2019	Jul NEWA
---	---	-------------------	---------------------	---------	-----	--------------	----------

KETOCONAZOLE

GEL;TOPICAL

XOLEGEL

+	!	ALMIRALL	2%	N021946	001	Jul 28, 2006	Feb CAHN
---	---	----------	----	---------	-----	--------------	----------

SHAMPOO;TOPICAL

KETOCONAZOLE

AB		PERRIGO ISRAEL	2%	A076419	001	Jan 07, 2004	May CAHN
----	--	----------------	----	---------	-----	--------------	----------

TABLET;ORAL

KETOCONAZOLE

@ HERITAGE PHARMA

200MG

A074971	001	Jun 15, 1999	May CAHN
---------	-----	--------------	----------

@

200MG

A075362	001	Jun 15, 1999	May CAHN
---------	-----	--------------	----------

AB	!	TARO	200MG	A075319	001	Jun 15, 1999	Apr CHRS
----	---	------	-------	---------	-----	--------------	----------

@ TEVA

200MG

A075273	001	Jun 15, 1999	Apr DISC
---------	-----	--------------	----------

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

AP		WEST-WARD PHARMS INT	15MG/ML	A075772	001	Jul 21, 2004	Feb CMFD
----	--	----------------------	---------	---------	-----	--------------	----------

AP			30MG/ML	A075772	002	Jul 21, 2004	Feb CMFD
----	--	--	---------	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC

KETOROLAC TROMETHAMINE

@ AUROBINDO PHARMA LTD

0.4%

A205191	001	Nov 15, 2018	May DISC
---------	-----	--------------	----------

AT		MICRO LABS LTD INDIA	0.5%	A203410	001	Apr 05, 2019	Mar NEWA
----	--	----------------------	------	---------	-----	--------------	----------

@ SANDOZ INC

0.4%

A078721	001	Nov 05, 2009	May DISC
---------	-----	--------------	----------

SPRAY, METERED;NASAL

SPRIX

+	!	ZYLA	15.75MG/SPRAY	N022382	001	May 14, 2010	Jul CAHN
---	---	------	---------------	---------	-----	--------------	----------

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION

KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE

AT		LUPIN LTD	EQ 0.3% BASE;EQ 1% BASE	A210183	001	Jul 01, 2019	Jun NFTG
----	--	-----------	-------------------------	---------	-----	--------------	----------

OMIDRIA

AT	+	!	OMEROS	EQ 0.3% BASE;EQ 1% BASE	N205388	001	May 30, 2014	Jun CFTG
----	---	---	--------	-------------------------	---------	-----	--------------	----------

L-GLUTAMINE

FOR SOLUTION;ORAL

NUTRESTORE

+	@	EMMAUS MEDCL	5GM/PACKET	N021667	001	Jun 10, 2004	Jun DISC
---	---	--------------	------------	---------	-----	--------------	----------

LABETALOL HYDROCHLORIDE

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB		CADILA PHARMS LTD	100MG	A211325	001	May 13, 2019	Apr NEWA
AB			200MG	A211325	002	May 13, 2019	Apr NEWA
AB			300MG	A211325	003	May 13, 2019	Apr NEWA
AB		HERITAGE PHARMA	100MG	A074787	001	Aug 03, 1998	Feb CAHN
AB			200MG	A074787	002	Aug 03, 1998	Feb CAHN
AB			300MG	A074787	003	Aug 03, 1998	Feb CAHN
AB		INVATECH PHARMA	100MG	A207863	001	Feb 04, 2019	Jan NEWA
AB			200MG	A207863	002	Feb 04, 2019	Jan NEWA
AB			300MG	A207863	003	Feb 04, 2019	Jan NEWA
		TRANDATE					
AB	+	CNTY LINE PHARMS	100MG	N018716	001	May 24, 1985	Jan CRLD
AB	+		200MG	N018716	002	Aug 01, 1984	Jan CRLD
AB	+		300MG	N018716	003	Aug 01, 1984	Jan CRLD

LACTULOSE

SOLUTION; ORAL

LACTULOSE

		@ BAJAJ	10GM/15ML	A075911	001	Feb 21, 2002	Jan CAHN
AA		TORRENT	10GM/15ML	A207786	001	Jun 11, 2018	Jan CAHN
>D>		@ XTTRIUM LABS INC	10GM/15ML	A075911	001	Feb 21, 2002	Aug CMFD
>A>	AA		10GM/15ML	A075911	001	Feb 21, 2002	Aug CMFD
		@	10GM/15ML	A075911	001	Feb 21, 2002	Mar CAHN

SOLUTION; ORAL, RECTAL

LACTULOSE

		@ BAJAJ	10GM/15ML	A076645	001	Jul 28, 2003	Jan CAHN
AA		TORRENT	10GM/15ML	A203762	001	Mar 27, 2015	Jan CAHN

LAMIVUDINE

TABLET; ORAL

LAMIVUDINE

AB		ANNORA	100MG	A211306	001	Mar 21, 2019	Mar NEWA
AB		MACLEODS PHARMS LTD	150MG	A090198	001	May 01, 2019	Apr NEWA
AB			300MG	A090198	002	May 01, 2019	Apr NEWA
		@ MYLAN	150MG	A204528	001	Mar 04, 2016	Apr DISC
		@	300MG	A204528	002	Mar 04, 2016	Apr DISC
AB		MYLAN LABS LTD	150MG	A078545	001	Mar 05, 2019	Feb NEWA
AB			300MG	A078545	002	Mar 05, 2019	Feb NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

>D>	AB	MYLAN	150MG; 300MG	A079079	001	Aug 12, 2019	Aug DISC
>A>		@	150MG; 300MG	A079079	001	Aug 12, 2019	Aug DISC
	AB		150MG; 300MG	A079079	001	Aug 12, 2019	Jul NEWA
		@	150MG; 300MG	A204005	001	Aug 28, 2014	Jan DISC

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

>A>		@ CELLTRION	25MG	A078982	001	Jan 27, 2009	Aug CAHN
>A>		@	100MG	A078982	002	Jan 27, 2009	Aug CAHN
>A>		@	150MG	A078982	003	Jan 27, 2009	Aug CAHN
>A>		@	200MG	A078982	004	Jan 27, 2009	Aug CAHN
AB		RUBICON	25MG	A078625	001	Jan 27, 2009	Jul CAHN
AB			100MG	A078625	002	Jan 27, 2009	Jul CAHN
AB			150MG	A078625	003	Jan 27, 2009	Jul CAHN
AB			200MG	A078625	004	Jan 27, 2009	Jul CAHN
>D>		@ WOCKHARDT	25MG	A078982	001	Jan 27, 2009	Aug CAHN
>D>		@	100MG	A078982	002	Jan 27, 2009	Aug CAHN
>D>		@	150MG	A078982	003	Jan 27, 2009	Aug CAHN
>D>		@	200MG	A078982	004	Jan 27, 2009	Aug CAHN

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

@	TEVA	5MG
@		25MG

A076420	001	Jun 21, 2006	Jul DISC
A076420	002	Jun 21, 2006	Jul DISC

TABLET, EXTENDED RELEASE; ORAL

LAMOTRIGINE

@	RUBICON	25MG
---	---------	------

A202887	001	Jun 17, 2013	Mar CAHN
---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL
LAMOTRIGINE

	@	50MG	A202887	002	Jun 17, 2013	Mar CAHN
AB		100MG	A202887	003	Jun 17, 2013	Mar CAHN
AB		200MG	A202887	004	Jun 17, 2013	Mar CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

AB		ALKEM LABS LTD	15MG	A207394	001	Jan 18, 2019	Jan NEWA
AB			30MG	A207394	002	Jan 18, 2019	Jan NEWA
	@	BRECKENRIDGE	15MG	A203964	001	Oct 17, 2018	May DISC
	@		30MG	A203964	002	Oct 17, 2018	May DISC
>A> AB		INVENTIA	15MG	A205868	001	Aug 30, 2017	Aug CAHN
>A> AB			30MG	A205868	002	Aug 30, 2017	Aug CAHN
>D> AB		INVENTIA HLTHCARE	15MG	A205868	001	Aug 30, 2017	Aug CAHN
>D> AB			30MG	A205868	002	Aug 30, 2017	Aug CAHN
	@	KRKA TOVARNA ZDRAVIL	15MG	A091212	001	Sep 16, 2013	Feb DISC
	@		30MG	A091212	002	Sep 16, 2013	Feb DISC
>D> AB		LABS LICONSA	15MG	A203203	001	Jul 25, 2016	Aug CAHN
>D> AB			30MG	A203203	002	Jul 25, 2016	Aug CAHN
>A> AB		XIROMED	15MG	A203203	001	Jul 25, 2016	Aug CAHN
>A> AB			30MG	A203203	002	Jul 25, 2016	Aug CAHN

LAROTRECTINIB

CAPSULE;ORAL
VITRAKVI

+	BAYER HLTHCARE	25MG	N210861	001	Nov 26, 2018	Feb CAHN
+	!	100MG	N210861	002	Nov 26, 2018	Feb CAHN

SOLUTION;ORAL
VITRAKVI

+	!	BAYER HEALTHCARE	20MG/ML	N211710	001	Nov 26, 2018	Feb CAHN
---	---	------------------	---------	---------	-----	--------------	----------

LAROTRECTINIB SULFATE

CAPSULE;ORAL
VITRAKVI

+	BAYER HLTHCARE	EQ 25MG BASE	N210861	001	Nov 26, 2018	Jun CAIN
+		EQ 25MG BASE	N210861	001	Nov 26, 2018	Jun CPOT
+	!	EQ 100MG BASE	N210861	002	Nov 26, 2018	Jun CAIN
+	!	EQ 100MG BASE	N210861	002	Nov 26, 2018	Jun CPOT

SOLUTION;ORAL
VITRAKVI

+	!	BAYER HEALTHCARE	EQ 20MG BASE/ML	N211710	001	Nov 26, 2018	Jun CAIN
+	!		EQ 20MG BASE/ML	N211710	001	Nov 26, 2018	Jun CPOT

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC
LATANOPROST

>A> AT		AUROBINDO PHARMA LTD	0.005%	A206519	001	Sep 03, 2019	Aug NEWA
--------	--	----------------------	--------	---------	-----	--------------	----------

LATANOPROST; NETARSUDIL DIMESYLATE

SOLUTION/DROPS;OPHTHALMIC
ROCKLATAN

+	!	AERIE PHARMS INC	0.005%;EQ 0.02% BASE	N208259	001	Mar 12, 2019	Mar NEWA
---	---	------------------	----------------------	---------	-----	--------------	----------

LEDIPASVIR; SOFOSBUVIR

>A> PELLETS;ORAL
>A> HARVONI

>A>	+	GILEAD SCIENCES INC	33.75MG;150MG/PACKET	N212477	001	Aug 28, 2019	Aug NEWA
>A>	+	!	45MG;200MG/PACKET	N212477	002	Aug 28, 2019	Aug NEWA

TABLET;ORAL
HARVONI

>A>	+	GILEAD SCIENCES INC	45MG;200MG	N205834	002	Aug 28, 2019	Aug NEWA
-----	---	---------------------	------------	---------	-----	--------------	----------

LEFAMULIN ACETATE

>A> SOLUTION;INTRAVENOUS
>A> XENLETA

>A>	+	NABRIVA	EQ 150MG BASE/15ML (EQ 10MG BASE/ML)	N211673	001	Aug 19, 2019	Aug NEWA
-----	---	---------	--------------------------------------	---------	-----	--------------	----------

>A>	TABLET;ORAL						
>A>	XENLETA						
>A>	+! NABRIVA	EQ 600MG BASE	N211672	001	Aug 19, 2019	Aug	NEWA
	<u>LEFLUNOMIDE</u>						
	TABLET;ORAL						
	LEFLUNOMIDE						
AB	ABHAI LLC	10MG	A212453	001	Jun 03, 2019	May	NEWA
AB		20MG	A212453	002	Jun 03, 2019	May	NEWA
AB	ZYDUS	10MG	A212308	001	Apr 24, 2019	Apr	NEWA
AB		20MG	A212308	002	Apr 24, 2019	Apr	NEWA
	<u>LESINURAD</u>						
	TABLET;ORAL						
	ZURAMPIC						
	+ @ IRONWOOD PHARMS INC	200MG	N207988	001	Dec 22, 2015	Apr	DISC
	<u>LETROZOLE</u>						
	TABLET;ORAL						
	LETROZOLE						
AB	FRESENIUS KABI USA	2.5MG	A090491	001	Jun 03, 2011	Feb	CAHN
	<u>LEUCOVORIN CALCIUM</u>						
	INJECTABLE;INJECTION						
	LEUCOVORIN CALCIUM						
AP	INGENUS PHARMS LLC	EQ 10MG BASE/ML	A210917	001	Nov 23, 2018	Feb	CPOT
	<u>LEUPROLIDE ACETATE</u>						
	FOR SUSPENSION;INTRAMUSCULAR						
	LUTRATE DEPOT KIT						
	+ @ GP-PHARM SA	22.5MG/VIAL	N205054	001	Aug 28, 2018	Jun	DISC
	<u>LEVETIRACETAM</u>						
	INJECTABLE;INTRAVENOUS						
	KEPPRA						
AP	+! UCB INC	500MG/5ML (100MG/ML)	N021872	001	Jul 31, 2006	Jun	CDFR
	LEVETIRACETAM						
>D> AP	AKORN	500MG/5ML (100MG/ML)	A209934	001	May 04, 2018	Aug	DISC
>A>	@	500MG/5ML (100MG/ML)	A209934	001	May 04, 2018	Aug	DISC
AP		500MG/5ML (100MG/ML)	A209934	001	May 04, 2018	Jun	CDFR
AP	AUROBINDO PHARMA LTD	500MG/5ML (100MG/ML)	A204312	001	Feb 01, 2016	Jun	CDFR
AP	FRESENIUS KABI USA	500MG/5ML (100MG/ML)	A090813	001	May 26, 2010	Jun	CDFR
AP		500MG/5ML (100MG/ML)	A090876	001	Aug 13, 2015	Jun	CDFR
AP	HAINAN POLY PHARM	500MG/5ML (100MG/ML)	A209781	001	Mar 20, 2018	Jun	CDFR
AP	HIKMA FARMACEUTICA	500MG/5ML (100MG/ML)	A090981	001	Oct 13, 2011	Jun	CDFR
AP	HOSPIRA INC	500MG/5ML (100MG/ML)	A202869	001	Apr 06, 2012	Jun	CDFR
AP	JUBILANT GENERICS	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016	Jun	CDFR
AP	MICRO LABS	500MG/5ML (100MG/ML)	A211954	001	Aug 09, 2019	Jul	NEWA
AP	MYLAN LABS LTD	500MG/5ML (100MG/ML)	A203308	001	Sep 16, 2016	Jun	CDFR
AP	SAGENT PHARMS	500MG/5ML (100MG/ML)	A091627	001	Jun 26, 2013	Jun	CDFR
AP	SUN PHARM INDS LTD	500MG/5ML (100MG/ML)	A090754	001	Jun 16, 2010	Jun	CDFR
AP	X GEN PHARMS	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Jun	CDFR
	LEVETIRACETAM IN SODIUM CHLORIDE						
AP	AUROBINDO PHARMA LTD	500MG/100ML (5MG/ML)	A207160	001	Jan 04, 2017	Jun	CDFR
AP		1000MG/100ML (10MG/ML)	A207160	002	Jan 04, 2017	Jun	CDFR
AP		1500MG/100ML (15MG/ML)	A207160	003	Jan 04, 2017	Jun	CDFR
AP	GLAND PHARMA LTD	500MG/100ML (5MG/ML)	A206880	001	Oct 25, 2017	Jun	CDFR
AP		1000MG/100ML (10MG/ML)	A206880	002	Oct 25, 2017	Jun	CDFR
AP		1500MG/100ML (15MG/ML)	A206880	003	Oct 25, 2017	Jun	CDFR
AP	+! HQ SPECIALITY PHARMA	500MG/100ML (5MG/ML)	N202543	001	Nov 09, 2011	Jun	CDFR
AP	+!	1000MG/100ML (10MG/ML)	N202543	002	Nov 09, 2011	Jun	CDFR
AP	+!	1500MG/100ML (15MG/ML)	N202543	003	Nov 09, 2011	Jun	CDFR
	SOLUTION;ORAL						
	LEVETIRACETAM						
>A> AA	ANDA REPOSITORY	100MG/ML	A079107	001	Jan 15, 2009	Aug	CAHN
>D> AA	TOLMAR	100MG/ML	A079107	001	Jan 15, 2009	Aug	CAHN

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
 LEVOBUNOLOL HYDROCHLORIDE
 @ SANDOZ INC 0.5%

A074850 001 Oct 28, 1996 May DISC

LEVOCARNITINE

SOLUTION;ORAL
 LEVOCARNITINE

AA NOVITIUM PHARMA 1GM/10ML
 LEVOCARNITINE SF
 AA NOVITIUM PHARMA 1GM/10ML

A211676 001 Aug 14, 2019 Jul NEWA

A211676 002 Aug 14, 2019 Jul NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL
 LEVOCETIRIZINE HYDROCHLORIDE

AA HETERO LABS LTD III 2.5MG/5ML

A210914 001 Apr 01, 2019 Mar NEWA

LEVOFLOXACIN

SOLUTION/DROPS;OPHTHALMIC
 LEVOFLOXACIN

MICRO LABS LTD INDIA 1.5%

A205600 001 Feb 27, 2019 Feb NEWA

TABLET;ORAL
 LEVOFLOXACIN

>A> AB CELLTRION 250MG
 >A> AB 500MG
 >A> AB 750MG
 AB HEC PHARM 250MG
 AB 500MG
 AB 750MG
 >D> AB WOCKHARDT 250MG
 >D> AB 500MG
 >D> AB 750MG

A090367 001 Jun 20, 2011 Aug CAHN
 A090367 002 Jun 20, 2011 Aug CAHN
 A090367 003 Jun 20, 2011 Aug CAHN
 A204968 001 Feb 05, 2019 Jan NEWA
 A204968 002 Feb 05, 2019 Jan NEWA
 A204968 003 Feb 05, 2019 Jan NEWA
 A090367 001 Jun 20, 2011 Aug CAHN
 A090367 002 Jun 20, 2011 Aug CAHN
 A090367 003 Jun 20, 2011 Aug CAHN

LEVOLEUCOVORIN

POWDER;INTRAVENOUS
 KHAPZORY

+! ACROTECH 175MG/VIAL
 +! 300MG/VIAL

N211226 001 Oct 19, 2018 Mar CAHN
 N211226 002 Oct 19, 2018 Mar CAHN

LEVOLEUCOVORIN CALCIUM

POWDER;INTRAVENOUS
 FUSILEV

AP +! ACROTECH EQ 50MG BASE/VIAL
 LEVOLEUCOVORIN CALCIUM
 + @ ACTAVIS LLC EQ 175MG BASE/VIAL
 >A> AP NANJING KING-FRIEND EQ 50MG BASE/VIAL

N020140 001 Mar 07, 2008 Mar CAHN
 N208723 001 Sep 29, 2016 Jun DISC
 A211003 001 Aug 22, 2019 Aug NEWA

SOLUTION;INTRAVENOUS
 FUSILEV

+ @ ACROTECH EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)
 + @ EQ 250MG BASE/25ML (EQ 10MG BASE/ML)

N020140 002 Apr 29, 2011 Mar CAHN
 N020140 003 Apr 29, 2011 Mar CAHN

LEVOLEUCOVORIN CALCIUM

>D> AP MYLAN TEORANTA EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)
 >A> @ EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)
 >D> AP EQ 250MG BASE/25ML (EQ 10MG BASE/ML)
 >A> @ EQ 250MG BASE/25ML (EQ 10MG BASE/ML)
 >A> AP NANJING KING-FRIEND EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)
 >A> AP EQ 250MG BASE/25ML (EQ 10MG BASE/ML)

A203576 001 Oct 20, 2015 Aug DISC
 A203576 001 Oct 20, 2015 Aug DISC
 A203576 002 Oct 20, 2015 Aug DISC
 A203576 002 Oct 20, 2015 Aug DISC
 A211002 001 Aug 16, 2019 Aug NEWA
 A211002 002 Aug 16, 2019 Aug NEWA

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
 FETZIMA

+ ALLERGAN SALES LLC EQ 20MG BASE
 AB + EQ 20MG BASE
 + EQ 40MG BASE
 AB + EQ 40MG BASE

N204168 001 Jul 25, 2013 Jun CTEC
 N204168 001 Jul 25, 2013 Jan CFTG
 N204168 002 Jul 25, 2013 Jun CTEC
 N204168 002 Jul 25, 2013 Jan CFTG

CAPSULE, EXTENDED RELEASE;ORAL							
FETZIMA							
	+	EQ 80MG BASE	N204168	003	Jul 25, 2013	Jun	CTEC
AB	+	EQ 80MG BASE	N204168	003	Jul 25, 2013	Jan	CFTG
	+!	EQ 120MG BASE	N204168	004	Jul 25, 2013	Jun	CTEC
AB	+!	EQ 120MG BASE	N204168	004	Jul 25, 2013	Jan	CFTG
LEVOMILNACIPRAN HYDROCHLORIDE							
	@ AMNEAL PHARMS CO	EQ 20MG BASE	A210790	001	Feb 04, 2019	Jun	DISC
AB		EQ 20MG BASE	A210790	001	Feb 04, 2019	Jan	NFTG
	@	EQ 40MG BASE	A210790	002	Feb 04, 2019	Jun	DISC
AB		EQ 40MG BASE	A210790	002	Feb 04, 2019	Jan	NFTG
	@	EQ 80MG BASE	A210790	003	Feb 04, 2019	Jun	DISC
AB		EQ 80MG BASE	A210790	003	Feb 04, 2019	Jan	NFTG
	@	EQ 120MG BASE	A210790	004	Feb 04, 2019	Jun	DISC
AB		EQ 120MG BASE	A210790	004	Feb 04, 2019	Jan	NFTG

LEVONORGESTREL

TABLET;ORAL							
LEVONORGESTREL							
AB	!	L PERRIGO CO	0.75MG	A090740	001	Dec 30, 2010	May CAHN

LEVORPHANOL TARTRATE

TABLET;ORAL							
LEVORPHANOL TARTRATE							
	@ SENTYNL THERAPS INC	1MG	A074278	002	Jun 18, 2018	Feb	DISC
	!	3MG	A074278	003	Jun 18, 2018	May	CMFD
	@	3MG	A074278	003	Jun 18, 2018	Feb	DISC

LEVOTHYROXINE SODIUM

POWDER;INTRAVENOUS							
LEVOTHYROXINE SODIUM							
	@ PAR STERILE PRODUCTS	200MCG/VIAL	A205366	001	Dec 07, 2015	Apr	DISC
SOLUTION;INTRAVENOUS							
LEVOTHYROXINE SODIUM							
	+! FRESENIUS KABI USA	100MCG/5ML (20MCG/ML)	N210632	001	Apr 11, 2019	Apr	NEWA
	+!	200MCG/5ML (40MCG/ML)	N210632	002	Apr 11, 2019	Apr	NEWA
	+!	500MCG/5ML (100MCG/ML)	N210632	003	Apr 11, 2019	Apr	NEWA
SOLUTION;ORAL							
TIROSINT-SOL							
	+ INSTITUT BIOCHIMIQUE	13MCG/ML	N206977	001	Dec 15, 2016	Jan	CMFD
	+	25MCG/ML	N206977	002	Dec 15, 2016	Jan	CMFD
	+	50MCG/ML	N206977	003	Dec 15, 2016	Jan	CMFD
	+	75MCG/ML	N206977	004	Dec 15, 2016	Jan	CMFD
	+	88MCG/ML	N206977	005	Dec 15, 2016	Jan	CMFD
	+	100MCG/ML	N206977	006	Dec 15, 2016	Jan	CMFD
	+	112MCG/ML	N206977	007	Dec 15, 2016	Jan	CMFD
	+	125MCG/ML	N206977	008	Dec 15, 2016	Jan	CMFD
	+	137MCG/ML	N206977	009	Dec 15, 2016	Jan	CMFD
	+	150MCG/ML	N206977	010	Dec 15, 2016	Jan	CMFD
	+	175MCG/ML	N206977	011	Dec 15, 2016	Jan	CMFD
	+!	200MCG/ML	N206977	012	Dec 15, 2016	Jan	CMFD

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL							
LEVOTHYROXINE SODIUM							
	@ AMNEAL PHARMS LLC	0.025MG	A210831	001	Feb 19, 2019	Jun	DISC
AB2		0.025MG	A210831	001	Feb 19, 2019	May	CTEC
AB1, AB2		0.025MG	A210831	001	Feb 19, 2019	Feb	NEWA
	@	0.05MG	A210831	002	Feb 19, 2019	Jun	DISC
AB2		0.05MG	A210831	002	Feb 19, 2019	May	CTEC
AB1, AB2		0.05MG	A210831	002	Feb 19, 2019	Feb	NEWA
	@	0.075MG	A210831	003	Feb 19, 2019	Jun	DISC
AB2		0.075MG	A210831	003	Feb 19, 2019	May	CTEC
AB1, AB2		0.075MG	A210831	003	Feb 19, 2019	Feb	NEWA
	@	0.088MG	A210831	004	Feb 19, 2019	Jun	DISC
AB2		0.088MG	A210831	004	Feb 19, 2019	May	CTEC
AB1, AB2		0.088MG	A210831	004	Feb 19, 2019	Feb	NEWA
	@	0.1MG	A210831	005	Feb 19, 2019	Jun	DISC

TABLET; ORAL						
LEVOTHYROXINE SODIUM						
AB2		0.1MG	A210831	005	Feb 19, 2019	May CTEC
AB1,		0.1MG	A210831	005	Feb 19, 2019	Feb NEWA
AB2	@	0.112MG	A210831	006	Feb 19, 2019	Jun DISC
AB2		0.112MG	A210831	006	Feb 19, 2019	May CTEC
AB1,		0.112MG	A210831	006	Feb 19, 2019	Feb NEWA
AB2	@	0.125MG	A210831	007	Feb 19, 2019	Jun DISC
AB2		0.125MG	A210831	007	Feb 19, 2019	May CTEC
AB1,		0.125MG	A210831	007	Feb 19, 2019	Feb NEWA
AB2	@	0.137MG	A210831	008	Feb 19, 2019	Jun DISC
AB2		0.137MG	A210831	008	Feb 19, 2019	May CTEC
AB1,		0.137MG	A210831	008	Feb 19, 2019	Feb NEWA
AB2	@	0.15MG	A210831	009	Feb 19, 2019	Jun DISC
AB2		0.15MG	A210831	009	Feb 19, 2019	May CTEC
AB1,		0.15MG	A210831	009	Feb 19, 2019	Feb NEWA
AB2	@	0.175MG	A210831	010	Feb 19, 2019	Jun DISC
AB2		0.175MG	A210831	010	Feb 19, 2019	May CTEC
AB1,		0.175MG	A210831	010	Feb 19, 2019	Feb NEWA
AB2	@	0.2MG	A210831	011	Feb 19, 2019	Jun DISC
AB2		0.2MG	A210831	011	Feb 19, 2019	May CTEC
AB1,		0.2MG	A210831	011	Feb 19, 2019	Feb NEWA
AB2	@	0.3MG	A210831	012	Feb 19, 2019	Jun DISC
AB2		0.3MG	A210831	012	Feb 19, 2019	May CTEC
AB1,		0.3MG	A210831	012	Feb 19, 2019	Feb NEWA
AB2		LUPIN ATLANTIS	A209713	001	Jan 18, 2019	Jan NEWA
AB2		0.025MG	A209713	002	Jan 18, 2019	Jan NEWA
AB2		0.05MG	A209713	003	Jan 18, 2019	Jan NEWA
AB2		0.075MG	A209713	004	Jan 18, 2019	Jan NEWA
AB2		0.088MG	A209713	005	Jan 18, 2019	Jan NEWA
AB2		0.1MG	A209713	006	Jan 18, 2019	Jan NEWA
AB2		0.112MG	A209713	007	Jan 18, 2019	Jan NEWA
AB2		0.125MG	A209713	008	Jan 18, 2019	Jan NEWA
AB2		0.137MG	A209713	009	Jan 18, 2019	Jan NEWA
AB2		0.15MG	A209713	010	Jan 18, 2019	Jan NEWA
AB2		0.175MG	A209713	011	Jan 18, 2019	Jan NEWA
AB2		0.2MG	A209713	012	Jan 18, 2019	Jan NEWA
AB2		0.3MG	A209713	012	Jan 18, 2019	Jan NEWA
THYRO-TABS						
AB2,	+	ALVOGEN	N021116	001	Oct 24, 2002	Mar CAHN
AB4						
AB2,	+	0.025MG	N021116	002	Oct 24, 2002	Mar CAHN
AB4						
AB2,	+	0.05MG	N021116	003	Oct 24, 2002	Mar CAHN
AB4						
AB2,	+	0.075MG	N021116	010	Oct 24, 2002	Mar CAHN
AB4						
AB2,	+	0.088MG	N021116	004	Oct 24, 2002	Mar CAHN
AB4						
AB2,	+	0.1MG	N021116	004	Oct 24, 2002	Mar CAHN
AB4						
AB2,	+	0.112MG	N021116	011	Oct 24, 2002	Mar CAHN
AB4						
AB2,	+	0.125MG	N021116	005	Oct 24, 2002	Mar CAHN
AB4						
AB2,	+	0.137MG	N021116	012	Dec 07, 2004	Mar CAHN
AB4						
AB2,	+	0.15MG	N021116	006	Oct 24, 2002	Mar CAHN
AB4						
AB2,	+	0.175MG	N021116	007	Oct 24, 2002	Mar CAHN
AB4						
AB2,	+	0.2MG	N021116	008	Oct 24, 2002	Mar CAHN
AB4						
AB2,	+	0.3MG	N021116	009	Oct 24, 2002	Mar CAHN
AB4	!					
AB2,	+	LLOYD	N021116	001	Oct 24, 2002	Feb CMFD
AB4						
AB2,	+	0.025MG	N021116	002	Oct 24, 2002	Feb CMFD
AB4						
AB2,	+	0.05MG	N021116	003	Oct 24, 2002	Feb CMFD
AB4						
AB2,	+	0.075MG	N021116	010	Oct 24, 2002	Feb CMFD
AB4						
AB2,	+	0.088MG	N021116	004	Oct 24, 2002	Feb CMFD
AB4						
AB2,	+	0.1MG	N021116	004	Oct 24, 2002	Feb CMFD

TABLET;ORAL
THYRO-TABS

AB4									
AB2, +		0.112MG		N021116	011	Oct 24, 2002	Feb	CMFD	
AB4									
AB2, +		0.125MG		N021116	005	Oct 24, 2002	Feb	CMFD	
AB4									
AB2, +		0.137MG		N021116	012	Dec 07, 2004	Feb	CMFD	
AB4									
AB2, +		0.15MG		N021116	006	Oct 24, 2002	Feb	CMFD	
AB4									
AB2, +		0.175MG		N021116	007	Oct 24, 2002	Feb	CMFD	
AB4									
AB2, +		0.2MG		N021116	008	Oct 24, 2002	Feb	CMFD	
AB4									
AB2, +!		0.3MG		N021116	009	Oct 24, 2002	Feb	CMFD	
AB4									

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE

AP	FRESENIUS KABI USA	1%		A080404	002		Jun	CTNA	
AP		2%		A080404	003		Jun	CTNA	
	@ LUITPOLD	1%		A080850	001		Mar	DISC	
	@	1%		A091564	001	Aug 14, 2015	Feb	DISC	

JELLY;TOPICAL
ANESTACON

	@ BIONPHARMA INC	2%		A080429	001		Apr	CAHN	
--	------------------	----	--	---------	-----	--	-----	------	--

SOLUTION;ORAL
XYLOCAINE VISCOUS

>D>	@ FRESENIUS KABI USA	2%		N009470	001		Aug	CRLD	
>A>	+ @	2%		N009470	001		Aug	CRLD	

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL
EMLA

AB	+! TEVA BRANDED PHARM	2.5%;2.5%		N019941	001	Dec 30, 1992	Apr	CAHN	
----	-----------------------	-----------	--	---------	-----	--------------	-----	------	--

LINEZOLID

TABLET;ORAL
LINEZOLID

AB	CELLTRION	600MG		A210702	001	Apr 25, 2019	Apr	NEWA	
	@ MYLAN	600MG		A078845	001	Dec 21, 2015	Jun	DISC	

LIOTHYRONINE SODIUM

TABLET;ORAL
CYTOMEL

AB	+ KING PHARMS	EQ 0.05MG BASE		N010379	003		Jun	CHRS	
	LIOTHYRONINE SODIUM								
	@ MYLAN	EQ 0.005MG BASE		A090326	001	Jul 14, 2009	Mar	DISC	
	@	EQ 0.025MG BASE		A090326	002	Jul 14, 2009	Mar	DISC	
	@	EQ 0.05MG BASE		A090326	003	Jul 14, 2009	Mar	DISC	
AB	! SIGMAPHARM LABS LLC	EQ 0.05MG BASE		A200295	003	Nov 29, 2012	Jun	CHRS	
	@ SUN PHARM	EQ 0.005MG BASE		A091382	001	Apr 20, 2016	Jun	DISC	
	@	EQ 0.025MG BASE		A091382	002	Apr 20, 2016	Jun	DISC	
	@	EQ 0.05MG BASE		A091382	003	Apr 20, 2016	Jun	DISC	
	@ TEVA PHARMS USA	EQ 0.005MG BASE		A211510	001	Oct 26, 2018	Apr	DISC	
	@	EQ 0.025MG BASE		A211510	002	Oct 26, 2018	Apr	DISC	
	@	EQ 0.05MG BASE		A211510	003	Oct 26, 2018	Apr	DISC	

LISINOPRIL

TABLET;ORAL
LISINOPRIL

>D>	AB	HERITAGE PHARMA	2.5MG	A075752	001	Jul 01, 2002	Aug	DISC	
>A>		@	2.5MG	A075752	001	Jul 01, 2002	Aug	DISC	
	AB		2.5MG	A075752	001	Jul 01, 2002	Feb	CAHN	
>D>	AB		5MG	A075752	002	Jul 01, 2002	Aug	DISC	
>A>		@	5MG	A075752	002	Jul 01, 2002	Aug	DISC	
	AB		5MG	A075752	002	Jul 01, 2002	Feb	CAHN	
>D>	AB		10MG	A075752	003	Jul 01, 2002	Aug	DISC	
>A>		@	10MG	A075752	003	Jul 01, 2002	Aug	DISC	
	AB		10MG	A075752	003	Jul 01, 2002	Feb	CAHN	
>D>	AB		20MG	A075752	004	Jul 01, 2002	Aug	DISC	
>A>		@	20MG	A075752	004	Jul 01, 2002	Aug	DISC	

TABLET;ORAL
LISINOPRIL

AB		20MG	A075752	004	Jul 01, 2002	Feb CAHN
>D>	AB	30MG	A075752	005	Jul 01, 2002	Aug DISC
>A>	@	30MG	A075752	005	Jul 01, 2002	Aug DISC
AB		30MG	A075752	005	Jul 01, 2002	Feb CAHN
>D>	AB	40MG	A075752	006	Jul 01, 2002	Aug DISC
>A>	@	40MG	A075752	006	Jul 01, 2002	Aug DISC
AB		40MG	A075752	006	Jul 01, 2002	Feb CAHN
>D>	AB	MYLAN 2.5MG	A076071	001	Jul 01, 2002	Aug DISC
>A>	@	2.5MG	A076071	001	Jul 01, 2002	Aug DISC
>D>	AB	5MG	A076071	002	Jul 01, 2002	Aug DISC
>A>	@	5MG	A076071	002	Jul 01, 2002	Aug DISC
>D>	AB	10MG	A076071	003	Jul 01, 2002	Aug DISC
>A>	@	10MG	A076071	003	Jul 01, 2002	Aug DISC
>D>	AB	20MG	A076071	004	Jul 01, 2002	Aug DISC
>A>	@	20MG	A076071	004	Jul 01, 2002	Aug DISC
>D>	AB	30MG	A076071	005	Jul 01, 2002	Aug DISC
>A>	@	30MG	A076071	005	Jul 01, 2002	Aug DISC
>D>	AB	40MG	A076071	006	Jul 01, 2002	Aug DISC
>A>	@	40MG	A076071	006	Jul 01, 2002	Aug DISC

LITHIUM CARBONATE

CAPSULE;ORAL
LITHIUM CARBONATE

AB	+	HIKMA	150MG	N017812	002	Jan 28, 1987	Apr CAHN
AB	+		300MG	N017812	001		Apr CAHN
AB	+	!	600MG	N017812	003	Jan 28, 1987	Apr CAHN
	@	MYLAN	600MG	A078763	001	Apr 15, 2008	Jun DISC

TABLET, EXTENDED RELEASE;ORAL

LITHIUM CARBONATE

@	HERITAGE PHARMA	300MG	A076170	001	Jun 10, 2002	May CAHN
@		450MG	A076366	001	Aug 21, 2003	May CAHN

LITHIUM CITRATE

SYRUP;ORAL
LITHIUM CITRATE

AA	+	!	HIKMA	EQ 300MG CARBONATE/5ML	N018421	001	Apr CAHN
----	---	---	-------	------------------------	---------	-----	----------

LORAZEPAM

CONCENTRATE;ORAL
LORAZEPAM

AA		LANNETT CO INC	2MG/ML	A079244	001	Apr 28, 2009	Jul CAHN
AA		SAPTALIS PHARMS	2MG/ML	A079244	001	Apr 28, 2009	Feb CAHN

INJECTABLE;INJECTION

ATIVAN

AP	+	!	HIKMA	2MG/ML	N018140	001	Mar CAHN
AP	+	!		4MG/ML	N018140	002	Mar CAHN

TABLET;ORAL

ATIVAN

AB	+	BAUSCH	0.5MG	N017794	001		Feb CAHN
AB	+		1MG	N017794	002		Feb CAHN
AB	+	!	2MG	N017794	003		Feb CAHN

LOSARTAN POTASSIUM

TABLET;ORAL
LOSARTAN POTASSIUM

AB		HISUN PHARM HANGZHOU	25MG	A204795	001	Apr 04, 2019	Mar NEWA
AB			50MG	A204795	002	Apr 04, 2019	Mar NEWA
AB			100MG	A204795	003	Apr 04, 2019	Mar NEWA
AB		MICRO LABS	25MG	A091541	001	Sep 24, 2012	Mar CAHN
AB			50MG	A091541	002	Sep 24, 2012	Mar CAHN
AB			100MG	A091541	003	Sep 24, 2012	Mar CAHN
AB		STRIDES PHARMA	25MG	A090382	001	Oct 06, 2010	Apr CAHN
AB			50MG	A090382	002	Oct 06, 2010	Apr CAHN
AB			100MG	A090382	003	Oct 06, 2010	Apr CAHN
	@	TEVA	25MG	A076958	001	Apr 06, 2010	Jul DISC
	@		50MG	A076958	002	Apr 06, 2010	Jul DISC
	@		100MG	A076958	003	Apr 06, 2010	Jul DISC

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEMAX SM

	+	BAUSCH AND LOMB INC	0.38%	N208219	001	Feb 22, 2019	Feb NEWA
		SUSPENSION/DROPS;OPHTHALMIC					
		LOTEMAX					
AB	+	BAUSCH AND LOMB	0.5%	N020583	001	Mar 09, 1998	Apr CFTG
		LOTEPREDNOL ETABONATE					
AB		HI TECH	0.5%	A207609	001	Apr 17, 2019	Apr NFTG

LOVASTATIN

TABLET;ORAL

LOVASTATIN

AB		BEXIMCO PHARMS USA	10MG	A075300	001	Dec 17, 2001	Feb CAHN
AB			20MG	A075300	002	Dec 17, 2001	Feb CAHN
AB			40MG	A075300	003	Dec 17, 2001	Feb CAHN
	@	MYLAN	10MG	A075451	001	Dec 17, 2001	Feb DISC
	@		20MG	A075451	002	Dec 17, 2001	Feb DISC
	@		40MG	A075451	003	Dec 17, 2001	Feb DISC

LOXAPINE

POWDER;INHALATION

ADASUVE

>A>	+	ALEXZA PHARMS	10MG	N022549	001	Dec 21, 2012	Aug CAHN
>D>	+	GALEN UK	10MG	N022549	001	Dec 21, 2012	Aug CAHN

LOXAPINE HYDROCHLORIDE

CONCENTRATE;ORAL

LOXITANE C

	@	TEVA BRANDED PHARM	EQ 25MG BASE/ML	N017658	001		Feb CAHN
--	---	--------------------	-----------------	---------	-----	--	----------

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXITANE

	+	@	TEVA BRANDED PHARM	EQ 5MG BASE	N017525	001	Feb CAHN
	+	@		EQ 10MG BASE	N017525	002	Feb CAHN
	+	@		EQ 25MG BASE	N017525	003	Feb CAHN
	+	@		EQ 50MG BASE	N017525	004	Feb CAHN

TABLET;ORAL

LOXITANE

	+	@	TEVA BRANDED PHARM	EQ 10MG BASE	N017525	006	Feb CAHN
	+	@		EQ 25MG BASE	N017525	007	Feb CAHN
	+	@		EQ 50MG BASE	N017525	008	Feb CAHN
	+	@		EQ 50MG BASE	N017525	008	Feb CAHN

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

	@	AMNEAL PHARMS CO	20MG	A208002	001	Jan 03, 2019	Jun DISC
	@		40MG	A208002	002	Jan 03, 2019	Jun DISC
	@		60MG	A208002	003	Jan 03, 2019	Jun DISC
	@		80MG	A208002	004	Jan 03, 2019	Jun DISC
	@		120MG	A208002	005	Jan 03, 2019	Jun DISC
>A>	AB	EMCURE PHARMS LTD	20MG	A208058	001	Sep 04, 2019	Aug NEWA
>A>	AB		40MG	A208058	002	Sep 04, 2019	Aug NEWA
>A>	AB		60MG	A208058	003	Sep 04, 2019	Aug NEWA
>A>	AB		80MG	A208058	004	Sep 04, 2019	Aug NEWA
	@	INVAGEN PHARMS	20MG	A208028	001	Jan 03, 2019	Jul DISC
	@		40MG	A208028	002	Jan 03, 2019	Jul DISC
	@		60MG	A208028	003	Jan 03, 2019	Jul DISC
	@		80MG	A208028	004	Jan 03, 2019	Jul DISC
	@		120MG	A208028	005	Jan 03, 2019	Jul DISC
	@	LUPIN LTD	20MG	A208031	001	Jan 03, 2019	Jul DISC
	@		40MG	A208031	002	Jan 03, 2019	Jul DISC
	@		60MG	A208031	003	Jan 03, 2019	Jul DISC
	@		80MG	A208031	004	Jan 03, 2019	Jul DISC
	@		120MG	A208031	005	Jan 03, 2019	Jul DISC
AB		TEVA PHARMS USA	20MG	A208060	001	May 17, 2019	May NEWA
AB			40MG	A208060	002	May 17, 2019	May NEWA
AB			60MG	A208060	003	May 17, 2019	May NEWA
AB			80MG	A208060	004	May 17, 2019	May NEWA

TABLET; ORAL

LURASIDONE HYDROCHLORIDE

AB		120MG	A208060	005	May 17, 2019	May NEWA
	@ TORRENT	20MG	A208055	001	Jan 03, 2019	Feb DISC
	@	40MG	A208055	002	Jan 03, 2019	Feb DISC
	@	80MG	A208055	003	Jan 03, 2019	Feb DISC
	@	120MG	A208055	004	Jan 03, 2019	Feb DISC
>D> AB	ZYDUS PHARMS	20MG	A208052	001	Mar 19, 2019	Aug DISC
>A>	@	20MG	A208052	001	Mar 19, 2019	Aug DISC
AB		20MG	A208052	001	Mar 19, 2019	Mar NEWA
>D> AB		40MG	A208052	002	Mar 19, 2019	Aug DISC
>A>	@	40MG	A208052	002	Mar 19, 2019	Aug DISC
AB		40MG	A208052	002	Mar 19, 2019	Mar NEWA
>D> AB		60MG	A208052	003	Mar 19, 2019	Aug DISC
>A>	@	60MG	A208052	003	Mar 19, 2019	Aug DISC
AB		60MG	A208052	003	Mar 19, 2019	Mar NEWA
>D> AB		80MG	A208052	004	Mar 19, 2019	Aug DISC
>A>	@	80MG	A208052	004	Mar 19, 2019	Aug DISC
AB		80MG	A208052	004	Mar 19, 2019	Mar NEWA
>D> AB		120MG	A208052	005	Mar 19, 2019	Aug DISC
>A>	@	120MG	A208052	005	Mar 19, 2019	Aug DISC
AB		120MG	A208052	005	Mar 19, 2019	Mar NEWA

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP	+!	FRESENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016	Jan CTEC
AP		HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015	Jan CTEC

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

POWDER; ORAL

COLPREP KIT

	+ @	GATOR PHARMS	1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	N204553	001	Dec 27, 2016	Mar DISC
--	-----	--------------	-----------------------------------	---------	-----	--------------	----------

MALATHION

LOTION; TOPICAL

MALATHION

>D> AT		SUVEN LIFE	0.5%	A091559	001	May 23, 2012	Aug CTEC
>A>	!		0.5%	A091559	001	May 23, 2012	Aug CHRS
>A>			0.5%	A091559	001	May 23, 2012	Aug CTEC
>D>		OVIDE					
>D> AT	+!	TARO PHARM INDS LTD	0.5%	N018613	001	Aug 02, 1982	Aug DISC
>A>	+ @		0.5%	N018613	001	Aug 02, 1982	Aug DISC

MANNITOL

INJECTABLE; INJECTION

MANNITOL 25%

	@	LUITPOLD	12.5GM/50ML	A087409	001	Jan 21, 1982	Mar DISC
--	---	----------	-------------	---------	-----	--------------	----------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT

AA	+	CASPER PHARMA LLC	12.5MG	N010721	006		Feb CMFD
	+	@	12.5MG	N010721	006		Jan CRLD
AA	+		25MG	N010721	004		Feb CMFD
	+	@	25MG	N010721	004		Jan CRLD
AA	+		50MG	N010721	001	Jan 20, 1982	Feb CMFD
	+	@	50MG	N010721	001	Jan 20, 1982	Jan CRLD

MECLIZINE HYDROCHLORIDE

AA	!	AMNEAL PHARMS	12.5MG	A201451	001	Feb 23, 2011	Jan CHRS
AA	!		25MG	A201451	002	Feb 23, 2011	Jan CHRS
	@	ANI PHARMS INC	12.5MG	A088732	001	Dec 11, 1985	May CAHN
AA		INDICUS PHARMA	12.5MG	A205136	001	Feb 22, 2019	Feb NEWA
AA			25MG	A205136	002	Feb 22, 2019	Feb NEWA
			50MG	A205136	003	Feb 22, 2019	Feb NEWA

TABLET, CHEWABLE; ORAL

ANTIVERT

AA	+	CASPER PHARMA LLC	25MG	N010721	005		Feb CMFD
	+	@	25MG	N010721	005		Jan CRLD

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION							
MEDROXYPROGESTERONE ACETATE							
	@ CIPLA	150MG/ML	A210335	001	Jan 25, 2019	Jul	DISC
AB		150MG/ML	A210335	001	Jan 25, 2019	Jan	NEWA
AB	SUN PHARM	150MG/ML	A210760	001	May 01, 2019	Apr	NEWA
AB		150MG/ML	A210761	001	Apr 24, 2019	Apr	NEWA
TABLET; ORAL							
MEDROXYPROGESTERONE ACETATE							
	@ UPSHER SMITH LABS	10MG	A088484	001	Jul 26, 1984	Jul	CAHN

MEFENAMIC ACID

CAPSULE; ORAL							
MEFENAMIC ACID							
	@ BRECKENRIDGE	250MG	A090359	001	Feb 05, 2013	Feb	DISC

MEGESTROL ACETATE

SUSPENSION; ORAL							
MEGESTROL ACETATE							
	@ PD PARTNERS	40MG/ML	A077404	001	Feb 16, 2006	May	CAHN

MELOXICAM

CAPSULE; ORAL							
VIVLODEX							
+	EGALET	5MG	N207233	001	Oct 22, 2015	Feb	CAHN
+	!	10MG	N207233	002	Oct 22, 2015	Feb	CAHN
+	ZYLA	5MG	N207233	001	Oct 22, 2015	Jul	CAHN
+	!	10MG	N207233	002	Oct 22, 2015	Jul	CAHN
SUSPENSION; ORAL							
MOBIC							
+	@ AVONDALE PHARMS	7.5MG/5ML	N021530	001	Jun 01, 2004	Jun	CAHN
TABLET; ORAL							
MELOXICAM							
AB	HERITAGE PHARMA	7.5MG	A077936	001	Jul 19, 2006	Feb	CAHN
AB		15MG	A077936	002	Jul 19, 2006	Feb	CAHN

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION							
ALKERAN							
AP	+ APOTEX INC	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992	Feb	CMFD
MELPHALAN HYDROCHLORIDE							
AP	ALVOGEN INC	EQ 50MG BASE/VIAL	A204817	001	May 17, 2019	May	NEWA
AP	GLAND PHARMA LTD	EQ 50MG BASE/VIAL	A209826	001	May 28, 2019	May	NEWA
AP	US WORLDMEDS LLC	EQ 50MG BASE/VIAL	A207032	001	May 03, 2019	Apr	NEWA
POWDER; INTRAVENOUS							
EVOMELA							
+	! ACROTECH	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Mar	CAHN

MEMANTINE HYDROCHLORIDE

SOLUTION; ORAL							
MEMANTINE HYDROCHLORIDE							
AA	! TORRENT	2MG/ML	A205446	001	Dec 07, 2015	Jan	CAHN
TABLET; ORAL							
MEMANTINE HYDROCHLORIDE							
	@ APOTEX INC	5MG	A090244	001	Jul 11, 2018	Jan	DISC
	@	10MG	A090244	002	Jul 11, 2018	Jan	DISC
AB	CADILA	5MG	A090961	001	Jul 10, 2017	Feb	CAHN
AB		10MG	A090961	002	Jul 10, 2017	Feb	CAHN
>A>	AB	CELLTRION	A090073	001	Sep 04, 2015	Aug	CAHN
>A>	AB	10MG	A090073	002	Sep 04, 2015	Aug	CAHN
>D>	AB	WOCKHARDT LTD	A090073	001	Sep 04, 2015	Aug	CAHN
>D>	AB	10MG	A090073	002	Sep 04, 2015	Aug	CAHN

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL							
DEMEROL							
>D>	AA	+! US PHARM HOLDINGS	N005010	001		Aug	DISC
>A>		+ @	N005010	001		Aug	DISC
>D>	AA	+!	N005010	004		Aug	DISC
>A>		+ @	N005010	004		Aug	DISC

TABLET;ORAL

MEPERIDINE HYDROCHLORIDE

>D> AA	MIKART	50MG	A040893	001	Jun 24, 2009	Aug DISC
>A>	@	50MG	A040893	001	Jun 24, 2009	Aug DISC
>D>		75MG	A040893	002	Jun 24, 2009	Aug DISC
>A>	@	75MG	A040893	002	Jun 24, 2009	Aug DISC
>D> AA		100MG	A040893	003	Jun 24, 2009	Aug DISC
>A>	@	100MG	A040893	003	Jun 24, 2009	Aug DISC
>D>		150MG	A040893	004	Jun 24, 2009	Aug DISC
>A>	@	150MG	A040893	004	Jun 24, 2009	Aug DISC
>D> AA	SPECGX LLC	50MG	A040352	001	Jun 13, 2000	Aug DISC
>A>	@	50MG	A040352	001	Jun 13, 2000	Aug DISC
>D> AA		100MG	A040352	002	Jun 13, 2000	Aug DISC
>A>	@	100MG	A040352	002	Jun 13, 2000	Aug DISC
>D> AA	WEST-WARD PHARMS INT	50MG	A040110	001	Mar 12, 1997	Aug CHRS
>A> AA	!	50MG	A040110	001	Mar 12, 1997	Aug CHRS
>D> AA		100MG	A040110	002	Mar 12, 1997	Aug CHRS
>A> AA	!	100MG	A040110	002	Mar 12, 1997	Aug CHRS

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERGAN

@ HIKMA	25MG/ML; 25MG/ML	N011730	001		Jun CAHN
---------	------------------	---------	-----	--	----------

MEQUINOL; TRETINOIN

SOLUTION;TOPICAL

SOLAGE

@ ALMIRALL	2%;0.01%	N020922	001	Dec 10, 1999	Feb CAHN
------------	----------	---------	-----	--------------	----------

MEROPENEM

INJECTABLE;INJECTION

MEROPENEM

>A> AP	HQ SPCLT PHARMA	500MG/VIAL	A210773	001	Aug 16, 2019	Aug NEWA
>A> AP		1GM/VIAL	A210773	002	Aug 16, 2019	Aug NEWA

MESALAMINE

CAPSULE, DELAYED RELEASE;ORAL

DELZICOL

AB	+! APIL	400MG	N204412	001	Feb 01, 2013	Apr CFTG
----	---------	-------	---------	-----	--------------	----------

MESALAMINE

AB	TEVA PHARMS USA	400MG	A207873	001	May 09, 2019	Apr NFTG
----	-----------------	-------	---------	-----	--------------	----------

SUPPOSITORY;RECTAL

MESALAMINE

AB	AMRING PHARMS	1GM	A208362	001	Jun 21, 2019	Jun NEWA
AB	PHARM SOURCING	1GM	A207448	001	Apr 19, 2019	Apr NEWA
AB	SANDOZ INC	1GM	A202065	001	Jun 12, 2019	May NEWA

TABLET, DELAYED RELEASE;ORAL

MESALAMINE

>D> AB	SUN PHARM	1.2GM	A211858	001	Jan 25, 2019	Aug DISC
>A>	@	1.2GM	A211858	001	Jan 25, 2019	Aug DISC
AB		1.2GM	A211858	001	Jan 25, 2019	Jan NEWA

MESTRANOL; NORETHINDRONE

TABLET;ORAL-28

NORINYL 1+50 28-DAY

+ @ ACTAVIS LABS UT INC	0.05MG;1MG	N016659	001		Jul DISC
-------------------------	------------	---------	-----	--	----------

METAPROTERENOL SULFATE

TABLET;ORAL

METAPROTERENOL SULFATE

@ HERITAGE PHARMA	10MG	A072519	001	Mar 30, 1990	May CAHN
@	20MG	A072520	001	Mar 30, 1990	May CAHN
@ PAR PHARM	10MG	A072024	001	Jun 28, 1988	Jul DISC
@	20MG	A072025	001	Jun 28, 1988	Jul DISC

METAXALONE

TABLET;ORAL

METAXALONE

AB	APPCO PHARMA LLC	800MG	A208774	001	Sep 24, 2018	Feb CAHN
----	------------------	-------	---------	-----	--------------	----------

METFORMIN HYDROCHLORIDE

>A>	FOR SUSPENSION, EXTENDED RELEASE;ORAL						
>A>	RIOMET ER						
>A>	+! SUN PHARM	500MG/5ML	N212595	001	Aug 29, 2019	Aug	NEWA
	TABLET;ORAL						
	GLUCOPHAGE						
	+ @ BRISTOL MYERS SQUIBB	500MG	N020357	001	Mar 03, 1995	Jun	DISC
	+ @	850MG	N020357	002	Mar 03, 1995	Jun	DISC
	+ @	1GM	N020357	005	Nov 05, 1998	Jun	DISC
	+ @ EMD SERONO INC	500MG	N020357	001	Mar 03, 1995	Jul	CAHN
	+ @	625MG	N020357	003	Nov 05, 1998	Jul	CAHN
	+ @	750MG	N020357	004	Nov 05, 1998	Jul	CAHN
	+ @	850MG	N020357	002	Mar 03, 1995	Jul	CAHN
	+ @	1GM	N020357	005	Nov 05, 1998	Jul	CAHN
	METFORMIN HYDROCHLORIDE						
AB	! GRANULES INDIA	1GM	A090564	003	Apr 22, 2010	Jun	CHRS
AB	HERITAGE PHARMA	500MG	A075978	001	Jan 25, 2002	Feb	CAHN
AB		850MG	A075978	002	Jan 25, 2002	Feb	CAHN
AB		1GM	A075978	003	Nov 05, 2002	Feb	CAHN
	@ SUNSHINE LAKE	500MG	A208999	001	Oct 12, 2018	Apr	DISC
	@	850MG	A208999	002	Oct 12, 2018	Apr	DISC
	@	1GM	A208999	003	Oct 12, 2018	Apr	DISC
	TABLET, EXTENDED RELEASE;ORAL						
	GLUCOPHAGE XR						
	+ @ BRISTOL MYERS SQUIBB	500MG	N021202	001	Oct 13, 2000	Jun	DISC
	+ @	750MG	N021202	004	Apr 11, 2003	Jun	DISC
	+ @ EMD SERONO INC	500MG	N021202	001	Oct 13, 2000	Jul	CAHN
	+ @	750MG	N021202	004	Apr 11, 2003	Jul	CAHN
	METFORMIN HYDROCHLORIDE						
AB	! AMNEAL PHARMS NY	750MG	A078596	002	Jan 03, 2008	Jun	CHRS
AB1	CADILA	500MG	A077060	001	Apr 20, 2005	Feb	CAHN
AB		750MG	A077078	001	Apr 21, 2005	Feb	CAHN
>A> AB1	INVENTIA	500MG	A201991	001	Jan 18, 2012	Aug	CAHN
>D> AB1	INVENTIA HLTHCARE	500MG	A201991	001	Jan 18, 2012	Aug	CAHN
AB2	! LUPIN LTD	1GM	A090692	002	Jun 29, 2011	Apr	CHRS
AB1	! SUN PHARM INDS (IN)	500MG	A077336	001	Feb 09, 2006	Jun	CHRS
	@ YICHANG HUMANWELL	500MG	A211052	001	Sep 24, 2018	Mar	DISC
	@	750MG	A211052	002	Sep 24, 2018	Mar	DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

@ MYLAN 500MG;EQ 15MG BASE

A090406 001 Feb 25, 2011 Jul DISC

@ 850MG;EQ 15MG BASE

A090406 002 Feb 25, 2011 Jul DISC

TABLET, EXTENDED RELEASE;ORAL

ACTOPLUS MET XR

+ @ TAKEDA PHARMS USA 1GM;EQ 15MG BASE

N022024 001 May 12, 2009 Mar DISC

+ @ 1GM;EQ 30MG BASE

N022024 002 May 12, 2009 Mar DISC

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL

METHADONE HYDROCHLORIDE

>A> AA	PHARM ASSOC	10MG/ML	A207368	001	Aug 22, 2019	Aug	NEWA
--------	-------------	---------	---------	-----	--------------	-----	------

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

@ MICRO LABS 25MG

A207438 001 Oct 05, 2018 Mar DISC

@ 50MG

A207438 002 Oct 05, 2018 Mar DISC

METHENAMINE HIPPURATE

TABLET;ORAL

METHENAMINE HIPPURATE

AB	MICRO LABS	1GM	A212172	001	Aug 01, 2019	Jul	NEWA
----	------------	-----	---------	-----	--------------	-----	------

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

AP	SLATE	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017	Feb	CAHN
----	-------	---------------------	---------	-----	--------------	-----	------

ROBAXIN

AP	+! HIKMA	1GM/10ML (100MG/ML)	N011790	001		Feb	CAHN
----	----------	---------------------	---------	-----	--	-----	------

TABLET;ORAL							
METHOCARBAMOL							
AA	!	GRANULES INDIA LTD	500MG	A209312	001	May 07, 2018	Jul CHRS
ROBAXIN							
	+	@ AUXILIUM PHARMS LLC	500MG	N011011	004		Jul DISC
<u>METHOTREXATE</u>							
SOLUTION;SUBCUTANEOUS							
RASUVO							
	+	MEDEXUS	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014	Apr CAHN
	+		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014	Apr CAHN
	+		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014	Apr CAHN
	+		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014	Apr CAHN
	+		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014	Apr CAHN
	+		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014	Apr CAHN
	+		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014	Apr CAHN
	+		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014	Apr CAHN
	+	@	27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014	Apr CAHN
	+		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014	Apr CAHN
<u>METHOXSALEN</u>							
CAPSULE;ORAL							
OXSORALEN-ULTRA							
>A> AB	+	BAUSCH	10MG	N019600	001	Oct 30, 1986	Aug CAHN
>D> AB	+	DOW PHARM	10MG	N019600	001	Oct 30, 1986	Aug CAHN
<u>METHSCOPOLAMINE BROMIDE</u>							
TABLET;ORAL							
METHSCOPOLAMINE BROMIDE							
	@	BRECKENRIDGE PHARM	2.5MG	A040642	001	Dec 06, 2011	Jun DISC
	@		5MG	A040642	002	Dec 06, 2011	Jun DISC
<u>METHYLDOPA</u>							
TABLET;ORAL							
METHYLDOPA							
AB		HERITAGE PHARMA	250MG	A070098	001	Feb 20, 1986	Feb CAHN
AB			500MG	A070343	001	Feb 20, 1986	Feb CAHN
<u>METHYLDOPATE HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
METHYLDOPATE HYDROCHLORIDE							
	@	LUITPOLD	50MG/ML	A071279	001	Oct 02, 1987	Mar DISC
<u>METHYLERGONOVINE MALEATE</u>							
TABLET;ORAL							
METHYLERGONOVINE MALEATE							
AB		TEVA PHARMS USA	0.2MG	A211455	001	Mar 20, 2019	Mar NEWA
<u>METHYLPHENIDATE HYDROCHLORIDE</u>							
CAPSULE, EXTENDED RELEASE;ORAL							
ADHANSIA XR							
	+	PURDUE PHARMA LP	25MG	N212038	001	Feb 27, 2019	Mar CRLD
			25MG	N212038	001	Feb 27, 2019	Feb NEWA
	+		35MG	N212038	002	Feb 27, 2019	Feb NEWA
	+		45MG	N212038	003	Feb 27, 2019	Feb NEWA
	+		55MG	N212038	004	Feb 27, 2019	Feb NEWA
	+		70MG	N212038	005	Feb 27, 2019	Feb NEWA
	+		85MG	N212038	006	Feb 27, 2019	Feb NEWA
METHYLPHENIDATE HYDROCHLORIDE							
AB1		GRANULES PHARMS	10MG	A211796	001	May 23, 2019	May NEWA
AB1			20MG	A211796	002	May 23, 2019	May NEWA
AB1			30MG	A211796	003	May 23, 2019	May NEWA
AB1			40MG	A211796	004	May 23, 2019	May NEWA
AB1			60MG	A211796	005	May 23, 2019	May NEWA
AB1	!	MAYNE PHARMA	60MG	A078458	004	Jun 23, 2016	May CTEC
FOR SUSPENSION, EXTENDED RELEASE;ORAL							
METHYLPHENIDATE HYDROCHLORIDE							
	@	ACTAVIS LABS FL INC	5MG/ML	A206049	001	May 17, 2018	Jan DISC
QUILLIVANT XR							
	+	NEXTWAVE	5MG/ML	N202100	001	Sep 27, 2012	Feb CAHN
	+	NEXTWAVE PHARMS	5MG/ML	N202100	001	Sep 27, 2012	Jan CTEC

METOPROLOL TARTRATE

		INJECTABLE; INJECTION							
		LOPRESSOR							
		+ @ NOVARTIS	1MG/ML	N018704	001	Mar 30, 1984	Jun	DISC	
		METOPROLOL TARTRATE							
AP	!	HOSPIRA	1MG/ML	A078085	001	Apr 29, 2008	Jun	CHRS	
	@	LUITPOLD	1MG/ML	A090386	001	Sep 30, 2009	Mar	DISC	
	@		1MG/ML	A091307	001	Dec 29, 2010	Feb	DISC	
		TABLET; ORAL							
		METOPROLOL TARTRATE							
AB		HERITAGE PHARMA	50MG	A074141	001	Jan 31, 1995	Apr	CAHN	
AB			100MG	A074141	002	Jan 31, 1995	Apr	CAHN	

METRONIDAZOLE

		GEL; VAGINAL							
		METROGEL-VAGINAL							
AB	+	BAUSCH	0.75%	N020208	001	Aug 17, 1992	Mar	CAHN	
		METRONIDAZOLE							
AB		GAGE DEVELOPMENT	0.75%	A211786	001	Jul 02, 2019	Jun	NEWA	
AB		PERRIGO UK FINCO	0.75%	A211786	001	Jul 02, 2019	Jul	CAHN	
		INJECTABLE; INJECTION							
		METRONIDAZOLE IN PLASTIC CONTAINER							
AP		INFORLIFE	500MG/100ML	A206191	001	Feb 25, 2019	Feb	NEWA	
		TABLET; ORAL							
		METRONIDAZOLE							
AB		CADILA	250MG	A206560	001	Nov 16, 2016	Mar	CAHN	
AB			500MG	A206560	002	Nov 16, 2016	Mar	CAHN	
AB		STRIDES PHARMA	250MG	A070040	001	Jan 29, 1985	Apr	CAHN	
AB			500MG	A070039	001	Jan 29, 1985	Apr	CAHN	

METYROSINE

		CAPSULE; ORAL							
		DEMSEER							
	+	BAUSCH	250MG	N017871	001		Mar	CAHN	

MICAFUNGIN SODIUM

		INJECTABLE; INTRAVENOUS							
		MICAFUNGIN SODIUM							
AP		FRESENIUS KABI USA	EQ 50MG BASE/VIAL	A207344	001	May 17, 2019	May	NFTG	
AP			EQ 100MG BASE/VIAL	A207344	002	May 17, 2019	May	NFTG	
		MYCAMINE							
AP	+	ASTELLAS	EQ 50MG BASE/VIAL	N021506	002	Mar 16, 2005	May	CFTG	
AP	+		EQ 100MG BASE/VIAL	N021506	003	Jun 27, 2006	May	CDFR	

MIDAZOLAM

		SPRAY; NASAL							
		NAYZILAM							
	+	UCB INC	5MG/SPRAY	N211321	001	May 17, 2019	May	NEWA	

MIDAZOLAM HYDROCHLORIDE

		INJECTABLE; INJECTION							
		MIDOZALAM HYDROCHLORIDE							
AP		MYLAN ASI	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Apr	CAHN	
AP			EQ 5MG BASE/ML	A090316	002	May 04, 2011	Apr	CAHN	
		SYRUP; ORAL							
		MIDAZOLAM HYDROCHLORIDE							
	@	PD PARTNERS	EQ 2MG BASE/ML	A077115	001	Sep 09, 2005	May	CAHN	

MIDODRINE HYDROCHLORIDE

		TABLET; ORAL							
		MIDODRINE HYDROCHLORIDE							
	@	CASI PHARMS INC	2.5MG	A076514	001	Sep 11, 2003	May	DISC	
	@		5MG	A076514	002	Sep 11, 2003	May	DISC	
	@		10MG	A076514	003	Jul 02, 2004	May	DISC	
AB		MYLAN PHARMS INC	5MG	A076577	002	Sep 10, 2003	May	CHRS	
>A>	AB	RUBICON	2.5MG	A212543	001	Aug 19, 2019	Aug	NEWA	
>A>	AB		5MG	A212543	002	Aug 19, 2019	Aug	NEWA	
>A>	AB		10MG	A212543	003	Aug 19, 2019	Aug	NEWA	
		ORVATEN							
AB	!	UPSHER SMITH LABS	5MG	A076725	002	Nov 03, 2004	May	CHRS	

MIFEPRISTONE

TABLET; ORAL

MIFEPREX

AB	+!	DANCO LABS LLC	200MG	N020687	001	Sep 28, 2000	Mar CFTG
AB		GENBIOPRO	200MG	A091178	001	Apr 11, 2019	Mar NFTG

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

AB	+	BAUSCH	EQ 50MG BASE	N050649	001	May 31, 1990	May CAHN
	+	@	EQ 75MG BASE	N050649	003	Feb 12, 2001	May CAHN
AB	+		EQ 100MG BASE	N050649	002	May 31, 1990	May CAHN

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

>A>		SUN PHARM INDS INC	EQ 45MG BASE	N201922	001	Jul 11, 2012	Aug CAHN
>A>		@	EQ 67.5MG BASE	N201922	002	Jul 11, 2012	Aug CAHN
>A>			EQ 90MG BASE	N201922	003	Jul 11, 2012	Aug CAHN
>A>		@	EQ 112.5MG BASE	N201922	004	Jul 11, 2012	Aug CAHN
>A>			EQ 135MG BASE	N201922	005	Jul 11, 2012	Aug CAHN
>D>		SUN PHARM INDS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	Aug CAHN
>D>		@	EQ 67.5MG BASE	N201922	002	Jul 11, 2012	Aug CAHN
>D>			EQ 90MG BASE	N201922	003	Jul 11, 2012	Aug CAHN
>D>		@	EQ 112.5MG BASE	N201922	004	Jul 11, 2012	Aug CAHN
>D>			EQ 135MG BASE	N201922	005	Jul 11, 2012	Aug CAHN

SUSPENSION; ORAL

MINOCIN

@ BAUSCH EQ 50MG BASE/5ML

N050445 001 May CAHN

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

>A>	AB	AUROBINDO PHARMA LTD	EQ 55MG BASE	A202261	008	Aug 21, 2019	Aug NEWA
	AB	BARR LABS INC	EQ 80MG BASE	A065485	007	Apr 26, 2017	Jan CMFD
	AB		EQ 105MG BASE	A065485	008	Apr 26, 2017	Jan CMFD
>A>		@ MYLAN	EQ 55MG BASE	A203443	001	Aug 21, 2019	Aug NEWA
>D>	AB	MYLAN LABS LTD	EQ 65MG BASE	A201467	001	Jul 30, 2019	Aug DISC
>A>		@	EQ 65MG BASE	A201467	001	Jul 30, 2019	Aug DISC
	AB		EQ 65MG BASE	A201467	001	Jul 30, 2019	Jul NEWA
>D>	AB		EQ 115MG BASE	A201467	002	Jul 30, 2019	Aug DISC
>A>		@	EQ 115MG BASE	A201467	002	Jul 30, 2019	Aug DISC
	AB		EQ 115MG BASE	A201467	002	Jul 30, 2019	Jul NEWA

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

@ WATSON LABS

15MG

A076312 001 Jun 19, 2003 May DISC

@

30MG

A076312 002 Jun 19, 2003 May DISC

@

45MG

A076312 003 Jun 19, 2003 May DISC

MISOPROSTOL

TABLET; ORAL

MISOPROSTOL

AB		ZYDUS PHARMS	0.1MG	A210201	001	Jul 02, 2019	Jun NEWA
AB			0.2MG	A210201	002	Jul 02, 2019	Jun NEWA

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

AP		WEST-WARD PHARMS INT	20MG/VIAL	A064117	002	Apr 19, 1995	Jan CMFD
AP			40MG/VIAL	A064117	003	Jun 02, 1999	Jan CMFD

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

@ MYLAN INSTITUTIONAL

EQ 20MG BASE/10ML (EQ 2MG BASE/ML)

A078980 001 Apr 13, 2009 Mar DISC

@

EQ 30MG BASE/15ML (EQ 2MG BASE/ML)

A078980 002 Apr 13, 2009 Mar DISC

MODAFINILTABLET;ORAL
MODAFINIL

>D>	@ CADILA	100MG	A209966	001	Sep 14, 2017	Aug CMFD	
>A>	AB	100MG	A209966	001	Sep 14, 2017	Aug CMFD	
	@	100MG	A209966	001	Sep 14, 2017	May CAHN	
>D>	@	200MG	A209966	002	Sep 14, 2017	Aug CMFD	
>A>	AB	200MG	A209966	002	Sep 14, 2017	Aug CMFD	
	@	200MG	A209966	002	Sep 14, 2017	May CAHN	
>D>	AB	HIKMA PHARMS	100MG	A090543	001	Sep 26, 2012	Aug DISC
>A>	@	100MG	A090543	001	Sep 26, 2012	Aug DISC	
>D>	AB	200MG	A090543	002	Sep 26, 2012	Aug DISC	
>A>	@	200MG	A090543	002	Sep 26, 2012	Aug DISC	
	@ ZYDUS PHARMS	100MG	A209966	001	Sep 14, 2017	Apr DISC	
	@	200MG	A209966	002	Sep 14, 2017	Apr DISC	

MOMETASONE FUROATEAEROSOL, METERED;INHALATION
ASMANEX HFA

>A>	+	MERCK SHARP DOHME	0.05MG/INH	N205641	003	Aug 12, 2019	Aug NEWA	
		CREAM;TOPICAL						
>D>		ELOCON						
>D>	AB	+!	MERCK SHARP DOHME	0.1%	N019625	002	Apr 19, 2013	Aug DISC
>A>		+	@	0.1%	N019625	002	Apr 19, 2013	Aug DISC
			MOMETASONE FUROATE					
>D>	AB		GLENMARK GENERICS	0.1%	A078541	001	May 28, 2008	Aug CHRS
>A>	AB	!		0.1%	A078541	001	May 28, 2008	Aug CHRS
			OINTMENT;TOPICAL					
			ELOCON					
		+	@ MERCK SHARP DOHME	0.1%	N019543	001	Apr 30, 1987	Jul DISC
			MOMETASONE FUROATE					
	AB	!	GLENMARK GENERICS	0.1%	A078571	001	May 28, 2008	Jul CHRS

MONTELUKAST SODIUMGRANULE;ORAL
MONTELUKAST SODIUM

	@ MYLAN PHARMS INC	EQ 4MG BASE/PACKET	A202776	001	Dec 18, 2012	Feb DISC
AB	TORRENT	EQ 4MG BASE/PACKET	A210431	001	Jul 31, 2018	Mar CAHN
	TABLET;ORAL					
	MONTELUKAST SODIUM					
AB	L PERRIGO CO	EQ 10MG BASE	A206112	001	Apr 26, 2017	May CAHN
	@ MYLAN PHARMS INC	EQ 10MG BASE	A079103	001	Aug 03, 2012	Jul DISC
	@ VINTAGE PHARMS LLC	EQ 10MG BASE	A091576	001	Aug 03, 2012	Feb DISC
	TABLET, CHEWABLE;ORAL					
	MONTELUKAST SODIUM					
	@ MYLAN PHARMS INC	EQ 4MG BASE	A079142	001	Aug 03, 2012	Apr DISC
	@	EQ 5MG BASE	A079142	002	Aug 03, 2012	Apr DISC
	@ VINTAGE PHARMS LLC	EQ 4MG BASE	A091588	001	Aug 03, 2012	Feb DISC
	@	EQ 5MG BASE	A091588	002	Aug 03, 2012	Feb DISC

MORPHINE SULFATEINJECTABLE;INJECTION
ASTRAMORPH PF

	@ FRESENIUS KABI USA	0.5MG/ML	A071050	001	Oct 07, 1986	Mar DISC	
	MITIGO						
>D>	AP	PIRAMAL CRITICAL	10MG/ML	A204393	001	Jul 16, 2018	Aug CAHN
>A>	AP		10MG/ML	A204393	001	Jul 16, 2018	Aug CAHN
>D>	AP		25MG/ML	A204393	002	Jul 16, 2018	Aug CAHN
>A>	AP		25MG/ML	A204393	002	Jul 16, 2018	Aug CAHN
	SOLUTION;ORAL						
	MORPHINE SULFATE						
	@ LANNETT CO INC	10MG/5ML	A202309	001	Nov 25, 2015	Feb DISC	
	@	20MG/5ML	A202310	001	Oct 30, 2015	Jan DISC	
	@	100MG/5ML	N201517	001	Jun 23, 2011	Jan DISC	
	@ VISTAPHARM	10MG/5ML	A201947	001	Jan 05, 2012	Jul DISC	
	TABLET;ORAL						
	MORPHINE SULFATE						
AB	+	HIKMA	15MG	N022207	001	Mar 17, 2008	Jul CFTG
	+		15MG	N022207	001	Mar 17, 2008	Jun CAHN
AB	+	!	30MG	N022207	002	Mar 17, 2008	Jul CFTG
	+	!	30MG	N022207	002	Mar 17, 2008	Jun CAHN

TABLET;ORAL							
MORPHINE SULFATE							
AB	UPSHER SMITH LABS	15MG	A210610	001	Jul 22, 2019	Jul	NFTG
AB		30MG	A210610	002	Jul 22, 2019	Jul	NFTG
TABLET, EXTENDED RELEASE;ORAL							
ARYMO ER							
	+ @ EGALET	15MG	N208603	001	Jan 09, 2017	Mar	CAHN
	+ @	30MG	N208603	002	Jan 09, 2017	Mar	CAHN
	+ @	60MG	N208603	003	Jan 09, 2017	Mar	CAHN
	+ @ ZYLA	15MG	N208603	001	Jan 09, 2017	Jul	CAHN
	+ @	30MG	N208603	002	Jan 09, 2017	Jul	CAHN
	+ @	60MG	N208603	003	Jan 09, 2017	Jul	CAHN
MORPHINE SULFATE							
>D> AB	MYLAN PHARMS INC	15MG	A200824	001	Oct 18, 2011	Aug	DISC
>A>	@	15MG	A200824	001	Oct 18, 2011	Aug	DISC
>D> AB		30MG	A200824	002	Oct 18, 2011	Aug	DISC
>A>	@	30MG	A200824	002	Oct 18, 2011	Aug	DISC
>D> AB		60MG	A200824	003	Oct 18, 2011	Aug	DISC
>A>	@	60MG	A200824	003	Oct 18, 2011	Aug	DISC
>D> AB		100MG	A200824	004	Oct 18, 2011	Aug	DISC
>A>	@	100MG	A200824	004	Oct 18, 2011	Aug	DISC
	@	200MG	A200824	005	Oct 18, 2011	Feb	DISC
<u>MOXIFLOXACIN HYDROCHLORIDE</u>							
SOLUTION/DROPS;OPHTHALMIC							
MOXIFLOXACIN HYDROCHLORIDE							
AT1	ALEMBIC PHARMS LTD EQ 0.5% BASE		A209469	001	Feb 13, 2019	Jan	NEWA
TABLET;ORAL							
MOXIFLOXACIN HYDROCHLORIDE							
	@ SUNSHINE LAKE EQ 400MG BASE		A206295	001	Sep 28, 2018	Mar	DISC
<u>MUPIROCIN</u>							
OINTMENT;TOPICAL							
MUPIROCIN							
AB	! PERRIGO ISRAEL	2%	A065123	001	Nov 07, 2003	May	CAHN
<u>MYCOPHENOLATE MOFETIL</u>							
SUSPENSION;ORAL							
MYCOPHENOLATE MOFETIL							
AB	VISTAPHARM	200MG/ML	A210370	001	Feb 12, 2019	Jan	NEWA
TABLET;ORAL							
MYCOPHENOLATE MOFETIL							
>D> AB	OXFORD PHARMS	500MG	A090606	001	Jul 16, 2010	Aug	DISC
>A>	@	500MG	A090606	001	Jul 16, 2010	Aug	DISC
<u>NABUMETONE</u>							
TABLET;ORAL							
NABUMETONE							
>A> AB	NEXGEN PHARMA INC	500MG	A203166	001	Aug 30, 2019	Aug	NEWA
>A> AB		750MG	A203166	002	Aug 30, 2019	Aug	NEWA
>A>		1GM	A203166	003	Aug 30, 2019	Aug	NEWA
<u>NADOLOL</u>							
TABLET;ORAL							
NADOLOL							
AB	HERITAGE PHARMA	20MG	A074229	001	Aug 30, 1996	Apr	CAHN
AB		40MG	A074229	002	Aug 30, 1996	Apr	CAHN
AB		80MG	A074255	001	Jan 24, 1996	Apr	CAHN
	@	120MG	A074255	002	Jan 24, 1996	Apr	CAHN
	@	160MG	A074255	003	Jan 24, 1996	Apr	CAHN
<u>NAFTIFINE HYDROCHLORIDE</u>							
GEL;TOPICAL							
NAFTIFINE HYDROCHLORIDE							
	@ TARO	2%	A208201	001	Apr 10, 2019	May	DISC
AB		2%	A208201	001	Apr 10, 2019	Mar	NFTG
AB	TOLMAR	1%	A206165	001	Mar 20, 2019	Mar	NFTG
NAFTIN							
AB	+! SEBELA IRELAND LTD	1%	N019356	001	Jun 18, 1990	Mar	CFTG
AB	+!	2%	N204286	001	Jun 27, 2013	Mar	CFTG

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION							
NALBUPHINE HYDROCHLORIDE							
	@ DR REDDYS	10MG/ML	A074471	001	Mar 19, 1998	May	CAHN
	@	20MG/ML	A074471	002	Mar 19, 1998	May	CAHN
AP	MYLAN LABS LTD	10MG/ML	A206506	001	Feb 06, 2019	Jan	NEWA
AP		20MG/ML	A206506	002	Feb 06, 2019	Jan	NEWA

NALDEMEDINE TOSYLATE

TABLET; ORAL
SYMPROIC

+! BDSI EQ 0.2MG BASE N208854 001 Mar 23, 2017 Apr CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION							
NALOXONE HYDROCHLORIDE							
AP	VIRTUS PHARMS	0.4MG/ML	A207846	001	Dec 17, 2018	Jul	CAHN
SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS							
EVZIO (AUTOINJECTOR)							
	+! KALEO INC	2MG/0.4ML (2MG/0.4ML)	N209862	001	Oct 19, 2016	Feb	CTNA
SPRAY, METERED; NASAL							
NALOXONE HYDROCHLORIDE							
	@ TEVA PHARMS USA	4MG/SPRAY	A209522	001	Apr 19, 2019	May	DISC
AB		4MG/SPRAY	A209522	001	Apr 19, 2019	Apr	NFTG
NARCAN							
	+! ADAPT	4MG/SPRAY	N208411	001	Nov 18, 2015	May	CTEC
AB	+!	4MG/SPRAY	N208411	001	Nov 18, 2015	Apr	CFTG

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL							
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE							
AB	LUPIN	EQ 0.5MG BASE; EQ 50MG BASE	A075735	001	Jul 11, 2001	Feb	CAHN

NANDROLONE DECANOATE

INJECTABLE; INJECTION							
NANDROLONE DECANOATE							
	@ LUITPOLD	200MG/ML	A091252	001	Aug 30, 2010	Feb	DISC

NAPROXEN

SUSPENSION; ORAL							
NAPROSYN							
AB	+ ATNAHS PHARMA US	25MG/ML	N018965	001	Mar 23, 1987	Jun	CHRS
NAPROXEN							
AB	! WEST-WARD PHARMS INT	25MG/ML	A074190	001	Mar 30, 1994	Jun	CHRS
TABLET; ORAL							
NAPROXEN							
AB	PERRIGO PHARMS CO	250MG	A077339	001	Apr 27, 2005	Apr	CAHN
AB		375MG	A077339	002	Apr 27, 2005	Apr	CAHN
AB		500MG	A077339	003	Apr 27, 2005	Apr	CAHN

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL							
TREXIMET							
	+ @ CURRAX	60MG; EQ 10MG BASE	N021926	002	May 14, 2015	Apr	CAHN
AB	+!	500MG; EQ 85MG BASE	N021926	001	Apr 15, 2008	Apr	CAHN

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL							
NARATRIPTAN							
	@ CASI PHARMS INC	EQ 1MG BASE	A090288	001	Jul 07, 2010	Jun	DISC
	@	EQ 2.5MG BASE	A090288	002	Jul 07, 2010	Jun	DISC

NATEGLINIDE

TABLET; ORAL							
NATEGLINIDE							
AB	CADILA PHARMS LTD	60MG	A206432	001	Apr 19, 2019	Apr	NEWA
AB		120MG	A206432	002	Apr 19, 2019	Apr	NEWA
AB	! ZYDUS PHARMS	120MG	A205248	002	Jul 06, 2016	Jul	CHRS
STARLIX							
	+ @ NOVARTIS	60MG	N021204	001	Dec 22, 2000	Jul	DISC

TABLET; ORAL

STARLIX

+ @	120MG	N021204	002	Dec 22, 2000	Jul DISC
-----	-------	---------	-----	--------------	----------

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

@ LANNETT CO INC	500MG	A204435	001	Jun 10, 2016	Jun DISC
------------------	-------	---------	-----	--------------	----------

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

@ WATSON LABS	EQ 40MG BASE/ML; 200,000 UNITS/ML	A062664	001	Apr 08, 1986	Jul DISC
---------------	-----------------------------------	---------	-----	--------------	----------

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

AP	AMRING PHARMS	5MG/10ML (0.5MG/ML)	A210989	001	Aug 22, 2018	Jan CAHN
AP		10MG/10ML (1MG/ML)	A210989	002	Aug 22, 2018	Jan CAHN
AP	BE PHARMS	5MG/10ML (0.5MG/ML)	A212512	001	May 13, 2019	Apr NEWA
AP		10MG/10ML (1MG/ML)	A212512	002	May 13, 2019	Apr NEWA

>D> NESIRITIDE RECOMBINANT

>D> FOR SOLUTION; INTRAVENOUS

>D> NATRECOR

>D>	+! SCIOS LLC	1.5MG/VIAL	N020920	001	Aug 10, 2001	Aug DISC
-----	--------------	------------	---------	-----	--------------	----------

>A>	+ @	1.5MG/VIAL	N020920	001	Aug 10, 2001	Aug DISC
-----	-----	------------	---------	-----	--------------	----------

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

AB	MYLAN	500MG	A203742	001	Feb 22, 2019	Feb NEWA
AB		750MG	A203742	002	Feb 22, 2019	Feb NEWA
AB		1GM	A203742	003	Feb 22, 2019	Feb NEWA
AB	YICHANG HUMANWELL	500MG	A212017	001	Jun 10, 2019	May NEWA
AB		750MG	A212017	002	Jun 10, 2019	May NEWA
AB		1GM	A212017	003	Jun 10, 2019	May NEWA

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

AB2	NOVAST LABS	30MG	A210614	001	Mar 12, 2019	Feb NEWA
AB2		60MG	A210614	002	Mar 12, 2019	Feb NEWA
AB2		90MG	A210614	003	Mar 12, 2019	Feb NEWA
AB2	OSMOTICA PHARM US	90MG	A077127	003	Oct 03, 2007	Apr CMS1
AB2	SPIL	30MG	A210838	001	Apr 16, 2019	Apr NEWA
AB2		60MG	A210838	002	Apr 16, 2019	Apr NEWA
AB2		90MG	A210838	003	Apr 16, 2019	Apr NEWA

NITISINONE

CAPSULE; ORAL

NITISINONE

>A>						
>A>	AB	NOVITIUM PHARMA	2MG	A211041	001	Aug 26, 2019
>A>	AB		5MG	A211041	002	Aug 26, 2019
>A>	AB		10MG	A211041	003	Aug 26, 2019

ORFADIN

>D>	+	SWEDISH ORPHAN	2MG	N021232	001	Jan 18, 2002	Aug CFTG
>A>	AB	+	2MG	N021232	001	Jan 18, 2002	Aug CFTG
>D>	+		5MG	N021232	002	Jan 18, 2002	Aug CFTG
>A>	AB	+	5MG	N021232	002	Jan 18, 2002	Aug CFTG
>D>	+		10MG	N021232	003	Jan 18, 2002	Aug CFTG
>A>	AB	+	10MG	N021232	003	Jan 18, 2002	Aug CFTG

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

@ MYLAN	50MG	A074967	001	Jul 09, 1997	Jul DISC
---------	------	---------	-----	--------------	----------

@	100MG	A077025	001	Aug 18, 2004	Jul DISC
---	-------	---------	-----	--------------	----------

NITROGLYCERIN

AEROSOL, METERED;SUBLINGUAL					
NITROMIST					
+	!	EVUS	0.4MG/SPRAY	N021780	001 Nov 02, 2006 May CAHN
FILM, EXTENDED RELEASE;TRANSDERMAL					
MINITRAN					
	@	MEDICIS	0.4MG/HR	A089773	001 Aug 30, 1996 May DISC
	@	VALEANT PHARMS	0.1MG/HR	A089771	001 Aug 30, 1996 May DISC
	@		0.6MG/HR	A089774	001 Aug 30, 1996 Jun DISC
	@	VALEANT PHARMS NORTH	0.2MG/HR	A089772	001 Aug 30, 1996 May DISC
NITRO-DUR					
+	!	USPHARMA	0.1MG/HR	N020145	001 Apr 04, 1995 May CTEC
+	!		0.2MG/HR	N020145	002 Apr 04, 1995 May CTEC
+	!		0.4MG/HR	N020145	004 Apr 04, 1995 May CTEC
+	!		0.6MG/HR	N020145	005 Apr 04, 1995 Jun CTEC
NITROGLYCERIN					
AB2		HERCON PHARM	0.1MG/HR	A089885	002 Oct 30, 2017 Feb NEWA
AB2	!	MYLAN TECHNOLOGIES	0.1MG/HR	A074559	004 Feb 06, 1998 Feb CTEC
TABLET;SUBLINGUAL					
NITROGLYCERIN					
AB		ALVOGEN	0.3MG	A211604	001 Apr 30, 2019 Apr NEWA
AB			0.4MG	A211604	002 Apr 30, 2019 Apr NEWA
AB			0.6MG	A211604	003 Apr 30, 2019 Apr NEWA

NORETHINDRONE

TABLET;ORAL-28					
MICRONOR					
+	@	JANSSEN PHARMS	0.35MG	N016954	001 Mar DISC
NORETHINDRONE					
AB2	!	MYLAN LABS LTD	0.35MG	A200980	001 Jun 12, 2013 Mar CHRS

NORETHINDRONE ACETATE

TABLET;ORAL					
NORETHINDRONE ACETATE					
AB		RISING	5MG	A206490	001 Nov 05, 2018 May CAHN

NYSTATIN

CREAM;TOPICAL					
NYSTATIN					
AT		TORRENT	100,000 UNITS/GM	A212557	001 Jul 24, 2019 Jul NEWA
OINTMENT;TOPICAL					
NYSTATIN					
AT		TORRENT	100,000 UNITS/GM	A211838	001 Jan 28, 2019 Jan NEWA
POWDER;TOPICAL					
NYSTATIN					
AT		LUPIN	100,000 UNITS/GM	A065138	001 Jul 23, 2004 Feb CAHN
TABLET;ORAL					
NYSTATIN					
	@	UPSHER SMITH LABS	500,000 UNITS	A062524	001 Nov 26, 1985 Jul CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

OINTMENT;TOPICAL					
NYSTATIN AND TRIAMCINOLONE ACETONIDE					
	@	ZYDUS PHARMS	100,000 UNITS/GM;0.1%	A207764	001 Nov 08, 2018 Mar DISC

OCTREOTIDE ACETATE

INJECTABLE;INJECTION					
OCTREOTIDE ACETATE					
AP		HERITAGE PHARMS INC	EQ 0.05MG BASE/ML	A204669	001 Dec 27, 2018 Apr CAHN
AP			EQ 0.1MG BASE/ML	A204669	002 Dec 27, 2018 Apr CAHN
	@		EQ 0.2MG BASE/ML	A203765	001 Sep 07, 2018 Mar DISC
AP			EQ 0.2MG BASE/ML	A203765	001 Sep 07, 2018 Jan CAHN
AP			EQ 0.5MG BASE/ML	A204669	003 Dec 27, 2018 Apr CAHN
	@		EQ 1MG BASE/ML	A203765	002 Sep 07, 2018 Mar DISC
AP			EQ 1MG BASE/ML	A203765	002 Sep 07, 2018 Jan CAHN
	@	SUN PHARM INDS	EQ 0.05MG BASE/ML	A077372	001 Aug 14, 2007 Jul DISC
	@		EQ 0.1MG BASE/ML	A077372	002 Aug 14, 2007 Jul DISC
	@		EQ 0.2MG BASE/ML	A077373	001 Aug 14, 2007 Jul DISC
	@		EQ 0.5MG BASE/ML	A077372	003 Aug 14, 2007 Jul DISC
	@		EQ 1MG BASE/ML	A077373	002 Aug 14, 2007 Jul DISC

OFLOXACINSOLUTION/DROPS;OPHTHALMIC
OFLOXACIN

AT	APOTEX INC	0.3%	A076513	001	May 14, 2004	Feb CMFD
	@ SANDOZ INC	0.3%	A076231	001	May 14, 2004	Mar DISC

SOLUTION/DROPS;OTIC
OFLOXACIN

>A> AT	AMNEAL PHARMS CO	0.3%	A211525	001	Aug 30, 2019	Aug NEWA
	@ SANDOZ INC	0.3%	A078222	001	Mar 17, 2008	Mar DISC

OLANZAPINE

TABLET;ORAL

OLANZAPINE

@ SUNSHINE LAKE	2.5MG	A206238	001	Nov 19, 2018	Apr DISC
@	5MG	A206238	002	Nov 19, 2018	Apr DISC
@	7.5MG	A206238	003	Nov 19, 2018	Apr DISC
@	10MG	A206238	004	Nov 19, 2018	Apr DISC
@	15MG	A206238	005	Nov 19, 2018	Apr DISC
@	20MG	A206238	006	Nov 19, 2018	Apr DISC

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

@ HEC PHARM	5MG	A208146	001	Jul 02, 2018	Feb DISC
@	10MG	A208146	002	Jul 02, 2018	Feb DISC
@	15MG	A208146	003	Jul 02, 2018	Feb DISC
@	20MG	A208146	004	Jul 02, 2018	Feb DISC

OLIVE OIL; SOYBEAN OIL

EMULSION;INTRAVENOUS

CLINOLIPID 20%

>D>	+ @ BAXTER HLTHCARE CORP	16%(160GM/1000ML);4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Aug CMFD
>A>	+!	16%(160GM/1000ML);4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Aug CMFD
	+ @	16%(160GM/1000ML);4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Jun CDFR

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

AB	SUNSHINE LAKE	5MG	A211049	001	Feb 22, 2019	Feb NEWA
AB		20MG	A211049	002	Feb 22, 2019	Feb NEWA
AB		40MG	A211049	003	Feb 22, 2019	Feb NEWA
AB	UMEDICA LABS PVT LTD	5MG	A207135	001	Jul 18, 2019	Jul NEWA
AB		20MG	A207135	002	Jul 18, 2019	Jul NEWA
AB		40MG	A207135	003	Jul 18, 2019	Jul NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AT	ALEMBIC PHARMS LTD	EQ 0.2% BASE	A209420	001	Apr 29, 2019	Apr NEWA
AT	AUROBINDO PHARMA LTD	EQ 0.2% BASE	A209995	001	Apr 04, 2019	Mar NEWA
AT	GLAND PHARMA LTD	EQ 0.1% BASE	A209619	001	Aug 02, 2019	Jul NEWA
AT	USV	EQ 0.1% BASE	A203152	001	Dec 07, 2015	Jun CAHN

OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET;ORAL

TECHNIVIE

+ @ ABBVIE INC	12.5MG;75MG;50MG	N207931	001	Jul 24, 2015	Apr DISC
----------------	------------------	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

OMEGA-3-ACID ETHYL ESTERS

AB	ASCENT PHARMS INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A207420	001	Feb 25, 2019	Feb NEWA
AB	BIONPHARMA INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A206455	001	Aug 07, 2019	Jul NEWA
	@ PAR PHARM INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091018	001	Jun 24, 2014	Jun DISC
AB	SOFGEN PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY	A211355	001	Jul 10, 2019	Jun NEWA

CAPSULE;ORAL
OMEGA-3-ACID ETHYL ESTERS

AB	ZYDUS	ACIDS 1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210107	001	Jun 14, 2019	Jun NEWA
----	-------	---	---------	-----	--------------	----------

OMEPRAZOLECAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE
@ MYLAN 10MG

A075876 001 May 29, 2003 Jun DISC

OMEPRAZOLE; SODIUM BICARBONATEFOR SUSPENSION;ORAL
ZEGERID

AB	+	SALIX	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Apr CAHN
AB	+	!	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Apr CAHN

ONDANSETRON HYDROCHLORIDEINJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE@ LUITPOLD EQ 2MG BASE/ML
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

A079039 001 Nov 18, 2008 Feb DISC

@ HIKMA FARMACEUTICA EQ 2MG BASE/ML

A076780 001 Dec 26, 2006 Feb DISC

@ LUITPOLD EQ 2MG BASE/ML

A079032 001 Nov 18, 2008 Feb DISC

>D> AP TEVA EQ 2MG BASE/ML

A076759 001 Nov 22, 2006 Aug DISC

>A> @ EQ 2MG BASE/ML

A076759 001 Nov 22, 2006 Aug DISC

SOLUTION;ORAL

ONDANSETRON HYDROCHLORIDE

AA PD PARTNERS EQ 4MG BASE/5ML

A078127 001 Jun 25, 2007 May CAHN

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

@ MYLAN EQ 24MG BASE

A076930 004 Jun 25, 2007 Feb DISC

ORPHENADRINE CITRATEINJECTABLE;INJECTION
NORFLEX

+ @ TELIGENT 30MG/ML

N013055 001 Jan CRLD

TABLET, EXTENDED RELEASE;ORAL

ORPHENADRINE CITRATE

AB LUPIN 100MG

A040284 001 Jun 19, 1998 Feb CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB ALEMBIC PHARMS LTD EQ 30MG BASE

A211823 001 Jun 24, 2019 Jun NEWA

AB EQ 45MG BASE

A211823 002 Jun 24, 2019 Jun NEWA

AB EQ 75MG BASE

A211823 003 Jun 24, 2019 Jun NEWA

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB TEVA PHARMS USA EQ 6MG BASE/ML

A211125 001 Feb 27, 2019 Feb NEWA

OXACILLIN SODIUMINJECTABLE;INJECTION
OXACILLIN SODIUM

AP PIRAMAL CRITICAL EQ 1GM BASE/VIAL

A206681 001 Sep 11, 2017 Jul CAHN

AP EQ 2GM BASE/VIAL

A206681 002 Sep 11, 2017 Jul CAHN

AP EQ 10GM BASE/VIAL

A206760 001 Oct 26, 2017 Jul CAHN

OXALIPLATININJECTABLE;INTRAVENOUS
ELOXATIN

+ @ SANOFI AVENTIS US 50MG/VIAL

N021492 001 Aug 09, 2002 Feb CDFR

AP +! 50MG/10ML (5MG/ML)

N021759 001 Jan 31, 2005 Feb CDFR

+ @ 100MG/VIAL

N021492 002 Aug 09, 2002 Feb CDFR

AP +! 100MG/20ML (5MG/ML)

N021759 002 Jan 31, 2005 Feb CDFR

+ @ 200MG/40ML (5MG/ML)

N021759 003 Nov 17, 2006 Feb CDFR

OXALIPLATIN

AP ACCORD HLTHCARE 50MG/10ML (5MG/ML)

A207474 001 Mar 21, 2017 Feb CDFR

AP 100MG/20ML (5MG/ML)

A207474 002 Mar 21, 2017 Feb CDFR

AP 200MG/40ML (5MG/ML)

A207474 003 Mar 21, 2017 Feb CDFR

AP ACTAVIS LLC 50MG/10ML (5MG/ML)

A204880 001 Mar 05, 2018 Feb CDFR

INJECTABLE; INTRAVENOUS OXALIPLATIN									
AP			100MG/20ML (5MG/ML)	A204880	002	Mar 05, 2018	Feb	CDFR	
AP	!	ACTAVIS TOTOWA	50MG/VIAL	A078803	001	Aug 08, 2012	Jul	CHRS	
AP			50MG/VIAL	A078803	001	Aug 08, 2012	Feb	CDFR	
AP	!		100MG/VIAL	A078803	002	Aug 08, 2012	Jul	CHRS	
AP			100MG/VIAL	A078803	002	Aug 08, 2012	Feb	CDFR	
AP		CIPLA	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	Feb	CDFR	
AP			100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	Feb	CDFR	
AP		EUGIA PHARMA	50MG/10ML (5MG/ML)	A205529	001	Sep 06, 2017	Feb	CDFR	
AP			100MG/20ML (5MG/ML)	A205529	002	Sep 06, 2017	Feb	CDFR	
AP		FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A078811	001	Jun 10, 2010	Feb	CDFR	
AP			100MG/20ML (5MG/ML)	A078811	002	Jun 10, 2010	Feb	CDFR	
AP			50MG/VIAL	A078819	001	Jun 02, 2010	Feb	CDFR	
AP			50MG/10ML (5MG/ML)	A090030	001	Jan 31, 2017	Feb	CDFR	
AP			100MG/VIAL	A078819	002	Jun 02, 2010	Feb	CDFR	
AP			100MG/20ML (5MG/ML)	A090030	002	Jan 31, 2017	Feb	CDFR	
AP			200MG/40ML (5MG/ML)	A090030	003	Jan 31, 2017	Feb	CDFR	
AP		GLAND PHARMA LTD	50MG/10ML (5MG/ML)	A207325	001	Feb 10, 2017	Feb	CDFR	
AP			50MG/VIAL	A207385	001	May 23, 2017	Feb	CDFR	
AP			100MG/20ML (5MG/ML)	A207325	002	Feb 10, 2017	Feb	CDFR	
AP			100MG/VIAL	A207385	002	May 23, 2017	Feb	CDFR	
AP			200MG/40ML (5MG/ML)	A207325	003	Oct 18, 2017	Feb	CDFR	
AP		HOSPIRA WORLDWIDE	50MG/10ML (5MG/ML)	A078813	001	Aug 07, 2009	Feb	CDFR	
AP			100MG/20ML (5MG/ML)	A078813	002	Aug 07, 2009	Feb	CDFR	
AP		INGENUS PHARMS LLC	50MG/10ML (5MG/ML)	A207562	001	Oct 16, 2018	Feb	CDFR	
AP			100MG/20ML (5MG/ML)	A207562	002	Oct 16, 2018	Feb	CDFR	
AP		JIANGSU HENGRUI MED	50MG/10ML (5MG/ML)	A203869	001	Jun 18, 2014	Feb	CDFR	
AP			100MG/20ML (5MG/ML)	A203869	002	Jun 18, 2014	Feb	CDFR	
AP		MYLAN LABS LTD	50MG/10ML (5MG/ML)	A091358	001	Aug 07, 2012	Feb	CDFR	
AP			50MG/VIAL	A200979	001	Aug 08, 2012	Feb	CDFR	
AP			100MG/20ML (5MG/ML)	A091358	002	Aug 07, 2012	Feb	CDFR	
AP			100MG/VIAL	A200979	002	Aug 08, 2012	Feb	CDFR	
AP			200MG/40ML (5MG/ML)	A091358	003	Nov 14, 2017	Feb	CDFR	
AP		QILU PHARM CO LTD	50MG/10ML (5MG/ML)	A204368	001	Jun 07, 2016	Feb	CDFR	
AP			50MG/VIAL	A204616	001	May 11, 2016	Feb	CDFR	
AP			100MG/20ML (5MG/ML)	A204368	002	Jun 07, 2016	Feb	CDFR	
AP			100MG/VIAL	A204616	002	May 11, 2016	Feb	CDFR	
AP	!		200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Feb	CDFR	
AP		SANDOZ	50MG/10ML (5MG/ML)	A078817	001	Jan 24, 2011	Feb	CDFR	
	@		50MG/VIAL	A090849	001	Apr 28, 2011	Feb	CDFR	
AP			100MG/20ML (5MG/ML)	A078817	002	Jan 24, 2011	Feb	CDFR	
	@		100MG/VIAL	A090849	002	Apr 28, 2011	Feb	CDFR	
	@	SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Feb	CDFR	
	@		100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Feb	CDFR	
	@	SUN PHARM	50MG/VIAL	A078818	001	Aug 07, 2009	Jul	DISC	
	@		50MG/10ML (5MG/ML)	A202922	001	Apr 08, 2014	Jul	DISC	
	@		100MG/VIAL	A078818	002	Aug 07, 2009	Jul	DISC	
	@		100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014	Jul	DISC	
	@		200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019	Jul	DISC	
AP			200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019	Apr	CDFR	
AP	!	SUN PHARMA GLOBAL	50MG/VIAL	A078818	001	Aug 07, 2009	Feb	CDFR	
AP			50MG/10ML (5MG/ML)	A202922	001	Apr 08, 2014	Feb	CDFR	
AP	!		100MG/VIAL	A078818	002	Aug 07, 2009	Feb	CDFR	
AP			100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014	Feb	CDFR	
AP	+	TEVA PHARMS	50MG/10ML (5MG/ML)	N022160	001	Aug 07, 2009	Feb	CDFR	
AP	+		100MG/20ML (5MG/ML)	N022160	002	Aug 07, 2009	Feb	CDFR	

INJECTABLE; IV (INFUSION)

OXALIPLATIN									
AP		SUN PHARMA GLOBAL	200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019	Feb	NEWA	

OXAPROZIN

TABLET; ORAL

OXAPROZIN

	@	BEXIMCO PHARMS USA	600MG	A075842	001	Apr 12, 2001	Mar	CAHN	
--	---	--------------------	-------	---------	-----	--------------	-----	------	--

OXYBUTYNIN CHLORIDE

SYRUP; ORAL

OXYBUTYNIN CHLORIDE

	@	PD PARTNERS	5MG/5ML	A074997	001	Oct 15, 1997	May	CAHN	
--	---	-------------	---------	---------	-----	--------------	-----	------	--

TABLET; ORAL

OXYBUTYNIN CHLORIDE

AB		EMCURE PHARMS LTD	5MG	A211682	001	May 10, 2019	Apr	NEWA	
----	--	-------------------	-----	---------	-----	--------------	-----	------	--

Line	Product	Strength	Formulation	Manufacturer	Lot	Exp Date	Source
	<u>TABLET;ORAL</u>						
	OXYBUTYNIN CHLORIDE						
AB	INVATECH PHARMA	5MG			A211062	001 Feb 06, 2019	Jan NEWA
	TABLET, EXTENDED RELEASE;ORAL						
	OXYBUTYNIN CHLORIDE						
>D> AB	ACCORD HLTHCARE	15MG			A207138	003 Feb 29, 2016	Aug CHRS
>A> AB	!	15MG			A207138	003 Feb 29, 2016	Aug CHRS
AB	AJANTA PHARMA LTD	5MG			A211655	001 Feb 28, 2019	Feb NEWA
AB		10MG			A211655	002 Feb 28, 2019	Feb NEWA
AB		15MG			A211655	003 Feb 28, 2019	Feb NEWA
>D> AB	! MYLAN PHARMS INC	15MG			A076644	002 May 10, 2007	Aug CHRS
>A> AB		15MG			A076644	002 May 10, 2007	Aug CHRS
	<u>OXYCODONE HYDROCHLORIDE</u>						
	SOLUTION;ORAL						
	OXYCODONE HYDROCHLORIDE						
AA	ALKEM LABS LTD	5MG/5ML			A211748	001 Feb 07, 2019	Feb NEWA
AA		100MG/5ML			A211749	001 Feb 04, 2019	Jan NEWA
	@ LANNETT CO INC	100MG/5ML			A204085	001 Sep 09, 2014	Jan DISC
AA	PHARM ASSOC	5MG/5ML			A206914	001 Feb 01, 2019	May CPOT
AA		5MG/ML			A206914	001 Feb 01, 2019	Jan NEWA
	TABLET;ORAL						
	OXAYDO						
	ZYLA	5MG			N202080	001 Jun 17, 2011	Jul CAHN
		7.5MG			N202080	002 Jun 17, 2011	Jul CAHN
	OXYCODONE HYDROCHLORIDE						
	@ VINTAGE PHARMS	5MG			A077712	003 Mar 02, 2009	Apr DISC
	@	10MG			A077712	004 Apr 13, 2015	Apr DISC
	@	15MG			A077712	001 Jan 31, 2007	Apr DISC
	@	20MG			A077712	005 Apr 13, 2015	Apr DISC
	@	30MG			A077712	002 Jan 31, 2007	Apr DISC
	<u>OXYTOCIN</u>						
	INJECTABLE;INJECTION						
	OXYTOCIN						
	@ DR REDDYS	10USP UNITS/ML (10USP UNITS/ML)			A077453	001 Jan 24, 2008	May CAHN
	@	100USP UNITS/10ML (10USP UNITS/ML)			A077453	002 Jan 24, 2008	May CAHN
	<u>PACLITAXEL</u>						
	INJECTABLE;INJECTION						
	PACLITAXEL						
	@ ACCORD HLTHCARE	6MG/ML			A205720	001 Aug 17, 2018	Mar DISC
	<u>PALIPERIDONE</u>						
	TABLET, EXTENDED RELEASE;ORAL						
	PALIPERIDONE						
>A> AB	INVENTIA	1.5MG			A204452	001 Jun 12, 2019	Aug CAHN
>A> AB		3MG			A204452	002 Jun 12, 2019	Aug CAHN
>A> AB		6MG			A204452	003 Jun 12, 2019	Aug CAHN
>A> AB		9MG			A204452	004 Jun 12, 2019	Aug CAHN
>D> AB	INVENTIA HLTHCARE	1.5MG			A204452	001 Jun 12, 2019	Aug CAHN
AB		1.5MG			A204452	001 Jun 12, 2019	May NEWA
>D> AB		3MG			A204452	002 Jun 12, 2019	Aug CAHN
AB		3MG			A204452	002 Jun 12, 2019	May NEWA
>D> AB		6MG			A204452	003 Jun 12, 2019	Aug CAHN
AB		6MG			A204452	003 Jun 12, 2019	May NEWA
>D> AB		9MG			A204452	004 Jun 12, 2019	Aug CAHN
AB		9MG			A204452	004 Jun 12, 2019	May NEWA
	<u>PALONOSETRON HYDROCHLORIDE</u>						
	INJECTABLE;INTRAVENOUS						
	PALONOSETRON HYDROCHLORIDE						
	@ DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)			A201533	001 Apr 21, 2016	Mar DISC
	SOLUTION;INTRAVENOUS						
	PALONOSETRON HYDROCHLORIDE						
	HIKMA	EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML)			N207963	001 Aug 22, 2016	Jul CAHN

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION
PAMIDRONATE DISODIUM

AP	DR REDDYS	30MG/10ML (3MG/ML)	A078156	001	Aug 19, 2008	May CAHN
AP		60MG/10ML (6MG/ML)	A078156	002	Aug 19, 2008	May CAHN
AP		90MG/10ML (9MG/ML)	A078156	003	Aug 19, 2008	May CAHN
	@ LUITPOLD	30MG/10ML (3MG/ML)	A078942	001	Jul 25, 2008	Mar DISC
	@	90MG/10ML (9MG/ML)	A078942	002	Jul 25, 2008	Mar DISC

PANCURONIUM BROMIDE

INJECTABLE;INJECTION
PANCURONIUM BROMIDE

AP	! DR REDDYS	1MG/ML	A072759	001	Jul 31, 1990	May CAHN
	!	2MG/ML	A072760	001	Jul 31, 1990	May CAHN

PANOBINOSTAT LACTATE

CAPSULE;ORAL
FARYDAK

+	SECURA	EQ 10MG BASE	N205353	001	Feb 23, 2015	Jun CAHN
+		EQ 15MG BASE	N205353	002	Feb 23, 2015	Jun CAHN
+	!	EQ 20MG BASE	N205353	003	Feb 23, 2015	Jun CAHN

PANTOPRAZOLE SODIUM

INJECTABLE;IV (INFUSION)
PANTOPRAZOLE SODIUM

>A>	AP	SUN PHARM	EQ 40MG BASE/VIAL	A077674	001	Aug 19, 2019	Aug NEWA
		POWDER;IV (INFUSION)					
		PANTOPRAZOLE SODIUM					
		HIKMA	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Jul CAHN
		TABLET, DELAYED RELEASE;ORAL					
		PANTOPRAZOLE SODIUM					
>D>	AB	APOTEX INC	EQ 20MG BASE	A090807	001	May 02, 2012	Aug CAHN
>D>	AB		EQ 40MG BASE	A090807	002	May 02, 2012	Aug CAHN
	AB	INGENUS PHARMS LLC	EQ 40MG BASE	A211368	001	Mar 01, 2019	Feb NEWA
	AB	L PERRIGO CO	EQ 20MG BASE	A203024	001	May 07, 2014	May CAHN
>A>	AB	RUBICON	EQ 20MG BASE	A090807	001	May 02, 2012	Aug CAHN
>A>	AB		EQ 40MG BASE	A090807	002	May 02, 2012	Aug CAHN

PENICILLAMINE

CAPSULE;ORAL
CUPRIMINE

	@ VALEANT PHARMS INTL	125MG	N019853	002		Jan CAHN
AB	+	250MG	N019853	001		Apr CFTG
	+	250MG	N019853	001		Jan CAHN
	PENICILLAMINE					
AB	AMERIGEN PHARMS LTD	250MG	A209921	001	May 07, 2019	Apr NFTG
AB	WATSON LABS INC	250MG	A210976	001	Jun 24, 2019	Jun NEWA

PENTAMIDINE ISETHIONATE

FOR SOLUTION;INHALATION
NEBUPENT

AN	+	FRESENIUS KABI USA	300MG/VIAL	N019887	001	Jun 15, 1989	Apr CFTG
		PENTAMIDINE ISETHIONATE					
AN		SETON PHARMS	300MG/VIAL	A206667	001	Apr 24, 2019	Apr NFTG

PENTOSTATIN

INJECTABLE;INJECTION
PENTOSTATIN

@ MYLAN INSTITUTIONAL	10MG/VIAL	A203554	001	Sep 19, 2014	Mar DISC
-----------------------	-----------	---------	-----	--------------	----------

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL
PENTOXIFYLLINE

@ ANI PHARMS INC	400MG	A074878	001	Jul 09, 1997	May CAHN
@ MYLAN	400MG	A074425	001	Jul 08, 1997	Jun DISC

PERMETHRINCREAM; TOPICAL
PERMETHRIN

AB	ENCUBE ETHICALS	5%	A211303	001	Apr 03, 2019	Mar	NEWA
AB	PERRIGO ISRAEL	5%	A076369	001	Apr 21, 2003	May	CAHN

>A> PEXIDARTINIB HYDROCHLORIDE>A> CAPSULE; ORAL
>A> TURALIO

>A>	+	DAIICHI SANKYO INC	EQ 200MG BASE	N211810	001	Aug 02, 2019	Aug	NEWA
-----	---	--------------------	---------------	---------	-----	--------------	-----	------

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE
@ UPSHER SMITH LABS

35MG

A084399 001

Jul CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

>D>	AP	AMNEAL PHARMS CO	10MG/ML (10MG/ML)	A211079	001	Jul 05, 2018	Aug	CTEC	
>A>	AP1		10MG/ML (10MG/ML)	A211079	001	Jul 05, 2018	Aug	CTEC	
>D>	AP		50MG/5ML (10MG/ML)	A211078	001	Jul 19, 2018	Aug	CTEC	
>A>	AP1		50MG/5ML (10MG/ML)	A211078	001	Jul 19, 2018	Aug	CTEC	
>D>	AP		100MG/10ML (10MG/ML)	A211078	002	Jul 19, 2018	Aug	CTEC	
>A>	AP1		100MG/10ML (10MG/ML)	A211078	002	Jul 19, 2018	Aug	CTEC	
	AP	FRESENIUS KABI USA	10MG/ML (10MG/ML)	A210665	001	Jan 29, 2019	Jan	NEWA	
>D>	AP		50MG/5ML (10MG/ML)	A210666	001	Jan 30, 2019	Aug	CTEC	
>A>	AP1		50MG/5ML (10MG/ML)	A210666	001	Jan 30, 2019	Aug	CTEC	
	AP		50MG/5ML (10MG/ML)	A210666	001	Jan 30, 2019	Jan	NEWA	
>D>	AP		100MG/10ML (10MG/ML)	A210666	002	Jan 30, 2019	Aug	CTEC	
>A>	AP1		100MG/10ML (10MG/ML)	A210666	002	Jan 30, 2019	Aug	CTEC	
	AP		100MG/10ML (10MG/ML)	A210666	002	Jan 30, 2019	Jan	NEWA	
>D>	AP	MEITHEAL	10MG/ML (10MG/ML)	A210334	001	Apr 27, 2018	Aug	CTEC	
>A>	AP2		10MG/ML (10MG/ML)	A210334	001	Apr 27, 2018	Aug	CTEC	
	AP		10MG/ML (10MG/ML)	A210334	001	Apr 27, 2018	Jun	CAHN	
>D>	AP		50MG/5ML (10MG/ML)	A210333	001	Apr 27, 2018	Aug	CTEC	
>A>	AP1		50MG/5ML (10MG/ML)	A210333	001	Apr 27, 2018	Aug	CTEC	
	AP		50MG/5ML (10MG/ML)	A210333	001	Apr 27, 2018	Jun	CAHN	
>D>	AP		100MG/10ML (10MG/ML)	A210333	002	Apr 27, 2018	Aug	CTEC	
>A>	AP1		100MG/10ML (10MG/ML)	A210333	002	Apr 27, 2018	Aug	CTEC	
	AP		100MG/10ML (10MG/ML)	A210333	002	Apr 27, 2018	Jun	CAHN	
>D>	AP	PAR STERILE PRODUCTS	10MG/ML (10MG/ML)	A210025	001	Dec 21, 2018	Aug	CTEC	
>A>	AP1		10MG/ML (10MG/ML)	A210025	001	Dec 21, 2018	Aug	CTEC	
>D>	AP		50MG/5ML (10MG/ML)	A210025	002	Dec 21, 2018	Aug	CTEC	
>A>	AP1		50MG/5ML (10MG/ML)	A210025	002	Dec 21, 2018	Aug	CTEC	
>D>	AP		100MG/10ML (10MG/ML)	A210025	003	Dec 21, 2018	Aug	CTEC	
>A>	AP1		100MG/10ML (10MG/ML)	A210025	003	Dec 21, 2018	Aug	CTEC	
>D>	AP	SANDOZ INC	10MG/ML (10MG/ML)	A208905	001	Jan 31, 2019	Aug	CTEC	
>A>	AP1		10MG/ML (10MG/ML)	A208905	001	Jan 31, 2019	Aug	CTEC	
	AP		10MG/ML (10MG/ML)	A208905	001	Jan 31, 2019	Jan	NEWA	
>D>	AP		50MG/5ML (10MG/ML)	A208905	002	Jan 31, 2019	Aug	CTEC	
>A>	AP1		50MG/5ML (10MG/ML)	A208905	002	Jan 31, 2019	Aug	CTEC	
	AP		50MG/5ML (10MG/ML)	A208905	002	Jan 31, 2019	Jan	NEWA	
>D>	AP		100MG/10ML (10MG/ML)	A208905	003	Jan 31, 2019	Aug	CTEC	
>A>	AP1		100MG/10ML (10MG/ML)	A208905	003	Jan 31, 2019	Aug	CTEC	
	AP		100MG/10ML (10MG/ML)	A208905	003	Jan 31, 2019	Jan	NEWA	
>D>	AP	+	WEST WARD PHARM CORP	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	Aug	CTEC
>A>	AP2	+		10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	Aug	CTEC
>A>	AP2	+		50MG/5ML (10MG/ML)	N203826	002	Jun 19, 2019	Aug	NEWA
>A>	AP2	+		100MG/10ML (10MG/ML)	N203826	003	Jun 19, 2019	Aug	NEWA

VAZCULEP

>D>	AP	+	AVADEL LEGACY	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Aug	CHRS
>A>	AP	+		10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Aug	CHRS
>D>	AP	+		50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Aug	CHRS
>A>	AP	+		50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Aug	CHRS
>D>	AP	+		100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Aug	CTEC
>A>	AP1	+		100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Aug	CTEC

SOLUTION/DROPS; OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

AT	+	AKORN INC	2.5%	N207926	001	Jan 15, 2015	Jan	CTEC
AT	+		10%	N207926	002	Jan 15, 2015	Jan	CTEC
AT	+	PARAGON BIOTECK	2.5%	N203510	001	Mar 21, 2013	Jan	CTEC

SOLUTION/DROPS;OPHTHALMIC
PHENYLEPHRINE HYDROCHLORIDE

AT	+	!		10%		N203510	002	Mar 21, 2013	Jan CTEC
----	---	---	--	-----	--	---------	-----	--------------	----------

PHENYTOIN SODIUM

CAPSULE;ORAL

EXTENDED PHENYTOIN SODIUM

@ SUN PHARM INDS (IN) 100MG EXTENDED

A040621	001	Dec 11, 2006	Jul DISC
---------	-----	--------------	----------

INJECTABLE;INJECTION

PHENYTOIN SODIUM

@ LUITPOLD 50MG/ML

A040781	001	Dec 04, 2007	Feb DISC
---------	-----	--------------	----------

PHYTONADIONE

INJECTABLE;INJECTION

PHYTONADIONE

AB		DR REDDYS LABS LTD	10MG/ML		A207719	001	May 22, 2019	May NEWA
----	--	--------------------	---------	--	---------	-----	--------------	----------

VITAMIN K1

AB	!	HOSPIRA	10MG/ML		A087955	001	Jul 25, 1983	May CTEC
----	---	---------	---------	--	---------	-----	--------------	----------

TABLET;ORAL

MEPHYTON

AB	+	!	BAUSCH	5MG	N010104	003		Feb CAHN
----	---	---	--------	-----	---------	-----	--	----------

AB	+	!	VALEANT PHARMS INTL	5MG	N010104	003		Jan CAHN
----	---	---	---------------------	-----	---------	-----	--	----------

PHYTONADIONE

AB		ZYDUS	5MG		A210189	001	Feb 20, 2019	Feb NEWA
----	--	-------	-----	--	---------	-----	--------------	----------

PILOCARPINE HYDROCHLORIDE

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	5MG		A212377	001	Aug 13, 2019	Jul NEWA
----	--	----------------------	-----	--	---------	-----	--------------	----------

AB			7.5MG		A212377	002	Aug 13, 2019	Jul NEWA
----	--	--	-------	--	---------	-----	--------------	----------

SALAGEN

AB	+	CONCORDIA	5MG		N020237	001	Mar 22, 1994	Jul CAHN
----	---	-----------	-----	--	---------	-----	--------------	----------

AB	+	!		7.5MG	N020237	002	Apr 18, 2003	Jul CAHN
----	---	---	--	-------	---------	-----	--------------	----------

PIMAVANSERIN TARTRATE

TABLET;ORAL

NUPLAZID

+ @ ACADIA PHARMS INC EQ 17MG BASE

N207318	001	Apr 29, 2016	Jan DISC
---------	-----	--------------	----------

PIMECROLIMUS

CREAM;TOPICAL

ELIDEL

>A>	AB	+	!	BAUSCH	1%	N021302	001	Dec 13, 2001	Aug CAHN
-----	----	---	---	--------	----	---------	-----	--------------	----------

>D>	AB	+	!	VALEANT BERMUDA	1%	N021302	001	Dec 13, 2001	Aug CAHN
-----	----	---	---	-----------------	----	---------	-----	--------------	----------

PIMECROLIMUS

>A>	AB		GLENMARK PHARMS LTD	1%	A211769	001	Aug 29, 2019	Aug NEWA
-----	----	--	---------------------	----	---------	-----	--------------	----------

PINDOLOL

TABLET;ORAL

PINDOLOL

AB		BAYSHORE PHARMS LLC	5MG		A211712	001	Aug 01, 2019	Jul NEWA
----	--	---------------------	-----	--	---------	-----	--------------	----------

AB			10MG		A211712	002	Aug 01, 2019	Jul NEWA
----	--	--	------	--	---------	-----	--------------	----------

@ ZYDUS PHARMS

@ 10MG

A209866	001	Aug 18, 2017	Jun DISC
---------	-----	--------------	----------

A209866	002	Aug 18, 2017	Jun DISC
---------	-----	--------------	----------

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP		ASTRAL	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL		A212287	001	Jul 29, 2019	Jul NEWA
----	--	--------	-------------------------------------	--	---------	-----	--------------	----------

AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL		A212287	002	Jul 29, 2019	Jul NEWA
----	--	--	-------------------------------------	--	---------	-----	--------------	----------

AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL		A212287	003	Jul 29, 2019	Jul NEWA
----	--	--	-------------------------------------	--	---------	-----	--------------	----------

PIROXICAM

CAPSULE;ORAL

PIROXICAM

>A>	AB		BRECKENRIDGE	10MG	A206136	001	Jun 20, 2017	Aug CAHN
-----	----	--	--------------	------	---------	-----	--------------	----------

>A>	AB			20MG	A206136	002	Jun 20, 2017	Aug CAHN
-----	----	--	--	------	---------	-----	--------------	----------

AB		CADILA	10MG		A205585	001	Jul 17, 2018	Feb CAHN
----	--	--------	------	--	---------	-----	--------------	----------

AB			20MG		A205585	002	Jul 17, 2018	Feb CAHN
----	--	--	------	--	---------	-----	--------------	----------

CAPSULE;ORAL							
PIROXICAM							
>D>	AB	PII	10MG	A206136	001	Jun 20, 2017	Aug CAHN
>D>	AB		20MG	A206136	002	Jun 20, 2017	Aug CAHN
<u>PITAVASTATIN CALCIUM</u>							
TABLET;ORAL							
PITAVASTATIN CALCIUM							
	@ MYLAN		EQ 1MG BASE	A206070	001	Apr 04, 2019	Apr DISC
	@		EQ 2MG BASE	A206070	002	Apr 04, 2019	Apr DISC
	@		EQ 4MG BASE	A206070	003	Apr 04, 2019	Apr DISC
AB	MYLAN PHARMS INC		EQ 1MG BASE	A206070	001	Apr 04, 2019	Mar NEWA
AB			EQ 2MG BASE	A206070	002	Apr 04, 2019	Mar NEWA
AB			EQ 4MG BASE	A206070	003	Apr 04, 2019	Mar NEWA
<u>PITOLISANT HYDROCHLORIDE</u>							
TABLET;ORAL							
WAKIX							
>A>	+	BIOPROJET PHARMA	EQ 4.45MG BASE	N211150	001	Aug 14, 2019	Aug NEWA
>A>	+	!	EQ 17.8MG BASE	N211150	002	Aug 14, 2019	Aug NEWA
<u>PLAZOMICIN SULFATE</u>							
SOLUTION;INTRAVENOUS							
ZEMDRI							
	+	CIPLA USA	EQ 500MG BASE/10ML (EQ 50MG BASE/ML)	N210303	001	Jun 25, 2018	Jul CAHN
<u>PLECANATIDE</u>							
TABLET;ORAL							
TRULANCE							
	+	BAUSCH	3MG	N208745	001	Jan 19, 2017	Mar CAHN
	+	SALIX	3MG	N208745	001	Jan 19, 2017	Apr CAHN
<u>POLYETHYLENE GLYCOL 3350</u>							
FOR SOLUTION;ORAL							
GLYCOLAX							
	@	LANNETT CO INC	17GM/SCOOPFUL	A076652	001	Jul 02, 2004	May DISC
	POLYETHYLENE GLYCOL 3350						
	@	NEXGEN PHARMA INC	17GM/SCOOPFUL	A077706	001	Sep 27, 2006	May DISC
	@	PADDOCK LLC	17GM/SCOOPFUL	A077893	001	May 26, 2006	May DISC
<u>POSACONAZOLE</u>							
TABLET, DELAYED RELEASE;ORAL							
NOXAFIL							
>D>	+	MERCK SHARP DOHME	100MG	N205053	001	Nov 25, 2013	Aug CFTG
>A>	AB	+	100MG	N205053	001	Nov 25, 2013	Aug CFTG
>A>	POSACONAZOLE						
>A>	AB	SINOTHERAPEUTICS INC	100MG	A212411	001	Aug 21, 2019	Aug NFTG
<u>POTASSIUM CHLORIDE</u>							
CAPSULE, EXTENDED RELEASE;ORAL							
POTASSIUM CHLORIDE							
>A>	AB	ANDA REPOSITORY	8MEQ	A205549	001	Dec 08, 2015	Aug CAHN
>A>	AB		10MEQ	A205549	002	Dec 08, 2015	Aug CAHN
>D>	AB	PII	8MEQ	A205549	001	Dec 08, 2015	Aug CAHN
>D>	AB		10MEQ	A205549	002	Dec 08, 2015	Aug CAHN
	AB	PRINSTON INC	8MEQ	A209026	001	Jun 11, 2019	May NEWA
	AB		10MEQ	A209026	002	Jun 11, 2019	May NEWA
	AB	ZYDUS PHARMS	8MEQ	A208445	001	Mar 11, 2019	Feb NEWA
	AB		10MEQ	A208445	002	Mar 11, 2019	Feb NEWA
FOR SOLUTION;ORAL							
POTASSIUM CHLORIDE							
AA	AMNEAL PHARMS LLC		20MEQ	A210902	001	May 23, 2019	May NEWA
AA	BELCHER PHARMS LLC		20MEQ	A212183	001	May 06, 2019	Apr NEWA
SOLUTION;ORAL							
POTASSIUM CHLORIDE							
AA	PHARM ASSOC		20MEQ/15ML	A210766	001	Mar 29, 2019	Mar NEWA
AA			40MEQ/15ML	A210766	002	Mar 29, 2019	Mar NEWA
TABLET, EXTENDED RELEASE;ORAL							
KLOR-CON M15							
AB1	UPSHER SMITH LABS		15MEQ	A074726	003	Jun 06, 2003	Mar CTEC

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

AB1	ADARE PHARMS INC	10MEQ	A076368	002	Jun 05, 2019	Jun NEWA
>A>	@ ANDA REPOSITORY	8MEQ	A206881	001	Jan 22, 2019	Aug CAHN
>A>	@	10MEQ	A206881	002	Jan 22, 2019	Aug CAHN
>A>	AB1 BRECKENRIDGE	10MEQ	A206630	001	Mar 29, 2019	Aug CAHN
>A>	AB3	10MEQ	A210097	001	Jun 17, 2019	Aug CAHN
>A>	AB1	15MEQ	A206630	002	Mar 29, 2019	Aug CAHN
>A>	AB1	20MEQ	A206630	003	Mar 29, 2019	Aug CAHN
>A>	AB2	20MEQ	A210098	001	Apr 26, 2019	Aug CAHN
>D>	@ PII	8MEQ	A206881	001	Jan 22, 2019	Aug CAHN
	@	8MEQ	A206881	001	Jan 22, 2019	Jul DISC
	AB2	8MEQ	A206881	001	Jan 22, 2019	Jan NEWA
>D>	AB1	10MEQ	A206630	001	Mar 29, 2019	Aug CAHN
	AB1	10MEQ	A206630	001	Mar 29, 2019	Mar NEWA
>D>	@	10MEQ	A206881	002	Jan 22, 2019	Aug CAHN
	@	10MEQ	A206881	002	Jan 22, 2019	Jul DISC
	AB2	10MEQ	A206881	002	Jan 22, 2019	Jan NEWA
>D>	AB3	10MEQ	A210097	001	Jun 17, 2019	Aug CAHN
	AB3	10MEQ	A210097	001	Jun 17, 2019	Jun NEWA
>D>	AB1	15MEQ	A206630	002	Mar 29, 2019	Aug CAHN
	AB1	15MEQ	A206630	002	Mar 29, 2019	Mar NEWA
>D>	AB1	20MEQ	A206630	003	Mar 29, 2019	Aug CAHN
	AB1	20MEQ	A206630	003	Mar 29, 2019	Mar NEWA
>D>	AB2	20MEQ	A210098	001	Apr 26, 2019	Aug CAHN
	AB2	20MEQ	A210098	001	Apr 26, 2019	Apr NEWA
	AB1 PRINSTON INC	10MEQ	A209922	001	Apr 30, 2019	Apr NEWA
	AB1	15MEQ	A209922	002	Apr 30, 2019	Apr NEWA
	AB1	20MEQ	A209922	003	Apr 30, 2019	Apr NEWA

PRALATREXATE

SOLUTION; INTRAVENOUS
FOLOTYN

+	ACROTECH	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009	Mar CAHN
+	!	40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009	Mar CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

	PRAMIPEXOLE DIHYDROCHLORIDE					
AB	HERITAGE PHARMA	0.125MG	A077724	001	Feb 19, 2008	May CAHN
	@	0.125MG	A091254	001	Nov 30, 2010	May CAHN
AB		0.25MG	A077724	002	Feb 19, 2008	May CAHN
	@	0.25MG	A091254	002	Nov 30, 2010	May CAHN
AB		0.5MG	A077724	003	Feb 19, 2008	May CAHN
	@	0.5MG	A091254	003	Nov 30, 2010	May CAHN
	@	0.75MG	A091254	004	Nov 30, 2010	May CAHN
AB		1MG	A077724	004	Feb 19, 2008	May CAHN
	@	1MG	A091254	005	Nov 30, 2010	May CAHN
AB		1.5MG	A077724	005	Feb 19, 2008	May CAHN
	@	1.5MG	A091254	006	Nov 30, 2010	May CAHN

PRAVASTATIN SODIUM

TABLET;ORAL

	PRAVASTATIN SODIUM					
AB	APNAR PHARMA LP	10MG	A076397	003	Oct 23, 2006	Jun CAHN
AB		20MG	A076397	002	Oct 23, 2006	Jun CAHN
AB		40MG	A076397	001	Oct 23, 2006	Jun CAHN
AB		80MG	A077491	001	Feb 11, 2008	Jun CAHN

PREDNISOLONE

SYRUP;ORAL

	PREDNISOLONE					
	@ PD PARTNERS	5MG/5ML	A040570	001	Aug 25, 2005	May CAHN
	@	15MG/5ML	A040571	001	Aug 25, 2005	May CAHN

PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC
ECONOPRED

	@ EYEVANCE	0.125%	N017468	001		May CAHN
--	------------	--------	---------	-----	--	----------

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

!	BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995	May CTEC
@	SANDOZ INC	EQ 0.23% PHOSPHATE;10%	A073630	001	May 27, 1993	May DISC

PREDNISONE

TABLET;ORAL

PREDNISONE

AB	GENEYORK PHARMS	1MG	A211496	001	Dec 28, 2018	Jul CMFD
	@	1MG	A211496	001	Dec 28, 2018	May DISC
AB		2.5MG	A211495	001	Dec 07, 2018	Jul CMFD
	@	2.5MG	A211495	001	Dec 07, 2018	May DISC
AB		5MG	A211495	002	Dec 07, 2018	Jul CMFD
	@	5MG	A211495	002	Dec 07, 2018	May DISC
AB		10MG	A210525	001	Dec 04, 2018	Jul CMFD
	@	10MG	A210525	001	Dec 04, 2018	May DISC
AB		20MG	A210525	002	Dec 04, 2018	Jul CMFD
	@	20MG	A210525	002	Dec 04, 2018	May DISC
AB		50MG	A210525	003	Dec 04, 2018	Jul CMFD
	@	50MG	A210525	003	Dec 04, 2018	May DISC
AB	SUN PHARM INDUSTRIES	5MG	A089247	002	Dec 04, 1985	Jan CMS1
AB		10MG	A089247	003	Dec 04, 1985	Jan CMS1

PREGABALIN

CAPSULE;ORAL

LYRICA

AB	+	PF PRISM CV	25MG	N021446	001	Dec 30, 2004	Jul CFTG
AB	+		50MG	N021446	002	Dec 30, 2004	Jul CFTG
AB	+		75MG	N021446	003	Dec 30, 2004	Jul CFTG
AB	+		100MG	N021446	004	Dec 30, 2004	Jul CFTG
AB	+		150MG	N021446	005	Dec 30, 2004	Jul CFTG
AB	+		200MG	N021446	006	Dec 30, 2004	Jul CFTG
AB	+		225MG	N021446	007	Dec 30, 2004	Jul CFTG
AB	+		300MG	N021446	008	Dec 30, 2004	Jul CFTG

PREGABALIN

AB	ALEMBIC PHARMS LTD	25MG	A203459	001	Jul 19, 2019	Jul NFTG
AB		50MG	A203459	002	Jul 19, 2019	Jul NFTG
AB		75MG	A203459	003	Jul 19, 2019	Jul NFTG
AB		100MG	A203459	004	Jul 19, 2019	Jul NFTG
AB		150MG	A203459	005	Jul 19, 2019	Jul NFTG
AB		200MG	A203459	006	Jul 19, 2019	Jul NFTG
AB		225MG	A203459	007	Jul 19, 2019	Jul NFTG
AB		300MG	A203459	008	Jul 19, 2019	Jul NFTG
AB	ALKEM LABS LTD	75MG	A207799	001	Jul 19, 2019	Jul NFTG
AB		100MG	A207799	002	Jul 19, 2019	Jul NFTG
AB		150MG	A207799	003	Jul 19, 2019	Jul NFTG
AB		200MG	A207799	004	Jul 19, 2019	Jul NFTG
AB		225MG	A207799	005	Jul 19, 2019	Jul NFTG
AB		300MG	A207799	006	Jul 19, 2019	Jul NFTG
AB	AMNEAL PHARMS CO	25MG	A209743	001	Jul 19, 2019	Jul NFTG
AB		50MG	A209743	002	Jul 19, 2019	Jul NFTG
AB		75MG	A209743	003	Jul 19, 2019	Jul NFTG
AB		100MG	A209743	004	Jul 19, 2019	Jul NFTG
AB		150MG	A209743	005	Jul 19, 2019	Jul NFTG
AB		200MG	A209743	006	Jul 19, 2019	Jul NFTG
AB		225MG	A209743	007	Jul 19, 2019	Jul NFTG
AB		300MG	A209743	008	Jul 19, 2019	Jul NFTG
AB	DR REDDYS	25MG	A209664	001	Jul 19, 2019	Jul NFTG
AB		50MG	A209664	002	Jul 19, 2019	Jul NFTG
AB		75MG	A209664	003	Jul 19, 2019	Jul NFTG
AB		100MG	A209664	004	Jul 19, 2019	Jul NFTG
AB		150MG	A209664	005	Jul 19, 2019	Jul NFTG
AB		200MG	A209664	006	Jul 19, 2019	Jul NFTG
AB		225MG	A209664	007	Jul 19, 2019	Jul NFTG
AB		300MG	A209664	008	Jul 19, 2019	Jul NFTG
AB	INVAGEN PHARMS	25MG	A211384	001	Jul 19, 2019	Jul NFTG
AB		50MG	A211384	002	Jul 19, 2019	Jul NFTG
AB		75MG	A211384	003	Jul 19, 2019	Jul NFTG
AB		100MG	A211384	004	Jul 19, 2019	Jul NFTG
AB		150MG	A211384	005	Jul 19, 2019	Jul NFTG
AB		200MG	A211384	006	Jul 19, 2019	Jul NFTG

CAPSULE;ORAL
PREGABALIN

AB		225MG	A211384	007	Jul 19, 2019	Jul NFTG
AB		300MG	A211384	008	Jul 19, 2019	Jul NFTG
AB	MSN LABS PVT LTD	25MG	A209357	001	Jul 19, 2019	Jul NFTG
AB		50MG	A209357	002	Jul 19, 2019	Jul NFTG
AB		75MG	A209357	003	Jul 19, 2019	Jul NFTG
AB		100MG	A209357	004	Jul 19, 2019	Jul NFTG
AB		150MG	A209357	005	Jul 19, 2019	Jul NFTG
AB		200MG	A209357	006	Jul 19, 2019	Jul NFTG
AB		225MG	A209357	007	Jul 19, 2019	Jul NFTG
AB		300MG	A209357	008	Jul 19, 2019	Jul NFTG
AB	RISING	25MG	A210432	001	Jul 19, 2019	Jul NFTG
AB		50MG	A210432	002	Jul 19, 2019	Jul NFTG
AB		75MG	A210432	003	Jul 19, 2019	Jul NFTG
AB		100MG	A210432	004	Jul 19, 2019	Jul NFTG
AB		150MG	A210432	005	Jul 19, 2019	Jul NFTG
AB		200MG	A210432	006	Jul 19, 2019	Jul NFTG
AB		225MG	A210432	007	Jul 19, 2019	Jul NFTG
AB		300MG	A210432	008	Jul 19, 2019	Jul NFTG
AB	SCIEGEN PHARMS INC	25MG	A208677	001	Jul 19, 2019	Jul NFTG
AB		50MG	A208677	002	Jul 19, 2019	Jul NFTG
AB		75MG	A208677	003	Jul 19, 2019	Jul NFTG
AB		100MG	A208677	004	Jul 19, 2019	Jul NFTG
AB		150MG	A208677	005	Jul 19, 2019	Jul NFTG
AB		200MG	A208677	006	Jul 19, 2019	Jul NFTG
AB		225MG	A208677	007	Jul 19, 2019	Jul NFTG
AB		300MG	A208677	008	Jul 19, 2019	Jul NFTG
AB	TEVA PHARMS	25MG	A091219	001	Jul 19, 2019	Jul NFTG
AB		50MG	A091219	002	Jul 19, 2019	Jul NFTG
AB		75MG	A091224	001	Jul 19, 2019	Jul NFTG
AB		100MG	A091224	002	Jul 19, 2019	Jul NFTG
AB		150MG	A091224	003	Jul 19, 2019	Jul NFTG
AB		200MG	A091224	004	Jul 19, 2019	Jul NFTG
AB		225MG	A091224	005	Jul 19, 2019	Jul NFTG
AB		300MG	A091224	006	Jul 19, 2019	Jul NFTG

SOLUTION;ORAL
LYRICA

AA	+! PF PRISM CV	20MG/ML	N022488	001	Jan 04, 2010	Jul CFTG
AA	PREGABALIN					
AA	ALKEM LABS LTD	20MG/ML	A207623	001	Jul 19, 2019	Jul NFTG

>A> PRETOMANID

>A> TABLET;ORAL

>A> PRETOMANID

>A>	+! TB ALLIANCE	200MG	N212862	001	Aug 14, 2019	Aug NEWA
-----	----------------	-------	---------	-----	--------------	----------

PROCHLORPERAZINE EDISYLATE

INJECTABLE;INJECTION

PROCHLORPERAZINE EDISYLATE

AP	NEXUS PHARMS	EQ 5MG BASE/ML	A204860	001	Feb 15, 2019	Feb NEWA
----	--------------	----------------	---------	-----	--------------	----------

PROCHLORPERAZINE MALEATE

TABLET;ORAL

PROCHLORPERAZINE MALEATE

@	TEVA PHARMS	EQ 5MG BASE	A040120	001	Jul 11, 1996	Jul DISC
@		EQ 10MG BASE	A040120	002	Jul 11, 1996	Jul DISC

PROGESTERONE

INJECTABLE;INJECTION

PROGESTERONE

@	LUITPOLD	50MG/ML	A090845	001	Jun 22, 2009	Mar DISC
---	----------	---------	---------	-----	--------------	----------

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY;RECTAL

PROMETHAZINE HYDROCHLORIDE

AB	PERRIGO ISRAEL	12.5MG	A040500	001	Jun 30, 2003	May CAHN
AB		25MG	A040500	002	Jun 30, 2003	May CAHN

TABLET;ORAL

PROMETHAZINE HYDROCHLORIDE

@	IMPAX LABS	12.5MG	A040791	002	Feb 12, 2008	Mar DISC
@		25MG	A040791	003	Feb 12, 2008	Mar DISC

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL									
INNOPRAN XL									
BX	+	ANI PHARMS INC	80MG	N021438	001	Mar 12, 2003	Jul	CRLD	
BX	+	!	120MG	N021438	002	Mar 12, 2003	Jul	CHRS	
BX	+		120MG	N021438	002	Mar 12, 2003	Jul	CRLD	
TABLET;ORAL									
PROPRANOLOL HYDROCHLORIDE									
	@	INNOGENIX	10MG	A070322	002	Oct 22, 1985	May	CMS1	
	@		20MG	A070322	003	Oct 22, 1985	May	CMS1	
	@		40MG	A070322	004	Oct 22, 1985	May	CMS1	
	@		60MG	A070322	005	Sep 24, 1986	May	CMS1	
	@		80MG	A070322	001	Aug 04, 1986	Mar	CAHN	

PROTRIPTYLINE HYDROCHLORIDE

TABLET;ORAL									
VIVACTIL									
AB		HERITAGE PHARMA	5MG	A073644	001	Aug 24, 1995	May	CAHN	
AB	!		10MG	A073645	001	Aug 24, 1995	May	CAHN	

PYRIDOSTIGMINE BROMIDE

INJECTABLE;INJECTION									
MESTINON									
AP	+	!	BAUSCH	5MG/ML	N009830	001		Feb	CAHN
SYRUP;ORAL									
MESTINON									
AA	+	!	BAUSCH	60MG/5ML	N015193	001		Feb	CFTG
	+	!		60MG/5ML	N015193	001		Feb	CAHN
PYRIDOSTIGMINE BROMIDE									
AA			NOVITIUM PHARMA	60MG/5ML	A211694	001	Mar 08, 2019	Feb	NFTG
TABLET;ORAL									
MESTINON									
AB	+	!	BAUSCH	60MG	N009829	002		Feb	CAHN
PYRIDOSTIGMINE BROMIDE									
			APNAR PHARMA LP	30MG	A211181	002	May 14, 2019	May	NEWA
TABLET, EXTENDED RELEASE;ORAL									
MESTINON									
AB	+	!	BAUSCH	180MG	N011665	001		Feb	CAHN

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION									
PYRIDOXINE HYDROCHLORIDE									
	@	DR REDDYS	100MG/ML	A080572	001			May	CAHN

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL									
QUETIAPINE FUMARATE									
	@	AMNEAL PHARMS	EQ 400MG BASE	A211405	001	Oct 26, 2018	Apr	DISC	

QUININE SULFATE

CAPSULE;ORAL									
QUININE SULFATE									
	@	MYLAN PHARMS INC	324MG	A202581	001	Dec 14, 2012	Mar	DISC	

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL									
RABEPRAZOLE SODIUM									
	@	MYLAN	20MG	A076885	001	Nov 08, 2013	Jul	DISC	
AB		RUBICON	20MG	A204237	001	Nov 18, 2015	Feb	CAHN	

RAMELTEON

TABLET;ORAL									
RAMELTEON									
AB		ZYDUS PHARMS	8MG	A211567	001	Jul 22, 2019	Jul	NEWA	

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

AB	APPCO PHARMA LLC	EQ 150MG BASE	A211893	001	Apr 05, 2019	Mar NEWA
AB		EQ 300MG BASE	A211893	002	Apr 05, 2019	Mar NEWA

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

	@ TORRENT	EQ 15MG BASE/ML	A090102	001	May 26, 2009	Jul DISC
AA		EQ 15MG BASE/ML	A090102	001	May 26, 2009	Jan CAHN

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

AB	HERITAGE PHARMA	EQ 150MG BASE	A075165	001	Sep 30, 1998	Feb CAHN
AB		EQ 300MG BASE	A075165	002	Sep 30, 1998	Feb CAHN
AB	STRIDES PHARMA	EQ 150MG BASE	A210010	001	Aug 01, 2018	Apr CAHN
AB		EQ 300MG BASE	A210010	002	Aug 01, 2018	Apr CAHN
AB	VKT PHARMA PVT LTD	EQ 150MG BASE	A211289	001	Jan 31, 2019	Jan NEWA
AB		EQ 300MG BASE	A211289	002	Jan 31, 2019	Jan NEWA

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANEXA

AB	+ GILEAD	500MG	N021526	002	Jan 27, 2006	Feb CTEC
AB	+!	1GM	N021526	001	Feb 12, 2007	Feb CTEC

RANOLAZINE

AB	ACTAVIS ELIZABETH	500MG	A208862	001	May 28, 2019	May NEWA
AB		1GM	A208862	002	May 28, 2019	May NEWA
AB	AJANTA PHARMA LTD	500MG	A210054	001	May 28, 2019	May NEWA
AB		1GM	A210054	002	May 28, 2019	May NEWA
>A> AB	CADILA	500MG	A210188	001	Aug 19, 2019	Aug NEWA
>A> AB		1GM	A210188	002	Aug 19, 2019	Aug NEWA
AB	CIPLA	500MG	A211291	001	May 28, 2019	May NEWA
AB		1GM	A211291	002	May 28, 2019	May NEWA
AB	GLENMARK PHARMS LTD	500MG	A211082	001	Jul 05, 2019	Jun NEWA
AB		1GM	A211082	002	Jul 05, 2019	Jun NEWA
AB	LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Feb CMFD
AB		1GM	A201046	002	Jul 29, 2013	Feb CMFD
AB	SCIEGEN PHARMS INC	500MG	A211829	001	Jun 04, 2019	May NEWA
AB		1GM	A211829	002	Jun 04, 2019	May NEWA
AB	SUN PHARM	500MG	A211707	001	May 28, 2019	May NEWA
AB		1GM	A211707	002	May 28, 2019	May NEWA

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

AB	MICRO LABS	EQ 0.5MG BASE	A207004	001	Mar 29, 2019	Mar NEWA
AB		EQ 1MG BASE	A207004	002	Mar 29, 2019	Mar NEWA

REPAGLINIDE

TABLET;ORAL

PRANDIN

	+ @ GEMINI LABS LLC	0.5MG	N020741	001	Dec 22, 1997	Mar DISC
	+ @	1MG	N020741	002	Dec 22, 1997	Mar DISC
	+ @	2MG	N020741	003	Dec 22, 1997	Mar DISC

REPAGLINIDE

AB	! AUROBINDO PHARMA LTD	2MG	A203820	003	Jan 22, 2014	Mar CHRS
	@ MYLAN	0.5MG	A090252	001	Aug 23, 2013	Feb DISC
	@	1MG	A090252	002	Jan 22, 2014	Jul DISC
	@	2MG	A090252	003	Jan 22, 2014	Jul DISC

RETAPAMULIN

OINTMENT;TOPICAL

ALTABAX

	+! ALMIRALL	1%	N022055	001	Apr 12, 2007	Mar CAHN
--	-------------	----	---------	-----	--------------	----------

RIBAVIRIN

CAPSULE;ORAL

RIBAVIRIN

	@ CASI PHARMS INC	200MG	A076192	001	Apr 06, 2004	Jun DISC
--	-------------------	-------	---------	-----	--------------	----------

SOLUTION;ORAL

REBETOL

	+ @ SCHERING	40MG/ML	N021546	001	Jul 29, 2003	Jun DISC
--	--------------	---------	---------	-----	--------------	----------

TABLET;ORAL

RIBAVIRIN

AB	BEXIMCO PHARMS USA	200MG	A202546	001	Aug 12, 2014	Feb CAHN
AB		400MG	A202546	002	Aug 12, 2014	Feb CAHN
AB		500MG	A202546	003	Aug 12, 2014	Feb CAHN
AB		600MG	A202546	004	Aug 12, 2014	Feb CAHN
AB	HERITAGE PHARMA	200MG	A077053	001	Dec 05, 2005	May CAHN

RILUZOLE

TABLET;ORAL

RILUZOLE

@	DAITO PHARMS CO LTD	50MG	A204430	001	Oct 16, 2018	Mar DISC
---	---------------------	------	---------	-----	--------------	----------

RIMANTADINE HYDROCHLORIDE

TABLET;ORAL

RIMANTADINE HYDROCHLORIDE

@	HERITAGE PHARMA	100MG	A076375	001	Jan 14, 2003	May CAHN
---	-----------------	-------	---------	-----	--------------	----------

RIMEXOLONE

SUSPENSION/DROPS;OPHTHALMIC

VEXOL

@	EYEVANCE	1%	N020474	001	Dec 30, 1994	May CAHN
---	----------	----	---------	-----	--------------	----------

RISEDRONATE SODIUM

TABLET;ORAL

RISEDRONATE SODIUM

>D>	AB	HANGZHOU BINJIANG	35MG	A207516	001	Feb 15, 2019	Aug DISC
>A>		@	35MG	A207516	001	Feb 15, 2019	Aug DISC
	AB		35MG	A207516	001	Feb 15, 2019	Feb NEWA
		@ MYLAN	5MG	A200477	001	Nov 30, 2015	May DISC
		@	30MG	A200477	002	Nov 30, 2015	May DISC
		@	35MG	A200477	003	Nov 30, 2015	May DISC
		@	75MG	A200477	004	Jun 10, 2014	May DISC
		@	150MG	A200477	005	Jun 10, 2014	May DISC
	AB	ORCHID HLTHCARE	30MG	A205280	001	May 13, 2019	Apr NEWA
	AB		35MG	A205280	002	May 13, 2019	Apr NEWA

TABLET, DELAYED RELEASE;ORAL

RISEDRONATE SODIUM

AB	SUN PHARM	35MG	A203925	001	Jul 09, 2019	Jun NEWA
	@ ZYDUS PHARMS	35MG	A203822	001	Sep 11, 2018	Feb DISC

RISPERIDONE

SOLUTION;ORAL

RISPERIDONE

AA	TORRENT	1MG/ML	A078909	001	Jul 29, 2009	Jan CAHN
----	---------	--------	---------	-----	--------------	----------

TABLET;ORAL

RISPERIDONE

>A>	AB	CELLTRION	0.25MG	A078871	001	Oct 09, 2008	Aug CAHN
>A>	AB		0.5MG	A078871	002	Oct 09, 2008	Aug CAHN
>A>	AB		1MG	A078871	003	Oct 09, 2008	Aug CAHN
>A>	AB		2MG	A078871	004	Oct 09, 2008	Aug CAHN
>A>	AB		3MG	A078871	005	Oct 09, 2008	Aug CAHN
>A>	AB		4MG	A078871	006	Oct 09, 2008	Aug CAHN
>D>	AB	HERITAGE PHARMA	0.25MG	A076228	001	Jun 30, 2008	Aug DISC
>A>		@	0.25MG	A076228	001	Jun 30, 2008	Aug DISC
	AB		0.25MG	A076228	001	Jun 30, 2008	May CAHN
	AB		0.25MG	A077769	001	Oct 16, 2008	May CAHN
>D>	AB		0.5MG	A076228	002	Jun 30, 2008	Aug DISC
>A>		@	0.5MG	A076228	002	Jun 30, 2008	Aug DISC
	AB		0.5MG	A076228	002	Jun 30, 2008	May CAHN
	AB		0.5MG	A077769	002	Oct 16, 2008	May CAHN
>D>	AB		1MG	A076228	003	Jun 30, 2008	Aug DISC
>A>		@	1MG	A076228	003	Jun 30, 2008	Aug DISC
	AB		1MG	A076228	003	Jun 30, 2008	May CAHN
	AB		1MG	A077769	003	Oct 16, 2008	May CAHN
>D>	AB		2MG	A076228	004	Jun 30, 2008	Aug DISC
>A>		@	2MG	A076228	004	Jun 30, 2008	Aug DISC
	AB		2MG	A076228	004	Jun 30, 2008	May CAHN
	AB		2MG	A077769	004	Oct 16, 2008	May CAHN
>D>	AB		3MG	A076228	005	Jun 30, 2008	Aug DISC
>A>		@	3MG	A076228	005	Jun 30, 2008	Aug DISC
	AB		3MG	A076228	005	Jun 30, 2008	May CAHN

TABLET;ORAL
RISPERIDONE

AB		3MG	A077769	005	Oct 16, 2008	May CAHN
>D>	AB	4MG	A076228	006	Jun 30, 2008	Aug DISC
>A>	@	4MG	A076228	006	Jun 30, 2008	Aug DISC
AB		4MG	A076228	006	Jun 30, 2008	May CAHN
AB		4MG	A077769	006	Oct 16, 2008	May CAHN
>D>	AB	WOCKHARDT 0.25MG	A078871	001	Oct 09, 2008	Aug CAHN
>D>	AB	0.5MG	A078871	002	Oct 09, 2008	Aug CAHN
>D>	AB	1MG	A078871	003	Oct 09, 2008	Aug CAHN
>D>	AB	2MG	A078871	004	Oct 09, 2008	Aug CAHN
>D>	AB	3MG	A078871	005	Oct 09, 2008	Aug CAHN
>D>	AB	4MG	A078871	006	Oct 09, 2008	Aug CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
RISPERIDONE

AB	HERITAGE PHARMA	0.5MG	A076908	001	Mar 12, 2012	May CAHN
AB		1MG	A076908	002	Mar 12, 2012	May CAHN
AB		2MG	A076908	003	Mar 12, 2012	May CAHN

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL
RIVASTIGMINE

AB	ZYDUS NOVELTECH INC	4.6MG/24HR	A206318	001	Mar 04, 2019	Feb NEWA
AB		9.5MG/24HR	A206318	002	Mar 04, 2019	Feb NEWA
AB		13.3MG/24HR	A206318	003	Mar 04, 2019	Feb NEWA

RIVASTIGMINE TARTRATE

CAPSULE;ORAL
EXELON

>D>	AB	+! NOVARTIS	EQ 1.5MG BASE	N020823	003	Apr 21, 2000	Aug DISC
>A>		+ @	EQ 1.5MG BASE	N020823	003	Apr 21, 2000	Aug DISC
>D>	AB	+	EQ 3MG BASE	N020823	004	Apr 21, 2000	Aug DISC
>A>		+ @	EQ 3MG BASE	N020823	004	Apr 21, 2000	Aug DISC
>D>	AB	+	EQ 4.5MG BASE	N020823	005	Apr 21, 2000	Aug DISC
>A>		+ @	EQ 4.5MG BASE	N020823	005	Apr 21, 2000	Aug DISC
>D>	AB	+!	EQ 6MG BASE	N020823	006	Apr 21, 2000	Aug DISC
>A>		+ @	EQ 6MG BASE	N020823	006	Apr 21, 2000	Aug DISC

RIVASTIGMINE TARTRATE

>D>	AB	DR REDDYS LABS INC	EQ 1.5MG BASE	A077130	001	Oct 31, 2007	Aug CHRS
>A>	AB	!	EQ 1.5MG BASE	A077130	001	Oct 31, 2007	Aug CHRS
>D>	AB		EQ 6MG BASE	A077130	004	Oct 31, 2007	Aug CHRS
>A>	AB	!	EQ 6MG BASE	A077130	004	Oct 31, 2007	Aug CHRS

ROCURONIUM BROMIDE

INJECTABLE;INJECTION
ROCURONIUM BROMIDE

>D>	AP	CAMARGO PHARM	50MG/5ML (10MG/ML)	A210437	001	Aug 13, 2019	Aug CAHN
	AP		50MG/5ML (10MG/ML)	A210437	001	Aug 13, 2019	Jul NEWA
>D>	AP		100MG/10ML (10MG/ML)	A210437	002	Aug 13, 2019	Aug CAHN
	AP		100MG/10ML (10MG/ML)	A210437	002	Aug 13, 2019	Jul NEWA
>A>	AP	SANOVEL ILAC	50MG/5ML (10MG/ML)	A210437	001	Aug 13, 2019	Aug CAHN
>A>	AP		100MG/10ML (10MG/ML)	A210437	002	Aug 13, 2019	Aug CAHN

ROFLUMILAST

TABLET;ORAL
ROFLUMILAST

AB	MICRO LABS	500MCG	A208180	001	Mar 22, 2019	Mar NEWA
----	------------	--------	---------	-----	--------------	----------

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL
ROPINIROLE HYDROCHLORIDE

AB	CADILA	EQ 0.25MG BASE	A090411	001	Jun 01, 2009	Feb CAHN
AB		EQ 0.5MG BASE	A090411	002	Jun 01, 2009	Feb CAHN
AB		EQ 1MG BASE	A090411	003	Jun 01, 2009	Feb CAHN
AB		EQ 2MG BASE	A090411	004	Jun 01, 2009	Feb CAHN
AB		EQ 3MG BASE	A090411	005	Jun 01, 2009	Feb CAHN
AB		EQ 4MG BASE	A090411	006	Jun 01, 2009	Feb CAHN
AB		EQ 5MG BASE	A090411	007	Jun 01, 2009	Feb CAHN
AB	CELLTRION	EQ 0.25MG BASE	A079050	001	May 29, 2008	Jul CAHN
AB		EQ 0.5MG BASE	A079050	002	May 29, 2008	Jul CAHN
AB		EQ 1MG BASE	A079050	003	May 29, 2008	Jul CAHN
AB		EQ 2MG BASE	A079050	004	May 29, 2008	Jul CAHN
AB		EQ 3MG BASE	A079050	005	May 29, 2008	Jul CAHN

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB EQ 4MG BASE
AB EQ 5MG BASE

A079050 006 May 29, 2008 Jul CAHN
A079050 007 May 29, 2008 Jul CAHN

TABLET, EXTENDED RELEASE;ORAL

ROPINIROLE HYDROCHLORIDE

>A> AB CELLTRION EQ 2MG BASE
>A> AB EQ 4MG BASE
>A> AB EQ 6MG BASE
>A> AB EQ 8MG BASE
>A> AB EQ 12MG BASE
>D> AB WOCKHARDT LTD EQ 2MG BASE
>D> AB EQ 4MG BASE
>D> AB EQ 6MG BASE
>D> AB EQ 8MG BASE
>D> AB EQ 12MG BASE

A091395 001 Aug 27, 2012 Aug CAHN
A091395 002 Aug 27, 2012 Aug CAHN
A091395 003 Aug 27, 2012 Aug CAHN
A091395 004 Aug 27, 2012 Aug CAHN
A091395 005 Aug 27, 2012 Aug CAHN
A091395 001 Aug 27, 2012 Aug CAHN
A091395 002 Aug 27, 2012 Aug CAHN
A091395 003 Aug 27, 2012 Aug CAHN
A091395 004 Aug 27, 2012 Aug CAHN
A091395 005 Aug 27, 2012 Aug CAHN

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

@ AMNEAL PHARMS CO 5MG
@ 10MG
@ 20MG
@ 40MG
@ MYLAN 5MG
@ 10MG
@ 20MG
@ 40MG
AB SCIEGEN PHARMS INC 5MG
AB 10MG
AB 20MG
AB 40MG
AB SHANDONG 5MG
AB 10MG
AB 20MG
AB 40MG
@ TEVA PHARMS USA 5MG
@ 10MG
@ 20MG
@ 40MG
AB UMEDICA LABS PVT LTD 5MG
AB 10MG
AB 20MG
AB 40MG
>D> AB ZYDUS PHARMS 5MG
>A> @ 5MG
AB 5MG
>D> AB 10MG
>A> @ 10MG
AB 10MG
>D> AB 20MG
>A> @ 20MG
AB 20MG
>D> AB 40MG
>A> @ 40MG
AB 40MG

A208850 001 Oct 16, 2018 Apr DISC
A208850 002 Oct 16, 2018 Apr DISC
A208850 003 Oct 16, 2018 Apr DISC
A208850 004 Oct 16, 2018 Apr DISC
A079161 001 Jul 19, 2016 Jul DISC
A079161 002 Jul 19, 2016 Jul DISC
A079161 003 Jul 19, 2016 Jul DISC
A079161 004 Jul 19, 2016 Jul DISC
A206381 001 Apr 24, 2019 Apr NEWA
A206381 002 Apr 24, 2019 Apr NEWA
A206381 003 Apr 24, 2019 Apr NEWA
A206381 004 Apr 24, 2019 Apr NEWA
A207375 001 May 07, 2019 Apr NEWA
A207375 002 May 07, 2019 Apr NEWA
A207375 003 May 07, 2019 Apr NEWA
A207375 004 May 07, 2019 Apr NEWA
A079166 001 Jul 19, 2016 Jul DISC
A079166 002 Jul 19, 2016 Jul DISC
A079166 003 Jul 19, 2016 Jul DISC
A079166 004 Jul 19, 2016 Jul DISC
A207626 001 Apr 09, 2019 Mar NEWA
A207626 002 Apr 09, 2019 Mar NEWA
A207626 003 Apr 09, 2019 Mar NEWA
A207626 004 Apr 09, 2019 Mar NEWA
A206513 001 Mar 01, 2019 Aug DISC
A206513 001 Mar 01, 2019 Aug DISC
A206513 001 Mar 01, 2019 Feb NEWA
A206513 002 Mar 01, 2019 Aug DISC
A206513 002 Mar 01, 2019 Aug DISC
A206513 002 Mar 01, 2019 Feb NEWA
A206513 003 Mar 01, 2019 Aug DISC
A206513 003 Mar 01, 2019 Aug DISC
A206513 003 Mar 01, 2019 Feb NEWA
A206513 004 Mar 01, 2019 Aug DISC
A206513 004 Mar 01, 2019 Aug DISC
A206513 004 Mar 01, 2019 Feb NEWA

RUFINAMIDE

SUSPENSION;ORAL

BANZEL

AB +! EISAI INC 40MG/ML
RUFINAMIDE
AB BIONPHARMA INC 40MG/ML
AB HIKMA 40MG/ML

N201367 001 Mar 03, 2011 Apr CFTG
A211388 001 Apr 23, 2019 Apr NFTG
A207363 001 Apr 23, 2019 Apr NFTG

TABLET;ORAL

RUFINAMIDE

@ MYLAN 200MG
@ 400MG

A205095 001 May 16, 2016 Feb DISC
A205095 002 May 16, 2016 Feb DISC

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL

KUVAN

>D>	+	BIOMARIN PHARM	100MG/PACKET	N205065	001	Dec 19, 2013	Aug CFTG
>A>	AB	+	100MG/PACKET	N205065	001	Dec 19, 2013	Aug CFTG
>D>		+	500MG/PACKET	N205065	002	Oct 27, 2015	Aug CFTG
>A>	AB	+	500MG/PACKET	N205065	002	Oct 27, 2015	Aug CFTG
>A>		SAPROPTERIN DIHYDROCHLORIDE					
>A>	AB	PAR PHARM INC	100MG/PACKET	A207207	001	Aug 20, 2019	Aug NFTG
>A>	AB		500MG/PACKET	A210027	001	Aug 20, 2019	Aug NFTG

TABLET;ORAL

KUVAN

	+	BIOMARIN PHARM	100MG	N022181	001	Dec 13, 2007	May CTEC
AB	+		100MG	N022181	001	Dec 13, 2007	Apr CFTG
		SAPROPTERIN DIHYDROCHLORIDE					
	@	PAR PHARM INC	100MG	A207200	001	May 10, 2019	May DISC
AB			100MG	A207200	001	May 10, 2019	Apr NFTG

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

SCOPOLAMINE

AB		MYLAN TECHNOLOGIES	1MG/72HR	A203753	001	Jun 19, 2019	Jun NEWA
----	--	--------------------	----------	---------	-----	--------------	----------

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

AB		BOSCOGEN	5MG	A074912	001	Apr 30, 1998	Jun CAHN
AB		KENTON	5MG	A074912	001	Apr 30, 1998	Mar CAHN
>D>	AB	MYLAN	5MG	A074866	001	Nov 26, 1997	Aug DISC
>A>		@	5MG	A074866	001	Nov 26, 1997	Aug DISC

TABLET, ORALLY DISINTEGRATING;ORAL

ZELAPAR

	+	BAUSCH	1.25MG	N021479	001	Jun 14, 2006	Mar CAHN
--	---	--------	--------	---------	-----	--------------	----------

SELENIOS ACID

SOLUTION;INTRAVENOUS

SELENIOS ACID

	+	AM REGENT	EQ 600MCG BASE/10ML (EQ 60MCG BASE/ML)	N209379	001	Apr 30, 2019	Apr NEWA
--	---	-----------	--	---------	-----	--------------	----------

SELINEXOR

TABLET;ORAL

XPOVIO

	+	KARYOPHARM THERAPS	20MG	N212306	001	Jul 03, 2019	Jul NEWA
--	---	--------------------	------	---------	-----	--------------	----------

SERTACONAZOLE NITRATE

CREAM;TOPICAL

ERTACZO

	+	BAUSCH	2%	N021385	001	Dec 10, 2003	Jun CAHN
--	---	--------	----	---------	-----	--------------	----------

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

	@	CADILA	EQ 25MG BASE	A077106	001	Feb 06, 2007	Jun DISC
AB			EQ 25MG BASE	A077106	001	Feb 06, 2007	Feb CAHN
	@		EQ 50MG BASE	A077106	002	Feb 06, 2007	Jun DISC
AB			EQ 50MG BASE	A077106	002	Feb 06, 2007	Feb CAHN
	@		EQ 100MG BASE	A077106	003	Feb 06, 2007	Jun DISC
AB			EQ 100MG BASE	A077106	003	Feb 06, 2007	Feb CAHN
AB		HERITAGE PHARMA	EQ 25MG BASE	A076465	001	Aug 11, 2006	May CAHN
	@		EQ 25MG BASE	A077299	001	Feb 06, 2007	May CAHN
	@		EQ 25MG BASE	A077345	001	Feb 06, 2007	May CAHN
AB			EQ 50MG BASE	A076465	002	Aug 11, 2006	May CAHN
	@		EQ 50MG BASE	A077299	002	Feb 06, 2007	May CAHN
	@		EQ 50MG BASE	A077345	002	Feb 06, 2007	May CAHN
AB			EQ 100MG BASE	A076465	003	Aug 11, 2006	May CAHN
	@		EQ 100MG BASE	A077299	003	Feb 06, 2007	May CAHN
	@		EQ 100MG BASE	A077345	003	Feb 06, 2007	May CAHN
	@	MYLAN PHARMS INC	EQ 25MG BASE	A078626	001	Jan 31, 2008	May DISC
	@		EQ 50MG BASE	A078626	002	Jan 31, 2008	May DISC

SEVELAMER HYDROCHLORIDE

TABLET; ORAL

RENAGEL

AB	+	GENZYME	400MG	N021179	001	Jul 12, 2000	Feb CFTG
AB	+	!	800MG	N021179	002	Jul 12, 2000	Feb CFTG
SEVELAMER HYDROCHLORIDE							
AB		GLENMARK PHARMS LTD	400MG	A204724	001	Feb 08, 2019	Feb NFTG
AB			800MG	A204724	002	Feb 08, 2019	Feb NFTG

SILDENAFIL CITRATE

FOR SUSPENSION; ORAL

REVATIO

AB	+	!	PFIZER	EQ 10MG BASE/ML	N203109	001	Aug 30, 2012	May CFTG
SILDENAFIL CITRATE								
AB			NOVITIUM PHARMA	EQ 10MG BASE/ML	A212260	001	May 31, 2019	May NFTG
TABLET; ORAL								
SILDENAFIL CITRATE								
AB			LUPIN LTD	EQ 25MG BASE	A212051	001	Mar 22, 2019	Mar NEWA
AB				EQ 50MG BASE	A212051	002	Mar 22, 2019	Mar NEWA
AB				EQ 100MG BASE	A212051	003	Mar 22, 2019	Mar NEWA
AB			MYLAN	EQ 25MG BASE	A201171	001	Mar 25, 2019	Mar NEWA
AB				EQ 50MG BASE	A201171	002	Mar 25, 2019	Mar NEWA
AB				EQ 100MG BASE	A201171	003	Mar 25, 2019	Mar NEWA

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB			MICRO LABS	5MG	A090383	001	Sep 16, 2011	Mar CAHN
AB				10MG	A090383	002	Sep 16, 2011	Mar CAHN
AB				20MG	A090383	003	Sep 16, 2011	Mar CAHN
AB				40MG	A090383	004	Sep 16, 2011	Mar CAHN
AB				80MG	A090383	005	Sep 16, 2011	Mar CAHN

SIPONIMOD

TABLET; ORAL

MAYZENT

	+		NOVARTIS PHARMS CORP	0.25MG	N209884	001	Mar 26, 2019	Mar NEWA
	+	!		2MG	N209884	002	Mar 26, 2019	Mar NEWA

SIPONIMOD FUMARIC ACID

TABLET; ORAL

MAYZENT

	+		NOVARTIS PHARMS CORP	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Apr CAIN
	+	!		EQ 2MG BASE	N209884	002	Mar 26, 2019	Apr CAIN

SIROLIMUS

SOLUTION; ORAL

RAPAMUNE

AA	+	!	PF PRISM CV	1MG/ML	N021083	001	Sep 15, 1999	Jan CFTG
SIROLIMUS								
AA			NOVITIUM PHARMA	1MG/ML	A211040	001	Jan 28, 2019	Jan NFTG

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE

			EXELA PHARMA SCS LLC	0.5MEQ/ML	A211091	001	Jun 20, 2019	Jun NEWA
AP				0.9MEQ/ML	A211091	002	Jun 20, 2019	Jun NEWA
AP				1MEQ/ML	A211091	003	Jun 20, 2019	Jun NEWA

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	+	!	LIEBEL-FLARSHEIM	405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Aug DISC
>A>	+	@		405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Aug DISC
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER								
AP			FRESENIUS KABI USA	3GM/100ML	A209476	001	Mar 13, 2019	Feb NEWA

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION
SODIUM CHROMATE CR 51
@ CURIUM

100uCi/ML

N016708 001

Jan CAHN

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F-18

AP DECATUR

10-200mCi/ML

A204464 001 Oct 21, 2014

Apr CAHN

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I 131

@ CURIUM

0.8-100mCi

N016515 002

Jan CAHN

+ @

0.8-100mCi

N016517 001

Jan CAHN

@

15-100uCi

N016517 002

Jan CAHN

SOLUTION; ORAL

SODIUM IODIDE I 131

+ @ CURIUM

3.5-150mCi/VIAL

N016515 001

Jan CAHN

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

SODIUM NITROPRUSSIDE

AP DR REDDYS LABS LTD

25MG/ML

A210114 001 Apr 10, 2019

Mar NEWA

@ SUN PHARM

25MG/ML

A210467 001 Nov 26, 2018

Jul DISC

AP VIRTUS PHARM

25MG/ML

A209834 001 Jun 26, 2018

Jul CAHN

SOLUTION; INTRAVENOUS

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

+ @ EXELA PHARMA SCS LLC 10MG/50ML (0.2MG/ML)

N209387 002 Dec 07, 2017

Jul DISC

SODIUM PHENYLBUTYRATE

POWDER; ORAL

BUPHENYL

AB +! HORIZON THERAP

3GM/TEASPOONFUL

N020573 001 Apr 30, 1996

Feb CAHN

TABLET; ORAL

BUPHENYL

AB +! HORIZON THERAP

500MG

N020572 001 May 13, 1996

Feb CAHN

SOFOSBUVIR

>A> PELLETS; ORAL

>A> SOVALDI

>A> + GILEAD SCIENCES INC

150MG/PACKET

N212480 001 Aug 28, 2019

Aug NEWA

>A> +!

200MG/PACKET

N212480 002 Aug 28, 2019

Aug NEWA

TABLET; ORAL

SOVALDI

>A> + GILEAD SCIENCES INC

200MG

N204671 002 Aug 28, 2019

Aug NEWA

SOLIFENACIN SUCCINATE

TABLET; ORAL

SOLIFENACIN SUCCINATE

AB AJANTA PHARMA LTD

5MG

A205483 001 May 20, 2019

May NEWA

AB

10MG

A205483 002 May 20, 2019

May NEWA

AB ALEMBIC PHARMS LTD

5MG

A205575 001 May 20, 2019

May NEWA

AB

10MG

A205575 002 May 20, 2019

May NEWA

AB ALKEM LABS LTD

5MG

A210224 001 May 20, 2019

May NEWA

AB

10MG

A210224 002 May 20, 2019

May NEWA

AB AMNEAL PHARMS CO

5MG

A209719 001 May 20, 2019

May NEWA

AB

10MG

A209719 002 May 20, 2019

May NEWA

AB BRECKENRIDGE

5MG

A209818 001 May 20, 2019

May NEWA

AB

10MG

A209818 002 May 20, 2019

May NEWA

AB CELLTRION

5MG

A210582 001 May 20, 2019

May NEWA

AB

10MG

A210582 002 May 20, 2019

May NEWA

AB CIPLA

5MG

A209839 001 May 20, 2019

May NEWA

AB

10MG

A209839 002 May 20, 2019

May NEWA

AB GLENMARK PHARMS INC

5MG

A209239 001 May 20, 2019

May NEWA

AB

10MG

A209239 002 May 20, 2019

May NEWA

AB JIANGXI BOYA SEEHOT

5MG

A210281 001 May 20, 2019

May NEWA

AB

10MG

A210281 002 May 20, 2019

May NEWA

AB MSN LABS PVT LTD

5MG

A210688 001 May 20, 2019

May NEWA

AB

10MG

A210688 002 May 20, 2019

May NEWA

AB QILU PHARM CO LTD

5MG

A209333 001 May 20, 2019

May NEWA

TABLET;ORAL
SOLIFENACIN SUCCINATE

	AB		10MG		A209333	002	May 20, 2019	May	NEWA
	AB	SCIEGEN PHARMS INC	5MG		A211657	001	May 20, 2019	May	NEWA
	AB		10MG		A211657	002	May 20, 2019	May	NEWA
>A>	AB	UNICHEM LABS LTD	5MG		A211701	001	Aug 27, 2019	Aug	NEWA
>A>	AB		10MG		A211701	002	Aug 27, 2019	Aug	NEWA
	AB	WATSON LABS INC	5MG		A202551	001	May 20, 2019	May	NEWA
	AB		10MG		A202551	002	May 20, 2019	May	NEWA

SOLRIAMFETOL

TABLET;ORAL
SUNOSI

+	JAZZ	75MG	N211230	001	Jun 17, 2019	Jun NEWA
+		150MG	N211230	002	Jun 17, 2019	Jun NEWA

>A> SOMATROPIN

>A> INJECTABLE;INJECTION
>A> GENOTROPIN

>A> BX	+	PHARMACIA AND UPJOHN	5.8MG/VIAL	N020280	006	Aug 24, 1995	Aug CAIN
>A>	+		13.8MG/VIAL	N020280	007	Oct 23, 1996	Aug CAIN
>A>		GENOTROPIN PRESERVATIVE	FREE				
>A>	+	PHARMACIA AND UPJOHN	0.2MG/VIAL	N020280	001	Jan 27, 1998	Aug CAIN
>A>	+		0.4MG/VIAL	N020280	002	Jan 27, 1998	Aug CAIN
>A>	+		0.6MG/VIAL	N020280	003	Jan 27, 1998	Aug CAIN
>A>	+		0.8MG/VIAL	N020280	005	Jan 27, 1998	Aug CAIN
>A>	+		1MG/VIAL	N020280	008	Jan 27, 1998	Aug CAIN
>A>	+		1.2MG/VIAL	N020280	009	Jan 27, 1998	Aug CAIN
>A>	+		1.4MG/VIAL	N020280	010	Jan 27, 1998	Aug CAIN
>A>	+	@	1.5MG/VIAL	N020280	004	Aug 24, 1995	Aug CAIN
>A>	+		1.6MG/VIAL	N020280	011	Jan 27, 1998	Aug CAIN
>A>	+		1.8MG/VIAL	N020280	012	Jan 27, 1998	Aug CAIN
>A>	+	!	2MG/VIAL	N020280	013	Jan 27, 1998	Aug CAIN
>A>		NORDITROPIN					
>A>		@ NOVO NORDISK INC	5MG/1.5ML	N021148	001	Jun 20, 2000	Aug CAIN
>A>		@	10MG/1.5ML	N021148	002	Jun 20, 2000	Aug CAIN
>A>		@	15MG/1.5ML	N021148	003	Jun 20, 2000	Aug CAIN
>A>		NORDITROPIN FLEXPRO					
>A> BX		NOVO NORDISK INC	5MG/1.5ML	N021148	008	Mar 01, 2010	Aug CAIN
>A> BX			10MG/1.5ML	N021148	009	Mar 01, 2010	Aug CAIN
>A>			15MG/1.5ML	N021148	010	Mar 01, 2010	Aug CAIN
>A>			30MG/3ML	N021148	011	Jan 23, 2015	Aug CAIN
>A>		NORDITROPIN NORDIFLEX					
>A>		@ NOVO NORDISK INC	5MG/1.5ML	N021148	004	Oct 01, 2004	Aug CAIN
>A>		@	10MG/1.5ML	N021148	005	Oct 01, 2004	Aug CAIN
>A>		@	15MG/1.5ML	N021148	006	Oct 01, 2004	Aug CAIN
>A>		@	30MG/3ML	N021148	007	Mar 10, 2009	Aug CAIN
>A>		NUTROPIN					
>A>		@ GENENTECH	5MG/VIAL	N020168	001	Nov 17, 1993	Aug CAIN
>A>		@	10MG/VIAL	N020168	002	Nov 17, 1993	Aug CAIN
>A>		NUTROPIN AQ					
>A>		@ GENENTECH	10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995	Aug CAIN
>A>		NUTROPIN AQ NUSPIN					
>A>	+	! GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008	Aug CAIN
>A>	+	!	10MG/2ML (5MG/ML)	N020522	005	Jan 03, 2008	Aug CAIN
>A>	+	!	20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008	Aug CAIN
>A>		NUTROPIN AQ PEN					
>A>	+	@ GENENTECH	10MG/2ML (5MG/ML)	N020522	002	Apr 22, 2002	Aug CAIN
>A>	+	@	20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008	Aug CAIN
>A>		OMNITROPE					
>A> BX		SANDOZ	1.5MG/VIAL	N021426	002	May 30, 2006	Aug CAIN
>A> BX			5MG/1.5ML	N021426	003	Jan 16, 2008	Aug CAIN
>A> BX			5.8MG/VIAL	N021426	001	May 30, 2006	Aug CAIN
>A> BX			10MG/1.5ML	N021426	004	Aug 25, 2008	Aug CAIN
>A>		SAIZEN					
>A>		@ EMD SERONO	4MG/VIAL	N019764	005	Jan 16, 2007	Aug CAIN
>A> BX	+		5MG/VIAL	N019764	002	Oct 08, 1996	Aug CAIN
>A>		@	6MG/VIAL	N019764	001	Oct 08, 1996	Aug CAIN
>A>	+	!	8.8MG/VIAL	N019764	003	Aug 29, 2000	Aug CAIN
>A>		SEROSTIM					
>A>		EMD SERONO	4MG/VIAL	N020604	003	Jul 25, 1997	Aug CAIN
>A> BX			5MG/VIAL	N020604	002	Aug 23, 1996	Aug CAIN

>A>	INJECTABLE;INJECTION						
>A>	SEROSTIM						
>A> BX		6MG/VIAL	N020604	001	Aug 23, 1996	Aug	CAIN
>A>	@	8.8MG/VIAL	N020604	004	Sep 06, 2001	Aug	CAIN
>A>	INJECTABLE;SUBCUTANEOUS						
>A>	SEROSTIM LQ						
>A>	@ EMD SERONO	6MG/0.5ML (6MG/0.5ML)	N020604	005	Feb 11, 2005	Aug	CAIN
>D>	<u>SOMATROPIN RECOMBINANT</u>						
>D>	INJECTABLE;INJECTION						
>D>	GENOTROPIN						
>D> BX	+! PHARMACIA AND UPJOHN	5.8MG/VIAL	N020280	006	Aug 24, 1995	Aug	CAIN
>D>	+!	13.8MG/VIAL	N020280	007	Oct 23, 1996	Aug	CAIN
>D>	GENOTROPIN PRESERVATIVE FREE						
>D>	+ PHARMACIA AND UPJOHN	0.2MG/VIAL	N020280	001	Jan 27, 1998	Aug	CAIN
>D>	+	0.4MG/VIAL	N020280	002	Jan 27, 1998	Aug	CAIN
>D>	+	0.6MG/VIAL	N020280	003	Jan 27, 1998	Aug	CAIN
>D>	+	0.8MG/VIAL	N020280	005	Jan 27, 1998	Aug	CAIN
>D>	+	1MG/VIAL	N020280	008	Jan 27, 1998	Aug	CAIN
>D>	+	1.2MG/VIAL	N020280	009	Jan 27, 1998	Aug	CAIN
>D>	+	1.4MG/VIAL	N020280	010	Jan 27, 1998	Aug	CAIN
>D>	+ @	1.5MG/VIAL	N020280	004	Aug 24, 1995	Aug	CAIN
>D>	+	1.6MG/VIAL	N020280	011	Jan 27, 1998	Aug	CAIN
>D>	+	1.8MG/VIAL	N020280	012	Jan 27, 1998	Aug	CAIN
>D>	+!	2MG/VIAL	N020280	013	Jan 27, 1998	Aug	CAIN
>D>	NORDITROPIN						
>D>	@ NOVO NORDISK INC	5MG/1.5ML	N021148	001	Jun 20, 2000	Aug	CAIN
>D>	@	10MG/1.5ML	N021148	002	Jun 20, 2000	Aug	CAIN
>D>	@	15MG/1.5ML	N021148	003	Jun 20, 2000	Aug	CAIN
>D>	NORDITROPIN FLEXPOR						
>D> BX	NOVO NORDISK INC	5MG/1.5ML	N021148	008	Mar 01, 2010	Aug	CAIN
>D> BX		10MG/1.5ML	N021148	009	Mar 01, 2010	Aug	CAIN
>D>		15MG/1.5ML	N021148	010	Mar 01, 2010	Aug	CAIN
>D>		30MG/3ML	N021148	011	Jan 23, 2015	Aug	CAIN
>D>	NORDITROPIN NORDIFLEX						
>D>	@ NOVO NORDISK INC	5MG/1.5ML	N021148	004	Oct 01, 2004	Aug	CAIN
>D>	@	10MG/1.5ML	N021148	005	Oct 01, 2004	Aug	CAIN
>D>	@	15MG/1.5ML	N021148	006	Oct 01, 2004	Aug	CAIN
>D>	@	30MG/3ML	N021148	007	Mar 10, 2009	Aug	CAIN
>D>	NUTROPIN						
>D>	@ GENENTECH	5MG/VIAL	N020168	001	Nov 17, 1993	Aug	CAIN
>D>	@	10MG/VIAL	N020168	002	Nov 17, 1993	Aug	CAIN
>D>	NUTROPIN AQ						
>D>	@ GENENTECH	10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995	Aug	CAIN
>D>	NUTROPIN AQ NUSPIN						
>D>	+! GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008	Aug	CAIN
>D>	+!	10MG/2ML (5MG/ML)	N020522	005	Jan 03, 2008	Aug	CAIN
>D>	+!	20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008	Aug	CAIN
>D>	NUTROPIN AQ PEN						
>D>	+ @ GENENTECH	10MG/2ML (5MG/ML)	N020522	002	Apr 22, 2002	Aug	CAIN
>D>	+ @	20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008	Aug	CAIN
>D>	OMNITROPE						
>D> BX	SANDOZ	1.5MG/VIAL	N021426	002	May 30, 2006	Aug	CAIN
>D> BX		5MG/1.5ML	N021426	003	Jan 16, 2008	Aug	CAIN
>D> BX		5.8MG/VIAL	N021426	001	May 30, 2006	Aug	CAIN
>D> BX		10MG/1.5ML	N021426	004	Aug 25, 2008	Aug	CAIN
>D>	SAIZEN						
>D>	@ EMD SERONO	4MG/VIAL	N019764	005	Jan 16, 2007	Aug	CAIN
>D> BX	+	5MG/VIAL	N019764	002	Oct 08, 1996	Aug	CAIN
>D>	@	6MG/VIAL	N019764	001	Oct 08, 1996	Aug	CAIN
>D>	+!	8.8MG/VIAL	N019764	003	Aug 29, 2000	Aug	CAIN
>D>	SEROSTIM						
>D>	EMD SERONO	4MG/VIAL	N020604	003	Jul 25, 1997	Aug	CAIN
>D> BX		5MG/VIAL	N020604	002	Aug 23, 1996	Aug	CAIN
>D> BX		6MG/VIAL	N020604	001	Aug 23, 1996	Aug	CAIN
>D>	@	8.8MG/VIAL	N020604	004	Sep 06, 2001	Aug	CAIN
>D>	INJECTABLE;SUBCUTANEOUS						
>D>	SEROSTIM LQ						
>D>	@ EMD SERONO	6MG/0.5ML (6MG/0.5ML)	N020604	005	Feb 11, 2005	Aug	CAIN

SOTALOL HYDROCHLORIDE

TABLET; ORAL

BETAPACE

AB	+	COVIS PHARMA BV	80MG	N019865	001	Oct 30, 1992	May CTEC
AB	+		120MG	N019865	005	Apr 20, 1994	May CTEC
AB	+	!	160MG	N019865	002	Oct 30, 1992	May CTEC
AB	+		240MG	N019865	003	Oct 30, 1992	May CTEC

BETAPACE AF

AB	+	COVIS PHARMA BV	80MG	N021151	001	Feb 22, 2000	May CTEC
AB	+		120MG	N021151	002	Feb 22, 2000	May CTEC
AB	+	!	160MG	N021151	003	Feb 22, 2000	May CTEC

SORINE

AB		UPSHER SMITH LABS	80MG	A075500	001	Apr 27, 2001	May CTEC
AB			120MG	A075500	004	Apr 27, 2001	May CTEC
AB			160MG	A075500	002	Apr 27, 2001	May CTEC
AB			240MG	A075500	003	Apr 27, 2001	May CTEC

SOTALOL HYDROCHLORIDE

AB		APOTEX	80MG	A076214	001	Aug 27, 2003	May CTEC
AB			120MG	A076214	002	Aug 27, 2003	May CTEC
AB			160MG	A076214	003	Aug 27, 2003	May CTEC
AB		APOTEX INC	80MG	A076140	001	Sep 26, 2002	May CTEC
AB			120MG	A076140	002	Sep 26, 2002	May CTEC
AB			160MG	A076140	003	Sep 26, 2002	May CTEC
AB			240MG	A076140	004	Sep 26, 2002	May CTEC
AB		BEXIMCO PHARMS USA	80MG	A207428	001	Oct 21, 2016	May CTEC
AB			80MG	A207429	001	Nov 02, 2018	May CTEC
AB			120MG	A207428	002	Oct 21, 2016	May CTEC
AB			120MG	A207429	002	Nov 02, 2018	May CTEC
AB			160MG	A207428	003	Oct 21, 2016	May CTEC
AB			160MG	A207429	003	Nov 02, 2018	May CTEC
AB		EPIC PHARMA INC	80MG	A077070	001	Nov 04, 2005	May CTEC
AB			120MG	A077070	002	Nov 04, 2005	May CTEC
AB			160MG	A077070	003	Nov 04, 2005	May CTEC
AB		MYLAN	80MG	A077616	001	Feb 07, 2007	May CTEC
AB			120MG	A077616	002	Feb 07, 2007	May CTEC
AB			160MG	A077616	003	Feb 07, 2007	May CTEC
AB		OXFORD PHARMS	80MG	A075563	001	Nov 07, 2003	May CTEC
AB			120MG	A075563	002	Nov 07, 2003	May CTEC
AB			160MG	A075563	003	Nov 07, 2003	May CTEC
AB			240MG	A075563	004	Nov 07, 2003	May CTEC
AB		TEVA	80MG	A075429	001	May 01, 2000	May CTEC
AB			120MG	A075429	002	May 01, 2000	May CTEC
AB			160MG	A075429	003	May 01, 2000	May CTEC
AB			240MG	A075429	004	May 01, 2000	May CTEC
	@	UPSHER SMITH LABS	80MG	A075366	001	May 01, 2000	Jun DISC
AB			80MG	A075366	001	May 01, 2000	May CTEC
	@		120MG	A075366	002	May 01, 2000	Jun DISC
AB			120MG	A075366	002	May 01, 2000	May CTEC
	@		160MG	A075366	003	May 01, 2000	Jun DISC
AB			160MG	A075366	003	May 01, 2000	May CTEC
	@		240MG	A075366	004	May 01, 2000	Jun DISC
AB			240MG	A075366	004	May 01, 2000	May CTEC

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

	@	ACTAVIS ELIZABETH	25MG	A040353	003	Mar 15, 2006	Jun DISC
	@		50MG	A040353	001	Jul 29, 1999	Jun DISC
	@		100MG	A040353	002	Jul 29, 1999	Jun DISC
	@	CASI PHARMS INC	25MG	A086809	001		Jun DISC

STAVUDINE

FOR SOLUTION; ORAL

ZERIT

+	@	BRISTOL-MYERS SQUIBB	1MG/ML	N020413	001	Sep 06, 1996	Mar DISC
---	---	----------------------	--------	---------	-----	--------------	----------

STRONTIUM CHLORIDE SR-89

INJECTABLE; INJECTION

METASTRON

AP	+	!	Q BIOMED	1mCi/ML	N020134	001	Jun 18, 1993	Jan CAHN
----	---	---	----------	---------	---------	-----	--------------	----------

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
SUCCINYLCHOLINE CHLORIDE

AP	AMRING PHARMS	20MG/ML	A210231	001	Jun 04, 2018	Jan CAHN
AP	DR REDDYS	20MG/ML	A210698	001	Aug 02, 2019	Jul NEWA

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM

>D>	AP	MYLAN LABS LTD	80MG/ML; 16MG/ML	A206607	001	Aug 30, 2017	Aug CHRS	
>A>	AP	!	80MG/ML; 16MG/ML	A206607	001	Aug 30, 2017	Aug CHRS	
	AP	SOMERSET THERAPS LLC	80MG/ML; 16MG/ML	A212231	001	Jun 26, 2019	Jun NEWA	
>D>	AP	!	TEVA PHARMS USA	80MG/ML; 16MG/ML	A073303	001	Oct 31, 1991	Aug DISC
>A>		@	80MG/ML; 16MG/ML	A073303	001	Oct 31, 1991	Aug DISC	

TABLET; ORAL

		SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH					
AB		HERITAGE PHARMA	800MG; 160MG	A070037	001	Jun 02, 1987	May CAHN
		SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH					
AB		HERITAGE PHARMA	400MG; 80MG	A070030	001	Jun 02, 1987	May CAHN

SUMATRIPTAN

SPRAY; NASAL
TOSYMRA

+	!	DR REDDYS LABS LTD	10MG/SPRAY	N210884	001	Jan 25, 2019	Jan NEWA
+	!	UPSHER SMITH LABS	10MG/SPRAY	N210884	001	Jan 25, 2019	Jul CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

@	PAR STERILE PRODUCTS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077871	001	Jul 09, 2009	Apr DISC
@	ZYDUS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310	001	Aug 11, 2010	Apr CAHN

SOLUTION; SUBCUTANEOUS
ZEMBRACE SYMTOUCH

+	UPSHER SMITH LABS	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016	Jul CAHN
---	-------------------	---------------------------------------	---------	-----	--------------	----------

TACROLIMUS

OINTMENT; TOPICAL
TACROLIMUS

AB	ACCORD HLTHCARE	0.03%	A211688	001	Jan 31, 2019	Jan NEWA
AB		0.1%	A211688	002	Jan 31, 2019	Jan NEWA

TADALAFIL

TABLET; ORAL
ALYQ

AB2	TEVA PHARMS USA	20MG	A209942	001	Feb 05, 2019	Jan NEWA
	TADALAFIL					
AB	ACCORD HLTHCARE	2.5MG	A209167	001	Mar 26, 2019	Mar NEWA
AB		5MG	A209167	002	Mar 26, 2019	Mar NEWA
AB1		20MG	A209167	004	Mar 26, 2019	Mar NEWA
AB	AJANTA PHARMA LTD	2.5MG	A209654	001	Mar 26, 2019	Mar NEWA
AB		5MG	A209654	002	Mar 26, 2019	Mar NEWA
AB		10MG	A209654	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A209654	004	Mar 26, 2019	Mar NEWA
AB2		20MG	A210392	001	Feb 05, 2019	Jan NEWA
AB	ALEMBIC PHARMS LTD	2.5MG	A204809	001	Mar 26, 2019	Mar NEWA
AB		5MG	A204809	002	Mar 26, 2019	Mar NEWA
AB		10MG	A204809	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A204809	004	Mar 26, 2019	Mar NEWA
AB	AMNEAL PHARMS CO	2.5MG	A209744	001	Mar 26, 2019	Mar NEWA
AB		5MG	A209744	002	Mar 26, 2019	Mar NEWA
AB		10MG	A209744	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A209744	004	Mar 26, 2019	Mar NEWA
AB	AUROBINDO PHARMA LTD	2.5MG	A206285	001	Mar 26, 2019	Mar NEWA
AB		5MG	A206285	002	Mar 26, 2019	Mar NEWA
AB		10MG	A206285	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A206285	004	Mar 26, 2019	Mar NEWA
AB2		20MG	A206286	001	Feb 05, 2019	Jan NEWA
AB	CIPLA	2.5MG	A209539	001	Mar 26, 2019	Mar NEWA
AB		5MG	A209539	002	Mar 26, 2019	Mar NEWA

TABLET;ORAL

TADALAFIL

AB		10MG	A209539	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A209539	004	Mar 26, 2019	Mar NEWA
AB2		20MG	A210255	001	Feb 05, 2019	Jan NEWA
AB	DR REDDYS LABS LTD	2.5MG	A210069	001	Mar 26, 2019	Mar NEWA
AB		5MG	A210069	002	Mar 26, 2019	Mar NEWA
AB		10MG	A210069	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A210069	004	Mar 26, 2019	Mar NEWA
AB2		20MG	A210145	001	Feb 05, 2019	Jan NEWA
AB	HETERO LABS LTD III	2.5MG	A209908	001	Mar 26, 2019	Mar NEWA
AB		5MG	A209908	002	Mar 26, 2019	Mar NEWA
AB		10MG	A209908	003	Mar 26, 2019	Mar NEWA
AB2		20MG	A209907	001	Feb 05, 2019	Jan NEWA
AB1		20MG	A209908	004	Mar 26, 2019	Mar NEWA
AB	LUPIN LTD	2.5MG	A210567	001	Mar 26, 2019	Mar NEWA
AB		5MG	A210567	002	Mar 26, 2019	Mar NEWA
AB		10MG	A210567	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A210567	004	Mar 26, 2019	Mar NEWA
AB2		20MG	A210572	001	Feb 05, 2019	Jan NEWA
AB	MYLAN	2.5MG	A206956	001	Apr 29, 2019	Apr NEWA
AB		5MG	A206957	001	Apr 29, 2019	Apr NEWA
AB		10MG	A206956	002	Apr 29, 2019	Apr NEWA
AB1		20MG	A206956	003	Apr 29, 2019	Apr NEWA
AB	QILU PHARM CO LTD	2.5MG	A210420	001	Mar 26, 2019	Mar NEWA
AB		5MG	A210420	002	Mar 26, 2019	Mar NEWA
AB		10MG	A210420	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A210420	004	Mar 26, 2019	Mar NEWA
AB	SUN PHARM	2.5MG	A208934	001	Mar 26, 2019	Mar NEWA
AB		5MG	A208934	002	Mar 26, 2019	Mar NEWA
AB		10MG	A208934	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A208934	004	Mar 26, 2019	Mar NEWA
AB	SUNSHINE LAKE	2.5MG	A211335	001	Mar 26, 2019	Mar NEWA
AB		5MG	A211335	002	Mar 26, 2019	Mar NEWA
AB		10MG	A211335	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A211335	004	Mar 26, 2019	Mar NEWA
AB	TORRENT	2.5MG	A211839	001	Mar 26, 2019	Mar NEWA
AB		5MG	A211839	002	Mar 26, 2019	Mar NEWA
AB		10MG	A211839	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A211839	004	Mar 26, 2019	Mar NEWA
AB2		20MG	A212062	001	Mar 26, 2019	Mar NEWA
AB	UNICHEM LABS LTD	2.5MG	A209250	001	Mar 26, 2019	Mar NEWA
AB		5MG	A209250	002	Mar 26, 2019	Mar NEWA
AB		10MG	A209250	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A209250	004	Mar 26, 2019	Mar NEWA
AB	WATSON LABS INC	2.5MG	A205885	001	Mar 29, 2019	Mar NEWA
AB		5MG	A205885	002	Mar 29, 2019	Mar NEWA
AB		10MG	A205885	003	Mar 29, 2019	Mar NEWA
AB1		20MG	A205885	004	Mar 29, 2019	Mar NEWA
AB	ZYDUS PHARMS	2.5MG	A206693	001	Mar 26, 2019	Mar NEWA
AB		5MG	A206693	002	Mar 26, 2019	Mar NEWA
AB		10MG	A206693	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A206693	004	Mar 26, 2019	Mar NEWA

TAFAMIDIS

CAPSULE;ORAL

VYNDAMAX

+	!	FOLDRX PHARMS	61MG	N212161	001	May 03, 2019	May NEWA
---	---	---------------	------	---------	-----	--------------	----------

TAFAMIDIS MEGLUMINE

CAPSULE;ORAL

VYNDAQEL

+	!	FOLDRX PHARMS	20MG	N211996	001	May 03, 2019	May NEWA
---	---	---------------	------	---------	-----	--------------	----------

TAFLUPROST

SOLUTION/DROPS;OPHTHALMIC

TAFLUPROST

>A>							
>A>	AT	MICRO LABS	0.0015%	A209051	001	Aug 19, 2019	Aug NFTG
		ZIOPTAN					
>D>	+	OAK PHARMS INC	0.0015%	N202514	001	Feb 10, 2012	Aug CFTG
>A>	AT	+	0.0015%	N202514	001	Feb 10, 2012	Aug CFTG

TAMOXIFEN CITRATESOLUTION;ORAL
SOLTAMOX

>A>	FORTOVIA	EQ 20MG BASE/10ML	N021807	001	Oct 29, 2005	Aug CAHN
>D>	MIDATECH PHARMA US	EQ 20MG BASE/10ML	N021807	001	Oct 29, 2005	Aug CAHN

TAZAROTENECREAM;TOPICAL
TAZAROTENE

>D>	AB	FOUGERA PHARMS INC	0.1%	A211175	001	Jan 28, 2019	Aug DISC
>A>		@	0.1%	A211175	001	Jan 28, 2019	Aug DISC
	AB		0.1%	A211175	001	Jan 28, 2019	May CPOT
	AB		1%	A211175	001	Jan 28, 2019	Jan NEWA

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE;INJECTION

>D>		HEPATOLITE					
>D>		PHARMALUCENCE	N/A	N018467	001	Mar 16, 1982	Aug DISC
>A>		@	N/A	N018467	001	Mar 16, 1982	Aug DISC

TECHNETIUM TC-99M MERTIATIDE KITINJECTABLE;INJECTION
TECHNISCAN MAG3

AP	+	CURIUM	N/A	N019882	001	Jun 15, 1990	Jul CFTG
	+		N/A	N019882	001	Jun 15, 1990	Jan CAHN
		TECHNETIUM TC99M MERTIATIDE KIT					
AP		PHARMALUCENCE	N/A	A208994	001	Jul 12, 2019	Jul NFTG

TECHNETIUM TC-99M OXIDRONATE KITINJECTABLE;INJECTION
TECHNISCAN

+	CURIUM	N/A	N018321	001			Jan CAHN
---	--------	-----	---------	-----	--	--	----------

TECHNETIUM TC-99M PYROPHOSPHATE KITINJECTABLE;INJECTION
TECHNISCAN PYP KIT

AP		CURIUM	N/A	N017538	001		Jan CAHN
----	--	--------	-----	---------	-----	--	----------

TECHNETIUM TC-99M RED BLOOD CELL KITINJECTABLE;INJECTION
ULTRATAG

+	CURIUM	N/A	N019981	001	Jun 10, 1991		Jan CAHN
---	--------	-----	---------	-----	--------------	--	----------

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATORSOLUTION;INTRAVENOUS
ULTRA-TECHNEKOW FM

+	CURIUM	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014		Jan CAHN
@		0.25-3 CI/GENERATOR	N017243	002			Jan CAHN

SOLUTION;INTRAVENOUS, ORAL

TECHNETIUM TC 99M GENERATOR

+	@	GE HEALTHCARE	68-2703mCi/GENERATOR	N017693	002	Dec 13, 2013	Feb DISC
---	---	---------------	----------------------	---------	-----	--------------	----------

TEGASEROD MALEATETABLET;ORAL
ZELNORM

>A>	+	@	ALFASIGMA	EQ 2MG BASE	N021200	001	Jul 24, 2002	Aug CAHN
>A>	+	@		EQ 6MG BASE	N021200	002	Jul 24, 2002	Aug CAHN
>D>	+	@	US WORLDMEDS LLC	EQ 2MG BASE	N021200	001	Jul 24, 2002	Aug CAHN
	+	@		EQ 2MG BASE	N021200	001	Jul 24, 2002	Jul CRLD
>D>	+	@		EQ 6MG BASE	N021200	002	Jul 24, 2002	Aug CAHN
	+	@		EQ 6MG BASE	N021200	002	Jul 24, 2002	Jul CRLD

TELMISARTANTABLET;ORAL
TELMISARTAN

		@	CIPLA	20MG	A078710	001	Jan 08, 2014	Jun DISC
AB				20MG	A078710	001	Jan 08, 2014	Feb CAHN
		@		40MG	A078710	002	Jan 08, 2014	Feb CAHN
		@		80MG	A078710	003	Jan 08, 2014	Feb CAHN
>D>	AB		HISUN PHARM HANGZHOU	20MG	A207843	001	Feb 19, 2019	Aug DISC
>A>		@		20MG	A207843	001	Feb 19, 2019	Aug DISC

TABLET; ORAL
TELMISARTAN

AB		20MG	A207843	001	Feb 19, 2019	Feb NEWA
>D>	AB	40MG	A207843	002	Feb 19, 2019	Aug DISC
>A>	@	40MG	A207843	002	Feb 19, 2019	Aug DISC
AB		40MG	A207843	002	Feb 19, 2019	Feb NEWA
>D>	AB	80MG	A207843	003	Feb 19, 2019	Aug DISC
>A>	@	80MG	A207843	003	Feb 19, 2019	Aug DISC
AB		80MG	A207843	003	Feb 19, 2019	Feb NEWA
>A>	AB	20MG	A205150	001	Oct 30, 2015	Aug CAHN
>A>	AB	40MG	A205150	002	Oct 30, 2015	Aug CAHN
>A>	AB	80MG	A205150	003	Oct 30, 2015	Aug CAHN
>D>	AB	20MG	A205150	001	Oct 30, 2015	Aug CAHN
>D>	AB	40MG	A205150	002	Oct 30, 2015	Aug CAHN
>D>	AB	80MG	A205150	003	Oct 30, 2015	Aug CAHN
	@ MICRO LABS	20MG	A207016	001	Oct 03, 2017	Mar DISC
	@	40MG	A207016	002	Oct 03, 2017	Mar DISC
	@	80MG	A207016	003	Oct 03, 2017	Mar DISC
	@ WATSON LABS	80MG	A078710	003	Jan 08, 2014	Feb DISC

TEMOZOLOMIDE

CAPSULE; ORAL
TEMOZOLOMIDE

@	APOTEX INC	5MG	A204159	001	Jul 05, 2018	Jan DISC
@		20MG	A204159	002	Jul 05, 2018	Jan DISC
@		100MG	A204159	003	Jul 05, 2018	Jan DISC
@		140MG	A204159	004	Jul 05, 2018	Jan DISC
@		180MG	A204159	005	Jul 05, 2018	Jan DISC
@		250MG	A204159	006	Jul 05, 2018	Jan DISC

TEMSIROLIMUS

SOLUTION; INTRAVENOUS
TEMSIROLIMUS

>A>	AP	GLAND PHARMA LTD	25MG/ML (25MG/ML)	A207383	001	Aug 16, 2019	Aug NEWA
-----	----	------------------	-------------------	---------	-----	--------------	----------

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL
TENOFOVIR DISOPROXIL FUMARATE
@ APOTEX INC 300MG

A206481	001	Jul 26, 2018	Jan DISC
---------	-----	--------------	----------

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
TERAZOSIN HYDROCHLORIDE

AB	APNAR PHARMA LP	EQ 1MG BASE	A074823	001	Mar 30, 1998	Jun CAHN
AB	!	EQ 2MG BASE	A074823	002	Mar 30, 1998	Jun CAHN
AB		EQ 5MG BASE	A074823	003	Mar 30, 1998	Jun CAHN
AB		EQ 10MG BASE	A074823	004	Mar 30, 1998	Jun CAHN
	@ BEXIMCO PHARMS USA	EQ 1MG BASE	A075667	001	Jul 28, 2000	Feb CAHN
	@	EQ 2MG BASE	A075667	002	Jul 28, 2000	Feb CAHN
	@	EQ 5MG BASE	A075667	003	Jul 28, 2000	Feb CAHN
	@	EQ 10MG BASE	A075667	004	Jul 28, 2000	Feb CAHN
AB	HERITAGE PHARMA	EQ 1MG BASE	A075614	002	Jan 30, 2001	Mar CAHN
AB		EQ 2MG BASE	A075614	001	Jan 30, 2001	Mar CAHN
AB		EQ 5MG BASE	A075614	003	Jan 30, 2001	Mar CAHN
AB		EQ 10MG BASE	A075614	004	Jan 30, 2001	Mar CAHN
AB	HIKMA	EQ 1MG BASE	A075498	001	Apr 12, 2001	Jun CAHN
AB		EQ 2MG BASE	A075498	002	Apr 12, 2001	Jun CAHN
AB		EQ 5MG BASE	A075498	003	Apr 12, 2001	Jun CAHN
AB		EQ 10MG BASE	A075498	004	Apr 12, 2001	Jun CAHN

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL
TERBINAFINE HYDROCHLORIDE

AB	HERITAGE PHARMA	EQ 250MG BASE	A076377	001	Jul 02, 2007	May CAHN
----	-----------------	---------------	---------	-----	--------------	----------

TERBUTALINE SULFATE

INJECTABLE; INJECTION
TERBUTALINE SULFATE

@	DR REDDYS	1MG/ML	A076853	001	Jul 20, 2004	May CAHN
---	-----------	--------	---------	-----	--------------	----------

TERCONAZOLECREAM;VAGINAL
TERCONAZOLE

BX	+!	FOUGERA PHARMS INC	0.8%	N021735	001	Oct 01, 2004	May CAHN
		SUPPOSITORY;VAGINAL					
		TERCONAZOLE					

AB	!	PERRIGO ISRAEL	80MG	A077149	001	Mar 17, 2006	May CAHN
----	---	----------------	------	---------	-----	--------------	----------

TERIFLUNOMIDETABLET;ORAL
TERIFLUNOMIDE

AB		ALEMBIC PHARMS LTD	7MG	A209572	001	Apr 19, 2019	Apr NEWA
AB			14MG	A209572	002	Apr 19, 2019	Apr NEWA
	@	AMNEAL PHARMS CO	7MG	A209613	001	Sep 28, 2018	Feb DISC
	@		14MG	A209613	002	Sep 28, 2018	Feb DISC
	@	APOTEX INC	7MG	A209601	001	Nov 02, 2018	Jan DISC
	@		14MG	A209601	002	Nov 02, 2018	Jan DISC
	@	AUROBINDO PHARMA LTD	7MG	A209638	001	Oct 26, 2018	Feb DISC
	@		14MG	A209638	002	Oct 26, 2018	Feb DISC
AB		MSN LABS PVT LTD	7MG	A209623	001	Apr 24, 2019	Apr NEWA
AB			14MG	A209623	002	Apr 24, 2019	Apr NEWA
	@	TEVA PHARMS USA	7MG	A209700	001	Sep 04, 2018	Mar DISC
	@		14MG	A209700	002	Sep 04, 2018	Mar DISC
	@	WATSON LABS TEVA	7MG	A209549	001	Jul 27, 2018	Feb DISC
	@		14MG	A209549	002	Jul 27, 2018	Feb DISC
	@	ZYDUS PHARMS	7MG	A209668	001	Nov 30, 2018	May DISC
	@		14MG	A209668	002	Nov 30, 2018	May DISC

TESTOSTERONEGEL;TRANSDERMAL
TESTOSTERONE

@ PAR PHARM 25MG/2.5GM PACKET

A076744 001 May 23, 2007 Mar DISC

GEL, METERED;TRANSDERMAL
TESTOSTERONE

AB		ACTAVIS LABS UT INC	1.62% (20.25MG/1.25GM ACTUATION)	A204570	001	Apr 10, 2019	Mar NEWA
AB		AMNEAL PHARMS LLC	1.62% (20.25MG/1.25GM ACTUATION)	A207373	001	Apr 10, 2019	Mar NEWA
AB		DR REDDYS	1.62% (20.25MG/1.25GM ACTUATION)	A208620	001	Apr 10, 2019	Mar NEWA
AB		LUPIN ATLANTIS	1.62% (20.25MG/1.25GM ACTUATION)	A208560	001	Apr 10, 2019	Mar NEWA

TABLET, EXTENDED RELEASE;BUCCAL
STRIANT

+ @ AUXILIUM PHARMS LLC 30MG

N021543 001 Jun 19, 2003 Jul DISC

TESTOSTERONE CYPIONATEINJECTABLE;INJECTION
TESTOSTERONE CYPIONATE

@ MYLAN INSTITUTIONAL 200MG/ML

A040652 001 Dec 11, 2006 Mar DISC

AO WILSHIRE PHARMS INC 200MG/ML

A206368 001 Apr 24, 2019 Apr NEWA

TESTOSTERONE UNDECANOATECAPSULE;ORAL
JATENZO

+ CLARUS 158MG

N206089 001 Mar 27, 2019 Mar NEWA

+ 198MG

N206089 002 Mar 27, 2019 Mar NEWA

+! 237MG

N206089 003 Mar 27, 2019 Mar NEWA

TETRABENAZINETABLET;ORAL
TETRABENAZINE

@ LUPIN LTD 12.5MG

A210544 001 Apr 20, 2018 Feb DISC

@ 25MG

A210544 002 Apr 20, 2018 Feb DISC

AB MYLAN 12.5MG

A207682 001 Jan 31, 2017 Jul CAHN

AB 25MG

A207682 002 Jan 31, 2017 Jul CAHN

AB WEST-WARD PHARMS INT 12.5MG

A209739 001 Apr 08, 2019 Mar NEWA

AB 25MG

A209739 002 Apr 08, 2019 Mar NEWA

TETRACAINE HYDROCHLORIDESOLUTION;OPHTHALMIC
TETRACAINE HYDROCHLORIDE

BAUSCH 0.5%

N210821 001 Mar 12, 2019 Apr CAHN

VALEANT PHARMS 0.5%

N210821 001 Mar 12, 2019 Mar NEWA

THALLOUS CHLORIDE TL-201

INJECTABLE;INJECTION
THALLOUS CHLORIDE TL 201

AP	+!	CURIUM	1mCi/ML	N018150	001		Jan	CAHN
----	----	--------	---------	---------	-----	--	-----	------

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL
THEOPHYLLINE

AB	!	HERITAGE PHARMA	100MG	A089807	001	Apr 30, 1990	Feb	CAHN
AB	!		200MG	A089808	001	Apr 30, 1990	Feb	CAHN
AB			300MG	A089763	001	Apr 30, 1990	Feb	CAHN
	@		450MG	A081236	001	Nov 09, 1992	Feb	CAHN

THIOTHIXENE

CAPSULE;ORAL
THIOTHIXENE

AB		MYLAN	1MG	A071093	002	Jun 23, 1987	Mar	CTEC
AB			2MG	A071093	003	Jun 23, 1987	Mar	CTEC
AB			5MG	A071093	004	Jun 23, 1987	Jul	CHRS
AB	!		5MG	A071093	004	Jun 23, 1987	Mar	CTEC
AB			10MG	A071093	001	Jun 23, 1987	Mar	CTEC
AB		NOVITIUM PHARMA	1MG	A211642	001	Apr 05, 2019	Mar	NEWA
AB			2MG	A211642	002	Apr 05, 2019	Mar	NEWA
AB	!		5MG	A211642	003	Apr 05, 2019	Jul	CHRS
AB			5MG	A211642	003	Apr 05, 2019	Mar	NEWA
AB			10MG	A211642	004	Apr 05, 2019	Mar	NEWA

TICAGRELOR

TABLET;ORAL
BRILINTA

	+	ASTRAZENECA PHARMS	60MG	N022433	002	Sep 03, 2015	Jun	CTEC
	@	AMNEAL PHARMS CO	90MG	A208531	001	Jan 23, 2019	Jun	DISC
AB			90MG	A208531	001	Jan 23, 2019	Jan	NEWA
AB		HISUN PHARM HANGZHOU	90MG	A208575	001	Jan 23, 2019	Jan	NEWA
	@	WATSON LABS INC	60MG	A208390	001	Sep 04, 2018	Feb	DISC
	@		90MG	A208390	002	Sep 04, 2018	Feb	DISC

TIGECYCLINE

POWDER;INTRAVENOUS
TIGECYCLINE

AP		AMNEAL PHARMS LLC	50MG/VIAL	N211158	001	Aug 02, 2018	Jul	CMFD
	@		50MG/VIAL	N211158	001	Aug 02, 2018	Feb	DISC
AP		AUROBINDO PHARMA LTD	50MG/VIAL	A206335	001	Jun 11, 2019	May	NEWA

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC
TIMOPTIC

AT	+	VALEANT PHARMS INTL	EQ 0.25% BASE	N018086	001		Jan	CAHN
AT1	+		EQ 0.5% BASE	N018086	002		Jan	CAHN
		TIMOPTIC IN OCUDOSE						
	+	VALEANT PHARMS INTL	EQ 0.25% BASE	N019463	001	Nov 05, 1986	Jan	CAHN
	+		EQ 0.5% BASE	N019463	002	Nov 05, 1986	Jan	CAHN

TABLET;ORAL
BLOCADREN

	+	@ MERCK	5MG	N018017	001		Apr	CRLD
	+	@	10MG	N018017	002		Apr	CRLD
	+	@	20MG	N018017	004		Apr	CRLD

TIMOLOL MALEATE

AB		INVATECH PHARMA	5MG	A207556	001	May 02, 2019	Apr	NEWA
AB			10MG	A207556	002	May 02, 2019	Apr	NEWA
AB			20MG	A207556	003	May 02, 2019	Apr	NEWA
AB		MYLAN	5MG	A072668	002	Jun 08, 1990	Apr	CTEC
AB			10MG	A072668	003	Jun 08, 1990	Apr	CTEC
AB	!		20MG	A072668	001	Jun 08, 1990	Apr	CTEC

TIOPRONIN

TABLET, DELAYED RELEASE;ORAL
THIOLA EC

+ MISSION PHARMACAL CO 100MG
+! 300MG

N211843 001 Jun 28, 2019 Jun NEWA
N211843 002 Jun 28, 2019 Jun NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

AB ALKEM LABS LTD EQ 2MG BASE
AB EQ 4MG BASE
AB EQ 6MG BASE
AB CADILA PHARMS LTD EQ 2MG BASE
AB EQ 4MG BASE
AB EQ 6MG BASE
AB RICONPHARMA LLC EQ 2MG BASE
AB EQ 4MG BASE
AB EQ 6MG BASE

A212196 001 Mar 27, 2019 Mar NEWA
A212196 002 Mar 27, 2019 Mar NEWA
A212196 003 Mar 27, 2019 Mar NEWA
A210021 001 Mar 26, 2019 Mar NEWA
A210021 002 Mar 26, 2019 Mar NEWA
A210021 003 Mar 26, 2019 Mar NEWA
A210267 001 Mar 12, 2019 Feb NEWA
A210267 002 Mar 12, 2019 Feb NEWA
A210267 003 Mar 12, 2019 Feb NEWA

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

AB ALKEM LABS LTD EQ 2MG BASE
AB EQ 4MG BASE
@ ANI PHARMS INC EQ 2MG BASE
@ EQ 2MG BASE
@ EQ 4MG BASE
@ EQ 4MG BASE
@ PAR PHARM INC EQ 2MG BASE
@ EQ 4MG BASE

A211798 001 Jan 25, 2019 Jan NEWA
A211798 002 Jan 25, 2019 Jan NEWA
A076283 001 Jul 12, 2002 May CAHN
A076371 001 Apr 09, 2003 May CAHN
A076283 002 Jul 12, 2002 May CAHN
A076371 002 Apr 09, 2003 May CAHN
A207170 001 Jan 26, 2017 Mar DISC
A207170 002 Jan 26, 2017 Mar DISC

TOBRAMYCIN

SOLUTION;INHALATION

BETHKIS

+! CHIESI USA INC 300MG/4ML
AN +! 300MG/4ML

N201820 001 Oct 12, 2012 Jul CTEC
N201820 001 Oct 12, 2012 Jun CFTG

TOBRAMYCIN

AN DR REDDYS LABS SA 300MG/5ML
@ 300MG/5ML
@ TEVA PHARMS USA 300MG/4ML
AN 300MG/4ML

A207080 001 Jul 09, 2018 Mar CMFD
A207080 001 Jul 09, 2018 Jan DISC
A210915 001 Jun 26, 2019 Jul DISC
A210915 001 Jun 26, 2019 Jun NFTG

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

AT ALEMBIC PHARMS LTD 0.3%

A211847 001 Apr 19, 2019 Apr NEWA

TOFACITINIB CITRATE

TABLET;ORAL

XELJANZ

+ PF PRISM CV EQ 5MG BASE

N203214 001 Nov 06, 2012 May CHRS

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

@ COSETTE 100MG
@ 250MG
@ 500MG

N018894 001 Nov 02, 1984 Jun CAHN
N018894 002 Nov 02, 1984 Jun CAHN
N018894 003 Nov 02, 1984 Jun CAHN

TOLCAPONE

TABLET;ORAL

TASMAR

AB +! BAUSCH 100MG
@ 200MG

N020697 001 Jan 29, 1998 Mar CAHN
N020697 002 Jan 29, 1998 Mar CAHN

TOLCAPONE

AB KINEDEXE UK 100MG

A210095 001 Aug 01, 2019 Jul NEWA

TOLMETIN SODIUM

CAPSULE;ORAL

TOLMETIN SODIUM

@ ANI PHARMS INC EQ 400MG BASE

A073308 001 Jan 24, 1992 May CAHN

TABLET;ORAL

TOLMETIN SODIUM

@ ANI PHARMS INC EQ 600MG BASE

A073527 001 Jun 30, 1992 May CAHN

TOLTERODINE TARTRATECAPSULE, EXTENDED RELEASE;ORAL
TOLTERODINE TARTRATE

>A>	AB	INVENTIA HLTHCARE	2MG	A204562	001	Aug 19, 2019	Aug NEWA
>A>	AB		4MG	A204562	002	Aug 19, 2019	Aug NEWA

TOLVAPTANTABLET;ORAL
JYNARQUE

+	!	OTSUKA PHARM CO LTD	45MG	N204441	003	Apr 23, 2018	Jun CHRS
+			90MG	N204441	005	Apr 23, 2018	Jun CHRS

TOPIRAMATECAPSULE, EXTENDED RELEASE;ORAL
QUDEXY XR

BC	+	UPSHER SMITH LABS	25MG	N205122	001	Mar 11, 2014	Feb CTEC
BC	+		50MG	N205122	002	Mar 11, 2014	Feb CTEC
BC	+		100MG	N205122	003	Mar 11, 2014	Feb CTEC
BC	+	!	200MG	N205122	005	Mar 11, 2014	Feb CTEC
TROKENDI XR							
BC	+	SUPERNUS PHARMS	200MG	N201635	004	Aug 16, 2013	Apr CTEC

TRAMADOL HYDROCHLORIDETABLET;ORAL
TRAMADOL HYDROCHLORIDE

AB		POLYGEN PHARMS	50MG	A206706	001	Jul 02, 2019	Jun NEWA
AB		RUBICON	50MG	A208708	001	Jun 28, 2019	Jun NEWA
AB			100MG	A208708	002	Jun 28, 2019	Jun NEWA
AB		UNICHEM LABS LTD	50MG	A211825	001	Aug 09, 2019	Jul NEWA

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
TARKA

>D>	AB	+	ABBVIE	1MG;240MG	N020591	003	Oct 22, 1996	Aug DISC
>A>		+	@	1MG;240MG	N020591	003	Oct 22, 1996	Aug DISC
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE								
>D>	AB		GLENMARK GENERICS	1MG;240MG	A079135	004	Aug 30, 2010	Aug CTEC
>A>				1MG;240MG	A079135	004	Aug 30, 2010	Aug CTEC

TRANEXAMIC ACIDINJECTABLE;INJECTION
TRANEXAMIC ACID

AP		ACIC PHARMS	100MG/ML	A209326	001	Feb 22, 2019	Feb NEWA	
AP		APOLLO PHARMS INC	100MG/ML	A212676	001	Jul 17, 2019	Jul NEWA	
AP		CAPLIN	100MG/ML	A212360	001	Jul 17, 2019	Jul NEWA	
		+	!	EXELA PHARMA SCS LLC	10MG/ML	N212020	001	Apr 15, 2019
AP		MICRO LABS	100MG/ML	A206713	001	Jun 27, 2017	Mar CAHN	

SOLUTION;INTRAVENOUS
TRANEXAMIC ACID

+	!	EXELA PHARMA SCS LLC	1GM/100ML (10MG/ML)	N212020	001	Apr 15, 2019	May CPOT
---	---	----------------------	---------------------	---------	-----	--------------	----------

TREPROSTINIL DIOLAMINETABLET, EXTENDED RELEASE;ORAL
ORENITRAM

+	!	UNITED THERAP	EQ 1MG BASE	N203496	003	Dec 20, 2013	Feb CHRS
+			EQ 2.5MG BASE	N203496	004	Dec 20, 2013	Feb CHRS

TRETINOINCREAM;TOPICAL
TRETINOIN

AB1		TARO PHARMS	0.05%	A211644	001	Jan 25, 2019	Jan NEWA
AB			0.1%	A211645	001	Jan 22, 2019	Jan NEWA

TRIAMCINOLONE ACETONIDECREAM;TOPICAL
TRIAMCINOLONE ACETONIDE

AT		SAPTALIS PHARMS	0.025%	A040671	001	Jun 09, 2006	May CAHN
AT			0.1%	A040671	002	Jun 09, 2006	May CAHN
AT		STRIDES PHARMA	0.025%	A210346	001	Feb 11, 2019	Jan NEWA
AT			0.1%	A210346	002	Feb 11, 2019	Jan NEWA
AT			0.5%	A210346	003	Feb 11, 2019	Jan NEWA

INJECTABLE; INJECTION

KENALOG-80

	+!	APOTHECON	80MG/ML	N014901	002	Apr 12, 2019	Apr	NEWA
		TRIAMCINOLONE ACETONIDE						
AB		TEVA PHARMS USA	40MG/ML	A209852	001	Oct 05, 2018	Jul	CMFD
	@		40MG/ML	A209852	001	Oct 05, 2018	Mar	DISC

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

AT		SAPTALIS PHARMS	0.1%	A040672	002	Dec 13, 2006	May	CAHN
----	--	-----------------	------	---------	-----	--------------	-----	------

TRIAMTERENE

CAPSULE; ORAL

DYRENIUM

>D>	+	CONCORDIA	50MG	N013174	001		Aug	CFTG
>A>	AB	+	50MG	N013174	001		Aug	CFTG
>D>	+		100MG	N013174	002		Aug	CFTG
>A>	AB	+	100MG	N013174	002		Aug	CFTG
>A>		TRIAMTERENE						
>A>	AB	AGNITIO	50MG	A211581	001	Aug 19, 2019	Aug	NFTG
>A>	AB		100MG	A211581	002	Aug 19, 2019	Aug	NFTG

TRICLABENDAZOLE

TABLET; ORAL

EGATEN

	+	NOVARTIS PHARMS CORP	250MG	N208711	001	Feb 13, 2019	Feb	NEWA
--	---	----------------------	-------	---------	-----	--------------	-----	------

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

TRIENTINE HYDROCHLORIDE

AB		AMNEAL PHARMS LLC	250MG	A210619	001	Feb 08, 2019	Feb	NEWA
AB		DR REDDYS LABS LTD	250MG	A211076	001	Jul 03, 2019	Jun	NEWA
AB		MSN LABS PVT LTD	250MG	A211134	001	May 22, 2019	May	NEWA
AB		ZYDUS PHARMS	250MG	A211554	001	Apr 26, 2019	Apr	NEWA

TRIMETHADIONE

TABLET; ORAL

TRIDIONE

	+	@ ABBVIE	150MG	N005856	009		Jul	DISC
--	---	----------	-------	---------	-----	--	-----	------

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

TRIMETHOBENZAMIDE HYDROCHLORIDE

AB		LUPIN	300MG	A076546	001	Aug 20, 2003	Feb	CAHN
----	--	-------	-------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

TIGAN

	+	PAR STERILE PRODUCTS	100MG/ML	N017530	001		May	CTEC
--	---	----------------------	----------	---------	-----	--	-----	------

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

	+	@ ODYSSEY PHARMS	EQ 25MG BASE	N016792	001		Jul	DISC
	+	@	EQ 50MG BASE	N016792	002		Jul	DISC
	+	@	EQ 100MG BASE	N016792	003	Sep 15, 1982	Jul	DISC

TRIMIPRAMINE MALEATE

AB	!	CROSSMEDIKA SA	EQ 50MG BASE	A208127	002	Apr 15, 2016	Jul	CHRS
----	---	----------------	--------------	---------	-----	--------------	-----	------

>A> UPADACITINIB

>A> TABLET, EXTENDED RELEASE; ORAL

>A> RINVOQ

>A>	+	!	ABBVIE INC	EQ 15MG BASE	N211675	001	Aug 16, 2019	Aug	NEWA
-----	---	---	------------	--------------	---------	-----	--------------	-----	------

URSODIOL

CAPSULE; ORAL

URSODIOL

AB		AMNEAL PHARMS CO	300MG	A211301	001	Oct 16, 2018	Jun	CMFD
	@		300MG	A211301	001	Oct 16, 2018	Apr	DISC

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

@ WATSON LABS INC EQ 500MG BASE

A090370 001 Mar 16, 2011 Apr DISC

@ EQ 1GM BASE

A090370 002 Mar 16, 2011 Apr DISC

VALPROATE SODIUM

INJECTABLE; INJECTION

DEPACON

+ @ ABBVIE EQ 100MG BASE/ML

N020593 001 Dec 30, 1996 Apr DISC

VALPROATE SODIUM

AP ! HIKMA FARMACEUTICA EQ 100MG BASE/ML

A078523 001 Feb 17, 2010 Apr CHRS

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

AB NOVELGENIX THERAPS 250MG

A207611 001 Aug 05, 2019 Jul NEWA

@ UPSHER SMITH LABS 250MG

A070631 001 Jun 11, 1987 Jul CAHN

SYRUP; ORAL

DEPAKENE

>D> AA +! ABBVIE 250MG/5ML

N018082 001 Aug DISC

>A> + @ 250MG/5ML

N018082 001 Aug DISC

VALPROIC ACID

@ PD PARTNERS 250MG/5ML

A077105 001 Jul 29, 2005 May CAHN

>D> AA PHARM ASSOC 250MG/5ML

A075379 001 Dec 15, 2000 Aug CHRS

>A> AA ! 250MG/5ML

A075379 001 Dec 15, 2000 Aug CHRS

VALRUBICIN

SOLUTION; INTRAVESICAL

VALRUBICIN

AO CUSTOPHARM INC 40MG/ML

A206430 001 Apr 19, 2019 Apr NFTG

VALSTAR PRESERVATIVE FREE

AO +! ENDO PHARM 40MG/ML

N020892 001 Sep 25, 1998 Apr CFTG

VALSARTAN

TABLET; ORAL

VALSARTAN

AB ALKEM LABS LTD 40MG

A205536 001 Mar 12, 2019 Feb NEWA

AB 80MG

A205536 002 Mar 12, 2019 Feb NEWA

AB 160MG

A205536 003 Mar 12, 2019 Feb NEWA

AB 320MG

A205536 004 Mar 12, 2019 Feb NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOMYCIN HYDROCHLORIDE

AB ORIENT PHARMA CO LTD EQ 125MG BASE

A210729 001 Apr 29, 2019 Apr NEWA

AB EQ 250MG BASE

A210729 002 Apr 29, 2019 Apr NEWA

FOR SOLUTION; ORAL

VANCOCIN HYDROCHLORIDE

ANI PHARMS INC EQ 250MG BASE/5ML

A061667 002 Jul 13, 1983 Jul CMFD

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP HAINAN POLY PHARM EQ 500MG BASE/VIAL

A212332 001 Jun 12, 2019 May NEWA

AP EQ 1GM BASE/VIAL

A212332 002 Jun 12, 2019 May NEWA

SOLUTION; INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

+! XELLIA PHARMS APS EQ 500MG BASE/100ML

N211962 001 Feb 15, 2019 Feb NEWA

+! EQ 1GM BASE/200ML

N211962 002 Feb 15, 2019 Feb NEWA

+! EQ 1.5GM BASE/300ML

N211962 003 Feb 15, 2019 Feb NEWA

+! EQ 2GM BASE/400ML

N211962 004 Feb 15, 2019 Feb NEWA

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

VARDENAFIL HYDROCHLORIDE

@ AMNEAL PHARMS CO 5MG

A210738 001 Oct 31, 2018 Apr DISC

@ 10MG

A210738 002 Oct 31, 2018 Apr DISC

@ 20MG

A210738 003 Oct 31, 2018 Apr DISC

VASOPRESSINSOLUTION; INTRAVENOUS
VASOSTRICT+! PAR STERILE PRODUCTS 20UNITS/ML (20UNITS/ML)
+! 200UNITS/10ML (20UNITS/ML)N204485 001 Apr 17, 2014 Mar CDFR
N204485 002 Dec 17, 2016 Mar CDFRVECURONIUM BROMIDEINJECTABLE; INJECTION
VECURONIUM BROMIDEAP HIKMA 10MG/VIAL
AP 20MG/VIALA203725 001 Jul 30, 2019 Jul NEWA
A203725 002 Jul 30, 2019 Jul NEWAVENLAFAXINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
VENLAFAXINE HYDROCHLORIDEAB ANNORA PHARMA EQ 37.5MG BASE
AB EQ 75MG BASE
AB EQ 150MG BASEA212277 001 Jul 08, 2019 Jun NEWA
A212277 002 Jul 08, 2019 Jun NEWA
A212277 003 Jul 08, 2019 Jun NEWATABLET, EXTENDED RELEASE; ORAL
VENLAFAXINE HYDROCHLORIDE>A> AB CADILA PHARMS LTD EQ 75MG BASE
>A> AB EQ 150MG BASE
>A> AB EQ 225MG BASEA211323 001 Aug 29, 2019 Aug NEWA
A211323 002 Aug 29, 2019 Aug NEWA
A211323 003 Aug 29, 2019 Aug NEWAVERAPAMIL HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
VERAPAMIL HYDROCHLORIDE@ MYLAN 300MG
VERELAN PM

A078306 003 Aug 09, 2007 May DISC

+! RECRO GAINESVILLE 300MG

N020943 003 Nov 25, 1998 May CTEC

TABLET; ORAL
CALAN+ @ GD SEARLE LLC 80MG
AB + 120MGN018817 001 Sep 10, 1984 May DISC
N018817 002 Sep 10, 1984 May CHRS

VERAPAMIL HYDROCHLORIDE

AB ! HERITAGE PHARMS INC 120MG

A071881 001 Apr 05, 1988 May CHRS

VIGABATRINFOR SOLUTION; ORAL
VIGADRONEAA AUCTA 500MG/PACKET
AA SHANGHAI 500MG/PACKETA210196 001 Jun 21, 2018 Jun CAHN
A210196 001 Jun 21, 2018 Mar CAHNVINCRISTINE SULFATEINJECTABLE, LIPOSOMAL; INTRAVENOUS
MARQIBO KIT

+! ACROTECH 5MG/5ML (1MG/ML)

N202497 001 Aug 09, 2012 Mar CAHN

VINORELBINE TARTRATEINJECTABLE; INJECTION
NAVELBINE

+ @ PIERRE FABRE EQ 10MG BASE/ML

N020388 001 Dec 23, 1994 Jun DISC

VINORELBINE TARTRATE

AP INGENUS PHARMS LLC EQ 10MG BASE/ML

A208997 001 Aug 05, 2019 Jul NEWA

VORAPAXAR SULFATETABLET; ORAL
ZONTIVITY

+! TOPROL EQ 2.08MG BASE

N204886 001 May 08, 2014 May CAHN

VORICONAZOLEINJECTABLE; INTRAVENOUS
VFENDAP +! PF PRISM CV 200MG/VIAL
VORICONAZOLE

N021267 001 May 24, 2002 May CDFR

AP ALVOGEN INC 200MG/VIAL

A206398 001 Mar 23, 2016 May CDFR

AP HAINAN POLY PHARM 200MG/VIAL

A211661 001 Nov 30, 2018 May CDFR

AP SANDOZ INC 200MG/VIAL

A090862 001 May 30, 2012 May CDFR

AP ZYDUS PHARMS 200MG/VIAL

A208983 001 Jul 16, 2018 May CDFR

POWDER; INTRAVENOUS							
VORICONAZOLE							
AP	XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	May	CDFR
POWDER; IV (INFUSION)							
VORICONAZOLE							
AP	XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017	Feb	CTEC
TABLET; ORAL							
VORICONAZOLE							
AB	APPCO PHARMA LLC	50MG	A206762	001	May 24, 2016	Feb	CAHN
AB		200MG	A206762	002	May 24, 2016	Feb	CAHN
AB	CADILA	50MG	A206747	001	May 24, 2016	Apr	CAHN
AB		200MG	A206747	002	May 24, 2016	Apr	CAHN

WARFARIN SODIUM

TABLET; ORAL							
JANTOVEN							
AB	UPSHER SMITH LABS	1MG	A040416	001	Oct 02, 2003	Jul	CAHN
AB		2MG	A040416	002	Oct 02, 2003	Jul	CAHN
AB		2.5MG	A040416	003	Oct 02, 2003	Jul	CAHN
AB		3MG	A040416	004	Oct 02, 2003	Jul	CAHN
AB		4MG	A040416	005	Oct 02, 2003	Jul	CAHN
AB		5MG	A040416	006	Oct 02, 2003	Jul	CAHN
AB		6MG	A040416	007	Oct 02, 2003	Jul	CAHN
AB		7.5MG	A040416	008	Oct 02, 2003	Jul	CAHN
AB		10MG	A040416	009	Oct 02, 2003	Jul	CAHN

XENON XE-133

GAS; INHALATION							
XENON XE 133							
	CURIUM	10mCi/VIAL	N018327	001	Mar 09, 1982	May	CAHN
		20mCi/VIAL	N018327	002	Mar 09, 1982	May	CAHN

ZIDOVUDINE

INJECTABLE; INJECTION							
ZIDOVUDINE							
	@ LUITPOLD	10MG/ML	A091457	001	May 06, 2010	Feb	DISC

ZINC SULFATE

SOLUTION; INTRAVENOUS							
ZINC SULFATE							
+	AM REGENT	EQ 25MG BASE/5ML (EQ 5 BASE/ML)	N209377	002	Jul 18, 2019	Jul	NEWA
+		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	N209377	001	Jul 18, 2019	Jul	NEWA

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL							
ZIPRASIDONE HYDROCHLORIDE							
	@ CADILA	EQ 20MG BASE	A208988	001	Aug 22, 2017	Jun	DISC
AB		EQ 20MG BASE	A208988	001	Aug 22, 2017	Feb	CAHN
	@	EQ 40MG BASE	A208988	002	Aug 22, 2017	Jun	DISC
AB		EQ 40MG BASE	A208988	002	Aug 22, 2017	Feb	CAHN
	@	EQ 60MG BASE	A208988	003	Aug 22, 2017	Jun	DISC
AB		EQ 60MG BASE	A208988	003	Aug 22, 2017	Feb	CAHN
	@	EQ 80MG BASE	A208988	004	Aug 22, 2017	Jun	DISC
AB		EQ 80MG BASE	A208988	004	Aug 22, 2017	Feb	CAHN

ZOLEDRONIC ACID

	INJECTABLE; INTRAVENOUS							
	RECLAST							
AP	+	NOVARTIS	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007	Mar	CDFR
		ZOLEDRONIC						
AP		GLAND PHARMA LTD	EQ 4MG BASE/100ML	A205749	001	Jun 29, 2018	Mar	CDFR
		ZOLEDRONIC ACID						
AP		ACCORD HLTHCARE	EQ 4MG BASE/5ML	A205279	001	Nov 28, 2016	Mar	CDFR
	@	ACTAVIS INC	EQ 4MG BASE/5ML	A202472	001	Mar 04, 2013	Jul	DISC
AP			EQ 4MG BASE/5ML	A202472	001	Mar 04, 2013	Mar	CDFR
AP		AKORN	EQ 5MG BASE/100ML	A200918	001	Aug 21, 2014	Mar	CDFR
AP		AKORN INC	EQ 4MG BASE/5ML	A202548	001	May 22, 2014	Mar	CDFR
AP		APOTEX INC	EQ 5MG BASE/100ML	A204367	001	Dec 24, 2015	Mar	CDFR
AP		AUROBINDO PHARMA LTD	EQ 4MG BASE/5ML	A207751	001	Sep 26, 2016	Mar	CDFR
AP			EQ 5MG BASE/100ML	A209125	001	Dec 08, 2017	Mar	CDFR
AP		BPI LABS LLC	EQ 4MG BASE/5ML	A207341	001	Dec 29, 2017	Mar	CDFR
AP		BRECKENRIDGE	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013	Mar	CDFR

INJECTABLE; INTRAVENOUS
ZOLEDRONIC ACID

AP		EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Mar CDFR
AP	CIPLA	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	Mar CDFR
AP	DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	May CDFR
AP		EQ 5MG BASE/100ML	A091363	001	Mar 29, 2013	Mar CDFR
AP	EMCURE PHARMS LTD	EQ 4MG BASE/5ML	A201783	001	Mar 12, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Mar CDFR
AP	FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516	001	Apr 23, 2015	Mar CDFR
AP	GLAND PHARMA LTD	EQ 4MG BASE/5ML	A202930	001	Aug 05, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A204217	001	Aug 18, 2016	Mar CDFR
AP		EQ 5MG BASE/100ML	A209578	001	Aug 08, 2019	Jul NEWA
AP	HIKMA FARMACEUTICA	EQ 4MG BASE/5ML	A202182	001	Jun 03, 2013	Mar CDFR
AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar CDFR
AP		EQ 5MG BASE/100ML	A202837	001	Apr 05, 2013	Mar CDFR
AP	INFORLIFE	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A202828	001	Sep 23, 2013	Mar CDFR
AP	MYLAN LABS LTD	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A203841	001	Feb 14, 2017	Mar CDFR
AP		EQ 5MG BASE/100ML	A205254	001	Oct 27, 2017	Mar CDFR
AP	SAGENT PHARMS	EQ 4MG BASE/5ML	A091493	001	Nov 24, 2014	Mar CDFR
AP	SHILPA MEDICARE LTD	EQ 4MG BASE/5ML	A208513	001	May 15, 2019	Apr NEWA
	@ SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013	Mar CDFR
	@	EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013	Mar CDFR
AP	USV	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Jun CAHN
AP	USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar CDFR
	ZOMETA					
	+ @ NOVARTIS	EQ 4MG BASE/VIAL	N021223	001	Aug 20, 2001	Mar CDFR
AP	+	EQ 4MG BASE/5ML	N021223	002	Mar 07, 2003	Mar CDFR
AP	+	EQ 4MG BASE/100ML	N021223	003	Jun 17, 2011	Mar CDFR

INJECTABLE; IV (INFUSION)

ZOLEDRONIC ACID

AP	DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	Mar CDFR
	SOLUTION; INTRAVENOUS					
	ZOLEDRONIC ACID					
	HOSPIRA INC	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)	N204016	001	Dec 28, 2015	Mar CDFR

ZOLPIDEM TARTRATESPRAY, METERED; ORAL
ZOLPIMIST

+! AYTU

5MG/SPRAY

N022196 001 Dec 19, 2008 Feb CAHN

TABLET; ORAL

ZOLPIDEM TARTRATE

@ STRIDES PHARMA

5MG

A076062 001 Apr 23, 2007 Apr CAHN

@

10MG

A076062 002 Apr 23, 2007 Apr CAHN

>D> AB WOCKHARDT

5MG

A078426 001 May 15, 2007 Aug DISC

>A> @

5MG

A078426 001 May 15, 2007 Aug DISC

>D> AB

10MG

A078426 002 May 15, 2007 Aug DISC

>A> @

10MG

A078426 002 May 15, 2007 Aug DISC

TABLET; SUBLINGUAL

INTERMEZZO

+ @ PURDUE PHARMA

1.75MG

N022328 001 Nov 23, 2011 Mar DISC

+ @

3.5MG

N022328 002 Nov 23, 2011 Mar DISC

ZOLPIDEM TARTRATE

AB ! NOVEL LABS INC

3.5MG

A204299 002 Jun 03, 2015 Mar CHRS

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

AB BIONPHARMA INC

25MG

A077813 001 Aug 16, 2006 Apr CAHN

AB

50MG

A077813 002 Aug 16, 2006 Apr CAHN

AB

100MG

A077813 003 Aug 16, 2006 Apr CAHN

>A> AB CELLTRION

25MG

A077636 003 Jul 27, 2006 Aug CAHN

>A> AB

50MG

A077636 002 Jul 27, 2006 Aug CAHN

>A> AB

100MG

A077636 001 Dec 22, 2005 Aug CAHN

>D> AB WOCKHARDT

25MG

A077636 003 Jul 27, 2006 Aug CAHN

>D> AB

50MG

A077636 002 Jul 27, 2006 Aug CAHN

>D> AB

100MG

A077636 001 Dec 22, 2005 Aug CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

ACP NIMBLE	120MG	N018060	001		Feb CAHN
@	325MG	N018060	003	Dec 18, 1986	Feb CAHN
@	650MG	N018060	002		Feb CAHN

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

GRANULES INDIA LTD	650MG	A211544	001	Apr 16, 2019	Apr NEWA
@ HERITAGE PHARMA	650MG	A207035	001	May 31, 2018	Mar DISC

ADAPALENE

GEL;TOPICAL

ADAPALENE

GLENMARK GENERICS	0.1%	A091314	002	Jul 09, 2019	Jul NEWA
-------------------	------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

QUAGEN	5MG/5ML	A212266	001	May 16, 2019	May NEWA
--------	---------	---------	-----	--------------	----------

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019	Feb NEWA
@ PD PARTNERS	5MG/5ML	A090188	002	Apr 22, 2008	May CAHN
TORRENT	5MG/5ML	A090474	002	Mar 30, 2009	Jan CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@ PD PARTNERS	5MG/5ML	A090188	001	Apr 22, 2008	May CAHN
TORRENT	5MG/5ML	A090474	001	Mar 30, 2009	Jan CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@ HERITAGE PHARMA	5MG	A078615	003	Dec 28, 2007	May CAHN
@	10MG	A078615	004	Dec 28, 2007	May CAHN

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ PERRIGO R AND D	5MG;120MG	A210719	001	Nov 16, 2018	May DISC
-------------------	-----------	---------	-----	--------------	----------

CHLORHEXIDINE GLUCONATE

SOLUTION;TOPICAL

CHLORHEXIDINE GLUCONATE

BAJAJ	0.75%	N020111	001	Sep 11, 1997	Apr CTNA
	0.75%	N020111	001	Sep 11, 1997	Jan CMFD

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL

CHLORPHENIRAMINE MALEATE

! AVANTHI INC	12MG	A040829	001	May 13, 2009	Jan CHRS
---------------	------	---------	-----	--------------	----------

CLOTTRIMAZOLE

CREAM;VAGINAL

CLOTTRIMAZOLE

>D>	! ACTAVIS MID ATLANTIC	1%	A074165	001	Jul 16, 1993	Aug CAHN
>A>	! P AND L	1%	A074165	001	Jul 16, 1993	Aug CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

AUROBINDO PHARMA LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A210676	001	Feb 14, 2019	Jan NEWA
----------------------	--	---------	-----	--------------	----------

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

>D>	@ ACTAVIS ELIZABETH	25MG;220MG	A207597	001	Jan 25, 2019	Aug CAHN
	@	25MG;220MG	A207597	001	Jan 25, 2019	Jul DISC
		25MG;220MG	A207597	001	Jan 25, 2019	Jan NEWA
>A>	APOTEX INC	25MG;220MG	A211830	001	Aug 22, 2019	Aug NEWA
>A>	@ P AND L	25MG;220MG	A207597	001	Jan 25, 2019	Aug CAHN

TABLET;ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE
PERRIGO R AND D 25MG;220MG

A208499 001 May 10, 2019 Apr NEWA

DOCOSANOL

CREAM;TOPICAL
DOCOSANOL

>D>	ACTAVIS LABS UT INC	10%	A208754	001	Nov 19, 2018	Aug CAHN
>A>	P AND L	10%	A208754	001	Nov 19, 2018	Aug CAHN

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL
ESOMEPRAZOLE MAGNESIUM

AMNEAL PHARMS NY EQ 20MG BASE

A209716 001 Jun 05, 2019 May NEWA

TABLET, DELAYED RELEASE;ORAL
ESOMEPRAZOLE MAGNESIUM

>D>	@ ACTAVIS ELIZABETH	EQ 20MG BASE	A209202	001	Mar 05, 2019	Aug CAHN
	@	EQ 20MG BASE	A209202	001	Mar 05, 2019	Apr DISC
		EQ 20MG BASE	A209202	001	Mar 05, 2019	Feb NEWA
>A>	@ P AND L	EQ 20MG BASE	A209202	001	Mar 05, 2019	Aug CAHN

FAMOTIDINE

TABLET;ORAL
FAMOTIDINE

>D>	IVAX SUB TEVA PHARMS	10MG	A075512	001	Jul 26, 2001	Aug CAHN
>A>	P AND L	10MG	A075512	001	Jul 26, 2001	Aug CAHN

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

>D>	ACTAVIS MID ATLANTIC	30MG/5ML	A203330	001	Nov 18, 2014	Aug CAHN
>A>	P AND L	30MG/5ML	A203330	001	Nov 18, 2014	Aug CAHN

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

>D>	! ACTAVIS MID ATLANTIC	30MG/5ML	A203330	002	Nov 18, 2014	Aug CAHN
>A>	! P AND L	30MG/5ML	A203330	002	Nov 18, 2014	Aug CAHN

TABLET;ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

@ MYLAN 30MG

A077081 004 Jul 21, 2011 Jul DISC

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

@ MYLAN 30MG

A077081 005 Jul 21, 2011 Jul DISC

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

HI TECH 0.05MG/SPRAY

A208024 001 Apr 17, 2019 Apr NEWA

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

@ OHM LABS INC 600MG

A209254 001 Jul 16, 2018 Mar DISC

@ 1.2GM

A209254 002 Jul 16, 2018 Mar DISC

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

>D>	ACTAVIS MID ATLANTIC	100MG/5ML	A074916	001	Apr 30, 1999	Aug CAHN
	@ GUARDIAN DRUG	100MG/5ML	A210149	001	Aug 17, 2018	Feb DISC
>A>	P AND L	100MG/5ML	A074916	001	Apr 30, 1999	Aug CAHN

SUSPENSION/DROPS;ORAL

INFANT'S ADVIL

>A>	+! PFIZER	50MG/1.25ML	N020812	002	Jan 12, 2000	Aug NEWA
-----	-----------	-------------	---------	-----	--------------	----------

PEDIATRIC ADVIL

>D>	+! PFIZER	100MG/2.5ML	N020812	001	Jan 30, 1998	Aug DISC
>A>	+ @	100MG/2.5ML	N020812	001	Jan 30, 1998	Aug DISC

TABLET;ORAL

IBUPROFEN

! PERRIGO R AND D 200MG

A077349 001 Jun 21, 2005 Jun CHRS

MOTRIN IB

+ J AND J CONSUMER INC 200MG

N019012 003 Dec 17, 1990 May CHRS

ISOPROPYL ALCOHOLSOLUTION; TOPICAL
ZURAGARD

+! ZUREX PHARMA 70% (10.5ML) N210872 001 Apr 26, 2019 May CMS2

KETOCONAZOLESHAMPOO; TOPICAL
NIZORAL A-D

+! KRAMER 1% N020310 001 Oct 10, 1997 Jan CAHN

KETOTIFEN FUMARATESOLUTION/DROPS; OPHTHALMIC
ZADITOR

! ALCON PHARMS LTD EQ 0.025% BASE A077200 001 Sep 02, 2008 Feb CTNA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

PERRIGO R AND D

5MG

A211983 001 Mar 28, 2019 Jul CMS1

5MG

A211983 001 Mar 26, 2019 Mar NEWA

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

ACCORD HLTHCARE

1.5MG

A207660 001 May 02, 2019 Apr NEWA

ALVOGEN

1.5MG

A202246 001 Jun 05, 2015 Jul CAHN

@ APOTEX INC

1.5MG

A205329 001 Sep 18, 2018 Jan DISC

@ FDN CONSUMER

1.5MG

A200670 001 Jul 12, 2012 Jun DISC

! L PERRIGO CO

0.75MG

A090740 001 Dec 30, 2010 May CAHN

LORATADINE

CAPSULE; ORAL

LORATADINE

@ BIONPHARMA INC

10MG

A202538 001 Dec 21, 2018 Mar DISC

SYRUP; ORAL

LORATADINE

@ PD PARTNERS

1MG/ML

A075565 001 Oct 05, 2004 May CAHN

TABLET; ORAL

LORATADINE

GUARDIAN DRUG

10MG

A207569 001 Mar 12, 2019 Mar CAHN

NEWGEN PHARMS LLC

10MG

A207569 001 Mar 12, 2019 Feb NEWA

TABLET, CHEWABLE; ORAL

LORATADINE

PERRIGO PHARMA INTL

5MG

A210033 001 Jun 12, 2019 May NEWA

SUN PHARM

5MG

A210088 001 Apr 16, 2018 Mar CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

>D> ACTAVIS LABS FL INC 10MG; 240MG

A075706 001 Feb 21, 2003 Aug CAHN

@ HERITAGE PHARMA 5MG; 120MG

A076208 001 Jan 28, 2004 May CAHN

>A> P AND L 10MG; 240MG

A075706 001 Feb 21, 2003 Aug CAHN

MICONAZOLE NITRATE

CREAM; VAGINAL

MICONAZOLE 7

>D> ACTAVIS MID ATLANTIC 2%

A074164 001 Mar 29, 1996 Aug CAHN

>A> P AND L 2%

A074164 001 Mar 29, 1996 Aug CAHN

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

>D> ACTAVIS MID ATLANTIC 2%, 200MG

A074926 001 Apr 16, 1999 Aug CAHN

>A> P AND L 2%, 200MG

A074926 001 Apr 16, 1999 Aug CAHN

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE

>D> ACTAVIS PHARMA 100MG

A073507 001 Nov 19, 1993 Aug CAHN

>A> P AND L 100MG

A073507 001 Nov 19, 1993 Aug CAHN

MINOXIDILAEROSOL, FOAM;TOPICAL
MINOXIDIL (FOR MEN)

>A>	P AND L	5%	A208092	001	Feb 17, 2017	Aug CAHN
>D>	WATSON LABS INC	5%	A208092	001	Feb 17, 2017	Aug CAHN
MINOXIDIL (FOR WOMEN)						
>A>	P AND L	5%	A208092	002	Jul 27, 2017	Aug CAHN
	TARO	5%	A209074	002	Apr 22, 2019	Apr NEWA
>D>	WATSON LABS INC	5%	A208092	002	Jul 27, 2017	Aug CAHN
SOLUTION;TOPICAL						
MINOXIDIL (FOR MEN)						
>D>	ACTAVIS MID ATLANTIC	2%	A074588	001	Apr 05, 1996	Aug CAHN
>A>	P AND L	2%	A074588	001	Apr 05, 1996	Aug CAHN
MINOXIDIL EXTRA STRENGTH (FOR MEN)						
>D>	ACTAVIS MID ATLANTIC	5%	A075518	001	Nov 17, 2000	Aug CAHN
>A>	P AND L	5%	A075518	001	Nov 17, 2000	Aug CAHN

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

@ CATALENT

EQ 200MG BASE

A202807 001 Jan 04, 2019 Jul DISC

TABLET;ORAL

NAPROXEN SODIUM

>A>	YICHANG HUMANWELL	EQ 200MG BASE	A212033	001	Aug 30, 2019	Aug NEWA
-----	-------------------	---------------	---------	-----	--------------	----------

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

>D>	ACTAVIS LABS NY INC	EQ 2MG BASE	A074507	001	Mar 15, 1999	Aug CAHN
>D>		EQ 2MG BASE	A076569	001	Jul 29, 2004	Aug CAHN
>D>		EQ 2MG BASE	A078699	001	Dec 29, 2008	Aug CAHN
>D>		EQ 2MG BASE	A079216	001	Jul 08, 2009	Aug CAHN
>D>		EQ 2MG BASE	A204794	001	May 10, 2016	Aug CAHN
>D>		EQ 4MG BASE	A074707	001	Mar 19, 1999	Aug CAHN
>D>		EQ 4MG BASE	A076568	002	Jul 29, 2004	Aug CAHN
>D>		EQ 4MG BASE	A078697	001	Dec 29, 2008	Aug CAHN
>D>		EQ 4MG BASE	A079038	001	Jul 08, 2009	Aug CAHN
>D>		EQ 4MG BASE	A079219	001	Jul 08, 2009	Aug CAHN
>D>		EQ 4MG BASE	A204833	001	Feb 26, 2016	Aug CAHN
>A>	P AND L	EQ 2MG BASE	A074507	001	Mar 15, 1999	Aug CAHN
>A>		EQ 2MG BASE	A076569	001	Jul 29, 2004	Aug CAHN
>A>		EQ 2MG BASE	A078699	001	Dec 29, 2008	Aug CAHN
>A>		EQ 2MG BASE	A079044	001	Jul 08, 2009	Aug CAHN
>A>		EQ 2MG BASE	A079216	001	Jul 08, 2009	Aug CAHN
>A>		EQ 2MG BASE	A204794	001	May 10, 2016	Aug CAHN
>A>		EQ 4MG BASE	A074707	001	Mar 19, 1999	Aug CAHN
>A>		EQ 4MG BASE	A076568	002	Jul 29, 2004	Aug CAHN
>A>		EQ 4MG BASE	A078697	001	Dec 29, 2008	Aug CAHN
>A>		EQ 4MG BASE	A079038	001	Jul 08, 2009	Aug CAHN
>A>		EQ 4MG BASE	A079219	001	Jul 08, 2009	Aug CAHN
>A>		EQ 4MG BASE	A204833	001	Feb 26, 2016	Aug CAHN
>D>	WATSON LABS	EQ 2MG BASE	A079044	001	Jul 08, 2009	Aug CAHN

TROCHE/LOZENGE;ORAL

NICOTINE POLACRILEX

>A>	@ P AND L	EQ 2MG BASE	A209206	001	Jun 26, 2018	Aug CAHN
>A>	@	EQ 2MG BASE	A209519	001	Jul 02, 2018	Aug CAHN
>A>		EQ 2MG BASE	A210712	001	Sep 06, 2019	Aug NEWA
		EQ 2MG BASE	A212056	001	Jul 26, 2019	Jul CAHN
>A>	@	EQ 4MG BASE	A209206	002	Jun 26, 2018	Aug CAHN
>A>	@	EQ 4MG BASE	A209519	002	Jul 02, 2018	Aug CAHN
>A>		EQ 4MG BASE	A210712	002	Sep 06, 2019	Aug NEWA
		EQ 4MG BASE	A212056	002	Jul 26, 2019	Jul CAHN
	PLD ACQUISITIONS	EQ 2MG BASE	A207868	001	Feb 07, 2019	Feb NEWA
		EQ 4MG BASE	A207868	002	Feb 07, 2019	Feb NEWA
	TEVA PHARMS USA INC	EQ 2MG BASE	A212056	001	Jul 26, 2019	Jul NEWA
		EQ 4MG BASE	A212056	002	Jul 26, 2019	Jul NEWA
>D>	@ WATSON LABS INC	EQ 2MG BASE	A209206	001	Jun 26, 2018	Aug CAHN
	@	EQ 2MG BASE	A209206	001	Jun 26, 2018	Feb DISC
>D>	@	EQ 4MG BASE	A209206	002	Jun 26, 2018	Aug CAHN
	@	EQ 4MG BASE	A209206	002	Jun 26, 2018	Feb DISC
>D>	@ WATSON LABS TEVA	EQ 2MG BASE	A209519	001	Jul 02, 2018	Aug CAHN
	@	EQ 2MG BASE	A209519	001	Jul 02, 2018	Feb DISC

TROCHE/LOZENGE;ORAL
NICOTINE POLACRILEX

>D>	@	EQ 4MG BASE	A209519	002	Jul 02, 2018	Aug CAHN
	@	EQ 4MG BASE	A209519	002	Jul 02, 2018	Feb DISC

OMEPRAZOLETABLET, DELAYED RELEASE;ORAL
OMEPRAZOLE

>D>	APOTEX INC	20MG	A210070	001	Feb 11, 2019	Aug DISC
>A>	@	20MG	A210070	001	Feb 11, 2019	Aug DISC
		20MG	A210070	001	Feb 11, 2019	Apr CTEC

POLYETHYLENE GLYCOL 3350FOR SOLUTION;ORAL
GLYCOLAX

@	LANNETT CO INC	17GM/PACKET	A090600	001	Oct 06, 2009	Jun DISC
@		17GM/SCOOPFUL	A090600	002	Oct 06, 2009	Jun DISC

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

	STRIDES PHARMA	EQ 75MG BASE	A209160	001	Mar 05, 2018	Apr CAHN
		EQ 150MG BASE	A209161	001	Feb 22, 2018	Apr CAHN
>A>	UNIQUE PHARM LABS	EQ 75MG BASE	A210250	001	Aug 30, 2019	Aug NEWA
>A>		EQ 150MG BASE	A210228	001	Aug 30, 2019	Aug NEWA

SODIUM FLUORIDE; TRICLOSAN

PASTE;DENTAL

COLGATE TOTAL

+	@	COLGATE PALMOLIVE	0.24%;0.3%	N020231	001	Jul 11, 1997	Mar DISC
---	---	-------------------	------------	---------	-----	--------------	----------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 08 AUGUST 2019

NO AUGUST 2019 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO AUGUST 2019 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE - ABIRATERONE ACETATE</u>						
A 208327 001					PC	Apr 29, 2019
<u>ABIRATERONE ACETATE - YONSA</u>						
N 210308 001	10292990	May 20, 2034	U-2535			
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	10167291	Jul 01, 2036	DP U-2145			
	10272083	Jan 21, 2035	U-2519			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 002	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 10, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 003	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 10, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	10034867	Jul 07, 2020	DP U-2513			
	10034867	Jul 07, 2020	DP U-2514			
	10085974	Mar 13, 2029	DP U-2513			
	7078412	Jul 07, 2020	DS DP U-2513			
	9056100	Jul 07, 2020	DP U-2513			
	9333195	Jul 07, 2020	DP U-2513			
	RE46417	Feb 10, 2025	DS DP U-2513			
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595 001	10034867	Jul 07, 2020	DP U-2513		NC	Mar 29, 2022
	10034867	Jul 07, 2020	DP U-2514			
	10085974	Mar 13, 2029	DP U-2513			
	6681768	Aug 07, 2022	DP			
	7078412	Jul 07, 2020	DS DP U-2513			
	7750023	Jul 07, 2020	DP U-2513			
	8051851	Apr 22, 2027	DP			
	8129405	Jul 07, 2020	DP U-2513			
	9056100	Jul 07, 2020	DP U-2513			
	9333195	Jul 07, 2020	DP U-2513			
	RE46417	Feb 10, 2025	DS DP U-2513			
<u>ACYCLOVIR - AVACLYR</u>						
N 202408 001					ODE-235	Mar 29, 2026
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001					ODE-230	Jan 12, 2025
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002					ODE-230	Jan 12, 2025
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003					ODE-230	Jan 12, 2025
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	10124131	May 18, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636 002	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001	10183012	Nov 26, 2028	U-2104			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 002	10183012	Nov 26, 2028	U-2104			
<u>ALPELISIB - PIORAY</u>						
N 212526 001	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - PIORAY</u>						
N 212526 002	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - PIORAY</u>						
N 212526 003	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
<u>AMIFAMPRIDINE - RUZURGI</u>						
N 209321 001					ODE-244	May 06, 2026
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001	10251900	May 15, 2035	U-2414		ODE-214 GAIN	Sep 28, 2025 Sep 28, 2030
<u>AMINOCAPROIC ACID - AMINOCAPROIC ACID</u>						
A 212780 001					>A> CGT	Feb 26, 2020
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	10357567	Jan 12, 2038	U-804			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 001	>A> 10350171	Jun 14, 2038	DP			
	>A> 9662315	May 22, 2029	DP U-2410			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 002	>A> 10350171	Jun 14, 2038	DP			
	>A> 9662315	May 22, 2029	DP U-2410			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 003	>A> 10350171	Jun 14, 2038	DP			
	>A> 9662315	May 22, 2029	DP U-2410			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 001	10130580	Apr 19, 2024	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 002	10130580	Apr 19, 2024	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 003	10130580	Apr 19, 2024	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 004	10130580	Apr 19, 2024	DP			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	10335451	Dec 16, 2029	U-2581			
	9572856	Nov 20, 2030	U-2221			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	10335451	Dec 16, 2029	U-2581			
	9572856	Nov 20, 2030	U-2221			
<u>APREMILAST - OTEZLA</u>						
N 205437 001					I-803	Jul 19, 2022
				>A>	ODE-248	Jul 19, 2026
<u>APREMILAST - OTEZLA</u>						
N 205437 002					I-803	Jul 19, 2022
				>A>	ODE-248	Jul 19, 2026
<u>APREMILAST - OTEZLA</u>						
N 205437 003					I-803	Jul 19, 2022
				>A>	ODE-248	Jul 19, 2026
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	10226458	Nov 07, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	10226458	Nov 07, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	10226458	Nov 07, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
<u>ARIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	10226458	Nov 07, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238 001	8338429	Jun 30, 2023	U-2577		I-802	Jun 26, 2022
	8765764	Jan 15, 2023	U-2314		ODE-246	Jun 26, 2026
	8765764	Jan 15, 2023	U-2578			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Feb 24, 2022	DS DP U-2244			
	7112592	Feb 24, 2022	DS DP U-2508			
	7112592	Feb 24, 2022	DS DP U-282			
	8178554	Jul 24, 2021	DS DP U-2245			
	8178554	Jul 24, 2021	DS DP U-2509			
	8178554	Jul 24, 2021	DS DP U-282			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	10322085	Oct 24, 2023	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001 >A>	9387249	Jul 01, 2031	U-3			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002 >A>	9387249	Jul 01, 2031	U-3			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001					NCE	Oct 24, 2023
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002					NCE	Oct 24, 2023
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	6479535	May 06, 2024	DP U-594			
	6479535	May 06, 2024	DP U-904			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813 001	10188811	Oct 21, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813 002	10188811	Oct 21, 2031	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001				>A> NPP		Aug 09, 2022
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE</u>						
A 205128 001					PC	Aug 18, 2019
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	10220049	Jun 03, 2029	DP U-916			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	10220049	Jun 03, 2029	DP U-916			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	10179137	Aug 31, 2030	DP U-1858			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - TACLONEX</u>						
N 022185 001	6753013	Jan 27, 2020	DP U-1761		NPP	Jul 25, 2022
	6753013	Jan 27, 2020	DP U-193		PED	Jan 25, 2023
	6753013	Jan 27, 2020	DP U-88			
>A>	6787529	Jan 27, 2020	DP U-1761			
>A>	6787529	Jan 27, 2020	DP U-193			
>A>	6787529	Jan 27, 2020	DP U-88			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589 001	10130640	Jun 10, 2031	DP		NPP	Jul 30, 2022
	10130640*PED	Dec 10, 2031			PED	Jan 30, 2023
>A>	6753013	Jan 27, 2020	DP U-1761			
	9119781	Jun 10, 2031	DP U-1761			
	9119781*PED	Dec 10, 2031				
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001 >A>	10385067	Jun 19, 2035	U-257		NPP	Jun 18, 2022
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003	7417148	Dec 11, 2025	U-1283			
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	10286034	Nov 05, 2033	U-2568		NCE	Jun 21, 2024
	6579968	Jun 28, 2020	DS DP			
	6794489	Jun 28, 2020	DS DP			
	9352013	Nov 05, 2033	U-2568			
	9700592	Nov 05, 2033	U-2568			
<u>BREXANOLONE - ZULRESSO</u>						
N 211371 001	10117951	Mar 13, 2029	DP		NCE	Jun 17, 2024
	10251894	Nov 27, 2033	U-2552			
	10322139	Jan 23, 2033	DP			
	7635773	Mar 13, 2029	DP			
	8410077	Mar 13, 2029	DP			
	9200088	Mar 13, 2029	DP			
	9750822	Mar 13, 2029	DP			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Apr 12, 2026	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001 >A>	10385078	Nov 10, 2035	DS DP U-1927			
	9012462	Jul 31, 2030	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002 >A>	10385078	Nov 10, 2035	DS DP U-1927			
	9012462	Jul 31, 2030	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	>A> 10385078	Nov 10, 2035	DS DP U-1927			
	9012462	Jul 31, 2030	DS			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	10307368	Jul 10, 2021	DP			
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	10201517	Jun 13, 2031	DP			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	10307375	Sep 07, 2031	DP			
<u>BUDESONIDE - ORTIKOS</u>						
N 211929 001	10172802	Sep 09, 2036	U-2554			
	9707182	Sep 09, 2036	DP U-2554			
<u>BUDESONIDE - ORTIKOS</u>						
N 211929 002	10172802	Sep 09, 2036	U-2554			
	9707182	Sep 09, 2036	DP U-2554			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	>A> 10166247	Jan 29, 2023	DP U-2001			
	>A> 10166247	Jan 29, 2023	DP U-2002			
	>A> 10166247	Jan 29, 2023	DP U-2122			
	>A> 10166247*PED	Jul 29, 2023				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	>A> 10166247	Jan 29, 2023	DP U-2001			
	>A> 10166247	Jan 29, 2023	DP U-2002			
	>A> 10166247	Jan 29, 2023	DP U-2122			
	>A> 10166247*PED	Jul 29, 2023				
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	10198218	Jun 06, 2031	U-2489			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	10198218	Jun 06, 2031	U-2489			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	10285910	Oct 11, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	10285910	Oct 11, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	10285910	Oct 11, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	10285910	Oct 11, 2022	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	10231964	Jul 02, 2034	U-1583			
	10307376	Nov 08, 2027	U-1585			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	8927592	Oct 27, 2030	U-1630			
	8927592*PED	Apr 27, 2031				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOZANTINIB S-MALATE - CABOMETIX</u>						
N 208692 001	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETIX</u>						
N 208692 002	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETIX</u>						
N 208692 003	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	10213442	Feb 02, 2027	DP			
	10300078	Mar 14, 2034	DP			
	10357502	Mar 14, 2034	DP			
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 210906 001	10130646	Jul 25, 2037	DP			
	10342813	Jul 25, 2037	DP			
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 210906 002	10130646	Jul 25, 2037	DP			
	10342813	Jul 25, 2037	DP			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10195159	May 07, 2022	DS			
<u>CARBOPROST TROMETHAMINE - CARBOPROST TROMETHAMINE</u>						
A 211941 001					CGT	Dec 29, 2019
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	7737142	Mar 27, 2027	DS DP U-2543			
	7737142	Mar 27, 2027	DS DP U-2544			
	7737142	Mar 27, 2027	DS DP U-2545			
	RE47350	Jul 16, 2029	U-1750			
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	7737142	Mar 27, 2027	DS DP U-2543			
	7737142	Mar 27, 2027	DS DP U-2544			
	7737142	Mar 27, 2027	DS DP U-2545			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	7737142	Mar 27, 2027	DS DP U-2543			
	7737142	Mar 27, 2027	DS DP U-2544			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	7737142	Mar 27, 2027	DS DP U-2543			
	7737142	Mar 27, 2027	DS DP U-2544			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	10028963	Sep 07, 2032	U-2565			
	10028963	Sep 07, 2032	U-2566			
	>A> 10376496	Sep 09, 2034	U-2610			
	>A> 10376496	Sep 09, 2034	U-2611			
	9724353	Sep 07, 2032	U-2565			
	9724353	Sep 07, 2032	U-2566			
<u>CERITINIB - ZYKADIA</u>						
N 211225 001	7153964	Feb 26, 2021	DS DP		NCE	Apr 29, 2019
	7893074	Apr 25, 2026	DS DP			
	7964592	Jan 13, 2027	DS DP			
	8039479	Jun 29, 2030	DS DP			
	8188276	Jan 31, 2023	DS DP			
	8377921	Nov 20, 2027	U-1179			
	8399450	Nov 20, 2027	DS DP			
	8703787	Feb 02, 2032	U-1179			
	8835430	Jan 31, 2023	DS DP			
	9018204	Jan 31, 2023	DS DP			
	9309229	Jan 18, 2032	DS DP			
	9416112	Jan 31, 2023	DS DP			
<u>CHLOROPROCAINE HYDROCHLORIDE - CLOROTEKAL</u>						
N 208791 001	>A> 8969412	Sep 05, 2026	DP U-2609			
	>A> 9504666	Dec 11, 2033	DP			
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S ADVIL ALLERGY SINUS</u>						
N 021587 001	10238640	May 25, 2024	DP			
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO</u>						
N 212819 001	8487093	Nov 19, 2029	DS DP U-2586			
	8487093	Nov 19, 2029	DS DP U-2587			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589 001	9827231	Jun 26, 2034	DP U-2162			
<u>CLADRIBINE - MAVENCLAD</u>						
N 022561 001	7713947	Oct 16, 2026	U-2520		NP	Mar 29, 2022
	7888328	Apr 11, 2024	DP U-2521			
	8377903	May 31, 2026	U-2522			
	8785415	Apr 11, 2024	DP U-2523			
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	10231961	Feb 07, 2037	DP			
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	10226423	Dec 20, 2037	DP			
	9907751	Nov 22, 2036	DP			
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 210895 001	7229613	Apr 17, 2022	U-2516			
<u>CROFELEMER - MYTESI</u>						
N 202292 001	7341744	Jun 02, 2022	DP U-1319			
	9585868	Oct 31, 2031	U-1319			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	10328037	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	10328037	Aug 16, 2036	U-1399			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10166184	Oct 15, 2032	DP U-2341			
<u>DALFAMPRIDINE - DALFAMPRIDINE</u>						
A 206863 001					PC	Mar 09, 2019
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 001					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 002					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 003					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 004					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 005					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 006					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 007					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 008					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 009					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 010					NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287 011					NPP	May 16, 2022
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001					M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002					M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 001	6414126	Oct 04, 2020	DS DP U-493		NP	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 002	6414126	Oct 04, 2020	DS DP U-493		NP	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 002	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 003	6414126	Oct 04, 2020	DS DP U-493		NP	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 004	6414126	Oct 04, 2020	DS DP U-493		NP	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001	6414126	Oct 04, 2020	DS DP U-493		I-804	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-1976			
	6936590	Oct 04, 2020	U-1977			
	6936590	Oct 04, 2020	U-493			
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8501698	Jun 20, 2027	DP U-493			
	9198925	Oct 04, 2020	U-1976			
	9198925	Oct 04, 2020	U-1977			
	9198925	Oct 04, 2020	U-493			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 002	6414126	Oct 04, 2020	DS DP U-493		NS	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	RE44186	Jul 31, 2023	DS DP U-493			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
A 212667	001				CGT	Jan 12, 2020
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099	001	>A> 10010530	Jan 28, 2036	DS	NCE	Jul 30, 2024
		>A> 10383853	Jan 28, 2036	DS		
		>A> 8975254	Oct 27, 2030	DS DP U-2605		
		>A> 9657003	Oct 27, 2030	DS DP U-2605		
<u>DARUNAVIR - PREZISTA</u>						
N 021976	002	9889115	Jun 23, 2019	U-1305		
		9889115*PED	Dec 23, 2019			
<u>DARUNAVIR - PREZISTA</u>						
N 021976	004	9889115	Jun 23, 2019	U-1305		
		9889115*PED	Dec 23, 2019			
<u>DARUNAVIR - PREZISTA</u>						
N 021976	005	9889115	Jun 23, 2019	U-1305		
		9889115*PED	Dec 23, 2019			
<u>DARUNAVIR - PREZISTA</u>						
N 021976	006	9889115	Jun 23, 2019	U-1305		
		9889115*PED	Dec 23, 2019			
<u>DARUNAVIR - PREZISTA</u>						
N 202895	001	9889115	Jun 23, 2019	U-1305		
		9889115*PED	Dec 23, 2019			
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619	001	10201542	Oct 18, 2033	DP U-1753		
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624	001	10201541	May 17, 2032	DP		
		10201584	May 17, 2032	U-1889		
<u>DASATINIB - SPRYCEL</u>						
N 021986	001				ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986	002				ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986	003				ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986	004				ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986	005				ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986	006				ODE-225 PED	Dec 21, 2025 Jun 21, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560	001				PC	Apr 05, 2019
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560	002				PC	Apr 05, 2019
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560	003				PC	Apr 05, 2019
<u>DEFERASIROX - EXJADE</u>						
N 021882	001				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - EXJADE</u>						
N 021882	002				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - EXJADE</u>						
N 021882	003				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU</u>						
N 206910	001				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU</u>						
N 206910	002				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU</u>						
N 206910	003				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	001				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	002				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	003				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030	002	7049328	Jun 28, 2021	U-735		
		8703156	Oct 29, 2029	DP U-735		
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517	001	10307459	May 07, 2023	DP		
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517	002	10307459	May 07, 2023	DP		
<u>DESONIDE - VERDESO</u>						
N 021978	001	8460641	Aug 13, 2027	DP U-1412		
<u>DEXAMETHASONE - DEXTENZA</u>						
N 208742	001	8409606	May 14, 2030	DP	I-800	Jun 20, 2022
		8563027	Feb 12, 2030	U-2487	NP	Nov 30, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXAMETHASONE - DEXTENZA</u>						
N 208742 001	9254267	Sep 11, 2024	DP			
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001	10159683	May 23, 2034	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
A 208129 001					PC	Nov 30, 2019
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001	8129385	Oct 05, 2027	DS DP		NC	Apr 08, 2022
	9242986	Dec 08, 2029	DS DP			
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	10238620	May 18, 2027	U-620			
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	10238620	May 18, 2027	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	10058564	Apr 05, 2022	U-1063			
<u>DRONABINOL - SYNDROS</u>						
N 205525 001	10265293	Aug 06, 2028	DS DP			
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	>A> 10179140	Jun 28, 2031	U-2553		NP	May 23, 2022
	9603860	Jun 28, 2031	U-2553			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 001	9839626	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002	9839626	Apr 13, 2037	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003	9839626	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	9839626	Apr 13, 2037	DP			
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001					>A> M-243	Aug 09, 2022
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002					>A> M-243	Aug 09, 2022
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003					>A> M-243	Aug 09, 2022
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-2451			
	8052993	Aug 01, 2027	DP U-930			
	8052993*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-2451			
	8052994	Aug 01, 2027	DP U-930			
	8052994*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-2451			
	8062665	Aug 01, 2027	DP U-930			
	8062665*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293*PED	Nov 21, 2023				
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-2451			
	8071129	Aug 01, 2027	DP U-930			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 001	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1736			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1736			
	7332481*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1736			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 24, 2023				
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 002	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1736			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1736			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1736			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 21, 2023				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	10188632	Mar 14, 2033	DP			
	10213415	Mar 14, 2025	DS U-2152			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	10188632	Mar 14, 2033	DP			
	10213415	Mar 14, 2025	DS U-2152			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	10258637	Apr 03, 2034	U-2290			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 001	10294215	Jan 07, 2033	DP U-2087			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 002	10294215	Jan 07, 2033	DP U-2087			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001				>A> NCE		Aug 15, 2024
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002				>A> NCE		Aug 15, 2024
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 001	8796245	Aug 07, 2029	U-2380			
	8906887	Dec 28, 2030	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			
<u>ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE</u>						
A 091002 001					PC	Nov 05, 2019
<u>ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE</u>						
A 091002 002					PC	Nov 05, 2019
<u>ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE</u>						
A 091002 003					PC	Nov 05, 2019
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	8785500	Jul 09, 2031	U-2502		NCE*	Mar 05, 2024
	9592207	Mar 20, 2027	U-2502			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10258630	Dec 20, 2033	U-2316			
	10258630	Dec 20, 2033	U-2317			
	>A> 10398708	Dec 20, 2033	U-2317			
	>A> 10398708	Dec 20, 2033	U-2614			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10258630	Dec 20, 2033	U-2316			
	10258630	Dec 20, 2033	U-2317			
	>A> 10398708	Dec 20, 2033	U-2317			
	>A> 10398708	Dec 20, 2033	U-2614			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	10206932	Nov 21, 2032	U-2439			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	10344765	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	10344765	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	10344765	Jun 27, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	>A> 10337003	Mar 14, 2034	U-1918			
	>A> 10364431	Mar 14, 2034	U-1918			
	>A> 10364431	Mar 14, 2034	U-1919			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	>A> 10337003	Mar 14, 2034	U-1918			
	>A> 10364431	Mar 14, 2034	U-1918			
	>A> 10364431	Mar 14, 2034	U-1919			
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	>A> 6414126	Oct 04, 2020	U-2588			
	>A> 6515117	Oct 04, 2020	U-2588			
	>A> 6872700	Jan 14, 2020	U-2589			
	>A> 6872700	Jan 14, 2020	U-2590			
	>A> 6872700	Jan 14, 2020	U-2591			
	>A> 6872700	Jan 14, 2020	U-654			
	>A> 6936590	Oct 04, 2020	U-2588			
	>A> 7456254	Jun 30, 2025	DP U-1223			
	>A> 7456254	Jun 30, 2025	DP U-2588			
	>A> 7456254	Jun 30, 2025	DP U-2589			
	>A> 7456254	Jun 30, 2025	DP U-2590			
	>A> 7456254	Jun 30, 2025	DP U-2592			
	>A> 7612176	Apr 13, 2025	DP U-1223			
	>A> 7612176	Apr 13, 2025	DP U-2589			
	>A> 7612176	Apr 13, 2025	DP U-2590			
	>A> 7612176	Apr 13, 2025	DP U-2592			
	>A> 8329648	Aug 18, 2026	U-1313			
	>A> 8329648	Aug 18, 2026	U-2154			
	>A> 8329648	Aug 18, 2026	U-2155			
	>A> 8329648	Aug 18, 2026	U-2156			
	>A> 8329648	Aug 18, 2026	U-2588			
	>A> 8329648	Aug 18, 2026	U-2589			
	>A> 8329648	Aug 18, 2026	U-2590			
	>A> 8329648	Aug 18, 2026	U-2593			
	>A> 8329648	Aug 18, 2026	U-2594			
	>A> 8329648	Aug 18, 2026	U-2595			
	>A> 8329648	Aug 18, 2026	U-2596			
	>A> 8361972	Mar 21, 2028	U-2588			
	>A> 8431685	Apr 13, 2025	DP U-2589			
	>A> 8431685	Apr 13, 2025	DP U-2590			
	>A> 8431685	Apr 13, 2025	DP U-2597			
	>A> 8431685	Apr 13, 2025	DP U-2598			
	>A> 8431685	Apr 13, 2025	DP U-412			
	>A> 8461105	Apr 13, 2025	DP U-2589			
	>A> 8461105	Apr 13, 2025	DP U-2590			
	>A> 8461105	Apr 13, 2025	DP U-2597			
	>A> 8461105	Apr 13, 2025	DP U-2598			
	>A> 8461105	Apr 13, 2025	DP U-412			
	>A> 8501698	Jun 20, 2027	U-2588			
	>A> 8895033	Oct 04, 2030	DP U-1313			
	>A> 8895033	Oct 04, 2030	DP U-2157			
	>A> 8895033	Oct 04, 2030	DP U-2158			
	>A> 8895033	Oct 04, 2030	DP U-2589			
	>A> 8895033	Oct 04, 2030	DP U-2590			
	>A> 8895033	Oct 04, 2030	DP U-2597			
	>A> 8895033	Oct 04, 2030	DP U-2600			
	>A> 8895033	Oct 04, 2030	DP U-2601			
	>A> 8895033	Oct 04, 2030	DP U-2602			
	>A> 8906851	Aug 18, 2026	U-1313			
	>A> 8906851	Aug 18, 2026	U-2589			
	>A> 8906851	Aug 18, 2026	U-2590			
	>A> 8906851	Aug 18, 2026	U-2593			
	>A> 8906851	Aug 18, 2026	U-2597			
	>A> 9198925	Oct 04, 2020	U-2588			
	>A> 9238076	Apr 15, 2024	DP U-2589			
	>A> 9238076	Apr 15, 2024	DP U-2590			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	>A> 9238076	Apr 15, 2024	DP U-2597			
	>A> 9238076	Apr 15, 2024	DP U-2599			
	>A> 9238076	Apr 15, 2024	DP U-412			
	>A> 9884092	Aug 18, 2026	U-1313			
	>A> 9884092	Aug 18, 2026	U-2154			
	>A> 9884092	Aug 18, 2026	U-2155			
	>A> 9884092	Aug 18, 2026	U-2156			
	>A> 9884092	Aug 18, 2026	U-2589			
	>A> 9884092	Aug 18, 2026	U-2590			
	>A> 9884092	Aug 18, 2026	U-2593			
	>A> 9884092	Aug 18, 2026	U-2594			
	>A> 9884092	Aug 18, 2026	U-2595			
	>A> 9884092	Aug 18, 2026	U-2596			
	>A> 9884092	Aug 18, 2026	U-2597			
<u>FEDRATINIB HYDROCHLORIDE - INREBIC</u>						
N 212327 001	>A> 10391094	May 29, 2032	DP U-2607		>A> NCE	Aug 16, 2024
	>A> 7528143	Dec 16, 2026	DS			
	>A> 7825246	Dec 16, 2026	DS			
	>A> 8138199	Jun 30, 2028	U-2607			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7754702	Feb 15, 2028	DP U-1432			
	7754702	Feb 15, 2028	DP U-2555			
	7754702	Feb 15, 2028	DP U-2556			
	7754702	Feb 15, 2028	DP U-2557			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	10300039	Jul 21, 2030	U-2549		I-790	Nov 06, 2020
	5753706	Feb 03, 2020	DP U-1577			
<u>FERRIC MALTOL - ACCRUFER</u>						
N 212320 001	>A> 10179120	Jan 06, 2035	U-2603		NCE	Jul 25, 2024
	>A> 9248148	Mar 29, 2031	U-2603			
	>A> 9802973	Oct 23, 2035	DS DP U-2603			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 208551 001	7816404	Apr 17, 2029	U-1656			
	7857977	Sep 08, 2027	U-1656			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	8933097	Aug 02, 2030	DP			
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 001	>A> 9187405	Jun 25, 2027	U-1086			
	>A> 9187405	Jun 25, 2027	U-2612			
	>A> 9187405*PED	Dec 25, 2027				
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589 001	9566260	Jul 11, 2025	DP U-2366			
	9629821	Jul 11, 2025	DP U-2367			
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589 002	10350186	Nov 05, 2024	U-2585			
	9566260	Jul 11, 2025	DP U-2366			
	9629821	Jul 11, 2025	DP U-2367			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	10195375	Feb 14, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	10179216	Jul 08, 2033	DP U-2133			
	10252010	Feb 07, 2031	DP			
	10300229	Jul 07, 2035	DP U-2133			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9415008	Oct 06, 2034	DP U-645			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
	9987229	Sep 01, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
	9987229	Sep 01, 2024	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	8324266	May 28, 2030	U-2546			
	8703806	May 28, 2030	U-2546			
	8808713	May 28, 2030	DP U-2546			
	8815258	Mar 17, 2031	U-2546			
	9415009	May 28, 2030	U-2546			
	9463161	May 28, 2030	DP U-2546			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 001	7067502	May 21, 2020	DP U-1068		M-214	Dec 20, 2020
	7067502*PED	Nov 21, 2020			PED	Jun 20, 2021
	7566705	May 21, 2020	DP U-1068			
	7566705*PED	Nov 21, 2020				
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 002	7067502	May 21, 2020	DP U-1068		M-214	Dec 20, 2020
	7067502*PED	Nov 21, 2020			PED	Jun 20, 2021
	7566705	May 21, 2020	DP U-1068			
	7566705*PED	Nov 21, 2020				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	10208073	May 23, 2032	U-2301			
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122	Jan 09, 2021	U-1826			
	6774122	Jan 09, 2021	U-2108			
	6774122	Jan 09, 2021	U-2163			
	6774122	Jan 09, 2021	U-2504			
	6774122	Jan 09, 2021	U-596			
	6774122*PED	Jul 09, 2021				
	7456160	Jan 09, 2021	U-1826			
	7456160	Jan 09, 2021	U-2108			
	7456160	Jan 09, 2021	U-2163			
	7456160	Jan 09, 2021	U-2504			
	7456160	Jan 09, 2021	U-596			
	7456160*PED	Jul 09, 2021				
	8329680	Jan 09, 2021	U-1826			
	8329680	Jan 09, 2021	U-2108			
	8329680	Jan 09, 2021	U-2163			
	8329680	Jan 09, 2021	U-2504			
	8329680	Jan 09, 2021	U-596			
	8329680*PED	Jul 09, 2021				
	8466139	Jan 09, 2021	U-1826			
	8466139	Jan 09, 2021	U-2108			
	8466139	Jan 09, 2021	U-2163			
	8466139	Jan 09, 2021	U-2504			
	8466139	Jan 09, 2021	U-596			
	8466139*PED	Jul 09, 2021				
<u>FULVESTRANT - FULVESTRANT</u>						
N 210326 001	10188663	Feb 14, 2034	DP U-2540			
	9271990	May 17, 2034	DP U-2540			
	9833459	Feb 14, 2034	DP U-2540			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 001	6818787	Apr 06, 2025	DS DP			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 002	6818787	Apr 06, 2025	DS DP			
<u>GADOBUTROL - GADAVIST</u>						
N 201277 001					I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 003					I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 004					I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 005					I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006					I-801	Jul 12, 2022
<u>GALLIUM DOTATOC GA-68 - GALLIUM DOTATOC GA 68</u>						
N 210828 001				>A> NCE		Aug 21, 2024
				>A> W		Aug 21, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349 001					NCE	Nov 28, 2023
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	10028937	Jun 10, 2030	U-2141		NPP	Apr 30, 2022
	10028937	Jun 10, 2030	U-2532		ODE-232	Apr 30, 2026
	10039754	Jun 10, 2030	U-2141		ODE-233	Apr 30, 2026
	10039754	Jun 10, 2030	U-2532			
	10286029	Mar 14, 2034	U-2532			
	8648037	Jan 19, 2032	DS DP U-2141			
	8648037	Jan 19, 2032	DS DP U-2532			
	9586978	Jun 10, 2030	U-2141			
	9586978	Jun 10, 2030	U-2532			
<u>GLUCAGON - BAOSIMI</u>						
N 210134 001	>A> 10213487	Feb 16, 2036	DP U-2604		NP	Jul 24, 2022
	>A> 6938798	Jan 03, 2022	DP			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	10183002	Sep 22, 2030	U-1816			
	10183003	Sep 22, 2030	U-1816			
	10183004	Sep 22, 2030	U-1816			
	10183005	Sep 22, 2030	U-1816			
	10183006	Sep 22, 2030	U-1816			
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001	>A> 10376661	Sep 14, 2035	DP			
<u>GRANISETRON - SUSTOL</u>						
N 022445 001	10357570	Sep 28, 2024	U-2253			
<u>HALOBETASOL PROPIONATE - BRYHALI</u>						
N 209355 001	6517847	Aug 03, 2020	DP			
	8809307	Nov 02, 2031	DP			
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354 001	10251895	Jun 06, 2036	DP		NP	Apr 25, 2022
	6517847	Aug 03, 2020	DP			
	8809307	Nov 02, 2031	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	10322120	Jul 25, 2033	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	10322120	Jul 25, 2033	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	10322120	Jul 25, 2033	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	10322120	Jul 25, 2033	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	10322120	Jul 25, 2033	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	10322120	Jul 25, 2033	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 001	10369109	Jun 16, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 002	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 003	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 004	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 005	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 006	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 007	10369109	Jun 16, 2023	DP			
<u>HYDROCORTISONE VALERATE - HYDROCORTISONE VALERATE</u>						
A 211750 001					CGT	Jul 16, 2019
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10294231	Jun 03, 2033	DP		M-236	Jan 25, 2022
	10294232	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10294231	Jun 03, 2033	DP		M-236	Jan 25, 2022
	10294232	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022
<u>IBUPROFEN - CHILDREN'S ADVIL-FLAVORED</u>						
N 020589 002	10238640	May 25, 2024	DP			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 003	>A> 9072661	Mar 16, 2032	U-2264			
	>A> 9072710	Mar 16, 2032	U-2266			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	10238644	Dec 11, 2029	U-68			
	10238645	Aug 18, 2029	U-1455			
	10238645	Aug 18, 2029	U-172			
<u>INSULIN ASPART - FIASP FLEXTOUCH</u>						
N 208751 002	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
	RE46363	Aug 03, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL</u>						
N 020986 002	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	10220155	Jul 17, 2026	DP			
	>A> 10357616	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	10220155	Jul 17, 2026	DP			
	>A> 10357616	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	10220155	Jul 17, 2026	DP			
	>A> 10357616	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 003	>A> 7615532	Jun 28, 2029	DS DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	10220155	Jul 17, 2026	DP		>A> M-242	Aug 08, 2022
	10357616	Jan 20, 2026	DP			
	6268343	Aug 22, 2022	DS DP			
	6268343*PED	Feb 22, 2023				
	6899699	Jan 02, 2022	DP			
	7615532	Jun 28, 2029	DS DP			
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DS DP			
	8846618*PED	Dec 27, 2022				
	8920383	Jul 17, 2026	DP			
	8937042	May 05, 2029	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	RE46363	Aug 03, 2026	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001 >A>	10029011	Nov 11, 2030	DP			
	9011391	Mar 26, 2024		U-1923		
	9011391	Mar 26, 2024		U-2496		
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	10201672	Aug 02, 2030	DP			
	10342938	Jun 12, 2029	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	10201672	Aug 02, 2030	DP			
	10342938	Jun 12, 2029	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	10201672	Aug 02, 2030	DP			
	10342938	Jun 12, 2029	DP			
<u>ISOPROPYL ALCOHOL - ZURAGARD</u>						
N 210872 001					NP	Apr 26, 2022
<u>IVABRADINE - CORLANOR</u>						
N 209964 001	7361649	Feb 22, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Feb 22, 2026	DS DP U-1694		NP	Apr 22, 2022
	7867996	Feb 22, 2026	DS DP U-1694		ODE-234	Apr 22, 2026
	7879842	Feb 22, 2026	DS DP U-1694		PED	Oct 15, 2020
					PED	Oct 22, 2022
					PED	Oct 22, 2026
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	7361649	Feb 22, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361649*PED	Aug 22, 2026			PED	Oct 15, 2020
	7361650	Feb 22, 2026	DS DP U-1694			
	7361650*PED	Aug 22, 2026				
	7867996	Feb 22, 2026	DS DP U-1694			
	7867996*PED	Aug 22, 2026				
	7879842	Feb 22, 2026	DS DP U-1694			
	7879842*PED	Aug 22, 2026				
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	7361649	Feb 22, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361649*PED	Aug 22, 2026			PED	Oct 15, 2020
	7361650	Feb 22, 2026	DS DP U-1694			
	7361650*PED	Aug 22, 2026				
	7867996	Feb 22, 2026	DS DP U-1694			
	7867996*PED	Aug 22, 2026				
	7879842	Feb 22, 2026	DS DP U-1694			
	7879842*PED	Aug 22, 2026				
<u>IVACAFTOR - KALYDECO</u>						
N 203188 002					NPP	Jul 31, 2020
					ODE-186	Feb 21, 2021
					ODE-187	Dec 29, 2021
					ODE-189	Jul 31, 2024
					ODE-190	May 17, 2024
					ODE-199	Aug 15, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFITOR - KALYDECO</u>						
N 203188 002					NPP ODE-186 ODE-187 ODE-189 ODE-190 ODE-199	Jul 31, 2020 Feb 21, 2021 Dec 29, 2021 Jul 31, 2024 May 17, 2024 Aug 15, 2025
<u>IVACAFITOR - KALYDECO</u>						
N 207925 001	10272046	Feb 27, 2033	DP U-2531		NPP	Apr 29, 2022
	8324242	Aug 05, 2027	U-1311		ODE-236	Apr 29, 2026
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFITOR - KALYDECO</u>						
N 207925 002	10272046	Feb 27, 2033	DP U-2531		NPP	Apr 29, 2022
	8324242	Aug 05, 2027	U-1311		ODE-236	Apr 29, 2026
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFITOR - KALYDECO</u>						
N 207925 003	10272046	Feb 27, 2033	DP U-2531		NPP	Jul 31, 2020
	7495103	May 20, 2027	DS DP		NPP	Apr 29, 2022
	8324242	Aug 05, 2027	U-1311		ODE-188	Mar 17, 2022
	8324242	Aug 05, 2027	U-1906		ODE-189	Jul 31, 2024
	8324242	Aug 05, 2027	U-2527		ODE-190	May 17, 2024
	8354427	Jul 06, 2026	U-1311		ODE-199	Aug 15, 2025
	8354427	Jul 06, 2026	U-1905		ODE-236	Apr 29, 2026
	8354427	Jul 06, 2026	U-2528			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFITOR; IVACAFITOR, TEZACAFITOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10022352	Apr 09, 2027	DP U-2343		NPP	Jun 21, 2022
	10022352	Apr 09, 2027	DP U-2573		ODE-247	Jun 21, 2026
	10058546	Jul 15, 2033	U-2399			
	10058546	Jul 15, 2033	U-2572			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10239867	Apr 09, 2027	DS DP U-2512			
	10239867	Apr 09, 2027	DS DP U-2569			
	9931334	Dec 28, 2026	DP U-2275			
	9931334	Dec 28, 2026	DP U-2575			
	9974781	Apr 09, 2027	DP U-2318			
	9974781	Apr 09, 2027	DP U-2574			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10022352	Apr 09, 2027	DP U-2343		NPP	Jun 21, 2022
	10022352	Apr 09, 2027	DP U-2573		ODE-247	Jun 21, 2026
	10058546	Jul 15, 2033	U-2399			
	10058546	Jul 15, 2033	U-2572			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10239867	Apr 09, 2027	DS DP U-2512			
	10239867	Apr 09, 2027	DS DP U-2569			
	9931334	Dec 28, 2026	DP U-2275			
	9931334	Dec 28, 2026	DP U-2575			
	9974781	Apr 09, 2027	DP U-2318			
	9974781	Apr 09, 2027	DP U-2574			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10022352	Apr 09, 2027	DP U-2343		NCE	Feb 12, 2023
	10022352	Apr 09, 2027	DP U-2573		NPP	Jun 21, 2022
	10058546	Jul 15, 2033	U-2399		ODE-173	Feb 12, 2025
	10058546	Jul 15, 2033	U-2572		ODE-247	Jun 21, 2026
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10239867	Apr 09, 2027	DS DP U-2512			
	10239867	Apr 09, 2027	DS DP U-2569			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-2246			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-2246			
	8598181	May 01, 2027	U-2246			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-2247			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-2248			
	9670163	Dec 28, 2026	DP U-2246			
	9931334	Dec 28, 2026	DP U-2275			
	9931334	Dec 28, 2026	DP U-2575			
	9974781	Apr 09, 2027	DP U-2318			
	9974781	Apr 09, 2027	DP U-2574			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	10206939	Mar 13, 2034	U-1631			
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	9474779	Aug 19, 2033	DS DP U-2350		ODE-242	May 02, 2026
	9474779	Aug 19, 2033	DS DP U-2533			
	9474779	Aug 19, 2033	DS DP U-2534			
	9850277	Jan 18, 2033	DS DP U-2350			
	9850277	Jan 18, 2033	DS DP U-2533			
	9850277	Jan 18, 2033	DS DP U-2534			
	9968595	Mar 13, 2035	DP U-2351			
	9968595	Mar 13, 2035	DP U-2533			
	9968595	Mar 13, 2035	DP U-2534			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	10172861	Nov 16, 2035	DS DP		NCE	Nov 26, 2023
	10285993	Nov 16, 2035	U-2470			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	10172861	Nov 16, 2035	DS DP		NCE	Nov 26, 2023
	10285993	Nov 16, 2035	U-2470			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	10172861	Nov 16, 2035	DS DP		NCE	Nov 26, 2023
	10285993	Nov 16, 2035	U-2470			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	10172861	Nov 16, 2035	DS		NCE	Nov 26, 2023
<u>LATANOPROST - XELPROS</u>						
N 206185 001	9539262	Oct 15, 2028	U-2400			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10174017	Jan 27, 2030	DS DP U-1524		NC	Mar 12, 2022
	8394826	Nov 10, 2030	DS DP U-1524		NCE	Dec 18, 2022
	8450344	Jul 11, 2026	DS DP U-1524			
	9096569	Jul 11, 2026	DS DP U-1524			
	9415043	Mar 14, 2034	DS			
	9931336	Mar 14, 2034	DS DP U-1524			
	9993470	Mar 14, 2034	DS DP U-1524			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	10039779	Jan 30, 2034	DS DP U-2369		ODE-136	Apr 07, 2024
	10039779	Jan 30, 2034	DS DP U-2370		PED	Oct 07, 2024
	10039779*PED	Jul 30, 2034				
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	DP U-1470			
	9511056*PED	Nov 12, 2030				
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211672 001					>A> NCE	Aug 19, 2024
					>A> GAIN	Aug 19, 2029
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211673 001					>A> NCE	Aug 19, 2024
					>A> GAIN	Aug 19, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	10259791	Aug 26, 2035	DS			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	10259791	Aug 26, 2035	DS			
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	10183012	Nov 26, 2028	U-2311			
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	8962630	Dec 09, 2029	U-2505			
	9416136	Aug 20, 2029	U-2505			
	9868739	Nov 09, 2031	U-2505			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 001	8470367	Oct 31, 2027	DP			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 002	8470367	Oct 31, 2027	DP			
<u>LEVODOPA - INBRIJA</u>						
N 209184 001	6514482	Sep 19, 2020	DP U-2484		NP	Dec 21, 2021
	6613308	Sep 19, 2020	U-2484			
	6858199	Nov 04, 2021	U-2485			
	6921528	Jun 19, 2020	U-2485			
	6979437	Sep 19, 2020	U-2484			
	7146978	Apr 16, 2021	U-2486			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVODOPA - INBRIJA</u>						
N 209184 001	7182961	Feb 22, 2024	DP			
	7384649	Nov 20, 2022	DP			
	7556798	Nov 04, 2021	U-2485			
	8404276	Mar 19, 2023	U-2484			
	8545878	Nov 16, 2032	DP			
	8586093	Mar 19, 2023	U-2484			
	8628754	Jun 19, 2020	U-2485			
	8685442	Nov 16, 2032	DP			
	8945612	Nov 16, 2032	DP			
	9155699	Mar 19, 2023	DP			
	9393210	Nov 16, 2032	DP			
	RE43711	Feb 03, 2029	U-2484			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 001	9782376	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 002	9782376	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 003	9782376	Dec 01, 2036	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8802628	Oct 30, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8802628	Oct 30, 2031	DP			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	6268343	Aug 22, 2022	DS DP U-968		NPP	Jun 17, 2022
	6268343*PED	Feb 22, 2023			PED	Dec 17, 2022
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8114833	Aug 13, 2025	DS DP			
	8114833*PED	Feb 13, 2026				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8846618	Jun 27, 2022	DP			
	8846618*PED	Dec 27, 2022				
	9265893	Sep 23, 2032	DP			
	9265893*PED	Mar 23, 2033				
	9968659	Jan 09, 2037	U-2313			
	9968659*PED	Jul 09, 2037				
	RE41956	Jan 21, 2021	DP			
	RE41956*PED	Jul 21, 2021				
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	10220155	Jul 17, 2026	DP			
	10220155*PED	Jan 17, 2027				
	10357616	Jan 20, 2026	DP			
	6268343	Aug 22, 2022	DS DP U-1255			
	6268343*PED	Feb 22, 2023				
	6899699	Jan 01, 2022	DP			
	6899699*PED	Jul 01, 2022				
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8114833	Aug 13, 2025	DP			
	8114833*PED	Feb 13, 2026				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8672898	Jan 02, 2022	DP			
	8672898*PED	Jul 02, 2022				
	8684969	Oct 20, 2025	DP			
	8684969*PED	Apr 20, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	8846618	Jun 27, 2022	DP			
	8846618*PED	Dec 27, 2022				
	8920383	Jul 17, 2026	DP			
	8920383*PED	Jan 17, 2027				
	9108002	Jan 26, 2026	DP			
	9108002*PED	Jul 26, 2026				
	9132239	Feb 01, 2032	DP			
	9132239*PED	Aug 01, 2032				
	9457154	Sep 27, 2027	DP			
	9457154*PED	Mar 27, 2028				
	9486588	Jan 02, 2022	DP			
	9486588*PED	Jul 02, 2022				
	9616180	Jan 20, 2026	DP			
	9616180*PED	Jul 20, 2026				
	9687611	Feb 27, 2027	DP			
	9687611*PED	Aug 27, 2027				
	9775953	Jul 17, 2026	DP			
	9775953*PED	Jan 17, 2027				
	9861757	Jan 20, 2026	DP			
	9861757*PED	Jul 20, 2026				
	9968659	Jan 09, 2037	U-2438			
	9968659*PED	Jul 09, 2037				
	RE46363	Aug 03, 2026	DP			
	RE46363*PED	Feb 03, 2027				
<u>LISINAPRIL - OBRELIS</u>						
N 208401 001	10265370	Nov 06, 2035	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	10201663	Mar 10, 2034	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	10201663	Mar 10, 2034	DP			
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	10226471	Aug 31, 2031	DP			
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001					NS	Feb 22, 2022
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	10058511	May 03, 2033	DP U-2492			
	9056057	May 03, 2033	DP U-2491			
	9393213	May 03, 2033	DP			
	9532955	May 03, 2033	U-2491			
	9737491	May 03, 2033	U-2492			
	9827191	May 03, 2033	DP U-2493			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	8779187	Jan 23, 2027	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	10172874	Aug 08, 2031	DP			
	10183034	Aug 08, 2031	U-2490			
<u>METFORMIN HYDROCHLORIDE - RIOMET</u>						
N 021591 001	6890957	Aug 07, 2021	DP			
<u>METFORMIN HYDROCHLORIDE - RIOMET ER</u>						
N 212595 001	>A> 9962336	May 01, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	8628799	Jul 13, 2025	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	8628799	Jul 13, 2025	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	10231927	Jan 02, 2033	U-1349			
	10231927	Jan 02, 2033	U-1699			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001 >A>	10376584	Apr 08, 2024	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002 >A>	10376584	Apr 08, 2024	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003 >A>	10376584	Apr 08, 2024	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	10307417	Mar 10, 2031	DP			
>A>	10376505	Mar 10, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 002	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 003	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 004	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 004	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 006	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	9974752	Oct 30, 2035	DP			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	10238634	Jun 28, 2032	DP			
<u>MIDAZOLAM - NAYZILAM</u>						
N 211321 001	8217033	Jan 18, 2028	DP U-2526		NP	May 21, 2022
	8809322	Jan 18, 2028	DP		ODE-243	May 17, 2026
	9289432	Jan 18, 2028	DP U-2526			
	9687495	Jan 18, 2028	DP U-2526			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	10195214	Jun 19, 2037	U-1643			
	10231983	Aug 22, 2038	U-1643			
	10314850	Aug 22, 2038	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	10251873	May 30, 2038	U-2371			
	>A> 10383864	May 16, 2027	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCYCLINE HYDROCHLORIDE</u>						
A 091424 002					PC	Aug 21, 2019
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 001	10314788	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 002	10314788	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 003	10314788	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 004	10314788	Aug 12, 2028	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001	10166205	Jan 31, 2033	DP			
	10166206	Jan 31, 2033	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	10220158	Mar 20, 2035	DP U-2500			
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031	U-1907			
	10335549	Apr 30, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	10143792	May 24, 2031	U-2476			
	10220158	Mar 20, 2035	DP U-2500			
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031	U-1907			
	10335549	Apr 30, 2025	DP			
<u>NETARSUDIL DIMESYLATE - RHOPRESSA</u>						
N 208254 001	10174017	Jan 27, 2030	DS DP U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	10233154	Sep 25, 2035	DS			
<u>NICOTINE POLACRILEX - NICOTINE POLACRILEX</u>						
A 207868 001					>A> PC	Oct 01, 2019
<u>NICOTINE POLACRILEX - NICOTINE POLACRILEX</u>						
A 207868 002					>A> PC	Oct 01, 2019
<u>NITISINONE - NITYR</u>						
N 209449 001	10328029	Jan 05, 2035	DP U-1836			
<u>NITISINONE - NITYR</u>						
N 209449 002	10328029	Jan 05, 2035	DP U-1836			
<u>NITISINONE - NITYR</u>						
N 209449 003	10328029	Jan 05, 2035	DP U-1836			
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	10266822	Dec 05, 2025	DP U-1942			
	10266822	Dec 05, 2025	DP U-1943			
	10266822	Dec 05, 2025	DP U-1944			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8143241	Aug 12, 2027	U-2101		ODE-226	Dec 19, 2025
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8143241	Aug 12, 2027	U-2101		ODE-226	Dec 19, 2025
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8912187	Mar 12, 2024	U-2101			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	7326696	Sep 24, 2023	DS			
	7553828	Jun 02, 2023	DS			
	8383610	Sep 23, 2030	DS			
	9265740	Mar 05, 2029	U-1569			
	9314475	Mar 18, 2031	DP			
	9365500	Jun 29, 2021	U-1569			
	9365500	Jun 29, 2021	U-2576			
	9724358	Mar 05, 2029	U-1569			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	7326696	Sep 24, 2023	DS			
	7553828	Jun 02, 2023	DS			
	9265740	Mar 05, 2029	DP			
	9365500	Jun 29, 2021	U-1569			
	9365500	Jun 29, 2021	U-2576			
	9724358	Mar 05, 2029	U-1569			
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2020	DP			
	5948818	May 13, 2020	DP			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777			
	10183020	Jan 02, 2035	DP U-2289			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777			
	10183020	Jan 02, 2035	DP U-2289			
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2025	U-1370		I-793	Jan 25, 2022
	6245819	Jul 21, 2025	U-905			
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8236861	Aug 11, 2026	U-905			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
	8470890	Feb 13, 2024	U-905			
	8772353	Feb 13, 2024	U-1369			
	8772353	Feb 13, 2024	U-1370			
	8772353	Feb 13, 2024	U-905			
	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
	9241915	Feb 13, 2024	U-905			
	9855224	Feb 13, 2024	U-1369			
	9855224	Feb 13, 2024	U-1370			
	9855224	Feb 13, 2024	U-905			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	10272061	Apr 26, 2020	U-2525			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	10369109	Jun 16, 2023	DP			
	9060976	Aug 06, 2022	DP	Y		
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	10369109	Jun 16, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	10369109	Jun 16, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	10369109	Jun 16, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	10369109	Jun 16, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	10369109	Jun 16, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	10369109	Jun 16, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 001	10314788	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 002	10314788	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 003	10314788	Aug 12, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFADÉ</u>						
N 208552 001	10335391	Jun 11, 2035	U-2567			
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2020	DS			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 004	>A> 7473761	Dec 14, 2026	DS DP			
	>A> 7759308	Oct 25, 2026	DP			
	>A> 9351923	May 23, 2028	DP			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 005	>A> 7473761	Dec 14, 2026	DS DP			
	>A> 7759308	Oct 25, 2026	DP			
	>A> 9351923	May 23, 2028	DP			
<u>PENICILLAMINE - PENICILLAMINE</u>						
A 210976 001					CGT	Dec 22, 2019
<u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u>						
N 211810 001	>A> 10189833	May 05, 2036	U-2606		>A> NCE	Aug 02, 2024
	>A> 7893075	Oct 13, 2028	DS			
	>A> 8404700	Nov 21, 2027	DS			
	>A> 8461169	Apr 19, 2028	U-2606			
	>A> 8722702	Nov 21, 2027	DS			
	>A> 9169250	Nov 21, 2027	DS			
	>A> 9358235	Jun 08, 2033	U-2606			
	>A> 9802932	May 05, 2036	DS			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002					NCE	Apr 29, 2021
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	10188637	Mar 28, 2037	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	10188637	Mar 28, 2037	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	10188637	Mar 28, 2037	DP			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 001	5856336	Dec 25, 2020	DS	U-998	NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024		U-998		
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 002	5856336	Dec 25, 2020	DS	U-998	NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024		U-998		
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 003	5856336	Dec 25, 2020	DS	U-998	NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024		U-998		
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001					>A> NCE	Aug 14, 2024
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002					>A> NCE	Aug 14, 2024
<u>PREGABALIN - LYRICA</u>						
N 021446 001					NPP	May 23, 2022
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 002					NPP	May 23, 2022
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 003					NPP	May 23, 2022
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 004					NPP	May 23, 2022
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 005					NPP	May 23, 2022
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 006					NPP	May 23, 2022
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 007					NPP	May 23, 2022
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 008					NPP	May 23, 2022
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 022488 001					NPP	May 23, 2022
					PED	Nov 23, 2022
<u>PRETOMANID - PRETOMANID</u>						
N 212862 001					>A> NCE	Aug 14, 2024
					>A> GAIN	Aug 14, 2029

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410 001	8987262	Oct 16, 2028	U-1988			
<u>PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE</u>						
A 211694 001					CGT	Sep 04, 2019
<u>RANOLAZINE - RANOLAZINE</u>						
A 201046 001					PC	May 27, 2019
<u>RANOLAZINE - RANOLAZINE</u>						
A 201046 002					PC	May 27, 2019
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	RE47301	Feb 02, 2027	DP			
	RE47351	Jun 22, 2019	DS DP U-869			
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	10343995	Mar 10, 2025	U-2440			
	8541451	Aug 25, 2031	DS			
	9765028	Jul 14, 2030	DS			
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	10314828	Oct 02, 2029	U-1481			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	10314828	Oct 02, 2029	U-1481			
	10335397	Oct 02, 2029	U-2579			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 001	>A> 10376590	Feb 13, 2028	U-2608			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 002	>A> 10376590	Feb 13, 2028	U-2608			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001	10350174	Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002	10350174	Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003	10350174	Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 004	10350174	Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 005	10350174	Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 006	10350174	Dec 22, 2030	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	10278974	Feb 10, 2031	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	10278974	Feb 10, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	10278974	Feb 10, 2031	DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	10335390	Sep 04, 2035	U-2583			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 001					NCE	Apr 30, 2024
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	8999996	Sep 15, 2032	DS DP		NCE	Jul 03, 2024
	9079865	Jul 26, 2032	U-2584			
	9714226	Jul 26, 2032	DS DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	10220155	Jul 17, 2026	DP			
	10335462	Jun 21, 2033	U-2580			
	10357616	Jan 20, 2026	DP			
<u>SILDENAFIL CITRATE - SILDENAFIL CITRATE</u>						
A 212260 001					CGT	Nov 27, 2019
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679 001 >A>	10300041	Apr 26, 2030	DP			
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679 002 >A>	10300041	Apr 26, 2030	DP			
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 001	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	8492441	Nov 30, 2030	U-2511			
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 002	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	8492441	Nov 30, 2030	U-2511			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001					>A> M-244	Aug 12, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002					>A> M-244	Aug 12, 2022
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003					>A> M-244	Aug 12, 2022
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	10213400	Mar 15, 2033	U-2499		ODE-231	Oct 26, 2025
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 001	10300087	Oct 14, 2035	DS	U-2312		
	10335432	Feb 10, 2032		U-2312		
	9913860	Oct 22, 2033	DS	U-2312		
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 002	10300087	Oct 14, 2035	DS	U-2312		
	9913860	Oct 22, 2033	DS	U-2312		
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	7964580	Mar 26, 2029	DS DP	U-1470	NPP	Apr 07, 2020
	7964580*PED	Sep 26, 2029			ODE-135	Apr 07, 2024
	8334270	Mar 21, 2028	DS DP	U-1470	PED	Oct 07, 2024
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP	U-1470		
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP	U-1470		
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP	U-1470		
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029		DP U-1470		
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP	U-1470		
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP	U-1470		
	9284342*PED	Mar 13, 2031				
	9549941	Mar 26, 2029		U-1958		
	9549941*PED	Sep 26, 2029				
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	7964580	Mar 26, 2029	DS DP	U-1470		
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP	U-1470		
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP	U-1470		
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP	U-1470		
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP	U-1470		
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029		DP U-1470		
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP	U-1470		
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP	U-1470		
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	7964580	Mar 26, 2029	DS DP	U-2039		
	7964580	Mar 26, 2029	DS DP	U-2040		
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP	U-2039		
	8334270	Mar 21, 2028	DS DP	U-2040		
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP	U-2039		
	8580765	Mar 21, 2028	DS DP	U-2040		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-2039			
	8618076	Dec 11, 2030	DS DP U-2040			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-2039			
	8633309	Mar 26, 2029	DS DP U-2040			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DS DP U-2039			
	8889159	Mar 26, 2029	DS DP U-2040			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-2039			
	9085573	Mar 21, 2028	DS DP U-2040			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-2039			
	9284342	Sep 13, 2030	DS DP U-2040			
	9284342*PED	Mar 13, 2031				
<u>SOLRIAMFETOL - SUNOSI</u>						
N 211230 001	10195151	Sep 05, 2037	DP		NCE	Jun 17, 2024
	>A> 10351517	Jun 07, 2026	U-2548			
	8440715	Aug 25, 2027	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			
<u>SOLRIAMFETOL - SUNOSI</u>						
N 211230 002	10195151	Sep 05, 2037	DP		NCE	Jun 17, 2024
	>A> 10351517	Jun 07, 2026	U-2548			
	8440715	Aug 25, 2027	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148 008	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148 009	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148 010	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148 011	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	10206895	Apr 01, 2034	DP U-2096			
	10206895	Apr 01, 2034	DP U-2494			
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	10245228	Jan 05, 2027	DP U-1351			
	10342762	Jan 05, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001	10232061	Jul 06, 2038	DP			
	10335502	Jul 06, 2038	DP			
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884 001	8268791	May 09, 2026	DP			
	8440631	May 09, 2026	DP U-1719			
	9211282	Jul 19, 2031	DP U-1719			
	9283280	Jul 01, 2025	DP			
	9610280	Jun 16, 2030	DP U-1719			
	9974770	Jun 16, 2030	DP U-1719			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 001	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 002	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 003	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 004	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	10166190	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	10166190	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	10166190	May 30, 2028	DP			
<u>TADALAFIL - CIALIS</u>						
N 021368 003	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TADALAFIL - CIALIS</u>						
N 021368 004	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
<u>TAFAMIDIS - VYNDAMAX</u>						
N 212161 001	7214695	Apr 27, 2024	DS DP		NCE	May 03, 2024
	7214696	Dec 19, 2023	U-2524		ODE-237	May 03, 2026
	9770441	Aug 31, 2035	DS DP U-2524			
<u>TAFAMIDIS MEGLUMINE - VYNDAQEL</u>						
N 211996 001	7214695	Apr 27, 2024	DS DP		NCE	May 03, 2024
	7214696	Dec 19, 2023	U-2524		ODE-237	May 03, 2026
	8168663	Dec 19, 2023	DS DP			
	8653119	Jan 28, 2024	U-2524			
<u>TAFENOQUINE SUCCINATE - ARAKODA</u>						
N 210607 001	10342791	Dec 02, 2035	U-2582			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 001	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 002	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001 >A>	10376487	Jul 27, 2035	U-2615			
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001					NCE PED	Jul 07, 2019 Jan 07, 2020
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001	10065947	Feb 03, 2030	DP			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001	10065947	Feb 03, 2030	DP			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2020	DS DP U-1320		ODE-240	May 16, 2026
	5789379*PED	Oct 14, 2020			ODE-37	Dec 21, 2019
	7056886	Sep 18, 2022	DP U-1320		PED	Jun 21, 2020
	7056886*PED	Mar 18, 2023				
	7847061	Nov 01, 2025	U-1320			
	7847061*PED	May 01, 2026				
	9060992	Nov 01, 2025	U-1320			
	9060992*PED	May 01, 2026				
	9539310	Nov 01, 2025	U-1320			
	9539310*PED	May 01, 2026				
	9545434	Nov 01, 2025	U-1320			
	9545434*PED	May 01, 2026				
	9545435	Nov 01, 2025	U-1320			
	9545435*PED	May 01, 2026				
	9555079	Nov 01, 2025	U-1320			
	9555079*PED	May 01, 2026				
	9572867	Nov 01, 2025	U-1320			
	9572867*PED	May 01, 2026				
	9592273	Nov 01, 2025	U-1320			
	9592273*PED	May 01, 2026				
	9592274	Nov 01, 2025	U-1320			
	9592274*PED	May 01, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	9968655	Nov 01, 2025	U-2308			
	9968655*PED	May 01, 2026				
	9968656	Nov 01, 2025	U-2308			
	9968656*PED	May 01, 2026				
	9968658	Nov 01, 2025	U-1320			
	9968658*PED	May 01, 2026				
	9974835	Nov 01, 2025	U-1320			
	9974835*PED	May 01, 2026				
	9974837	Nov 01, 2025	U-1320			
	9974837*PED	May 01, 2026				
	9981014	Nov 01, 2025	U-1320			
	9981014*PED	May 01, 2026				
	9981016	Nov 01, 2025	U-1320			
	9981016*PED	May 01, 2026				
	9987334	Nov 01, 2025	U-1320			
	9987334*PED	May 01, 2026				
	9987335	Nov 01, 2025	U-1320			
	9987335*PED	May 01, 2026				
	9993528	Nov 01, 2025	U-1320			
	9993528*PED	May 01, 2026				
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	8241664	Mar 29, 2029	DP U-2506		NP	Mar 27, 2022
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	8241664	Mar 29, 2029	DP U-2506		NP	Mar 27, 2022
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	8241664	Mar 29, 2029	DP U-2506		NP	Mar 27, 2022
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 001					CGT	Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 002					CGT	Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 003					CGT	Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 004					CGT	Oct 02, 2019
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	10300065	Jan 27, 2036	U-2541			
	10300065	Jan 27, 2036	U-2542			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	10300065	Jan 27, 2036	U-2541			
	10300065	Jan 27, 2036	U-2542			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	RE46284	Dec 16, 2026	U-1751		I-794	Feb 22, 2022
	RE46284	Dec 16, 2026	U-2503		ODE-229	Feb 22, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	RE46284	Dec 16, 2026	U-1751		I-794	Feb 22, 2022
	RE46284	Dec 16, 2026	U-2503		ODE-229	Feb 22, 2026
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001	10207066	Nov 04, 2030	DP U-909			
	8664187	Jun 20, 2025	U-909			
	8869794	Sep 12, 2028	DP U-909			
	9421166	Dec 19, 2022	DP U-909			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	10363224	Mar 19, 2033	U-766			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	10363224	Mar 19, 2033	U-766			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	10363224	Mar 19, 2033	U-766			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	10363224	Mar 19, 2033	U-766			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	10363224	Mar 19, 2033	U-766			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	8703781	Oct 15, 2030	DS DP U-1712			
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	8703781	Oct 15, 2030	DS DP U-1712			
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	8703781	Oct 15, 2030	DS DP U-1712			
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 001					PC	Sep 21, 2019
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 002					PC	Sep 21, 2019
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 003					PC	Sep 21, 2019
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 004					PC	Sep 21, 2019
<u>TRETINOIN - ALTRENO</u>						
N 209353 001	6517847	Aug 03, 2020	DP U-2368			
<u>TRICLABENDAZOLE - EGATEN</u>						
N 208711 001					NCE ODE-228	Feb 13, 2024 Feb 13, 2026
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437 001	10166181	Feb 10, 2029	DP			
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001	10166181	Feb 10, 2029	DP			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	10159681 9844510	Apr 13, 2030 Dec 08, 2028	U-2510 DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001					>A> M-245	Jun 09, 2022
<u>UPADACITINIB - RINVOO</u>						
N 211675 001					>A> NCE	Aug 16, 2024
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001	6258795	Jul 10, 2023	DP			
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169 001	6258795	Jul 10, 2023	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 001	10039804 10188697	Nov 06, 2035 Nov 06, 2035	DP U-282 DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 002	10039804 10188697	Nov 06, 2035 Nov 06, 2035	DP U-282 DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 003	10039804 10188697	Nov 06, 2035 Nov 06, 2035	DP U-282 DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 004	10039804 10188697	Nov 06, 2035 Nov 06, 2035	DP U-282 DP U-282			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 001					M-237 PED	Feb 22, 2022 Aug 22, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 001					M-237 PED	Feb 22, 2022 Aug 22, 2022
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 002					M-237 PED	Feb 22, 2022 Aug 22, 2022
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	9174982	May 26, 2030	U-2323		I-795	May 15, 2022
	9174982	May 26, 2030	U-2445		ODE-239	May 15, 2026
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	9174982	May 26, 2030	U-2323		I-795	May 15, 2022
	9174982	May 26, 2030	U-2445		ODE-239	May 15, 2026
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	9174982	May 26, 2030	U-2323		I-795	May 15, 2022
	9174982	May 26, 2030	U-2445		ODE-239	May 15, 2026
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
<u>VORICONAZOLE - VFEND</u>						
N 021266 001					NPP	Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021266 002					NPP	Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021267 001					NPP	Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021630 001					NPP	Jan 29, 2022

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 39th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at
http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm